





GROWTH	  FACTOR	  PRIMING	  OF	  MURINE	  MESENCHYMAL	  






A	  thesis	  submitted	  to	  	  
The	  University	  of	  Birmingham	  
For	  the	  degree	  of	  	  
DOCTOR	  OF	  PHILOSOPHY	  
	  
	  
Centre	  for	  Liver	  Research	  
School	  of	  Immunity	  and	  Infection	  
College	  of	  Medical	  and	  Dental	  Sciences	  
















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 








Mesenchymal	   stem	  cells	   (MSCs)	  are	  a	   subset	  of	  multipotent	  cells	  with	  a	  variety	  of	   trophic	  
and	   immunosuppressive	   functions.	   Isolation	   of	   murine	   MSCs	   has	   traditionally	   been	  
hampered	   by	   the	   presence	   of	   contaminating	   cells	   in	   culture.	   In	   this	   study,	   I	   prospectively	  
isolate	  murine	  MSCs	   based	   on	   the	   co-­‐expression	   of	   platelet-­‐derived	   growth	   factor	   (PDGF)	  
receptor	  alpha	  and	  stem	  cell	  antigen-­‐1	  (PαS	  MSCs)	  and	  present	  novel	  data	  regarding	  their	  in	  
vitro	  phenotype,	  karyotype	  and	  immunomodulatory	  functions.	  However,	  PαS	  MSCs	  undergo	  
senescence	   after	   extended	   culture,	   resulting	   in	   a	   loss	   of	   function.	   Addition	   of	   fibroblast	  
growth	  factor	  2	  (FGF2),	  PDGF-­‐BB	  or	  transforming	  growth	  factor-­‐beta	  1	  (TGF-­‐β1)	  was	  able	  to	  
overcome	   senescence	   in	   MSC	   cultures.	   These	   factors	   also	   ‘lineage	   primed’	   MSCs	   down	  
specific	   fates	   at	   the	   genetic	   and	   phenotypic	   levels,	   with	   un-­‐supplemented	   MSCs	   primed	  
towards	   bone,	   FGF2	   or	   PDGF-­‐BB	   supplemented	   cells	   primed	   towards	   fat,	   and	   FGF2	  
supplemented	   cells	   primed	   towards	   cartilage.	   TGF-­‐β1	   supplementation	   attenuated	   tri-­‐
lineage	   differentiation	   of	   PαS	   MSCs	   but	   maintained	   their	   immunosuppressive	   functions.	  
These	   findings	   were	   confirmed	   in	   a	   mouse	  model	   of	   inflammatory	   liver	   injury,	   with	   late-­‐
passage	  TGF-­‐β1	  MSCs	  improving	  liver	  injury	  compared	  to	  controls.	  In	  summary,	  these	  results	  
have	   significant	   translational	   relevance	   as	   I	   reveal	   that	   culture	   conditions	   can	   functionally	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   Collagen	  type	  I	  
Col2	   Collagen	  type	  II	  
ConA	   Concanavalin	  A	  
CTV	   Cell	  Trace	  Violet	  
DAB	   3,3'-­‐Diaminobenzidine	  
DMB	   Dimethyl	  methylene	  blue	  
DMEM	   Dulbecco’s	  Modified	  Eagle	  Medium	  
ECM	   Extracellular	  matrix	  	  
EGF	   Epidermal	  growth	  factor	  
ELISA	   Enzyme-­‐linked	  immunosorbent	  assay	  
FACS	   Fluorescence	  activated	  cell	  sorting	  
FBS	   Foetal	  bovine	  serum	  
FC	   Flow	  Cytometry	  
FFPE	   Formalin-­‐fixed	  Paraffin-­‐embedded	  tissue	  
FGF	   Fibroblast	  growth	  factor	  
G-­‐banding	   Giemsa	  banding	  
GAG	   Glycosaminoglycans	  
GF	   Growth	  factor	  
GFP	   Green	  fluorescent	  protein	  
GvHD	   Graft-­‐versus-­‐host	  disease	  
HBSS	   Hank’s	  Balanced	  Salt	  Solution	  
HGF	   Hepatocyte	  growth	  factor	  
HLA	   Human	  Leukocyte	  Antigen	  
HRP	   Horseradish	  peroxidase	  
HSC	   Haematopoietic	  stem	  cell	  
IBMIR	   Instant	  Blood	  Mediated	  Inflammatory	  Reaction	  
IDO	   Indoleamine	  2,3-­‐dioxygenase	  
IFNγ	   Interferon-­‐γ	  
IGF	   Insulin-­‐like	  growth	  factor	  
IHC	   Immunohistochemistry	  
IL	   Interleukin	  
IMC	   Isotype	  matched	  control	  




iNOS	   Inducible	  nitric	  oxide	  synthase	  
IP	   Intraperitoneal	  infusion	  	  
ISCT	   International	  Society	  for	  Cellular	  Therapy	  
IV	   Intravenous	  
L-­‐NMMA	   NG-­‐Monomethyl-­‐L-­‐arginine	  
LPS	   Lipopolysaccharide	  
LVEF	   Left	  ventricular	  ejection	  fraction	  
MACS	   Magnetic-­‐activated	  cell	  sorting	  
MELD	   Model	  for	  End	  Stage	  Liver	  Disease	  
MHC	   Major	  histocompatibility	  antigens	  
MI	   Myocardial	  infarction	  
MLR	   Mixed	  lymphocyte	  reaction	  
MMP	   Matrix	  metalloproteinase	  
MSC	   Mesenchymal	  Stem	  Cell	  
NIHSS	   National	  Institutes	  of	  Health	  Stroke	  Scale	  
NK	   Natural	  killer	  
NO	   Nitric	  oxide	  
OA	   Osteoartharitis	  
OD	   Optical	  density	  
OI	   Osteogenesis	  Imperfecta	  
OVA	   Ovalbumin	  
P	   Passage	  number	  
PBC	   Primary	  biliary	  cirrhosis	  
PBS-­‐T	   PBS+0.05%	  Tween	  
PDGF-­‐BB	   Platelet	  derived	  growth	  factor-­‐BB	  
PGA	   Polyglycolic	  acid	  
PGE2	   Prostaglandin	  E2	  
PI	   Propidium	  Iodide	  
PSC	   Primary	  sclerosing	  cholangitis	  
PSG	   Penicillin/Streptomycin/Glutamine	  
PαS	   PDGFRα+Sca-­‐1+	  MSCs	  
QR	   Quadriradial	  
RBC	   Red	  blood	  cell	  
RCT	   Randomised	  controlled	  trial	  
RPMI	   Roswell	  Park	  Memorial	  Institute	  medium	  
SA-­‐β-­‐gal	   Senescence-­‐associated	  β-­‐galactosidase	  	  
Sca-­‐1	   Stem	  cell	  antigen	  1	  
SCE	   Sister	  chromatid	  exchange	  
SCF	   Stem	  cell	  factor	  
SDF-­‐1	   Stromal	  derived	  factor	  1	  
SDS	   Sodium	  dodecyl	  sulphate	  
SLE	   Systemic	  lupus	  erythematosus	  
SLEDAI	   Systemic	  lupus	  erythematosus	  disease	  activity	  index	  
TBS-­‐T	   Tris-­‐buffered	  saline	  +	  0.1%	  Tween20	  
TCR	   T	  Cell	  Receptor	  
TGF-­‐β	   Transforming	  growth	  factor	  beta	  
TLR	   Toll-­‐like	  receptor	  
TNFα	   Tumour	  necrosis	  factor	  alpha	  
Treg	   Regulatory	  T	  cells	  






























1.1	  Mesenchymal	  Stem	  Cells:	  A	  Historical	  Perspective	  
The	   term	   “Mesenchymal	   Stem	   Cell	   (MSC)”	   was	   first	   coined	   in	   1991	   by	   Arnold	   Caplan	   to	  
describe	  a	  rare	  population	  of	  bone	  marrow	  (BM)	  cells	  with	  the	  ability	  to	  differentiate	  into	  a	  
variety	  of	  skeletal	  tissues	  (Caplan,	  1991).	  His	  work	  can	  be	  traced	  back	  to	  a	  series	  of	  seminal	  
observations	   by	   Friedenstein	   and	   colleagues	   who	   showed	   that	   cells	   with	   osteogenic	  
potential	   resided	   in	   the	  non-­‐haematopoietic	  section	  of	  BM	  (Friedenstein	  et	  al.,	  1970).	  This	  
stromal	  population	  was	  characterised	  by	  their	  spindle	  shaped	  morphology,	  ability	  to	  adhere	  
onto	  tissue	  culture	  plastic,	  and	  their	  ability	  to	  form	  colonies.	  These	  cells	  were	  also	  capable	  of	  
forming	   heterotrophic	   bone	   when	   transplanted	   in	   mice,	   demonstrating	   a	   degree	   of	   self-­‐
renewal	  and	  multipotency	  that	  are	  defining	  features	  of	  stem	  cells	  (Friedenstein	  et	  al.,	  1966).	  
By	   combining	   the	   efforts	   of	   Friedenstein	   and	   other	   MSC	   biologists	   at	   the	   time,	   Caplan	  
championed	  the	  idea	  that	  multiple	  mesenchymal	  tissues	  could	  arise	  from	  a	  single	  stem	  cell	  
in	  a	  pathway	  termed	  ‘The	  Mesengenic	  Process’	  (Figure	  1.1;	  Caplan,	  1994).	  	  	  	  
	  
Although	   the	  early	  work	   in	  MSC	  biology	  was	  of	   limited	   interest	   to	   researchers	  outside	   the	  
field,	   the	   potential	   of	   MSCs	   was	   demonstrated	   to	   a	   worldwide	   audience	   upon	   the	  
publication	  of	  a	   landmark	  paper	  by	  Pittenger	  and	  colleagues	  (Pittenger	  et	  al.,	  1999a).	  They	  
isolated	   MSCs	   from	   human	   BM	   and	   cultured	   them	   in	   vitro	   before	   inducing	   tri-­‐lineage	  
differentiation	   into	   bone,	   fat	   and	   cartilage.	   These	   findings	   laid	   the	   framework	   for	   future	  
studies	  on	  MSC	  biology	  which	  revealed	  a	  broader	  differentiation	  potential	  (‘plasticity’)	  than	  
originally	  thought	  (Krause,	  2002),	  and	  a	  potent	  ability	  to	  suppress	  immune	  cell	  proliferation	  
(Bartholomew	  et	  al.,	  2002).	  MSC-­‐like	  cells	  have	  also	  been	  isolated	  from	  a	  variety	  of	  tissues,	  





suggesting	  a	  broad	  role	  for	  these	  cells	  in	  the	  maintenance	  of	  multiple	  organs	  (Murray	  et	  al.,	  
2014).	   Their	   ease-­‐of-­‐isolation,	   growth	   characteristics,	   plasticity	   and	   immunosuppressive	  
ability	  have	  made	  MSCs	  a	  desirable	  cell	  source	  for	  future	  stem	  cell	  therapies,	  with	  multiple	  
human	   clinical	   trials	   already	   underway	   (Mendicino	   et	   al.,	   2014).	   However,	   very	   little	   is	  
known	   about	   the	   in	   vivo	   location	   and	   function	   of	   these	   elusive	   cells	   due	   to	   the	   lack	   of	  
specific	  markers	  to	  prospectively	  identify	  MSCs.	  This	  has	  drawn	  criticism	  from	  certain	  groups,	  
who	   argue	   that	   the	   term	   “stem	   cell”	   should	   not	   be	   used	   to	   describe	   the	   heterogeneous	  
populations	  of	  MSCs	  that	  have	  been	  isolated	  over	  the	  past	  15	  years	  (Bianco	  et	  al.,	  2008).	  
	  
	  
Figure	  1.1	  |	  The	  Mesengenic	  Process.	  This	  hypothetical	  pathway	  describes	  the	  ability	  of	  MSCs	  to	  differentiate	  
into	  a	  variety	  of	  mature	  mesenchymal	   tissues,	  analogous	   to	   the	  proposed	  hierarchy	  of	  haematopoietic	   stem	  
cells.	  Figure	  taken	  from	  Caplan,	  1994.	  	  
	   	  





1.2	  What	  defines	  an	  MSC?	  
Traditionally,	  MSCs	  were	   defined	   by	   their	   ability	   to	   form	   spindle-­‐shaped	   colonies	   (Colony	  
forming	   unit-­‐fibroblastic;	   CFU-­‐F)	   on	   plastic	   and	   their	   ability	   to	   undergo	   in	   vitro	   tri-­‐lineage	  
differentiation	   towards	   bone,	   fat	   and	   cartilage.	   Over	   40	   years	   later,	   the	   same	   four	   tenets	  
(combined	  with	  the	  expression	  of	  certain	  surface	  markers)	  are	  still	  viewed	  as	  the	  benchmark	  
criteria	  to	  define	  putative	  MSCs	  (Dominici	  et	  al.,	  2006).	  This	  widely	  cited,	  but	  often	  criticised	  
position	  paper	  by	  the	  International	  Society	  for	  Cellular	  Therapy	  (ISCT)	  was	  the	  first	  to	  try	  and	  
standardise	  the	  heterogeneous	  populations	  of	  human	  BM	  cells	  used	  in	  past	  studies.	  Under	  
their	  criteria,	  MSCs	  should	  fulfil	  the	  following	  three	  requirements:	  (1)	  plastic	  adherence;	  (2)	  
express	   the	   surface	  markers	   CD105,	   CD73	   and	   CD90	   and	   lack	   expression	   of	   CD45,	   CD34,	  





Figure	   1.2	   |	   ISCT	   minimal	   criteria	   that	  
define	  MSCs.	  Human	  MSCs	  should	  be	  able	  
to	   adhere	   to	   plastic	   and	   expand	   under	  
normal	   culture	   conditions.	   They	   express	  
certain	   phenotypic	   markers	   and	   lack	  
expression	  of	  haematopoietic	  and	   immune	  
cell	   markers.	   Finally,	   they	   are	   able	   to	  
undergo	   tri-­‐lineage	   differentiation	   in	   vitro.	  









The	  main	  argument	  against	  the	  ISCT	  criteria	  revolves	  around	  whether	  MSCs	  could	  indeed	  be	  
called	  “stem	  cells”	  (Bianco	  et	  al.,	  2013,	  Bianco	  et	  al.,	  2008).	  A	  single,	  prospectively	  isolated	  
haematopoietic	   stem	  cell	   (HSC)	  has	   the	   capacity	   to	   serially	   recapitulate	  haematopoiesis	   in	  
lethally	  irradiated	  mice	  (Krause	  et	  al.,	  2001).	  In	  doing	  so,	  HSCs	  meet	  the	  benchmark	  used	  to	  
define	   stem	   cells:	   self-­‐renewal	   and	   multipotency	   in	   vivo.	   By	   contrast,	   MSCs	   have,	   until	  
recently,	  failed	  to	  meet	  these	  strict	  criteria	  since	  the	  biology	  of	  MSCs	  has	  been	  inferred	  from	  
the	  study	  of	  in	  vitro	  cultured	  cells.	  Self-­‐renewal	  is	  assumed	  after	  periods	  of	  in	  vitro	  expansion,	  
and	  multipotency	  demonstrated	  by	  the	  generation	  of	  small	  amounts	  of	  extracellular	  matrix	  
from	   non-­‐clonal	   cultures.	   Fibroblasts	   share	   many	   features	   with	   MSC	   populations	   when	  
assessed	   using	   these	   loose	   criteria,	   leading	   some	   to	   question	   whether	   MSCs	   are	  
phenotypically	  distinct	  from	  fibroblasts	  (Haniffa	  et	  al.,	  2009).	  As	  such,	  there	  has	  been	  a	  shift	  
in	  nomenclature	  towards	  “Multipotent	  mesenchymal	  stromal	  cells	  (MSCs)”	  due	  to	  the	  lack	  of	  
evidence	   of	   self-­‐renewal	   (Bianco	   et	   al.,	   2008).	   This	   evidence	   has	   only	   recently	   begun	   to	  
emerge	  with	   the	   identification	  of	  markers	   that	  allow	  prospective	   isolation	  of	  mouse	  MSCs	  
from	  BM	  (Pinho	  et	  al.,	  2013,	  Mendez-­‐Ferrer	  et	  al.,	  2010,	  Morikawa	  et	  al.,	  2009).	  	  	  
	  
Another	   disadvantage	  of	   the	   ISCT	   criteria	   is	   that	   it	   does	   not	   address	   the	  heterogeneity	   of	  
starting	  MSC	  populations.	  In	  addition	  to	  BM,	  MSC-­‐like	  cells	  have	  been	  isolated	  from	  adipose	  
tissue	  (Zuk	  et	  al.,	  2002),	  dental	  pulp	   (Pierdomenico	  et	  al.,	  2005),	  umbilical	  cord	   (Lee	  et	  al.,	  
2004)	  and	  placental	  tissue	  (Igura	  et	  al.,	  2004).	  When	  isolated	  using	  plastic	  adherence,	  these	  
cultures	  yield	  heterogeneous	  populations	  of	  non-­‐clonal	  cells	  that	  are	  all	  grouped	  together	  as	  
“MSCs”.	   They	   have	   then	   been	   cultured	   on	   different	   surfaces,	   under	   different	   oxygen	  





concentrations	  and	  in	  diverse	  culture	  media	  (Figure	  1.3;	  Wagner	  and	  Ho,	  2007).	  However,	  all	  
these	  cultures	  are	  able	  to	  form	  CFU-­‐Fs,	  express	  the	  relevant	  markers	  and	  undergo	  tri-­‐lineage	  
differentiation,	   thereby	   meeting	   ISCT	   criteria.	   This	   heterogeneity	   has	   made	   it	   difficult	   to	  
compare	   results	   between	   papers,	   and	   several	   different	   mechanisms	   of	   action	   have	   been	  
reported.	   For	   example,	   a	   myriad	   of	   small	   molecules	   have	   been	   reported	   to	   mediate	   the	  
therapeutic	  effects	  of	  MSCs	  in	  animal	  models	  (Caplan	  and	  Correa,	  2011).	  These	  findings	  are	  
rarely	  comparable	  and	  are	  usually	  redundant	  or	  contradictory,	  weakening	  the	  evidence	  base	  




Figure	  1.3|	  Factors	  contributing	  to	  the	  heterogeneity	  of	  MSC	  populations.	  Comparing	  results	  across	  studies	  is	  
difficult	  due	  to	  differences	  between	  MSC	  isolation	  and	  culture	  protocols.	  All	  the	  factors	  listed	  above	  can	  impact	  
on	  the	  efficacy	  of	  the	  resulting	  population	  of	  MSCs	  and	  needs	  to	  be	  taken	  into	  account	  when	  comparing	  studies.	  	  	  
	   	  





1.3	  Isolation	  of	  Murine	  MSCs	  
MSCs	  are	  an	  attractive	  source	  of	  cells	   for	   future	   therapies	  due	  to	   their	  potent	   trophic	  and	  
immunomodulatory	   characteristics.	   However,	   the	   heterogeneous	   populations	   of	   MSC-­‐like	  
cells	   used	   in	   previous	   studies	   have	   hampered	   efforts	   to	   reach	   agreement	   over	   potential	  
mechanisms	  of	  action.	  Additionally,	  the	  majority	  of	  studies	  have	  utilised	  human	  or	  rat	  MSCs	  
due	  to	  difficulties	  in	  isolating	  and	  culturing	  a	  purified	  population	  of	  mouse	  MSCs	  (Frenette	  et	  
al.,	   2013,	   Anjos-­‐Afonso	   and	   Bonnet,	   2011,	   Peister	   et	   al.,	   2004).	   Reasons	   behind	   this	   are	  
unclear,	  but	   the	   relative	   rarity	  of	   stromal	  cells	  and	   the	  high	  percentage	  of	  haematopoietic	  
cells	  found	  in	  mouse	  BM	  could	  play	  a	  part.	  It	  has	  also	  been	  argued	  that	  murine	  MSCs	  need	  
some	   haematopoietic	   contaminants	   in	   culture	   to	   grow,	   and	   the	   stepwise	   purification	   of	  
stromal	   cells	   described	   in	   newer	   isolation	   protocols	   could	   negatively	   impact	   MSC	   yields	  
(Anjos-­‐Afonso	   and	   Bonnet,	   2011).	   As	   such,	   our	   current	   understanding	   of	   MSC	   biology	   is	  
inferred	   from	   the	   study	  of	   in	   vitro	   cultured	  human	  cells.	   These	   issues	  have,	  until	   recently,	  
prevented	  the	  field	  from	  studying	  the	  basic	  biology	  and	   in	  vivo	  functions	  of	  MSCs	  using	  the	  
large	  number	  of	  transgenic	  mouse	  models	  available.	  	  
	  
To	  overcome	  these	  limitations,	  researchers	  have	  developed	  new	  methods	  of	  MSC	  isolation	  
that	  depends	  less	  on	  the	  plastic-­‐adherence	  property	  of	  these	  cells.	  As	  this	  thesis	  investigates	  
the	  effect	  of	  growth	  factors	  on	  a	  prospectively	  isolated	  population	  of	  mouse	  MSCs,	  I	  will	  be	  
focusing	  here	  on	  the	  progress	  made	  in	  isolating	  mouse	  MSCs	  over	  their	  human	  counterparts	  
(summarised	  in	  Table	  1.1).	  	  	  	  
	   	  





Table	  1.1	  |	  Advantages	  and	  disadvantages	  of	  murine	  MSC	  isolation	  methods.	  	  
Isolation	  
Method	  
Advantages	   Disadvantages	  
Plastic	  
adherence	  
þ Transferrable	  between	  mouse	  
strains	  
þ Low	  cost,	  easy	  to	  follow	  protocol	  
ý Heterogeneous	  populations	  of	  
stromal	  cells	  isolated	  
ý Persistence	  of	  haematopoietic	  
and	  endothelial	  cells	  in	  culture	  
ý Requires	  long-­‐term	  in	  vitro	  





þ Removal	  of	  haematopoietic	  cells	  
allowing	  expansion	  of	  a	  purer	  
MSC	  culture	  
þ Transferrable	  between	  mouse	  
strains	  
þ Low	  cost	  
ý Haematopoietic	  cells	  still	  persist	  
in	  culture	  
ý Relies	  on	  plastic-­‐adherence	  and	  
extended	  in	  vitro	  culture	  for	  
purification	  of	  stromal	  cells	  
ý Labour	  intensive,	  cultures	  require	  
attention	  every	  8	  hours	  
Immuno-­‐
depletion	  
þ Removes	  haematopoietic	  
contamination	  from	  MSC	  cultures	  
þ Transferrable	  between	  mouse	  
strains	  
ý Significantly	  increased	  population	  
doubling	  times	  
ý Relies	  on	  plastic-­‐adherence	  and	  
extended	  in	  vitro	  culture	  for	  
further	  purification	  
ý Cost	  of	  magnetic	  beads	  and	  
sorting	  equipment	  is	  high	  
Positive	  
selection	  
þ Enriches	  for	  cells	  with	  MSC	  
potential	  from	  BM	  
þ No	  effect	  on	  population	  doubling	  
times	  
ý Not	  suitable	  for	  all	  mouse	  strains	  
ý Some	  markers	  are	  not	  detectable	  
in	  uncultured	  BM	  cells	  




þ Pure	  populations	  of	  MSCs	  
without	  the	  need	  for	  extended	  in	  
vitro	  culture	  
þ Allows	  for	  the	  study	  of	  MSC	  
biology	  in	  vivo	  
þ Self-­‐renewal	  and	  multipotency	  
clearly	  demonstrated	  at	  the	  
single-­‐cell	  level	  
ý Some	  methods	  require	  use	  of	  
specialist	  transgenic	  mice	  
ý Requires	  access	  to	  a	  cell	  sorter	  
ý Labour-­‐intensive	  and	  expensive	  
	   	  





	   1.3.1	  Plastic	  Adherence	  
Initial	   attempts	   to	   isolate	   mouse	   MSCs	   mimicked	   those	   of	   their	   human	   counterparts	   by	  
plating	  whole	  BM	  onto	  tissue	  culture	  plastic	  and	  expanding	  the	  plastic-­‐adherent	  population.	  	  
Differences	   in	  CFU-­‐F	  ability	   and	  growth	  kinetics	  between	  mouse	   strains	  were	   immediately	  
clear,	   with	   Balb/c	   BM	   yielding	   the	  most	   CFU-­‐F	   (3	   per	   106	   cells)	   and	   C57BL/6	   BM	   yielding	  
nearly	   10	   fold	   lower	   numbers	   (Phinney	   et	   al.,	   1999).	   The	   plastic-­‐adherent	   population	  was	  
very	  heterogeneous,	  with	  80%	  of	  cells	  expressing	  CD11b	  (marker	  of	  myeloid	  cells)	  and	  CD45	  
(leukocyte	  marker).	  These	  contaminating	  cells	  were	  able	  to	  survive	  for	  several	  weeks	  as	  the	  
stromal	   fraction	   of	   mouse	   BM	   has	   been	   shown	   to	   support	   B-­‐cell	   lymphopoiesis	   and	  
granulopoiesis	  (Phinney,	  2008).	  	  
	  
Meirelles	  and	  Nadri	  demonstrated	  the	  importance	  of	  initial	  plating	  density	  on	  CFU-­‐F	  ability	  
(Meirelles	   Lda	   and	   Nardi,	   2003).	   A	   density	   of	   5x104	   BM	   cells/cm2	   showed	   the	   maximum	  
number	   of	   non-­‐overlapping	   colonies.	   They	   did	   detect	   the	   expression	   of	   CD11b	   in	   MSC	  
cultures	  at	  passage	   (P)	   six,	  but	   this	  was	   lost	  by	  P10.	  Cells	   remaining	  at	  P10	  onwards	  were	  
homogenous	   in	  size	  and	  shape	  and	  were	  negative	  for	  the	   leukocytic	  markers	  CD45,	  CD11b	  
and	  CD19.	   Interestingly,	  no	  differences	   in	  CFU-­‐F	  ability	  were	  observed	  between	  Balb/c	  and	  
C57BL/6	  mice	  in	  this	  study,	  which	  contradicts	  the	  earlier	  report	  by	  Phinney	  et	  al.	  (1999).	  
	  
	   	  





Peister	   and	   colleagues	   published	   a	   similar	   protocol	   emphasising	   the	   importance	   of	   initial	  
plating	   density	   on	  MSC	   isolation	   (Peister	   et	   al.,	   2004).	   Unlike	  Meirelles	   and	   Nadri	   (2003),	  
they	  initially	  used	  high-­‐density	  seeding	  of	  BM	  cells	  before	  swapping	  to	  a	  lower	  50	  cells/cm2	  
from	   P2	   onwards.	   Differences	   in	   growth	   kinetics,	   cell	   surface	   phenotype	   and	   tri-­‐lineage	  
differentiation	  were	  observed	  between	  the	  five	  mouse	  strains	  analysed.	  C57BL/6	  and	  Balb/c	  
strains	   showed	   the	   best	   growth	   characteristics,	   but	   failed	   to	   produce	   significant	  
proteoglycan	  deposits	  after	  chondrogenic	  differentiation.	  By	  contrast,	  MSCs	  from	  FVB/N	  and	  
DBA1	  mice	  divided	  slower	  but	  produced	  better	  cartilage.	  	  
	  
	   1.3.2	  Frequent	  Media	  Change	  
Protocols	   involving	   frequent	   media	   change	   were	   employed	   to	   combat	   the	   adherence	   of	  
haematopoietic	   cells	   in	   MSC	   cultures.	   Nadri	   and	   colleagues	   combined	   frequent	   media	  
change	  with	  shortened	  trypsin	  incubation	  time	  to	  increase	  the	  percentage	  of	  MSCs	  in	  mouse	  
BM	   preparations	   (Soleimani	   and	   Nadri,	   2009,	   Nadri	   et	   al.,	   2007).	   Non-­‐adherent	   BM	   cells	  
were	   removed	   3	   hours	   after	   plating	   and	   replaced	   with	   fresh	   media,	   and	   this	   step	   was	  
repeated	  every	  8	  hours	  for	  three	  days.	  Two	  minute	  trypsin	  incubation	  times	  was	  also	  used	  to	  
selectively	   lift	   MSCs	   from	   tissue	   culture	   plastic	   while	   leaving	   behind	   firmly-­‐adherent	  
macrophages.	  However,	  between	  5-­‐10%	  cells	  that	  were	  re-­‐plated	  still	  expressed	  CD11b	  and	  
CD45,	  showing	  that	  some	  haematopoietic	  cells	  were	  still	  able	  to	  persist	  in	  culture.	  	  
	   	  





	   1.3.3	  Immunodepletion	  of	  non-­‐MSCs	  
Baddoo	  and	  colleagues	  combined	  plastic	  adherence	  with	   immunodepletion	  to	   improve	  the	  
purity	  of	  murine	  MSC	  cultures	   (Baddoo	  et	  al.,	   2003).	   Eight	   to	   ten	  day	  old	  plastic-­‐adherent	  
cells	  were	  subject	  to	  three	  rounds	  of	  immunodepletion	  with	  antibodies	  against	  CD11b,	  CD34,	  
and	  CD45.	  The	  immunodepleted	  fraction	  (23%	  of	  plastic	  adherent	  cells	  in	  FVB/N	  mice,	  7%	  in	  
Balb/c	  mice)	  readily	  differentiated	  into	  bone,	  fat	  and	  cartilage	  and	  expressed	  typical	  markers	  
of	  murine	  MSCs.	  However,	  immunodepleted	  cells	  displayed	  a	  prolonged	  doubling	  time	  of	  5-­‐7	  
days	   due	   to	   the	   downregulation	   of	   genes	   regulating	   cell	   cycle	   progression.	   Addition	   of	  
fibroblast	   growth	   factor	   2	   (FGF2)	   increased	   the	   growth	   kinetics	   of	   immunodepleted	  MSC	  
populations	  but	  inhibited	  their	  tri-­‐lineage	  differentiation.	  	  
	  
Tropel	  et	  al.	  used	  a	  single	  round	  of	  immunodepletion	  against	  CD11b	  to	  remove	  myeloid	  cells	  
from	  mouse	  MSC	  cultures	  (Tropel	  et	  al.,	  2004).	  Despite	  this,	  CD11b+	  cells	  remained	  in	  culture	  
for	  many	  weeks	   (until	   P10),	  which	   could	   be	   due	   to	   the	   single	   round	   of	   immunodepletion	  
used	   in	   their	   study.	   Interestingly,	   Tropel	   et	   al.	   report	   a	   mean	   doubling	   time	   of	   1.7	   days,	  
which	   compares	   favourably	   with	   the	   longer	   5-­‐7	   days	   reported	   by	   Baddoo	   et	   al.	   (2003).	  
Immunodepleted	   MSCs	   were	   able	   to	   undergo	   tri-­‐lineage	   differentiation	   and	   prolonged	  
growth	  in	  vitro	  for	  up	  to	  30	  passages	  with	  no	  evidence	  of	  karyotypic	  transformation.	  	  	  
	   	  





	  	   1.3.4	  Positive	  Enrichment	  of	  MSCs	  
A	  key	  disadvantage	  of	  the	  isolation	  methods	  listed	  above	  is	  the	  reliance	  on	  extended	  periods	  
of	   in	   vitro	   culture	   for	  MSC-­‐like	   cells	   to	   “outlive”	   any	   contaminating	   haematopoietic	   cells.	  
Extended	  culture	  has	  been	  shown	  to	  induce	  replicative	  senescence	  in	  both	  mouse	  (Coutu	  et	  
al.,	   2011)	   and	   human	   MSCs	   (Wagner	   et	   al.,	   2008).	   It	   can	   also	   predispose	   cells	   towards	  
malignant	  transformation,	  a	  phenomenon	  that	  preferentially	  affects	  murine	  cells	  (Tolar	  et	  al.,	  
2007,	  Miura	  et	  al.,	  2006).	  To	  overcome	  these	  limitations,	  researchers	  began	  to	  use	  markers	  
that	  enriched	  for	  cells	  with	  CFU-­‐F	  and	  tri-­‐lineage	  potential	  from	  BM.	  	  
	  
The	   cell	   surface	   glycoprotein	   CD34	   has	   been	   used	   to	   enrich	   for	   MSCs	   in	   BM	   cultures.	  
Although	  CD34	   is	  primarily	   regarded	  as	  a	  marker	  of	  haematopoietic	   stem/progenitor	  cells,	  
recent	   evidence	   suggests	   it	   may	  mark	   a	   whole	   host	   of	   stem/progenitors,	   including	  MSCs	  
(Sidney	  et	  al.,	  2014,	  Lin	  et	  al.,	  2012).	  Nadri	  and	  Soleimani	  isolated	  CD34+	  cells	  from	  the	  BM	  of	  
C57BL/6	   mice	   using	   magnetic	   selection	   (Nadri	   and	   Soleimani,	   2007).	   No	   expression	   of	  
haematopoietic	  markers	  were	  observed	  in	  freshly-­‐sorted	  and	  cultured	  cells,	  and	  they	  were	  
able	   to	   undergo	   in	   vitro	   differentiation	   towards	   bone	   and	   fat.	   However,	   an	   increase	   in	  
population	   doubling	   time	  was	   seen	   at	   each	   passage	   and	   attempts	   to	   repeat	   this	   isolation	  
method	  on	  other	  strains	  of	  mice	  were	  unsuccessful.	  	  
	  
	  





Stem	  cell	  antigen	  1	  (Sca-­‐1,	  or	  Ly-­‐6A)	  can	  also	  be	  used	  to	  enrich	  MSCs	  from	  mouse	  BM	  (Boxall	  
and	  Jones,	  2012).	  Short	  et	  al.	  describe	  a	  protocol	  that	  uses	  fluorescence	  activated	  cell	  sorting	  
(FACS)	   to	   isolate	   a	   pure	   population	   of	   CD45-­‐CD31-­‐Sca-­‐1+	   MSCs	   with	   increased	   CFU-­‐F	  
potential	   from	   C57BL/6	   mice	   (Short	   et	   al.,	   2009).	   Sca-­‐1+	   MSCs	   also	   have	   increased	  
neurogenic	  potential	  compared	  to	  plastic-­‐adherent	  BM	  cells	  (Jamous	  et	  al.,	  2010).	  However,	  
Sca-­‐1	   expression	   varies	   between	  mouse	   strains	   due	   to	   post-­‐translational	   regulation,	   with	  
mice	  expressing	  the	  Ly6.2	  allele	  (e.g.	  C57BL/6,	  FVB/N)	  having	  higher	  expression	  of	  Sca-­‐1	  than	  
mice	  expressing	  the	  Ly6.1	  allele	  (e.g.	  Balb/c;	  Holmes	  and	  Stanford,	  2007).	  This	  limits	  its	  use	  
as	  a	  marker	  that	  can	  enrich	  MSCs	  across	  all	  mouse	  strains.	  	  
	  
Other	  markers,	   such	   as	   CD105,	   CD73,	   CD90,	   CD44	   and	   CD29	   are	   also	   highly	   expressed	   by	  
mouse	  MSCs	  (Boxall	  and	  Jones,	  2012).	  However,	  most	  of	   these	  markers	  are	  not	  specific	   to	  
stromal	   cells	   and	   are	   not	   detectable	   in	   fresh,	   uncultured	   BM	   (Anjos-­‐Afonso	   and	   Bonnet,	  
2011).	  As	  mentioned	  above,	   there	  are	  also	   strain-­‐specific	  differences	   in	  expression.	  Unlike	  
human	  MSCs,	  which	   can	  be	  purified	   to	  a	   reasonable	  degree	  using	  CD146	   (Sacchetti	   et	   al.,	  
2007)	  or	  LNGFR	  (Mabuchi	  et	  al.,	  2013b),	  no	  one	  cell	  surface	  protein	  alone	  can	  be	  used	  for	  
the	  prospective	  isolation	  of	  mouse	  MSCs.	  	  	  	  	  
	   	  





	   1.3.5	  Prospective	  isolation	  of	  MSCs	  
	   	   1.3.5.1	  PDGFRα+Sca-­‐1+	  MSCs	  
Morikawa	  and	  colleagues	  were	   the	   first	   to	  publish	  a	  method	   to	  prospectively	   identify	  and	  
isolate	   murine	   MSCs	   (Morikawa	   et	   al.,	   2009).	   The	   authors	   used	   FACS	   to	   isolate	   non-­‐
haematopoietic	   (CD45-­‐TER119-­‐)	   BM	   cells	   that	   co-­‐expressed	  platelet	   derived	   growth	   factor	  
receptor	   alpha	   (PDGFRα)	   and	   Sca-­‐1.	   They	   were	   able	   to	   isolate	   this	   double-­‐positive	   (PαS)	  
population	  from	  six	  inbred	  strains	  of	  mice,	  including	  C57BL/6,	  Balb/c,	  FVB/N	  and	  DBA1.	  PαS	  
MSCs	   were	   able	   to	   undergo	   tri-­‐lineage	   differentiation	   at	   the	   clonal	   level	   and	   showed	  
120,000-­‐fold	  higher	  CFU-­‐F	  frequency	  than	  unfractioned	  BM	  mononuclear	  cells.	  The	  reported	  
population	  doubling	  time	  was	  50.6	  hours,	  with	  cultures	  yielding	  over	  107	  cells	  from	  a	  starting	  
population	  of	  5000	  cells.	  PαS	  MSCs	  expressed	  standard	  MSC	  markers	  (CD29,	  CD49e,	  CD105,	  
CD133,	  CD34,	  CD90	  and	  CD146)	  and	  did	  not	  express	  haematopoietic	  markers	  (CD45,	  CD150	  
or	  CD117).	   Interestingly,	  undifferentiated	  PαS	  MSCs	  also	  expressed	  markers	  of	  endothelial	  
cells	  (Flk-­‐1	  and	  VEGFR3),	  with	  some	  clones	  being	  able	  to	  undergo	  angiogenic	  differentiation	  
into	  CD31+CD144+	  endothelial	  cells.	  	  	  	  	  	  
	  
In	  vivo	  studies	  revealed	  that	  PαS	  MSCs	  resided	  in	  the	  perivascular	  space	  of	  cortical	  bone	   in	  
vivo	   and	   expressed	   both	   angiopoietin-­‐1	   (Ang-­‐1)	   and	   CXCL12,	   two	   necessary	   factors	   for	  
haematopoiesis	  (Figure	  1.4).	  Systemic	  co-­‐transplantation	  of	  10,000	  green	  fluorescent	  protein	  
positive	  (GFP+)	  PαS	  cells	  alongside	  100	  CD34-­‐KSL	  HSCs	  restored	  haematopoiesis	  in	  irradiated	  
mice.	   Significant	   numbers	   of	   GFP+	   PαS	   cells	   were	   again	   found	   in	   the	   perivascular	   region	  
expressing	   CXCL12	   and	   Ang-­‐1,	   while	   others	   were	   found	   to	   give	   rise	   to	   functioning	  





osteoblasts	  and	  adipocytes,	  demonstrating	  that	  PαS	  cells	  can	  reconstitute	  their	  in	  vivo	  niche.	  
Furthermore,	  the	  authors	  were	  able	  to	  isolate	  secondary	  clonal	  GFP+	  CFU-­‐Fs	  from	  recipient	  
mice	  16	  weeks	  after	  transplantation	  and	  show	  they	  retained	  their	  tri-­‐lineage	  differentiation	  
potential.	   Thus,	   this	   paper	  was	   the	   first	   to	   convincingly	   show	   the	   in	   vivo	   self-­‐renewal	   and	  
multipotency	  of	  a	  specific	  cell	  type	  that	  displays	  many	  of	  the	  hypothesised	  functions	  of	  MSCs,	  







Figure	   1.4	   |	   In	   vivo	   localisation	   of	   PαS	  
MSCs	  in	  murine	  BM.	  PαS	  MSCs	  were	  found	  
in	  the	  perivascular	  space	  alongside	  vascular	  
smooth	  muscle	  cells	  (vSMC).	  They	  can	  give	  
rise	   to	   both	   osteoblasts	   and	   reticular	   cells	  
that	  function	  as	  haematopoietic	  niche	  cells.	  
Figure	   taken	   from	   Morikawa	   et	   al.,	   2009.	  	  	  
	  
	   	  





	   	   1.3.5.2	  Nestin+	  MSCs	  
A	   comprehensive	   and	   elegant	   study	   by	   the	   Frenette	   group	   identified	   the	   intermediate	  
filament	   protein	   Nestin	   as	   another	   marker	   for	   the	   prospective	   isolation	   of	   murine	   MSCs	  
(Mendez-­‐Ferrer	  et	  al.,	  2010).	  Nestin+	  MSCs	  represented	  0.08%	  of	  total	  BM	  mononuclear	  cells,	  
and	   60%	   of	   Nestin+	  MSCs	   were	   located	   directly	   adjacent	   to	   HSCs.	   Expression	   of	   key	   HSC	  
maintenance	   proteins	   were	   highest	   in	   the	   Nestin+	   population,	   and	   selective	   deletion	   of	  
Nestin+	  cells	   resulted	   in	  a	  50%	  reduction	   in	  BM	  HSC	  numbers.	  Deletion	  of	  Nestin+	  cells	  also	  
decreased	  the	  homing	  of	   infused	  HSCs	  towards	  the	  BM	  of	   lethally	   irradiated	  mice	  by	  up	  to	  




Figure	  1.5	  |	  In	  vivo	  self-­‐renewal	  of	  Nestin+	  MSCs.	  Single	  clonal	  mesenspheres	  attached	  onto	  phosphate	  cubes	  
were	   transplanted	   subcutaneously	   into	   recipient	   mice	   and	   left	   for	   two	   months.	   From	   these,	   310	   Nestin+	  
mesenspheres	   were	   isolated,	   of	   which	   38%	   showed	   multi-­‐lineage	   differentiation.	   Single	   secondary	   spheres	  
were	   transplanted	   into	   recipient	  mice	  and	   left	   for	  8	  months.	  A	   total	  of	  8,557	  Nestin+	   tertiary	  mesenspheres	  
could	  be	  isolated,	  demonstrating	  the	  remarkable	  self-­‐renewal	  properties	  of	  these	  cells	  in	  serial	  transplantations.	  
Figure	  taken	  from	  Mendez-­‐Ferrer	  et	  al.,	  2010.	  
	  
As	  Nestin	   is	   an	   intracellular	   protein,	   a	   transgenic	   Nestin-­‐GFP	  mouse	   is	   required	   to	   isolate	  
Nestin+	  MSCs	  using	  FACS.	  Nestin+	  cells	   can	  undergo	   tri-­‐lineage	  differentiation	  and	  could	  be	  
propagated	  as	  clonal	  3D	  “mesenspheres”	   in	  vitro.	  The	  authors	  convincingly	  demonstrate	   in	  
vivo	  self-­‐renewal	  at	  the	  single	  cell	  level	  using	  a	  heterotrophic	  bone	  ossicle	  assay	  (Figure	  1.5).	  





In	  vivo	  evidence	  of	  multi-­‐lineage	  differentiation	  was	  demonstrated	  by	  lineage-­‐tracing	  studies	  
showing	   GFP+	   Nestin	   cells	   contributing	   to	   both	   the	   osteogenic	   and	   chondrogenic	   lineages	  
under	   physiological	   conditions.	   This	   was	   the	   first	   study	   to	   demonstrate	   the	   in	   vivo	  
contribution	   of	   MSCs	   in	   the	   maintenance	   and	   turnover	   of	   skeletal	   cells	   without	   injury,	  
thereby	  confirming	  a	  long-­‐hypothesised	  function	  of	  MSCs.	  	  	  
	  
	   	   1.3.5.3	  PDGFRα+CD51+	  MSCs	  
The	   intracellular	   expression	   of	   Nestin	   precludes	   the	   use	   of	   this	   marker	   to	   prospectively	  
isolate	  MSCs	  from	  non-­‐transgenic,	  wild-­‐type	  mice.	  To	  address	  this	  issue,	  the	  Frenette	  group	  
set	  out	  to	  identify	  cell	  surface	  markers	  that	  define	  the	  BM	  Nestin+	  population	  (Pinho	  et	  al.,	  
2013).	   In	   another	   exhaustive	   study,	   they	   show	   that	   non-­‐haematopoietic	   (CD45-­‐TER-­‐119-­‐),	  
non-­‐endothelial	   (CD31-­‐)	   BM	   cells	   that	   express	   PDGFRα	   and	   CD51	   (alpha	   V	   integrin)	   also	  
express	  Nestin	  at	  high	  (≈75%)	  levels.	  This	  dual-­‐positive	  population	  of	  stromal	  cells	  were	  able	  
to	   recapitulate	   all	   the	  MSC	   activity	   reported	   in	   their	   earlier	   Nestin+	  MSC	   paper	   (Mendez-­‐
Ferrer	   et	   al.,	   2010).	   PDGFRα+CD51+	  MSCs	  were	   enriched	   for	   HSC-­‐maintenance	   factors	   and	  
expressed	  them	  at	  similar	  levels	  to	  Nestin+	  MSCs.	  PDGFRα+CD51+	  MSCs	  were	  also	  able	  to	  be	  
propagated	  in	  vitro	  as	  self-­‐renewing	  mesenspheres	  and	  clonally-­‐expanded	  cells	  were	  able	  to	  
undergo	   tri-­‐lineage	  differentiation.	   The	   in	   vivo	   self-­‐renewal	   and	  differentiation	   capacity	   of	  
PDGFRα+CD51+	  MSCs	  was	  proven	  by	  serial	  transplantation	  studies	  of	  bone	  ossicle	  formation.	  
The	   authors	   then	   go	   on	   to	   isolate	   PDGFRα+CD51+	  cells	   from	  human	   foetal	   BM,	   suggesting	  
that	  the	  identity	  of	  MSCs	  in	  both	  species	  may	  be	  conserved	  through	  evolution.	  	  
	   	  





	   	   1.3.5.4	  Comparison	  of	  PαS,	  Nestin+	  and	  PDGFRα+CD51+	  MSCs	  
These	  three	  studies	  were	  the	  first	  to	  comprehensively	  describe	  markers	  of	  murine	  MSCs.	  The	  
authors	  tested	  the	  stemness	  of	  their	  populations	  using	  traditional	  stem	  cell	  assays	  to	  prove	  
self-­‐renewal	   and	   multipotency	   in	   vivo	   (Figure	   1.6).	   Additionally,	   these	   papers	   have	   also	  
described	  the	  essential	  role	  of	  MSCs	  in	  maintaining	  the	  HSC	  niche.	  As	  such,	  they	  represent	  
major	  advances	  in	  the	  murine	  MSC	  field	  and	  should	  act	  as	  a	  platform	  for	  future	  research	  into	  
the	  biology	  of	  these	  cells.	  
	  
	  
Figure	   1.6	   |	   Methods	   used	   to	   test	   for	   stem	   cell	   characteristics	   in	   MSC	   populations.	   All	   three	   marker	  
combinations	  have	  demonstrated	  clonal	  tri-­‐lineage	  differentiation	  in	  vitro	  and	  (to	  a	  degree)	  in	  vivo.	  CFU-­‐F	  from	  
PαS	  MSCs	  were	  shown	  to	  self-­‐renew	  and	  re-­‐populate	   the	  haematopoietic	  niche	  after	   intravenous	   infusion	   in	  
irradiated	   mice.	   Mesenspheres	   from	   Nestin+	   and	   PDGFRα+CD51+	   MSCs	   were	   shown	   to	   self-­‐renew	   in	   bone	  
ossicle	  formation	  assays	  after	  serial	  transplantation.	  Figure	  modified	  from	  Frenette	  et	  al.,	  2013.	  	  





However,	   there	   are	   subtle	   differences	   between	   how	   the	   three	   MSC	   populations	   were	  
isolated	  and	  tested	  that	  suggest	  that	  they	  mark	  independent,	  non-­‐overlapping	  cells	  with	  an	  
MSC	  phenotype	   (Table	  1.2).	  Firstly,	  PαS	  MSCs	  are	   isolated	   from	  cortical	  bone	  with	  the	  BM	  
discarded	  at	  the	  start	  of	  the	  protocol	  (Houlihan	  et	  al.,	  2012).	  The	  Nestin+	  and	  PDGFRα+CD51+	  
MSCs	  are	   isolated	   from	  collagenase-­‐digested	  BM	  (Pinho	  et	  al.,	  2013,	  Mendez-­‐Ferrer	  et	  al.,	  
2010).	  As	  such,	  PαS	  enriches	  for	  cells	  with	  MSC	  potential	  from	  bone	  and	  not	  BM.	  Secondly,	  
PαS	  MSC	   clones	   show	  differences	   in	   their	   differentiation	   ability,	  with	   some	   clones	   able	   to	  
undergo	  angiogenic/endothelial	  differentiation.	  No	  vascular	  involvement	  has	  been	  reported	  
for	   Nestin+	   and	   PDGFRα+CD51+	  MSCs,	   and	   current	   evidence	   demonstrates	   contribution	   to	  
the	  skeletal	  lineage	  only.	  Thirdly,	  while	  the	  Nestin+	  and	  PDGFRα+CD51+	  MSCs	  have	  had	  their	  
self-­‐renewal	  proved	  using	  serial	  transplantation	  assays,	  the	  PαS	  MSCs	  have	  only	  been	  shown	  
to	  reconstitute	  their	  BM	  niche	  in	  one	  round	  of	  transplantation.	  	  
	  
The	   direct	   relationship	   between	   PαS	  MSCs	   and	   Nestin+	  MSCs	   was	   studied	   by	   Pinho	   et	   al.	  
(2013).	   They	   show	   that	   only	   6%	   of	   BM	   Nestin+	  MSCs	   express	   Sca-­‐1.	   When	   they	   isolated	  
Nestin+	  MSCs	  from	  compact	  bone,	  the	  percentage	  of	  Sca-­‐1	  expression	  increased	  to	  23%.	  This	  
suggests	   that	   both	   sets	   of	   markers	   identify	   distinct	   cell	   populations	   with	   MSC	   activity,	  
although	   there	   is	   a	   degree	   of	   phenotypic	   overlap	   between	   the	   two.	   The	   functional	  
differences	  and	  contribution	  to	  the	  HSC	  niche	  between	  bone-­‐derived	  MSCs	   (PαS	  cells)	  and	  
BM-­‐derived	  MSCs	  (Nestin+	  and	  PDGFRα+CD51+	  cells)	  still	  remain	  unexamined.	  	  
	  
	  







































































(nd)	   (nd)	   ü	   Pinho	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  (2013)	  
	  
Abbreviations:	  	  	   (nd),	  not	  determined	  
	   	  





1.4	  Therapeutic	  Potential	  of	  MSCs	  in	  Regenerative	  Medicine	  
MSCs	  have	  a	  number	  of	  features	  that	  make	  them	  particularly	  suitable	  as	  a	  cellular	  therapy.	  
Firstly,	   they	   can	   be	   isolated	   from	   a	   variety	   of	   adult	   tissues.	   Secondly,	   their	  
immunosuppressive	  and	   immune	  privileged	  properties	  allow	   for	  allogeneic	   transplantation	  
across	   major	   histocompatibility	   (MHC)	   antigens	   (Ankrum	   et	   al.,	   2014).	   Thirdly,	   their	  
differentiation	   potential	   and	   plasticity	   can	   be	   exploited	   in	   a	   variety	   of	   clinical	   settings.	  
Fourthly,	  MSCs	  can	  secrete	  a	  variety	  of	  bioactive	  molecules	  and	  trophic	  factors	  that	  promote	  
healing	   and	   dampen	   inflammation	   (Ranganath	   et	   al.,	   2012).	   Finally,	   MSCs	   can	   also	   be	  
cryopreserved	   and	   recovered	   as	   needed	   to	   form	   a	   bankable,	   “off-­‐the-­‐shelf”	   cell	   therapy	  
product	   (Ginis	   et	   al.,	   2012).	   In	   this	   section,	   I	   will	   review	   the	   evidence	   for	   MSCs	   in	  
regenerative	  medicine	   therapies,	   starting	  with	   traditional	  uses	  of	  MSCs	   to	   replace	   skeletal	  
tissue	  before	  focusing	  on	  their	  non-­‐mesenchymal	  potential.	  	  
	  
	   1.4.1	  MSCs	  in	  Bone	  Repair	  
There	   are	   numerous	   studies	   that	   have	  used	  MSCs	   to	   repair	   fractures	   due	   to	   osteogenesis	  
being	  the	  best	  characterised	  and	  well	  understood	  pathways	  of	  MSC	  differentiation.	  An	  early	  
study	   by	   Bruder	   et	   al.	   demonstrated	   that	   autologous	   MSCs	   seeded	   onto	   scaffolds	   could	  
repair	   a	   critical-­‐sized	   fracture	   in	   dogs	   (Bruder	   et	   al.,	   1998).	   By	   comparison,	   non-­‐union	  
fractures	  remained	   in	  animals	   treated	  with	  scaffolds	  alone.	  A	   follow	  up	  study	  by	  the	  same	  
group	   established	   similar	   results	   using	   allogeneic	   MSCs	   transplanted	   without	   the	   use	   of	  
immunosuppressive	  agents	  (Arinzeh	  et	  al.,	  2003).	  	  





The	   clinical	   translation	  of	   promising	  pre-­‐clinical	   data	  was	   swift,	  with	   the	   first	   report	  being	  
published	   in	  2001	   (Quarto	  et	  al.,	  2001).	  This	  study	  enrolled	  three	  patients	  with	   large	  bone	  
defects	  that	  were	  treated	  with	  autologous	  MSCs	  seeded	  onto	  hydroxyapatite	  scaffolds	  and	  
implanted	  at	  the	  lesion	  site.	  Over	  the	  12-­‐month	  follow	  up	  period,	  all	  patients	  regained	  limb	  
function	  and	   there	  was	   radiographic	  evidence	  of	  new	  bone	   formation,	   vascular	   infiltration	  
and	  integration	  with	  surrounding	  bone.	  A	  follow	  up	  study	  reported	  that	  all	  patients	  suffered	  
no	   complications,	   pain,	   inflammation,	   or	   swelling	   at	   the	   implant	   site	   seven	   years	   after	  
surgery	   (Marcacci	   et	   al.,	   2007).	  A	   larger,	   non-­‐controlled	   study	  by	  Hernigou	  and	   colleagues	  
reported	   successful	   fracture	   union	   in	   43/60	   patients	   treated	   with	   autologous	   MSC	   grafts	  
(Hernigou	  et	  al.,	  2005).	  The	  authors	  also	  demonstrated	  a	  positive	  correlation	  between	  the	  
number	  of	  CFU-­‐F	  found	  in	  the	  grafts	  and	  the	  volume	  of	  mineralised	  matrix	  produced.	  In	  7/17	  
patients	  who	  failed	  to	  reach	  fracture	  union,	  the	  number	  of	  CFU-­‐F	   in	  their	  MSC	  grafts	  were	  
significantly	  lower	  than	  that	  seen	  in	  successful	  patients.	  	  
	  
MSCs	  have	   also	  been	  used	   in	   small-­‐scale	   studies	  of	   patients	  with	  osteogenesis	   imperfecta	  
(OI),	  a	  genetic	  condition	  resulting	  in	  impaired	  type	  I	  collagen	  synthesis	  by	  osteoblasts	  leaving	  
patients	  susceptible	  to	  fractures.	  Horwitz	  et	  al.	  transplanted	  human	  leukocyte	  antigen	  (HLA)-­‐
matched	   BM	   into	   three	   children	  with	   severe	  OI	   (Horwitz	   et	   al.,	   1999).	   They	   hypothesised	  
that	  “healthy”	  BM	  containing	  functional	  MSCs	  could	  incorporate	  into	  the	  host	  and	  function	  
to	  increase	  bone	  mass.	  All	  three	  transplants	  engrafted	  well,	  and	  a	  77%	  increase	  in	  total	  body	  
bone	   mineral	   content	   (TBBMC)	   was	   seen	   in	   one	   patient	   100	   days	   post-­‐transplant	   (range	  
45%-­‐77%).	   However,	   the	   study	   design	   did	   not	   include	   a	   control	   group	   and	   the	   follow	   up	  





period	  was	  short.	  A	  later	  study	  by	  the	  same	  group	  addressed	  these	  limitations	  and	  looked	  at	  
clinical	  responses	  in	  3	  patients	  receiving	  bone	  marrow	  transplants	  compared	  to	  age-­‐matched	  
controls	   (Horwitz	   et	   al.,	   2001).	   Short-­‐term	   increases	   in	   height	   were	   observed,	   but	   this	  
plateaued	  at	  6	  months	  post-­‐transplant.	  A	  steady	  improvement	  in	  TBBMC	  was	  also	  observed,	  
reaching	   the	   lower	  end	  of	   the	  normal	   range	   seen	   in	  healthy	   children.	   These	   findings	  have	  
encouraged	  Horwitz	  and	  colleagues	  to	  start	  a	  phase	  I	  trial	  to	  evaluate	  the	  safety	  of	  repeated	  
autologous	  MSC	  infusions	  in	  children	  with	  OI	  (ClinicalTrials.gov	  ID	  Number:	  NCT01061099).	  	  
	  
1.4.2	  MSCs	  in	  Cartilage	  Repair	  
Cartilage	  damage	  due	  to	  trauma	  or	  ageing	  affects	  an	  increasing	  number	  of	  people	  and	  places	  
a	   large	   burden	   on	   the	  NHS.	   Current	   interventions	   range	   from	  drug	   therapy	   to	   autologous	  
chondrocyte	  implantation	  (ACI)	  and	  total	  joint	  replacement	  (Jones	  and	  Peterson,	  2006).	  ACI	  
is	  a	  procedure	  where	  chondrocytes	  are	  biopsied	  from	  the	  patient	  at	  a	  non-­‐load	  bearing	  site	  
and	   cultured	   in	   vitro	   to	   expand	   cell	   numbers.	   Culture-­‐expanded	   cells	   are	   then	   re-­‐seeded	  
onto	  the	  primary	  damage	  area	  in	  a	  second	  procedure	  (Brittberg	  et	  al.,	  1994).	  Although	  the	  
short-­‐to-­‐medium	   term	   clinical	   benefits	   are	   good,	   the	   key	   disadvantage	   of	   ACI	   is	   the	  
requirement	  for	  extracting	  healthy	  chondrocytes	  from	  the	  patient,	  which	  can	  lead	  to	  further	  
injury	   (Shenaq	  et	   al.,	   2010).	  Additionally,	   large	  or	   systemic	   cartilage	  defects	   such	  as	   those	  
seen	  in	  osteoarthritis	  (OA)	  would	  not	  be	  suitable	  for	  ACI	  as	  the	  cell	  numbers	  required	  for	  a	  
successful	   graft	   would	   be	   too	   high.	   As	   such,	  MSCs	   hold	   great	   promise	   for	   the	   repair	   and	  
regeneration	  of	  lost	  cartilage	  via	  differentiation	  into	  chondrocytes	  (Gupta	  et	  al.,	  2012).	  
	  





Wakitani	  and	  colleagues	  were	  among	  the	  first	  to	  perform	  a	  clinical	  trial	  evaluating	  the	  safety	  
and	  efficacy	  of	  autologous	  MSC	  transplantation	  in	  24	  patients	  with	  knee	  OA	  (Wakitani	  et	  al.,	  
2002).	  	  Twelve	  patients	  were	  randomised	  to	  receive	  MSCs	  seeded	  onto	  a	  collagen	  gel,	  while	  
the	   remaining	   12	   received	   cell-­‐free	   gels	   as	   controls.	   Although	   the	   histology	   score	   for	   the	  
MSC	   group	  was	   higher	   at	   the	   end	  of	   the	   study,	   no	   significant	   clinical	   improvements	  were	  
seen.	   A	   subsequent	   study	   by	   the	   same	   group	   did	   identify	   clinical	   benefits	   over	   cell-­‐free	  
controls,	  but	  the	  number	  of	  enrolled	  patients	  (n=3)	  was	  low	  (Wakitani	  et	  al.,	  2007).	  	  
	  
Although	   the	   above	   reports	   hint	   towards	   a	   clinical	   benefit	   when	   using	   MSCs	   to	   repair	  
cartilage	  lost	  due	  to	  OA,	  none	  have	  compared	  MSC	  therapy	  to	  ACI,	  the	  current	  gold	  standard.	  
To	   address	   this,	  Nejadnik	  et	   al.	   stratified	   72	  patients	   according	   to	   lesion	   site	   and	   age	   and	  
treated	   them	   with	   ACI	   (n=36)	   or	   MSCs	   (n=36)	   in	   a	   non-­‐randomised,	   non-­‐blinded	   fashion	  
(Nejadnik	  et	  al.,	  2010).	  Clinical	   improvements	  were	  measured	  at	  multiple	  time	  points	  using	  
validated	   scoring	   systems.	   Improvements	   were	   seen	   in	   patients	   receiving	   ACI	   or	   MSC	  
treatment	   compared	   to	   baseline	   values,	   but	   no	   significant	   differences	   were	   observed	  
between	   groups	   except	   for	   the	   “physical	   role	   functioning”	   score	   (the	   ability	   to	   work	   and	  
carry	  out	  other	  daily	  activities),	  in	  which	  MSC-­‐treated	  patients	  scored	  higher.	  	  
	  
Although	  larger	  studies	  have	  demonstrated	  the	  safety	  of	  autologous	  MSC	  transplantation	  for	  
cartilage	   repair,	   the	   degree	   of	   clinical	   benefit	   varied.	   Several	   other	   single-­‐patient	   case	  
reports	   further	  validate	   these	   findings	   (reviewed	   in	  Koga	  et	  al.,	   2009).	  MSC-­‐based	   therapy	  
has	  several	  advantages	  over	  ACI,	   including	  the	  ability	  to	  expand	  cell	  numbers	   in	  vitro	  while	  





maintaining	  chondrogenic	  differentiation	  potential.	  This	  opens	  up	  the	  possibility	  of	  treating	  
larger-­‐size	  cartilage	  defects	  outside	  the	  scope	  of	  ACI	  procedures.	  As	  of	  June	  2014,	  there	  are	  
17	   registered	  human	  clinical	   trials	   testing	  MSCs	   in	   cartilage	   repair	  on	   the	  US	  Clinical	  Trials	  
Database	   (www.clinicaltrials.gov).	   	   This	   list	   also	   includes	   commercial	   products	   such	   as	  
CARTISTEM®	  (NCT01733186)	  looking	  to	  tap	  into	  the	  cell	  therapy	  market.	  	  
	  
	   1.4.3	  MSCs	  in	  Non-­‐Mesenchymal	  Regenerative	  Therapies	  
Several	   groups	   have	   been	   able	   to	   differentiate	   MSCs	   down	   clinically	   relevant	   non-­‐
mesenchymal	  lineages	  in	  vitro	  and	  in	  vivo.	  Examples	  of	  MSC	  plasticity	  include	  differentiation	  
towards	  hepatocytes	  (Sato	  et	  al.,	  2005,	  Pittenger	  et	  al.,	  1999b),	  neurons	   (Woodbury	  et	  al.,	  
2000,	   Kopen	   et	   al.,	   1999),	   cardiomyocytes	   (Toma	   et	   al.,	   2002)	   and	   insulin-­‐producing	  
pancreatic	   β	   cells	   (Zanini	   et	   al.,	   2011).	   This	   trans-­‐germ	   layer	   differentiation	   has	   led	   some	  
groups	   to	   describe	  MSCs	   as	   pluripotent,	   with	   a	   differentiation	   potential	   to	  match	   that	   of	  
embryonic	  stem	  cells	  (Jiang	  et	  al.,	  2002).	  	  
	  
The	   topic	  of	  MSC	  plasticity	  has	   come	  under	   increasing	   scrutiny	  with	   recent	   reports	   linking	  
cases	  of	  transdifferentiation	  with	  cell	  fusion	  or	  transient	  reprogramming	  of	  cells	  to	  adopt	  a	  
new	  phenotype	  under	   strong	  chemical	   cues	   (Bianco	  et	  al.,	  2013).	  Cell	   fusion,	   in	  particular,	  
remains	  a	  strongly	  debated	  subject.	  Data	   from	  the	  HSC	  field	  demonstrates	  that	   fused	  cells	  
can	  display	  the	  phenotype	  of	  terminally	  differentiated	  somatic	  cells,	   leading	  to	  false	  claims	  
of	  transdifferentiation	  potential	  (Wang	  et	  al.,	  2003,	  Terada	  et	  al.,	  2002).	  Up	  to	  1%	  of	  MSCs	  





added	   to	   a	   co-­‐culture	   of	   lung	   epithelial	   cells	   underwent	   cell	   fusion	   and	   begun	   to	   express	  
genes	   characteristic	   of	   epithelial	   cells	   (Spees	   et	   al.,	   2003).	   	  Noiseux	   and	   colleagues	   report	  
low	  levels	  of	  cell	  fusion	  after	  infusion	  of	  MSCs	  in	  a	  model	  of	  ischaemic	  heart	  injury	  (Noiseux	  
et	  al.,	  2006).	  However,	  other	  groups	  have	  reported	  hepatic	  differentiation	  of	  human	  MSCs	  
without	   any	   evidence	   of	   cell	   fusion	   in	   a	   liver	   injury	   model	   (Sato	   et	   al.,	   2005).	   Similar	  
experiments	  also	  demonstrated	  the	  neurogenic	  (Tropel	  et	  al.,	  2006)	  and	  hepatic	  (Tao	  et	  al.,	  
2009)	  potential	  of	  MSCs	  at	  the	  clonal	  level,	  demonstrating	  the	  plasticity	  of	  individual	  MSCs.	  	  
	  	  
Nonetheless,	   as	   is	   commonly	   seen	   in	   the	   MSC	   field,	   this	   early	   pre-­‐clinical	   work	  
demonstrating	   transdifferentiation	  potential	   led	   to	   the	   creation	  of	  many	  human	  phase	   I/II	  
trials	   testing	   the	   efficacy	   of	  MSC	   infusion	   in	  multiple	   clinical	   settings,	   such	   as	   cardiac	   and	  
hepatic	   injury	   (Table	   1.3).	   A	   recent	  meta-­‐analysis	   of	  MSC	   clinical	   trials	   involving	   a	   total	   of	  
1012	  patients	  reported	  MSC	  infusion	  to	  be	  safe,	  with	  the	  only	  significantly	  increased	  adverse	  
event	  being	  transient	  fever	  following	  cell	  infusion	  (Lalu	  et	  al.,	  2012).	  However,	  the	  efficacy	  of	  
MSCs	  has	   yet	   to	  be	   convincingly	  proven	  due	   to	   low	  numbers	  of	   enrolled	  patients	   and	   the	  
lack	  of	  a	  comparator	  arm	  in	  many	  studies.	  Additionally,	   the	  mechanism	  behind	  any	  clinical	  
improvements	   seen	   following	  MSC	   infusion	   in	   vivo	   remains	   to	   be	   elucidated,	   with	   recent	  
studies	  reporting	  low	  levels	  of	  MSC	  engraftment	  and	  rapid	  clearance	  following	  infusion	  (von	  
Bahr	  et	  al.,	  2012).	  	  
	  





Table	  1.3	  |	  Summary	  of	  selected	  clinical	  trials	  using	  MSCs	  in	  non-­‐mesenchymal	  regenerative	  therapies.	  	  




? Phase	  I	  study	  
? 12	  month	  follow	  up	  
? Non-­‐randomised	  	  
? No	  control	  group	  
? Unblinded	  
? Autologous	  BM	  MSCs	  
? Used	  P2-­‐4	  cells	  
? Systemic	  IV	  infusion	  
? Improvements	  in	  MELD	  scores	  seen	  in	  2/4	  
patients	  
? QoL	  questionnaire	  scores	  improved	  in	  4/4	  
patients	  
? No	  adverse	  events	  reported	  
Mohamadnejad	  
et	  al.	  (2007)	  
Cirrhosis	  
(27	  patients)	  
? Phase	  II	  study	  
? 12	  month	  follow	  up	  
? RCT	  
? Single-­‐blinded	  
? Autologous	  BM	  MSCs	  
? Used	  P3-­‐4	  cells	  
? Systemic	  IV	  infusion	  
? No	  differences	  in	  MELD,	  Child-­‐Pugh,	  albumin	  
and	  serum	  transaminase	  levels	  
? No	  difference	  in	  total	  liver	  volume	  
? No	  adverse	  events	  reported	  
Mohamadnejad	  




? Phase	  II	  study	  
? 48	  week	  follow	  up	  
? Non-­‐randomised	  
? 105	  matched	  
controls	  
? Unblinded	  
? Autologous	  BM	  MSCs	  
? Used	  freshly	  isolated	  	  
? Hepatic	  artery	  
infusion	  
? Significant	  improvements	  in	  MELD	  and	  
albumin	  scores	  short	  term	  (4	  weeks)	  
? No	  differences	  observed	  in	  liver	  function	  
scores	  at	  end	  of	  study	  (48	  weeks)	  
? No	  adverse	  events	  reported	  (192	  weeks)	  








? Phase	  I	  study	  
? 12	  month	  follow	  up	  
? Non-­‐randomised	  
? No	  control	  group	  
? Unblinded	  
? Autologous	  BM	  MSCs	  
? Used	  <P3	  cells	  
? Systemic	  IV	  infusion	  
? Improvements	  in	  NIHSS	  score	  in	  all	  patients	  
for	  up	  to	  12	  months	  
? 7/12	  patients	  displayed	  >15%	  reduction	  in	  
lesion	  volume	  after	  MSC	  infusion	  
? One	  case	  of	  mild	  fever	  immediately	  
following	  MSC	  infusion	  reported	  





? Phase	  I	  study	  
? 6	  month	  follow	  up	  
? Non-­‐randomised	  
? No	  control	  group	  
? Unblinded	  
? Autologous	  BM	  MSCs	  
? Used	  P3	  cells	  
? Direct	  infusion	  into	  
damaged	  brain	  
? Significant	  improvements	  in	  neurologic	  
function	  at	  6	  months	  compared	  to	  baseline	  
? No	  adverse	  events	  reported	  
Zhang	  et	  al.	  
(2008b)	  





Table	  1.3	  |	  Summary	  of	  selected	  clinical	  trials	  using	  MSCs	  in	  non-­‐mesenchymal	  regenerative	  therapies.	  (Continued	  from	  previous	  page)	  




? Phase	  I/II	  study	  
? 5	  year	  follow	  up	  
? RCT	  
? Single-­‐blinded	  
? Autologous	  BM	  MSCs	  
? Culture	  expanded	  for	  4	  
weeks	  
? Two	  doses	  via	  systemic	  
IV	  infusion	  
? Significant	  increase	  in	  survival	  at	  5	  years	  in	  
the	  MSC-­‐treated	  group	  (75%	  compared	  to	  
42%)	  
? Significant	  increase	  in	  functional	  outcomes	  in	  
the	  MSC-­‐treated	  group.	  
? No	  major	  differences	  in	  adverse	  events	  
between	  both	  groups	  





? Phase	  I	  study	  
? RCT	  
? 6	  month	  follow	  up	  
? Double-­‐blinded	  
? Multicentre	  study	  
? Allogeneic	  BM	  MSCs	  
(PROCHYMAL®)	  from	  a	  
single,	  unrelated	  donor	  
? Culture	  expanded	  
? Systemic	  IV	  infusion	  
? Significant	  (4-­‐fold)	  reduction	  in	  arrhythmias	  
in	  MSC	  treated	  group	  
? Significant	  (6.7%)	  increase	  in	  LVEF	  in	  MSC	  
treated	  group	  
? No	  evidence	  of	  increased	  toxicity	  or	  adverse	  
events	  in	  the	  MSC-­‐treated	  group	  
Hare	  et	  al.	  
(2009)	  
Acute	  MI	  	  
(16	  patients)	  
? Phase	  I	  study	  
? 6	  month	  follow	  up	  
? Non-­‐randomised	  
? No	  control	  group	  
? Unblinded	  
? Autologous	  BM	  MSCs	  
? Culture	  expanded	  for	  3	  
weeks	  
? Direct	  infusion	  into	  
heart	  via	  coronary	  
artery	  
? Significant	  improvements	  in	  LVEF	  at	  6	  
months	  compared	  to	  baseline	  
? Significant	  increase	  in	  viable	  tissue	  at	  the	  
infarct	  site	  at	  6	  months	  compared	  to	  baseline	  
? No	  adverse	  events	  relating	  to	  direct	  cardiac	  
infusion	  or	  other	  symptoms	  were	  reported	  
Yang	  et	  al.	  
(2010)	  
	  
Abbreviations:	  	   RCT,	   randomised	   controlled	   trial;	  MELD,	  Model	   for	   End	   Stage	   Liver	   Disease;	   IV,	   intravenous;	   QoL,	   Quality	   of	   Life;	   NIHSS,	   National	   Institutes	   of	  
Health	  Stroke	  Scale;	  MI,	  myocardial	  infarction;	  LVEF,	  left	  ventricular	  ejection	  fraction.	  	  





1.5	  Mechanisms	  behind	  MSC-­‐mediated	  Tissue	  Repair	  
As	  described	  above,	  there	  is	  a	  growing	  body	  of	  evidence	  that	  proves	  MSC	  therapy	  to	  be	  safe	  
in	  many	  different	   clinical	   settings.	  However,	  our	  understanding	  of	   the	  mechanisms	  behind	  
any	  therapeutic	  benefit	  seen	  has	  changed	  over	  time	  and	  remains	  only	  partially	  understood.	  
What	  was	  originally	  thought	  to	  be	  “direct”	  repair	  via	  differentiation	  into	  functional,	  mature	  
cells	   to	   replace	   those	   lost	   due	   to	   injury	   has	   evolved	   to	   include	   a	   host	   of	   “indirect”	  
mechanisms	   such	   as	   the	   release	   of	   trophic	   and	   immunomodulatory	   factors	   (Caplan	   and	  
Correa,	  2011).	  In	  this	  section,	  I	  will	  review	  current	  evidence	  for	  both	  the	  direct	  and	  indirect	  
effect	  of	  MSCs	  in	  tissue	  repair.	  The	  immunosuppressive	  phenotype	  of	  MSCs	  will	  be	  discussed	  
in	  detail	  in	  a	  later	  section.	  	  	  
	  
	   1.5.1	  Differentiation	  to	  replace	  lost	  cells	  
The	   conceptual	   idea	   of	   MSCs	   as	   a	   vehicle	   for	   cell	   “replacement”	   therapies	   for	   skeletal	  
disorders	   is	   attractive	   and	   easily	   understood.	   In	   these	   cases,	   differentiation	   down	   an	  
osteogenic	  or	  chondrogenic	  lineage	  is	  well	  documented,	  and	  MSCs	  grafted	  directly	  at	  sites	  of	  
injury	   can	   generate	   mineralised	   matrix	   or	   immature	   chondrocytes	   which	   are	   maintained	  
over	  the	  long-­‐term	  (Nejadnik	  et	  al.,	  2010,	  Hernigou	  et	  al.,	  2005,	  Horwitz	  et	  al.,	  2001).	  Growth	  
factors	   or	   bioactive	   scaffolds	   have	   been	   used	   to	   promote	   differentiation	   down	   a	   specific	  
lineage	  and	  enhance	   repair	   (Marolt	  et	  al.,	   2010,	  Zhang	  et	  al.,	   2009).	  However,	   in	  all	   these	  
cases,	  MSCs	  were	  transplanted	  directly	  at	  sites	  of	   injury	  and	  were	  usually	   immobilised	   in	  a	  
gel	  or	  scaffold	  to	  promote	  successful	  engraftment	  with	  the	  host.	  	  	  	  	  





In	   conditions	  where	   implantation	  of	  MSCs	  directly	  at	   the	   site	  of	   injury	   is	  not	   feasible	   (e.g.	  
neural,	  hepatic	  or	  cardiac	  injuries),	  evidence	  supporting	  long-­‐term	  engraftment	  of	  MSCs	  and	  
differentiation	   into	   functional	   cells	   is	   inconclusive.	   Tao	   et	   al.	   showed	   that	   human	   MSC-­‐
derived	  hepatocyte	   like	  cells	   could	  be	  detected	   in	   the	   livers	  of	   carbon	   tetrachloride	   (CCL4)	  
treated	  mice	   (Tao	  et	  al.,	  2009).	  However,	   the	  engraftment	   frequency	  was	   less	   than	  0.25%,	  
suggesting	   that	   successful	   homing	   and	   transdifferentiation	  of	  MSCs	  was	   a	   rare	   event.	   Kao	  
and	  colleagues	  report	  a	  slightly	  higher	  engraftment	  frequency	  (4.2%	  at	  4	  weeks)	  in	  the	  same	  
model	   of	   injury,	   but	   no	   engrafted	   cells	   remained	   three	  months	   after	   infusion	   (Kuo	   et	   al.,	  
2008).	  Low	  levels	  of	  engraftment	  are	  also	  reported	  in	  papers	  testing	  MSC	  infusion	  in	  cardiac	  
injury	  (Leiker	  et	  al.,	  2008).	  In	  these	  cases,	  a	  separate	  mechanism	  must	  be	  active	  as	  the	  low	  
levels	  of	  engraftment	  and	  cell	  replacement	  cannot	  themselves	  be	  solely	  responsible	  for	  the	  
clinical	  improvements	  seen	  in	  animal	  models	  and	  human	  patients.	  	  	  	  
	  
	   1.5.2	  Indirect	  Repair	  Mechanisms	  
In	   recent	   years,	   there	   has	   been	   a	   shift	   in	   thinking	   towards	  MSCs	   promoting	   tissue	   repair	  
indirectly	  via	  the	  secretion	  of	  trophic	  factors	  which	  create	  a	  regenerative	  microenvironment	  
at	  sites	  of	  injury	  (Caplan	  and	  Correa,	  2011,	  Gnecchi	  et	  al.,	  2008).	  These	  factors	  can	  promote	  
the	  expansion	  of	  tissue-­‐resident	  progenitor	  cells,	  prevent	  further	  apoptosis	  of	  damaged	  cells,	  
and	  promote	   tissue	   repair	   in	   the	  absence	  of	  engrafted	  MSCs.	  An	  elegant	   study	  by	   Iso	  and	  
colleagues	  provides	  strong	  support	  for	  this	  theory	   in	  a	  mouse	  model	  of	  MI.	  They	  observed	  
significant	   improvements	   in	   cardiac	   function	   following	   human	   MSC	   infusion,	   but	   no	  
engraftment	  of	  human	  cells	  were	  detected	   in	  the	  hearts	  of	  each	  treated	  animal	   (Iso	  et	  al.,	  





2007).	  Several	  cardio-­‐protective	  factors	  were	  identified	  in	  MSC	  conditioned	  media	  that	  were	  
capable	   of	   preventing	   cardiomyocytes	   death	   in	   vitro.	   Furthermore,	   Gnecchi	   et	   al.	   showed	  
that	  MSC	  conditioned	  medium	  alone	  was	  sufficient	  to	  reduce	  infarct	  size	  and	  improve	  LEVF	  
in	  rats	  subject	  to	  MI	  (Gnecchi	  et	  al.,	  2006).	  	  
	  
	  
Figure	   1.7	   |	  Paracrine	   factors	   secreted	   by	  MSCs.	   This	   diagram	   lists	   the	   broad	   range	   of	   bioactive	  molecules	  
secreted	  by	  MSCs	  that	  have	  been	  reported	  in	  past	  literature.	  Figure	  taken	  from	  Meirelles	  et	  al.,	  2009.	  
	  
The	  variety	  of	  bioactive	  molecules	  secreted	  by	  MSCs	  can	  be	  broadly	  split	   into	  six	  different	  
families	  (Figure	  1.7;	  Meirelles	  et	  al.,	  2009)	  and	  has	  been	  referred	  to	  as	  the	  “MSC	  secretome”	  
(Ranganath	  et	  al.,	  2012).	  Evidence	  for	  these	  groups	  are	  described	  below.	   	  





	   	   1.5.2.1	  Anti-­‐apoptotic	  and	  Angiogenic	  factors	  	  
Anti-­‐apoptotic	   factors	   secreted	   by	   MSCs	   prevent	   further	   cell	   death	   following	   injury,	   and	  
angiogenic	   factors	   induce	   reinstallation	   of	   a	   blood	   supply	   for	   further	   repair	   of	   damaged	  
tissues.	  Kim	  and	  colleagues	  reported	  the	  release	  of	  FGF2,	  transforming	  growth	  factor	  beta	  1	  
(TGF-­‐β1)	   and	   VEGF	   by	   MSCs	   protect	   lung	   fibroblasts	   from	   undergoing	   apoptosis	   due	   to	  
cigarette	   smoke	   in	   vitro	   (Kim	   et	   al.,	   2012).	   An	   earlier	   study	   by	   the	   same	   group	   also	  
demonstrated	  that	  MSC	  CM	  alone	  can	  increase	  the	  number	  of	  small	  pulmonary	  vessels	  in	  a	  
rat	   model	   of	   emphysema	   (Huh	   et	   al.,	   2011).	   Further	   evidence	   of	   angiogenic	   activity	   is	  
provided	   by	   Chen	   et	   al.,	   who	   show	   that	   VEGF,	   insulin-­‐like	   growth	   factor	   1	   (IGF1),	   and	  
epidermal	  growth	  factor	  (EGF)	  secretion	  by	  mouse	  MSCs	  promotes	  vascularisation	  and	  faster	  
wound	  healing	  in	  vivo	  (Chen	  et	  al.,	  2008).	  	  
	  
	   	   1.5.2.2	  Factors	  that	  support	  local	  stem/progenitor	  cells	  
MSCs	   play	   a	   crucial	   role	   in	  maintaining	   the	   BM	   HSC	   niche	   under	   physiological	   conditions	  
(Mendez-­‐Ferrer	   et	   al.,	   2010).	   A	   population	   of	   perivascular	   BM	   cells	   (enriched	   for	   MSC	  
markers)	  secrete	  stem	  cell	  factor	  (SCF)	  that	  is	  crucial	  for	  HSC	  maintenance	  (Ding	  et	  al.,	  2012).	  
Deletion	  of	   these	  cells	   resulted	   in	  depletion	  of	  HSCs	   from	  their	  BM	  niche	  and	  reduced	  BM	  
cellularity.	  Under	  pathological	  conditions,	  stromal	  derived	  factor	  1	  (SDF-­‐1)	  and	  angiopoietin	  
secretion	   by	   MSCs	   can	   actively	   recruit	   endothelial	   progenitor	   cells	   to	   promote	   wound	  
healing	   and	   revascularisation	   (Chen	   et	   al.,	   2008).	   MSCs	   have	   also	   been	   shown	   to	   recruit	  
Nestin+	   neural	   progenitor	   cells	   that	   promote	   ocular	   regeneration	   in	   a	   murine	   glaucoma	  
model	  (Manuguerra-­‐Gagne	  et	  al.,	  2013).	  	  





	   	   1.5.2.3	  Anti-­‐fibrotic	  and	  Chemoattractive	  factors	  
Although	  reductions	  in	  fibrosis	  have	  been	  reported	  in	  both	  cardiac	  and	  hepatic	  injury	  models	  
following	  MSC	   infusion,	  pinpointing	  the	  molecules	  responsible	   for	   this	  has	  proven	  difficult.	  
One	  study	  reported	  that	  administration	  of	  chorionic	  plate-­‐derived	  MSCs	  in	  a	  rat	  CCL4	  model	  
resulted	   in	   increased	  levels	  of	  matrix	  metalloproteinase	  (MMP)	  2	  and	  9	  which	  reduced	  the	  
degree	   of	   liver	   fibrosis	   seen	   (Lee	   et	   al.,	   2010b).	   Additionally,	   secretion	   of	   FGF2	   by	  MSCs	  
inhibited	   the	   delta-­‐like	   1	   (Dlk1)	   dependent	   activation	   of	   hepatic	   stellate	   sells,	   resulting	   in	  
significantly	   attenuated	   fibrosis	   in	   CCL4	   treated	  mice	   (Pan	   et	   al.,	   2011).	   Finally,	  MSCs	   also	  
secrete	  a	  large	  number	  of	  chemokines	  to	  recruit	  other	  cell	  types	  at	  areas	  of	  injury,	  including	  
immune	  cells	  and	  other	  stem/progenitor	  cells	  (Meirelles	  et	  al.,	  2008).	  	  
	   	  





1.6	  MSC-­‐mediated	  Immunosuppression	  
One	  of	  the	  most	  exciting	  abilities	  of	  MSCs	  are	  their	  potent	  immunomodulatory	  functions	  (Le	  
Blanc	  and	  Mougiakakos,	  2012,	  Uccelli	  et	  al.,	  2008).	  Bartholomew	  and	  colleagues	  were	  first	  to	  
identify	   that	   baboon	   MSCs	   could	   reduce	   the	   proliferation	   of	   activated	   T	   cells	   in	   mixed	  
lymphocyte	   reactions	   (MLR)	   and	   prolong	   allogeneic	   skin	   graft	   survival	   in	   mismatched	  
recipients	   (Bartholomew	   et	   al.,	   2002).	   A	   similar	   anti-­‐proliferative	   effect	   was	   reported	   for	  
human	  MSCs	   in	  MLRs	   soon	   after	   (Di	  Nicola	   et	   al.,	   2002).	  We	   now	   know	  MSCs	   exert	   their	  
effect	   on	   both	   the	   innate	   and	   adaptive	   immune	   system	   through	   a	   variety	   of	  mechanisms	  
(Figure	  1.8;	  Uccelli	  et	  al.,	  2008).	  These	  studies	  have	  prompted	  rapidly	  growing	  interest	  in	  the	  
use	  of	  MSCs	  as	  a	  cellular	  therapy	  for	  autoimmune	  conditions	  alongside	  the	  more	  “traditional”	  
uses	  of	  MSCs	  in	  regenerative	  medicine.	  	  
	  
	  
Figure	  1.8	  |	   Immunosuppressive	  effects	  of	  MSCs	  on	   the	   innate	  and	  adaptive	   immune	  system.	  This	  diagram	  
summaries	  some	  of	  the	  known	  factors	  secreted	  by	  MSCs	  that	  can	  influence	  the	  activation,	  cytokine	  secretion	  
and	  proliferation	  of	  various	  immune	  cells.	  Figure	  taken	  from	  Uccelli	  et	  al.,	  2008.	  	  
	  





	   1.6.1	  Effect	  of	  MSCs	  on	  the	  Adaptive	  Immune	  System	  
	   	   	   1.6.1.1	  T	  Lymphocytes	  
The	  effect	  of	  MSCs	  on	  T	  lymphocytes	  has	  received	  the	  most	  research	  attention	  over	  the	  past	  
decade	  due	  to	  the	  crucial	  role	  they	  play	  in	  maintaining	  immune	  homeostasis.	  CD4	  T	  helper	  
cells	  recognise	  antigens	  that	  have	  been	  processed	  and	  presented	  in	  a	  MHC	  class	  II	  context.	  
After	  activation,	  these	  cells	  proliferate	  and	  secrete	  cytokines	  that	  attract	  other	  immune	  cells	  
to	  areas	  of	  injury.	  CD8	  cytotoxic	  T	  cells	  recognise	  antigen	  presented	  in	  a	  MHC	  class	  I	  context.	  
After	   activation,	   these	   cells	   release	   granules	   containing	   perforin	   and	   granzyme	   B	   which	  
induce	  apoptosis	  in	  target	  cells	  (Parkin	  and	  Cohen,	  2001).	  	  	  
	  
Both	  autologous	  and	  allogeneic	  MSCs	  can	   inhibit	   the	  proliferation	  of	  CD4	  T	  cells	   that	  have	  
been	  stimulated	  by	  mitogens	   (Di	  Nicola	  et	  al.,	  2002),	  alloantigen	   (Rasmusson	  et	  al.,	  2005),	  
and	  activating	  (CD3/CD28)	  antibodies	  (Krampera	  et	  al.,	  2002).	  We	  know	  that	  MSCs	  need	  to	  
be	   in	   an	   inflammatory	   environment	   to	   “switch	   on”	   certain	   immunomodulatory	   functions	  
(Ryan	  et	  al.,	  2007,	  Krampera	  et	  al.,	  2006).	  Once	  activated,	  MSCs	  can	  secrete	  a	  plethora	  of	  
soluble	  factors	  that	  mediate	  immunosuppression	  (summarised	  in	  Figure	  1.8).	  Neutralisation	  
of	   one	   or	   more	   of	   these	   factors	   does	   not	   result	   in	   a	   complete	   reversal	   of	   suppression,	  
suggesting	  that	  there	  are	  other	  non-­‐soluble,	  contact	  dependent	  factors	  in	  play	  (Ben-­‐Ami	  et	  
al.,	   2011).	   It	   is	   likely	   that	   there	   is	   a	   degree	   of	   redundancy	   in	   the	   immunosuppressive	  
phenotype	   of	   MSCs,	   and	   several	   molecules	   may	   work	   in	   unison	   to	   create	   an	   anti-­‐
inflammatory	  microenvironment	  conducive	  to	  tissue	  repair.	  	  





Human	  MSCs	  suppress	  via	   the	  secretion	  of	   indoleamine	  2,3-­‐dioxygenase	   (IDO),	  an	  enzyme	  
responsible	   for	   tryptophan	   catabolism	   (Meisel	   et	   al.,	   2004).	  Depletion	  of	   tryptophan	   from	  
the	   local	   microenvironment	   removes	   an	   essential	   amino	   acid	   required	   for	   lymphocyte	  
proliferation,	  resulting	  in	  lower	  numbers	  at	  sites	  of	  injury.	  Mouse	  MSCs	  secrete	  nitric	  oxide	  
(NO)	  to	  inhibit	  CD4	  T	  cell	  proliferation	  and	  causes	  cell	  cycle	  arrest	  at	  the	  G0/G1	  phase	  (Ren	  et	  
al.,	   2008,	   Glennie	   et	   al.,	   2005).	   Secretion	   of	   interleukin	   10	   (IL-­‐10)	   by	  mouse	   (Yang	   et	   al.,	  
2009)	   and	   human	   MSCs	   (Beyth	   et	   al.,	   2004)	   also	   exerts	   an	   anti-­‐proliferative	   effect	   on	  
lymphocytes.	  Secretion	  of	  prostaglandin	  E2	  (PGE2)	  has	  been	  shown	  to	  indirectly	  suppress	  T	  
cell	  proliferation	  by	  promoting	  IL-­‐10	  secretion	  from	  nearby	  macrophages	  in	  vivo	  (Nemeth	  et	  
al.,	  2009).	  Other	  molecules,	  such	  as	  TGF-­‐β1,	  hepatocyte	  growth	  factor	  (HGF),	  and	  IL-­‐6	  have	  
also	  been	  implicated	  in	  the	  suppression	  of	  CD4	  T	  cell	  proliferation	  (Ma	  et	  al.,	  2014).	  	  	  	  	  	  	  
	  
Studies	  reporting	  the	  effect	  of	  MSCs	  on	  cytotoxic	  CD8	  T	  lymphocytes	  are	  rarer.	  Rasmusson	  et	  
al.	  showed	  MSCs	  pulsed	  with	  viral	  peptides	  remained	  resistant	  to	  CD8	  T	  cell	  lysis	  and	  failed	  
to	  induce	  interferon-­‐γ	  (IFNγ)	  or	  tumour	  necrosis	  factor	  alpha	  (TNFα)	  production	  (Rasmusson	  
et	  al.,	  2007b).	  Human	  adipose-­‐derived	  MSCs	  were	  able	  to	  reduce	  levels	  of	  activation	  markers	  
CD28	   and	   CD44	   on	   CD8	   T	   cells	   after	   co-­‐culture	   (Hof-­‐Nahor	   et	   al.,	   2012).	   Reductions	   in	  
expression	  of	  the	  CD8	  receptor	  and	  production	  of	  IFNγ	  and	  granzyme	  B	  were	  also	  observed,	  
suggesting	  a	  loss	  in	  cytotoxicity.	  While	  MSC	  CM	  was	  sufficient	  to	  induce	  these	  changes,	  there	  
was	  a	  requirement	  for	  CD14+	  monocytes	  to	  be	  in	  direct	  contact	  with	  CD8	  T	  cells	  for	  this	  to	  
occur.	  The	  authors	  were	  unable	  to	  identify	  the	  soluble	  factor	  responsible	  for	  these	  changes,	  
but	  they	  have	  ruled	  out	  TGF-­‐β1	  and	  PGE2	  in	  their	  analysis	  (Hof-­‐Nahor	  et	  al.,	  2012).	  	   	  





	   1.6.1.2	  B	  Cells	  
B	   cells	   can	   function	   as	   antigen	   presenting	   cells	   (APCs)	   and	   can	   produce	   antigen-­‐specific	  
antibodies	  after	  differentiating	  into	  plasma	  cells.	  The	  effect	  of	  MSCs	  on	  B	  cell	  populations	  is	  
less	  well	  understood	  than	  their	  T	  cell	   counterparts	  and	  cases	  of	  contradictory	   results	  have	  
been	  published	   (Franquesa	  et	   al.,	   2012).	   The	   first	   study	   to	   examine	   the	  effect	   of	  MSC	   co-­‐
culture	  on	  B	  cells	  was	  published	   in	  2005	  by	   the	  Uccelli	  group	   (Corcione	  et	  al.,	  2005).	  They	  
demonstrated	   that	   soluble	   factors	   secreted	   by	   human	   MSCs	   were	   able	   to	   inhibit	   the	  
proliferation	  of	  CD19+	  B	  cells	  and	  prevent	  their	  differentiation	  towards	  plasma	  cells.	  Similar	  
anti-­‐proliferative	  effects	  were	  described	  for	  mouse	  MSCs	  in	  a	  later	  study	  (Asari	  et	  al.,	  2009).	  	  
	  
MSCs	   have	   also	   been	   shown	   to	   promote	  B	   cell	   proliferation	   and	   survival	   in	   some	   studies.	  
Rasmusson	  et	  al.	  report	  that	  human	  MSCs	  could	  enhance	  antibody	  production	  via	  a	  contact-­‐
dependent	  mechanism	  when	   cultured	   at	   low	   (10	   B	   cells:1	  MSC)	   ratios	   (Rasmusson	   et	   al.,	  
2007a).	  Tabera	  and	  colleagues	  show	  that	  MSCs	  can	  promote	  the	  viability	  and	  proliferation	  of	  
B	  cells	  under	  “weak”	  stimulation,	  but	  cause	  cell	  cycle	  arrest	  when	  B	  cells	  are	  activated	  using	  
a	   “strong”	   stimulus	   (Tabera	   et	   al.,	   2008).	   The	   reasons	   behind	   the	   disparity	   seen	   in	   these	  
studies	   could	   be	   due	   to	   the	   B	   cell:MSC	   dose,	   stimulation	   method	   and	   MSC	   population	  
(Franquesa	  et	  al.,	  2012).	  
	   	  





	   	   1.6.1.3	  Regulatory	  T	  cells	  
Regulatory	  T	  cells	  (Treg)	  are	  a	  subset	  of	  T	  lymphocytes	  that	  express	  the	  transcription	  factor	  
FOXP3	   and	   function	   to	   maintain	   immune	   homeostasis	   (Vignali	   et	   al.,	   2008).	   Early	  
experiments	  demonstrated	  that	  human	  MSCs	  could	  enhance	  the	  formation	  of	  CD4+CD25+	  T	  
cells	  in	  MLRs	  (Maccario	  et	  al.,	  2005).	  Further	  mechanistic	  insights	  were	  provided	  by	  English	  
et	  al.,	  who	  showed	  that	  cell-­‐cell	  contact	  followed	  by	  TGF-­‐β1	  and	  PGE2	  secretion	  is	  required	  
for	  the	  induction	  of	  FOXP3+	  Tregs	  (English	  et	  al.,	  2009).	  Secretion	  of	  the	  soluble	  protein	  HLA-­‐
G5	  has	  also	  been	  shown	  to	  have	  an	  effect	  on	  T	  cell	  proliferation	  and	  Treg	  formation	  in	  vitro	  
(Selmani	   et	   al.,	   2008).	   Treating	   co-­‐cultures	   with	   anti-­‐HLA-­‐G5	   antibody	   restored	   T	   cell	  
proliferation	  and	  caused	  a	  significant	  drop	  in	  FOXP3+	  CD4	  Treg	  cell	  numbers.	  	  
	  
	   1.6.2	  Effect	  of	  MSCs	  on	  the	  Innate	  Immune	  System	  
	   	   1.6.2.1	  Monocytes/Macrophages	  
Signals	   released	   from	   injured	   tissue	   rapidly	   recruit	   circulating	  monocytes,	  whereupon	   they	  
migrate	   into	   the	   organ	   and	   become	   macrophages.	   Macrophages	   act	   directly	   to	   clear	  
pathogens	  via	  phagocytosis	  and	  indirectly	  by	  instructing	  other	  immune	  cells	  to	  restore	  tissue	  
homeostasis.	  Depending	  on	  environmental	   cues,	  macrophages	   can	  be	  polarised	   towards	  a	  
pro-­‐inflammatory	   M1	   macrophage,	   or	   towards	   an	   anti-­‐inflammatory	   M2	   macrophage	  
(Murray	   and	   Wynn,	   2011).	   Current	   evidence	   suggests	   that	   MSCs	   interact	   closely	   with	  
macrophages	  at	  sites	  of	  injury	  and	  factors	  secreted	  by	  both	  cell	  types	  work	  synergistically	  to	  
create	  an	  anti-­‐inflammatory	  environment	  suitable	  for	  tissue	  repair	  (Figure	  1.9).	   	  








Figure	   1.9	   |	  MSCs	   promote	  macrophage	   polarisation	   towards	   a	  M2	   phenotype	   that	   further	   dampens	   the	  
immune	   response.	  Following	  activation	  by	   inflammatory	  stimuli	   (a),	  MSCs	  secrete	  a	   range	  of	  chemokines	   (b)	  
that	  mediate	  the	  recruitment	  of	  monocytes/macrophages	  to	  sites	  of	  damage	  (c).	  The	  secretion	  of	  TSG-­‐6,	   IDO	  
and	   PGE2	   (d,e)	   keep	   the	   activity	   of	   macrophages	   in	   check,	   and	   they	   can	   induce	   the	   repolarisation	   of	  
macrophages	   towards	   an	   M2	   phenotype	   if	   needed	   (f).	   M2	   macrophages	   can	   then	   further	   suppress	   T	   cell	  
proliferation	   (g),	   neutrophil	   recruitment	   (g)	   and	   induce	   Treg	   formation	   via	   the	   secretion	   of	   IL-­‐10	   (h).	   Figure	  
taken	  from	  Le	  Blanc	  and	  Mougiakakos,	  2012.	  	  
	  
	   	  





Human	  and	  mouse	  MSCs	  can	  actively	  recruit	  monocytes	  to	  areas	  of	  injury	  via	  the	  secretion	  
of	  monocyte	  chemoattractant	  proteins	  CCL2,	  CCL3,	  CXCL2	  and	  CCL12	  (Shi	  et	  al.,	  2011,	  Chen	  
et	   al.,	   2008).	   Once	   recruited,	   MSCs	   can	   skew	   the	   differentiation	   of	   monocytes	   into	   M2	  
macrophages	   in	  vitro	  and	   in	  vivo	   (Cho	  et	  al.,	  2014).	  MSC-­‐secreted	  proteins	  PGE2,	   IDO,	  and	  
TSG-­‐6	  have	  all	  been	  implicated	  in	  the	  preferential	  differentiation	  of	  macrophages	  towards	  an	  
anti-­‐inflammatory	  M2	   phenotype	   (Francois	   et	   al.,	   2012,	   Choi	   et	   al.,	   2011,	   Maggini	   et	   al.,	  
2010).	   	  M2	  macrophages	   can	   then	   further	   suppress	  T	   cell	  proliferation	  via	   IL-­‐10	   secretion,	  
prevent	  the	  ingress	  of	  neutrophils,	  and	  induce	  Treg	  formation	  (Murray	  and	  Wynn,	  2011).	  	  
	  
This	  synergistic	  interplay	  between	  MSCs,	  monocytes,	  macrophages	  and	  neutrophils	  is	  made	  
clear	   in	   an	   elegant	   study	   by	   Nemeth	   and	   colleagues,	   who	   reported	   increased	   survival	  
following	   MSC	   infusion	   in	   a	   mouse	   model	   of	   sepsis	   (Nemeth	   et	   al.,	   2009).	   Mechanistic	  
studies	  revealed	  that	  circulating	  bacterial	  toxins	  bind	  to	  and	  activate	  MSCs,	  causing	  them	  to	  
secrete	   PGE2.	   This	   causes	   a	   reduction	   in	   the	   numbers	   of	   circulating	   monocytes	   and	   a	  
subsequent	   increase	   in	   numbers	   of	   tissue	   macrophages.	   These	   macrophages	   are	   then	  
reprogrammed	   towards	   an	   IL-­‐10	   secreting,	   M2	   phenotype	   which	   dampen	   the	   immune	  
response	   against	   host	   tissues.	   Furthermore,	   IL-­‐10	   secretion	   prevented	   neutrophils	   from	  
entering	  organs	  to	  cause	  further	  damage	  and	  resulted	  in	  an	  increase	  in	  their	  total	  circulating	  
numbers.	  These	  circulating	  neutrophils	  were	  then	  able	  to	  clear	  bacterial	  pathogens	  from	  the	  
blood,	  preventing	  further	  immune-­‐mediated	  damage	  from	  taking	  place.	  	  	  
	   	  





	   	   1.6.2.2	  Neutrophils	  
Neutrophils	   form	  the	  majority	  of	  white	  blood	  cells	  and	  act	  as	  “first	   responders”	  at	  sites	  of	  
injury.	   They	   function	   to	   clear	   foreign	   objects	   and	   bacteria	   via	   phagocytosis,	   secretion	   of	  
antimicrobial	   proteins,	   the	   creation	   of	   NETs	   (neutrophil	   extracellular	   traps),	   and	   via	   the	  
generation	  of	  reactive	  oxygen	  species	  ("respiratory	  burst";	  Liaskou	  et	  al.,	  2012).	  	  
	  
IL-­‐6	   release	   from	   human	   MSCs	   was	   able	   to	   significantly	   increase	   neutrophil	   survival	   and	  
prevent	  activated	  neutrophils	  undergoing	  respiratory	  burst	  in	  vitro	  (Raffaghello	  et	  al.,	  2008).	  
A	   later	   study	   reported	  similar	  pro-­‐survival	  and	  anti-­‐apoptotic	  effects	  of	  MSC	  co-­‐culture	  on	  
neutrophils	  which	  was	  mediated	  via	  the	  release	  of	  IL-­‐6,	  IFN-­‐β,	  and	  GM-­‐CSF	  (Cassatella	  et	  al.,	  
2011).	  Brandau	  et	  al.	  reported	  that	  lipopolysaccharide	  (LPS)-­‐stimulated	  MSC	  secrete	  IL-­‐8	  and	  
MIF	   (macrophage	   migration	   inhibitory	   factor)	   to	   enhance	   neutrophil	   migration	   across	   a	  
transwell	   membrane	   (Brandau	   et	   al.,	   2010).	   Recruited	   neutrophils	   survived	   longer	   and	  
displayed	   enhanced	   inflammatory	   activity	   over	   control	   cells.	   These	   studies	   suggest	   MSCs	  
could	  play	  a	  crucial	  role	  in	  enhancing	  neutrophil	  recruitment	  at	  sites	  of	   injury	  to	  help	  clear	  
pathogens,	  but	  additional	  work	  is	  needed	  to	  elucidate	  the	  functional	  relevance	  of	  this	  in	  vivo.	  	  
	   	  





	   	   1.6.2.3	  Natural	  Killer	  cells	  
Natural	   killer	   (NK)	   cells	   function	   in	   an	   analogous	   fashion	   to	   CD8	   cytotoxic	   T	   lymphocytes,	  
however	   they	   do	   not	   require	   antigen	   presentation	   (in	   an	   MHC	   context)	   to	   be	   activated,	  
resulting	  in	  an	  expedited	  response	  against	  pathogens.	  NK	  cell	  activation	  is	  determined	  by	  the	  
overall	  balance	  of	  signals	  from	  a	  range	  of	  ‘activating’	  and	  ‘inhibitory’	  receptors	  expressed	  on	  
their	   surface.	   Activation	   results	   in	   the	   release	   of	   cytolytic	   granules	   against	   a	   target	   cell,	  
causing	  apoptosis	  and	  cell	  death	  (Vivier	  et	  al.,	  2008).	  	  	  
	  
MSCs	   were	   shown	   to	   inhibit	   the	   proliferation	   of	   NK	   cells	   stimulated	   with	   IL-­‐2	   or	   IL-­‐15	  
(Spaggiari	  et	  al.,	  2006).	  However,	  these	  MSCs	  were	  susceptible	  to	  NK-­‐mediated	  cell	  lysis	  due	  
to	  the	  expression	  of	   ligands	  that	  bind	  to	  NK	  activating	  receptors.	  Following	  pre-­‐stimulation	  
with	   IFNγ,	   MSCs	   upregulated	   MHC	   class	   I	   molecules	   which	   allowed	   them	   to	   evade	   NK-­‐
mediated	  lysis,	  highlighting	  the	  importance	  of	  an	  inflammatory	  environment	  in	  switching	  on	  
MSC	   immunosuppressive	   functions	   (Spaggiari	   et	   al.,	   2006).	  A	   follow-­‐up	   study	  by	   the	   same	  
group	   identified	  MSC-­‐secreted	   IDO	  and	  PGE2	  as	  key	  molecules	  preventing	  the	  proliferation	  
and	  cytokine	  production	  of	  NK	  cells	   in	  vitro	   (Spaggiari	  et	  al.,	  2008).	   Interestingly,	   they	  also	  
observed	  down-­‐regulation	  of	  activating	  NK	  receptors	  after	  MSC	  co-­‐culture.	  Secreted	  HLA-­‐G5,	  
an	  inhibitory	  NK	  receptor	  ligand,	  has	  also	  been	  shown	  to	  inhibit	  IFNγ	  production	  and	  protect	  
MSCs	  from	  NK-­‐mediated	  lysis	  (Selmani	  et	  al.,	  2008).	  
	   	  





	   	   1.6.2.4	  Dendritic	  cells	  
Dendritic	  cells	  (DCs)	  function	  as	  professional	  APCs	  to	  both	  CD4	  and	  CD8	  T	  cells.	  Compared	  to	  
other	   APCs,	   DCs	   are	   the	   most	   potent	   at	   activating	   T	   cells	   and	   are	   the	   only	   cells	   able	   to	  
present	  antigen	  to	  naïve	  T	  cells	  (Wieder,	  2003).	  They	  can	  be	  broadly	  subdivided	  into	  myeloid	  
DCs,	  which	  arise	  from	  CD34+	  myeloid	  progenitor	  cells	  and	  monocytes,	  or	  plasmacytoid	  DCs,	  
which	  arise	  from	  lymphoid	  progenitor	  cells.	  
	  
Jiang	   et	   al.	   reported	   that	   human	   MSCs	   could	   inhibit	   the	   differentiation	   of	   monocytes	  
towards	  myeloid	  DCs	   in	  vitro	  (Jiang	  et	  al.,	  2005).	  They	  also	  showed	  reduced	  IL-­‐12	  secretion	  
and	  reduced	  expression	  of	  antigen	  presentation	  and	  costimulatory	  molecules	  in	  mature	  DCs	  
after	   MSC	   co-­‐culture.	   MSCs	   could	   also	   inhibit	   the	   differentiation	   of	   CD34+	   myeloid	  
progenitor	   cells	   into	   DCs	   (Nauta	   et	   al.,	   2006).	   Any	   DCs	   that	  were	   formed	   after	   co-­‐culture	  
struggled	  to	   induce	  T	  cell	  activation.	  Mouse	  MSCs	  were	  able	  to	   induce	  the	  generation	  of	  a	  
‘regulatory’	  DC	  population	  via	  the	  upregulation	  of	  the	  notch	  signalling	  ligand	  Jagged-­‐2	  in	  DCs	  
(Zhang	   et	   al.,	   2008a,	   Li	   et	   al.,	   2008).	   This	   regulatory	   DC	   population	   could	   inhibit	   the	  
proliferation	   and	   cytokine	   secretion	   of	   alloantigen-­‐stimulated	   lymphocytes.	   The	   Uccelli	  
group	   were	   able	   to	   demonstrate	   an	   impaired	   ability	   of	   DCs	   to	   prime	   CD4	   T	   cells	   in	   vivo	  
(Chiesa	  et	  al.,	  2011).	  They	  also	  showed	  significantly	   reduced	  numbers	  of	  DCs	   in	   the	   lymph	  
nodes	  of	  animals	  after	  treatment,	  suggesting	  a	  reduction	  in	  their	  migratory	  capacity	  as	  well.	  	  
	   	  





The	  effect	  of	  MSCs	  on	  plasmacytoid	  DCs	  is	  less	  well	  understood,	  but	  there	  is	  some	  evidence	  
that	   suggests	   human	   MSCs	   can	   alter	   the	   cytokine	   secretion	   profile	   of	   plasmacytoid	   DCs	  
towards	  more	  anti-­‐inflammatory	  (IL-­‐10	  secreting)	  phenotype	  (Aggarwal	  and	  Pittenger,	  2005).	  
These	  data	  suggest	  that	  MSCs	  can	  affect	  DCs	  across	  all	  stages	  of	  their	  development,	  from	  the	  
initial	   differentiation	   of	   progenitor	   cells	   to	   antigen	   presentation,	   lymph	   node	   homing	   and	  
stimulation	  of	  T	  cells	  (Figure	  1.10).	  	  
	  
	  
Figure	  1.10	  |	  Modulation	  of	  DC	  differentiation	  and	  function	  by	  MSCs.	  MSCs	  can	  inhibit	  the	  differentiation	  and	  
maturation	   of	  DCs	   using	   a	   combination	   of	   secreted	   factors	   and	   cell-­‐cell	   contact.	   DCs	   co-­‐cultured	  with	  MSCs	  
typically	  show	  reduced	  IL-­‐12	  secretion	  and	  an	  impaired	  ability	  to	  present	  antigen	  and	  migrate	  to	  nearby	  lymph	  
nodes.	   ‘Regulatory’	   DCs	   are	   also	   able	   to	   inhibit	   the	   proliferation	   and	   cytokine	   secretion	   of	   alloantigen-­‐
stimulated	  T	  lymphocytes	  in	  vitro.	  	  
	   	  
	   	  





1.6.3	  Clinical	  Evidence	  for	  Immunosuppression	  
MSCs	  have	  shown	  efficacy	  in	  modulating	  the	  immune	  response	  in	  pre-­‐clinical	  animal	  models	  
of	   sepsis	   (Nemeth	   et	   al.,	   2009),	   graft-­‐versus-­‐host	   disease	   (GvHD;	   Ren	   et	   al.,	   2008),	  
experimental	  autoimmune	  encephalomyelitis	  (Zappia	  et	  al.,	  2005),	  skin	  grafts	  (Bartholomew	  
et	   al.,	   2002),	   and	   type	   1	   diabetes	   (Urban	   et	   al.,	   2008).	   These	   promising	   results	   have	  
encouraged	  the	  translation	  of	  pre-­‐clinical	  work	  into	  human	  diseases	  with	  immune-­‐mediated	  
pathogenesis.	   As	   seen	  with	  MSC-­‐based	   regenerative	   therapies,	   early-­‐phase	   clinical	   results	  
have	   demonstrated	  MSC	   infusion	   to	   be	   safe	   in	   immune-­‐mediated	   disorders,	   although	   the	  
degree	  of	  clinical	  benefit	  varied	  (summarised	  in	  Table	  1.4).	  	  
	  
	   	   1.6.3.1	  MSCs	  in	  GvHD	  
Of	  the	  various	  immune-­‐mediated	  disorders	  studied,	  the	  effect	  of	  MSCs	  on	  patients	  suffering	  
from	   GvHD	   is	   the	   most	   striking.	   GvHD	   is	   a	   complication	   of	   allogeneic	   transplantation	  
(particularly	   bone	   marrow	   transplants)	   where	   donor	   T	   cells	   in	   the	   graft	   recognise	   host	  
antigens	  as	   foreign	  and	   initiate	  an	   immune	  reaction	  against	  the	  host	   (Ferrara	  et	  al.,	  2009).	  
GvHD	  affects	  many	  organs,	  including	  the	  skin,	  liver	  and	  lower	  gastrointestinal	  tract	  resulting	  
in	  high	  morbidity	  and	  mortality.	  Current	  therapy	  is	  inadequate	  and	  involves	  treatment	  with	  
immunosuppressive	   agents	  which	   further	   increases	   their	   risk	   of	   infections.	   Additionally,	   a	  
subset	  of	  patients	  do	  not	  respond	  to	  initial	  therapy	  (“treatment-­‐resistant	  GvHD”),	  resulting	  
in	  a	  bleak	  prognosis	   (Deeg,	  2007).	  As	   the	  pathophysiology	  of	  GvHD	   involves	   the	  activation	  
and	   proliferation	   of	   a	   variety	   of	   immune	   cell	   subsets,	   it	   was	   believed	  MSCs	   could	   play	   a	  
crucial	  role	  in	  regulating	  this	  process	  and	  preventing	  further	  damage.	  	  





Table	  1.4	  |	  Summary	  of	  selected	  clinical	  trials	  using	  MSCs	  in	  immune-­‐mediated	  conditions.	  	  
Disease	   Study	  Design	   Cell	  Type	  &	  Route	   Outcomes	   Reference	  
GvHD	  
? Case	  study	  	  
? 1	  patient	  
? 12	  month	  follow	  up	  
? HLA-­‐matched	  MSCs	  
? Culture	  expanded	  for	  3	  weeks	  
? Systemic	  IV	  Infusion	  (2	  doses)	  
? Rapid	  restoration	  of	  liver	  and	  gut	  function	  
? Symptom	  free	  for	  up	  to	  1	  year	  post-­‐transplant	  
? No	  adverse	  events	  reported	  
Le	  Blanc	  et	  
al.	  (2004b)	  
? Phase	  I	  trial	  
? 8	  Patients	  
? Up	  to	  16	  month	  follow	  up	  
? No	  control	  group	  
? Non-­‐randomised,	  Unblinded	  
? Mixture	  of	  HLA-­‐matched	  and	  
mismatched	  donor	  MSCs.	  
? P1	  to	  P4	  cells	  used	  
? Systemic	  IV	  infusion	  (1-­‐2	  
doses)	  
? Resolution	  of	  GvHD	  seen	  in	  6/8	  patients	  
? No	  difference	  in	  efficacy	  between	  HLA-­‐
matched	  and	  mismatched	  MSCs	  
? No	  adverse	  events	  reported	  
Ringdén	  et	  
al.	  (2006)	  
? Phase	  II	  trial	  
? 55	  patients	  
? Median	  16	  month	  follow	  up	  
? No	  control	  group	  
? Non-­‐randomised,	  Unblinded	  
? Mixture	  of	  HLA-­‐matched	  and	  
mismatched	  donor	  MSCs	  
? P1	  to	  P4	  cells	  used	  
? Systemic	  IV	  infusion	  (1-­‐5	  
doses)	  
? Complete	  resolution	  seen	  in	  30/55	  patients,	  
partial	  response	  seen	  in	  9/55	  
? Children	  (21/39)	  showed	  a	  greater	  response	  	  
? Response	  seen	  in	  27/55	  after	  one	  MSC	  infusion	  
? 8/30	  patients	  with	  complete	  resolution	  had	  
discontinued	  all	  immunosuppressive	  drugs	  
Le	  Blanc	  et	  
al.	  (2008)	  
? Phase	  III	  trial	  
? 244	  patients	  
? RCT	  
? Double-­‐blinded	  
? PROCHYMAL®	  allogeneic	  
MSCs	  
? Unknown	  passage	  
? Systemic	  IV	  infusion	  (8	  doses)	  
? No	  difference	  in	  complete	  response	  for	  >28	  
days	  (response	  rate:	  35%	  MSCs	  vs.	  30%	  
placebo,	  p=0.3)	  
? Significant	  improvements	  in	  response	  in	  
patients	  with	  GvHD	  affecting	  liver,	  skin	  and	  gut	  
(rate:	  63%	  MSCs	  vs.	  0%	  placebo,	  p<0.05)	  
Martin	  et	  al.	  
(2010)	  
? Phase	  II	  trial	  
? 75	  paediatric	  patients	  
? 100	  day	  follow	  up	  
? No	  control	  group	  
? Non-­‐randomised,	  Unblinded	  
? PROCHYMAL®	  allogeneic	  
MSCs	  
? Unknown	  passage	  
? Systemic	  IV	  infusion	  (8	  doses)	  
? Complete	  response	  seen	  in	  46/75	  patients	  28	  
days	  after	  last	  MSC	  infusion	  	  
? Complete	  responders	  had	  significantly	  
increased	  survival	  compared	  to	  non-­‐









Table	  1.4	  |	  Summary	  of	  selected	  clinical	  trials	  using	  MSCs	  in	  immune-­‐mediated	  conditions.	  (Continued	  from	  previous	  page)	  
Disease	   Study	  Design	   Cell	  Type	  &	  Route	   Outcomes	   Reference	  
SLE	  
? Phase	  I	  trial	  
? 15	  patients	  
? 17	  month	  follow	  up	  
? No	  control	  group	  
? Non-­‐randomised,	  
Unblinded	  
? HLA	  mismatched	  donor	  
MSCs	  
? P3	  to	  P5	  cells	  used	  
? Systemic	  IV	  infusion	  (1	  dose)	  
? Significant	  reductions	  in	  SLEDAI	  score	  at	  12	  
months	  compared	  to	  baseline	  
? Significant	  reductions	  in	  proteinuria	  at	  12	  months	  
compared	  to	  baseline	  
? Significant	  increases	  in	  CD4+FOXP3+	  cells	  at	  1,	  3	  
and	  6	  weeks	  post-­‐MSC	  transplant	  




? Phase	  I	  trial	  
? 9	  patients	  
? 6	  month	  follow	  up	  
? No	  control	  group	  
? Non-­‐randomised,	  
Unblinded	  
? Autologous	  MSCs	  
? Up	  to	  P3	  cells	  used	  
? Systemic	  IV	  infusion	  (2	  
doses)	  
? CDAI	  scores	  improved	  in	  5/9	  patients,	  with	  3/9	  
showing	  a	  reduction	  >70	  units	  
? No	  patients	  achieved	  complete	  remission	  
? 7/9	  patients	  showed	  no	  endoscopic	  improvement	  
? No	  adverse	  events	  due	  to	  MSC	  infusions	  reported	  
Duijvestein	  
et	  al.	  (2010)	  
Ulcerative	  
Colitis	  
? 3	  patient	  case	  series	  
? 19	  month	  follow	  up	  
? Allogeneic	  MSCs	  isolated	  
from	  BM	  or	  umbilical	  cord	  
? Unknown	  passage	  
? Systemic	  IV	  infusion	  (1	  dose)	  
? Significant	  reductions	  in	  CAI	  scores	  in	  3/3	  patients	  
? One	  patient	  showed	  significant	  endoscopic	  
improvement	  
? One	  patient	  had	  transient	  fever	  for	  2	  days	  
following	  MSC	  infusion	  	  





? Two	  patient	  case	  series	  
? Kidney	  transplantation	  
? 12	  month	  follow	  up	  
? Autologous	  MSCs	  	  
? Used	  at	  P2	  or	  less	  
? Systemic	  IV	  infusion	  (1	  dose)	  
7	  days	  post	  kidney	  transplant	  
? Transient	  increase	  in	  serum	  creatinine	  7-­‐14	  days	  
after	  MSC	  infusion	  which	  improved	  over	  time	  
? Both	  patients	  showed	  no	  signs	  of	  graft	  rejection	  
up	  to	  1	  year	  post-­‐transplant	  with	  no	  background	  
immunosuppression	  
Perico	  et	  al.	  
(2011)	  
	  
Abbreviations:	  	   SLE,	  systemic	  lupus	  erythematosus;	  SLEDAI,	  systemic	  lupus	  erythematosus	  disease	  activity	  index;	  CDAI,	  Chron’s	  disease	  activity	  index;	  CAI,	  clinical	  
activity	  index	  	  	  





Studies	  on	  the	  effects	  of	  MSC	  infusion	  in	  patients	  with	  GvHD	  mainly	  originate	  from	  Katarina	  
Le	  Blanc’s	  group	  at	  the	  Karolinska	   Institute,	  Stockholm.	  Her	   initial	  case	  report	  showed	  that	  
matched	  MSC	   infusion	   caused	   a	   rapid	   improvement	   in	   gut	   and	   liver	   function	   in	   a	   young	  
patient	  who	  was	  unresponsive	   to	  steroid	   therapy	   (Le	  Blanc	  et	  al.,	  2004b).	  A	   later	  study	  by	  
the	  same	  group	  expanded	  the	  numbers	  of	  MSC-­‐treated	  patients	  with	  steroid-­‐resistant	  GvHD	  
to	  eight	  (Ringdén	  et	  al.,	  2006).	  They	  showed	  resolution	  of	  acute	  GvHD	  in	  6/8	  patients,	  with	  
the	   remaining	   two	   patients	   showing	   no	   response	   to	   MSC	   treatment.	   Survival	   rates	   for	  
patients	  receiving	  MSC	  treatment	  were	  significantly	  improved	  compared	  to	  control	  patients.	  
Importantly,	  no	  side	  effects	  were	  noted	   in	   the	   four	  patients	  who	  received	  unrelated,	  HLA-­‐
mismatched	  MSC	  transplants.	  	  	  
	  
A	   phase	   II,	   multicentre	   trial	   involving	   55	   patients	   was	   performed	   on	   the	   back	   of	   these	  
promising	  case	  reports.	  Over	  50%	  (30/55)	  of	  patients	  showed	  a	  complete	  response	  to	  MSC	  
therapy,	  with	  a	  further	  16%	  (9/55)	  showing	  a	  partial	  response	  (Le	  Blanc	  et	  al.,	  2008).	  Over	  
half	  (27/55)	  showed	  a	  complete	  response	  after	  a	  single	  infusion	  of	  MSCs.	  An	  increase	  in	  2-­‐
year	  survival	  was	  observed	  in	  patients	  responding	  to	  MSC	  treatment	  compared	  to	  controls	  
(52%	   vs.	   10%).	   No	   side	   effects	   were	   noted	   and	   allogeneic	   MSCs	   were	   shown	   to	   be	   as	  
effective	  as	  autologous	  cells	  in	  this	  study.	  However,	  a	  later	  retrospective	  cohort	  study	  of	  60	  
patients	   who	   died	   of	   pneumonia-­‐related	   death	   after	   BM	   transplants	   at	   the	   Karolinska	  
Institute	   identified	  MSC	   infusion	  being	   a	   significant	   risk	   factor	   (Forslöw	  et	   al.,	   2012).	   	   This	  
study	   highlights	   the	   urgent	   need	   for	   larger,	   longer	   RCTs	   to	   assess	   both	   the	   safety	   and	  
efficacy	  of	  MSC	  infusion	  in	  patients	  with	  GvHD.	  





To	  date,	  there	  has	  only	  been	  one	  published	  phase	  III	  RCT	  (NCT00366145)	  looking	  at	  MSCs	  in	  
GvHD.	  This	  trial,	  funded	  and	  performed	  by	  Osiris	  Therapeutics	  Inc.	  (Columbia,	  USA)	  enrolled	  
244	   patients,	   with	   163	   receiving	   PROCHYMAL®	   (generic	   name	   remestemcel-­‐L)	   and	   81	  
patients	  receiving	  placebo	  (Martin	  et	  al.,	  2010).	  No	  significant	  differences	  were	  observed	  in	  
the	   primary	   endpoint	   of	   overall	   complete	   response	   rate	   between	   PROCHYMAL®-­‐treated	  
patients	   and	   controls	   (p=0.3).	   However,	   significant	   differences	   were	   observed	   in	   some	  
secondary	  endpoints,	  with	  patients	  suffering	  from	  severe	  GvHD	  affecting	  the	  skin,	  liver	  and	  
gut	   showing	  a	  63%	  complete	  or	  partial	   response	   to	  PROCHYMAL®	   treatment	   compared	   to	  
0%	  in	  the	  placebo	  arm.	  Although	  this	  result	  represents	  a	  major	  setback	  for	  Osiris,	  they	  have	  
recently	  gained	  Canadian	  marketing	  approval	  for	  PROCHYMAL®	  in	  the	  treatment	  of	  GvHD	  in	  
children	  on	  the	  back	  smaller	  studies	  focusing	  on	  paediatric	  patients	  (Kurtzberg	  et	  al.,	  2014,	  
Prasad	   et	   al.,	   2011).	   The	   Canadian	   Health	   Authority	   have	   stated	   that	   although	   there	   is	  
currently	   limited	   evidence	   indicating	   a	   therapeutic	   benefit	   with	   PROCHYMAL®,	   the	   safety	  
profile	   of	   the	   therapy	  warrants	   further	   investigation	   in	   the	   treatment	   of	   paediatric	   GvHD	  
(Health	  Canada,	  2012).	  	  
	   	  





1.7	  Enhancing	  the	  Regenerative	  and	  Immunosuppressive	  Potential	  of	  MSCs	  
Although	  clinical	  evidence	  has	  proven	  MSC	  therapy	  to	  be	  safe,	  the	  degree	  of	  clinical	  benefit	  
observed	  was	  modest.	  The	  recent	  failure	  of	  PROCHYMAL®	  in	  phase	  III	  clinical	  trials	  highlights	  
the	  need	  to	  better	  understand	  ways	  to	  improve	  the	  efficacy	  of	  MSC	  therapy.	  In	  this	  final	  part	  
of	   the	   introduction,	   I	   will	   summarise	   the	   different	   methods	   used	   to	   enhance	   the	  
regenerative	  and	  immunosuppressive	  potential	  of	  these	  cells.	  	  
	  
	   1.7.1	  Prospective	  Isolation	  and	  the	  use	  of	  Lower-­‐Passage	  Cells	  
Markers	  for	  the	  prospective	  isolation	  of	  mouse	  (Mendez-­‐Ferrer	  et	  al.,	  2010,	  Morikawa	  et	  al.,	  
2009)	   and	   human	   MSCs	   (Pinho	   et	   al.,	   2013,	   Mabuchi	   et	   al.,	   2013b)	   represent	   major	  
advancements	  for	  the	  study	  of	  MSC	  biology	  and	  for	  future	  therapeutic	  applications.	  Unlike	  
plastic-­‐adherent	  cells,	  prospectively	  isolated	  MSCs	  are	  highly	  enriched	  for	  CFU-­‐F	  ability	  and	  
have	   been	   shown	   to	   self-­‐renew	   and	   undergo	   multi-­‐lineage	   differentiation	   in	   vivo.	   No	  
publications	   to	   date	   have	   compared	   the	   efficacy	   of	   prospectively	   isolated	   MSCs	   against	  
classically	  isolated	  plastic-­‐adherent	  cells,	  although	  one	  would	  expect	  the	  purified	  population	  
to	  perform	  better.	  Additionally,	  by	  starting	  off	  with	  a	  pure	  population	  of	  stem	  cells,	  the	  MSC	  
field	   can	   reach	   agreement	   over	   potential	   mechanisms	   of	   action	   and	   generate	   more	  
reproducible	   results.	   This	   could	   lead	   to	   more	   effective	   uses	   of	   MSCs	   in	   the	   clinic,	   and	  
therefore	  lead	  to	  facilitated	  regulatory	  approval.	  
	   	  





Another	   benefit	   of	   prospective	   isolation	   is	   the	   ability	   to	   study	  MSC	   function	   without	   the	  
prerequisite	  of	  ex	  vivo	  expansion,	  allowing	  us	  to	  use	  lower	  passage	  cells	  in	  vivo	  (Mabuchi	  et	  
al.,	  2013a).	  Previous	  studies	  have	  shown	  that	  MSCs	  are	  susceptible	  to	  replicative	  senescence	  
as	  early	  as	  P7,	  resulting	  in	  reduced	  growth	  kinetics	  and	  differentiation	  ability	  (Wagner	  et	  al.,	  
2008,	  Kretlow	  et	  al.,	  2008).	  Prolonged	  in	  vitro	  culture	  can	  also	  increase	  the	  risk	  of	  karyotypic	  
abnormalities	  in	  murine	  MSCs,	  leading	  to	  transformation	  and	  tumour	  formation	  (Tolar	  et	  al.,	  
2007,	  Miura	  et	  al.,	  2006).	   In	  vitro	  expansion	  can	  also	   impair	   the	  ability	  of	  murine	  MSCs	   to	  
migrate	  back	  to	  BM	  due	  to	  decreased	  expression	  of	  chemotactic	  receptors	  (Karp	  and	  Teol,	  
2009,	  Rombouts	  and	  Ploemacher,	  2003).	  	  
	  
The	  consequences	  of	  passage	  number	  on	  clinical	  efficacy	  are	  made	  clear	  in	  two	  publications	  
from	   the	   Le	   Blanc	   group.	   A	   retrospective	   analysis	   of	   patients	   receiving	   MSCs	   for	   GvHD	  
showed	   that	   the	   1-­‐year	   survival	   rate	   of	   patients	   receiving	   P1-­‐P2	   MSCs	   was	   significantly	  
higher	   than	   those	   receiving	   P3-­‐P4	  MSCs	   (75%	   vs	   21%;	   von	   Bahr	   et	   al.,	   2012).	   A	   complete	  
response	   was	   detected	   in	   86%	   of	   patients	   receiving	   young	   cells	   compared	   to	   only	   36%	  
receiving	  older	  MSCs.	  Interestingly,	  the	  authors	  did	  not	  detect	  any	  differences	  in	  the	  in	  vitro	  
immunomodulatory	   properties	   of	   P2	   and	   P7	  MSCs.	   Another	   study	   has	   shown	   that	   higher	  
passage	  (>P5)	  MSCs	  are	  more	  rapidly	  cleared	  by	  the	  host	  compared	  to	   lower	  passage	  cells	  
(Moll	   et	   al.,	   2012).	   Culture	   expanded	   MSCs	   were	   at	   higher	   risk	   of	   IBMIR	   (Instant	   Blood	  
Mediated	   Inflammatory	   Reaction)	   due	   to	   increased	   expression	   of	   pro-­‐thrombotic	   proteins	  
on	  their	  cell	  surface	  resulting	  in	  quicker	  activation	  of	  the	  coagulation	  cascade.	  	  
	   	  





	   1.7.2	  Augmenting	  MSC	  function	  using	  Growth	  Factors	  
Growth	   factors	   (GFs)	   have	   been	   used	   to	   augment	   MSC	   growth	   and	   differentiation	   in	  
previous	  publications	  (Rodrigues	  et	  al.,	  2010).	  Selected	  factors	  include	  FGF2	  (Ito	  et	  al.,	  2008),	  
TGF-­‐β1	  (Mimura	  et	  al.,	  2011),	  platelet-­‐derived	  growth	  factor-­‐BB	  (PDGF-­‐BB;	  Betsholtz,	  2004),	  
hepatocyte	  growth	  factor	  (HGF;	  Neuss	  et	  al.,	  2004),	  VEGF	  (Pons	  et	  al.,	  2008),	  EGF	  (Tamama	  
et	  al.,	  2006),	  and	  IGF1	  (Huang	  et	  al.,	  2012).	  	  	  	  
	  
Of	  these	  GFs,	  FGF2	  is	  possibly	  the	  most	  commonly	  used	  cytokine	  in	  MSC	  literature.	  FGF2	  has	  
a	  potent	  mitogenic	  effect,	  thereby	  reducing	  the	  in	  vitro	  expansion	  time	  required	  to	  reach	  cell	  
numbers	   for	   therapeutic	   infusions	   (Lai	   et	   al.,	   2011).	   Human	   MSCs	   cultured	   with	   FGF2	  
underwent	  25	  population	  doublings	  over	  a	  100	  day	  period	  while	  control	  cells	  underwent	  <10	  
doublings	  over	  the	  same	  time	  course	  (Gharibi	  and	  Hughes,	  2012).	  It	  can	  also	  delay	  the	  onset	  
of	  senescence	  in	  mouse	  MSCs	  by	  promoting	  the	  hyper-­‐phosphorylation	  of	  Mdm2,	  resulting	  
in	  enhanced	  degradation	  of	  p53	  tumour	  suppressor	  gene	  and	  increased	  cell	  growth	  (Coutu	  
et	  al.,	  2011).	  Finally,	  FGF2	  can	  also	  promote	  the	  tri-­‐lineage	  differentiation	  of	  MSCs	  towards	  
bone	  (Ito	  et	  al.,	  2008),	  fat	  (Song	  et	  al.,	  2014)	  and	  cartilage	  (Handorf	  and	  Li,	  2011).	  	  
	  
Recent	  work	  has	  concentrated	  on	  moving	  towards	  serum-­‐free	  media	  for	  the	  culture	  of	  MSCs,	  
thereby	  avoiding	  the	  undefined	  nature	  of	  foetal	  bovine	  serum	  (FBS;	  Jung	  et	  al.,	  2012).	  Chase	  
and	   colleagues	   show	   that	   serum-­‐free	   basal	   media	   supplemented	   with	   FGF2,	   TGF-­‐β1	   and	  
PDGF-­‐BB	   was	   able	   to	   expand	   human	  MSC	   populations	   while	   maintaining	   their	   tri-­‐lineage	  





differentiation	  potential	  (Chase	  et	  al.,	  2010).	  However,	  Jung	  et	  al.	  show	  that	  PDGF-­‐BB	  has	  a	  
negative	  effect	  on	  MSC	  growth,	  and	  a	  combination	  of	  FGF2	  and	  TGF-­‐β1	  was	  optimal	  for	  the	  
serum-­‐free	   isolation	  and	  expansion	  of	  human	  MSCs	   (Jung	  et	  al.,	  2010).	  The	   reason	  behind	  
these	   contradictory	   findings	   could	  be	  due	   to	  heterogeneity	   in	   the	  plastic-­‐adherent	  human	  
MSC	  populations	  used	  in	  both	  studies.	  	  	  	  	  
	  
	   1.7.3	  Hypoxia	  
MSCs,	   like	  most	   cultured	   cells,	   are	   frequently	  maintained	   at	   atmospheric	   oxygen	   tensions	  
(20%	  O2).	  Hypoxic	  culture	  conditions	  (<5%	  O2)	  more	  closely	  match	  the	  oxygen	  tension	  found	  
in	  BM	  and	  confers	  several	  positive	  effects	  on	  MSC	  function	  (Das	  et	  al.,	  2010).	  Firstly,	  hypoxia	  
exhibits	   a	   pro-­‐proliferative	   effect	   on	   MSCs.	   Ren	   and	   colleagues	   show	   that	   hypoxia	  
significantly	  increased	  murine	  MSC	  numbers	  due	  to	  a	  higher	  percentage	  of	  cells	  entering	  the	  
G2-­‐M	   phase	   of	   the	   cell	   cycle	   (Ren	   et	   al.,	   2006).	   Similar	  mitogenic	   effects	   have	   also	   been	  
described	  for	  human	  MSCs	  (Grayson	  et	  al.,	  2007).	  The	  effect	  of	  hypoxia	  on	  MSC	  tri-­‐lineage	  
differentiation	  is	  mixed,	  with	  some	  studies	  reporting	  enhanced	  differentiation	  (Lennon	  et	  al.,	  
2001)	  and	  others	  reporting	  an	  unaltered	  or	  decreased	  potential	  (Salim	  et	  al.,	  2004).	  	  
	  
Hypoxic	  pre-­‐conditioning	  can	  also	  increase	  the	  survival	  of	   in	  vivo	   infused	  cells	  and	  enhance	  
repair	   in	   models	   of	   injury.	   Pre-­‐conditioned	   rat	   MSCs	   (1%	   O2	   for	   24h)	   increased	   overall	  
survival	   and	   serum	   albumin	   levels	   in	   a	   rat	   hepatectomy	   model	   (Yu	   et	   al.,	   2013).	   Similar	  
results	  were	  not	  observed	  with	  MSCs	  grown	  at	  atmospheric	  oxygen	  tension.	  This	  was	  due	  to	  





increased	  VEGF	  secretion	  by	  hypoxic	  pre-­‐conditioned	  MSCs,	  suggesting	  that	  hypoxia	  can	  also	  
alter	   the	   gene	   and	   protein	   expression	   of	  MSC	   populations.	   Human	  MSCs	   have	   also	   been	  
shown	   to	   increase	   production	   of	   trophic	   factors	   including	   VEGF,	   IL-­‐6	   and	   MCP-­‐1	   after	  
hypoxic	  culture	  (Hung	  et	  al.,	  2007).	  	  
	  
Finally,	   hypoxic	   culture	   can	   also	   increase	   the	   migratory	   capacity	   of	   MSCs	   by	   increasing	  
expression	   of	   chemokine	   receptors.	   Increased	   expression	   of	   CXCR4	   in	   rat	  MSCs	   enhanced	  
their	  migration	  towards	  injured	  tissue	  in	  a	  rat	  brain	  injury	  model	  (Kuo	  et	  al.,	  2008).	  Hypoxic	  
pre-­‐conditioning	   of	   human	   MSCs	   also	   improved	   their	   migration	   in	   a	   hind	   limb	   ischemia	  
model,	   resulting	   in	   significantly	   improved	   blood	   flow	   to	   the	   injured	   limb	   compared	   to	  
normoxic-­‐MSCs	  (Rosová	  et	  al.,	  2008).	  	  
	  
	   1.7.4	  Matrix	  Stiffness	  	  
The	   culture	   matrix	   has	   an	   important	   role	   to	   play	   in	   directing	   stem	   cell	   behaviour,	   with	  
traditional	   culture	   protocols	   using	   uncoated	   tissue	   culture	   plastic	   for	   the	   expansion	   and	  
differentiation	  of	  MSCs	  in	  vitro.	  However,	  newer	  studies	  have	  demonstrated	  the	  importance	  
of	   the	  culture	  matrix	   in	  directing	  MSC	  differentiation	  down	  specific	   lineages.	  McBeath	  and	  
colleagues	   were	   able	   to	   control	   the	   differentiation	   of	   human	   MSCs	   down	   osteogenic	   or	  
adipogenic	  lineages	  solely	  by	  controlling	  the	  shape	  of	  the	  cell	   (McBeath	  et	  al.,	  2004).	  MSCs	  
that	  were	  cultured	  as	   small,	   round	  cells	  underwent	  adipogenic	  differentiation,	  while	  MSCs	  
that	   were	   able	   to	   adhere	   and	   spread	   underwent	   osteogenic	   differentiation.	   Oh	   and	  





colleagues	   were	   able	   to	   differentiate	  MSCs	   towards	   bone	   irrespective	   of	   any	   osteogenic-­‐
inducing	  media	  by	  culturing	  cells	  on	  nanotubes	  that	  promoted	  adhesion	  and	  spreading	  (Oh	  
et	  al.,	  2009).	  	  
	  
The	  importance	  of	  surface	  rigidity	  has	  been	  demonstrated	  in	  a	  well-­‐cited	  study	  by	  Engler	  et	  
al.,	  who	  observed	  profound	  gene	  and	  protein	  expression	  changes	   in	  human	  MSCs	  cultured	  
on	  polyacrylamide	  gels	  of	  varying	  stiffness	  (Engler	  et	  al.,	  2006).	  MSCs	  cultured	  on	  “soft”	  gels	  
expressed	   proteins	   found	   in	   neurons,	   while	   MSCs	   that	   were	   cultured	   on	   “medium”	   and	  
“hard”	  gels	  expressed	  myogenic	  and	  osteogenic	  markers	  respectively.	  A	  similar	  finding	  was	  
reported	   when	   human	  MSCs	   were	   cultured	   in	   3D	   on	   gels	   of	   varying	   stiffness	   (Pek	   et	   al.,	  
2010a).	   These	   studies	   demonstrate	   how	   the	   culture	   matrix	   can	   work	   in	   synergy	   with	  
inductive	  signals	  from	  culture	  media	  to	  enhance	  MSC	  differentiation	  down	  a	  specific	  lineage.	  	  
	  
	   1.7.5	  MSC	  “Licensing”	  and	  TLR	  signalling	  
MSCs,	  although	  regarded	  primarily	  as	   immunosuppressive	  cells,	   can	  have	  proinflammatory	  
functions	  by	  acting	  as	  APCs	  (Chan	  et	  al.,	  2006)	  and	  by	  supporting	  the	  survival	  and	  function	  of	  
B	  cells	  (Rasmusson	  et	  al.,	  2007a)	  and	  neutrophils	  (Raffaghello	  et	  al.,	  2008).	  As	  such,	  we	  now	  
know	   that	   the	   immunosuppressive	   functions	   of	   MSCs	   are	   not	   constitutively	   active,	   but	  
tightly	  regulated	  by	  the	  inflammatory	  microenvironment	  it	  encounters.	  This	  balance	  centres	  
on	   the	   number	   of	   ‘immunosuppressive	   signals’	   provided	   by	   proinflammatory	   cytokines	  
compared	  to	  ‘immunosupportive	  signals’	  mediated	  by	  toll-­‐like	  receptor	  (TLR)	  signalling.	  The	  





stepwise	  process	  resulting	  in	  the	  eventual	  activation	  of	  MSC	  immunosuppressive	  machinery	  
has	   been	   termed	   MSC	   “licensing”,	   and	   the	   importance	   of	   this	   process	   is	   increasingly	  
becoming	  clear	  (Krampera,	  2011).	  	  
	  
The	  proinflammatory	   cytokine	   IFNγ	  plays	  a	   crucial	   role	   in	   the	   licensing	  process.	  Binding	  of	  
IFNγ	  to	   its	  receptor	  on	  MSCs	   is	  required	  for	  MSC-­‐mediated	   immunosuppression	  (Krampera	  
et	  al.,	  2006).	  Addition	  of	  an	  IFNγ	  antibody	  neutralised	  this	  suppressive	  activity.	  IFNγ	  receptor	  
knockout	  MSCs	  failed	  to	  prevent	  T	  cell	  proliferation	  in	  vitro	  and	  also	  failed	  to	  prevent	  GvHD	  
in	  experimental	  animals.	  Other	  pro-­‐inflammatory	  cytokines	  TNFα,	  IL-­‐1α	  and	  IL-­‐1β	  have	  also	  
been	   shown	   to	   work	   synergistically	   with	   IFNγ	   to	   induce	   immunosuppression	   (Ren	   et	   al.,	  
2008).	  Finally,	  MSCs	  that	  were	  pre-­‐stimulated	  with	  IFNγ	  could	  prevent	  GvHD	  more	  efficiently	  
(5x	   less	   cell	   number	   required)	   than	   unstimulated	   control	   cells.	   However,	   MSCs	   failed	   to	  
prevent	   the	   proliferation	   of	   IFNγ-­‐/-­‐	   T	   cells,	   highlighting	   the	   importance	   of	   IFNγ	   in	   the	  
initiation	  of	  MSC-­‐derived	  immunosuppression	  (Polchert	  et	  al.,	  2008).	  	  	  	  	  
	  
TLR	   signalling	   can	   counterbalance	   the	   immunosuppressive	   signals	   provided	   by	   IFNγ	   and	  
other	   inflammatory	   cytokines	   (Keating,	   2012).	   TLRs	   are	   expressed	   on	   innate	   immune	   cells	  
and	   recognise	  a	   variety	  of	   “danger	   signals”	   such	  as	  bacterial	   proteins	  or	   viral	  RNA	   (Patten	  
and	  Collett,	  2013).	  Both	  human	  and	  mouse	  MSCs	  express	  TLRs	  1-­‐6,	  with	  TLR3	  and	  TLR4	  being	  
particularly	  important	  in	  regulating	  immunosuppressive	  functions	  (DelaRosa	  and	  Lombardo,	  
2010).	   Priming	   of	   MSCs	   using	   TLR3	   ligands	   (double	   stranded	   RNA,	   a	   hallmark	   of	   viral	  
infection)	  resulted	   in	  the	  production	  of	  anti-­‐inflammatory	  cytokines	  and	  the	   inhibition	  of	  T	  





cell	   proliferation.	   Conversely,	   TLR4	   priming	   (using	   LPS,	   a	   hallmark	   of	   bacterial	   infection)	  
results	   in	   the	   production	   of	   proinflammatory	   cytokines	   and	   enhanced	   T	   cell	   proliferation	  
(Waterman	  et	  al.,	  2010,	  Tomchuck	  et	  al.,	  2008).	  	  
	  	  
Figure	   1.11	   |	   TLR	   signalling	   in	   MSCs.	   TLR4	   activation	   polarises	   MSCs	   towards	   a	   proinflammatory	   cell	   that	  
enhances	   the	   proliferation	   of	   activated	   T	   cells.	   TLR3	   activation	   polarises	   MSCs	   towards	   a	   more	  
immunosuppressive	  phenotype.	  Figure	  modified	  from	  Keating,	  2012.	  	  
	  
The	   current	   hypothesis	   is	   that	   MSCs	   can	   respond	   to	   signals	   in	   the	   inflammatory	  
microenvironment	   to	  both	  promote	   (TLR4	  primed)	  or	   suppress	   (TLR3	  primed)	   the	   immune	  
system	  at	  different	  stages	  of	  tissue	  injury	  (Figure	  1.11;	  Keating,	  2012).	  Future	  studies	  should	  
examine	  the	  effect	  of	  TLR3	  priming	  and	  IFNγ	  licensing	  on	  the	  therapeutic	  properties	  of	  MSCs	  
in	  vivo	  to	  see	  if	  this	  hypothesis	  remains	  true.	  	  
	   	  





1.8	  Aims	  and	  Objectives	  
MSCs	  hold	   great	  promise	   in	   future	  uses	   as	   a	   regenerative	  or	   immunosuppressive	   therapy.	  
However,	   previous	   work	   in	   the	   murine	   MSC	   field	   has	   been	   confounded	   by	   the	  
heterogeneous	   population	   of	   plastic-­‐adherent	   cells	   used	   in	   most	   studies.	   Three	   recent	  
publications	   detailing	   the	   prospective	   isolation	   of	   murine	   MSCs	   have	   the	   potential	   to	  
revolutionise	  this	  field,	  but	  the	  uptake	  of	  these	  techniques	  by	  the	  wider	  scientific	  community	  
has	  been	  slow.	  If	  the	  claims	  made	  by	  these	  groups	  are	  reproducible,	  we	  would	  venture	  that	  
all	  further	  studies	  on	  murine	  MSCs	  utilise	  these	  cells	  exclusively.	  	  
	  
In	  this	  study,	  I	  set	  out	  to	  prospectively	  isolate	  murine	  PαS	  MSCs	  based	  on	  the	  expression	  of	  
PDGFRα	  and	  Sca-­‐1	  (Morikawa	  et	  al.,	  2009).	  PαS	  MSCs	  formed	  the	  substrate	  for	  my	   in	  vitro	  
and	  in	  vivo	  studies	  on	  MSC	  biology,	  and	  the	  specific	  aims	  for	  my	  project	  were	  to:	  
	  
1. Isolate	   PαS	   MSCs	   and	   characterise	   their	   growth,	   CFU-­‐F,	   differentiation	   and	  
immunosuppressive	  properties	  
2. Examine	  the	  effect	  of	  extended	  culture	  on	  PαS	  MSC	  function	  
3. Examine	   the	   effect	   of	   FGF2,	   PDGF-­‐BB	   and	   TGF-­‐β1	   supplementation	   for	   the	  
enhancement	  of	  PαS	  MSC	  function	  and	  the	  reduction	  of	  senescence	  


































2.1	  Prospective	  Isolation	  of	  Murine	  PαS	  MSCs	  
The	   prospective	   isolation	   of	   PαS	   MSCs	   was	   performed	   as	   described	   by	   Morikawa	   et	   al.	  
(2009).	   We	   typically	   processed	   10	   mice	   per	   isolation	   and	   the	   sample	   preparation	   took	  
approximately	  five	  hours	  until	  it	  was	  ready	  for	  cell	  sorting.	  The	  majority	  of	  experiments	  were	  
performed	   using	   PαS	   MSCs	   isolated	   from	   C57BL/6	   mice,	   with	   some	   in	   vitro	  
immunosuppression	   assays	   performed	   using	   Balb/c-­‐derived	   PαS	   MSCs.	   Instances	   where	  
Balb/c-­‐derived	  cells	  were	  used	  have	  clearly	  been	  indicated	  in	  text.	  	  
	  
	   2.1.1	  Cell	  isolation	  from	  Compact	  Bone	  
Male	  8-­‐12	  week	  old	  C57BL/6	  (Harlan,	  Bicester,	  UK)	  or	  Balb/c	  mice	  (Jackson	  Laboratory,	  ME,	  
USA)	  were	  sacrificed	  by	  cervical	  dislocation.	  The	  femur	  and	  tibia	  were	  dissected	  out	  of	  the	  
lower	  limbs	  and	  all	  soft	  tissue	  removed	  using	  tissue	  paper.	  Cleaned	  bones	  were	  stored	  in	  ice-­‐
cold	  PBS	  while	  the	  remaining	  animals	  were	  processed.	  	  
	  
Cleaned	  bones	  were	  washed	  three	  times	  in	  sterile	  PBS	  to	  remove	  any	  non-­‐adherent	  tissue.	  
They	   were	   then	   placed	   in	   a	   sterile	   pestle	   and	  mortar	   and	   gently	   crushed	   to	   achieve	   one	  
fracture	   per	   bone.	   Bone	   fragments	   were	   then	   further	   cut	   using	   sterile	   scissors	   until	   a	  
homogenous	  paste	  was	   formed.	  The	   resulting	  paste	  was	  washed	  once	   in	  5ml	  PBS	  and	   the	  
bone	  marrow	  was	  discarded.	  Compact	  bone	  fragments	  were	  then	  incubated	  in	  20ml	  DMEM	  
(Dulbecco’s	  Modified	   Eagle	  Medium;	   Gibco,	   Paisley,	   UK)	   supplemented	   with	   0.2%	   (40mg)	  
collagenase	   (Wako	   Chemicals,	   Neuss,	   DE)	   and	   1x	   penicillin/streptomycin/glutamine	   (PSG;	  
Gibco)	  for	  60	  minutes	  in	  a	  temperature-­‐regulated	  shaker	  set	  at	  37°C	  and	  125rpm.	   	  





Following	   incubation,	   the	   cell	   suspension	   was	   filtered	   through	   a	   sterile	   70µm	   strainer	  
(Corning,	   Amsterdam,	   NL)	   and	   the	   larger	   bone	   fragments	   placed	   back	   in	   the	  mortar.	   The	  
fragments	  were	   then	  placed	   in	   2.5ml	   ice-­‐cold	  HBSS	   (Hank’s	  Balanced	   Salt	   Solution;	  Gibco)	  
supplemented	  with	  2%	  FBS	   (Gibco),	  10mM	  HEPES	   (Sigma-­‐Aldrich,	  Dorset,	  UK)	  and	  1x	  PSG.	  
Resuspended	  bone	  fragments	  were	  gently	  tapped	  50	  times	  with	  the	  pestle	  before	  a	  further	  
2.5mls	  of	  supplemented-­‐HBSS	  was	  added.	  This	  solution	  was	  pipetted	  up	  and	  down	  several	  
times	   to	   liberate	   cells	   from	   the	   bone	   fragments.	   The	   liquid	   supernatant	   was	   carefully	  
aspirated	  and	  passed	  through	  a	  sterile	  70µm	  strainer	   into	  the	  same	  falcon	  tube	  containing	  
the	   filtrate	   from	   earlier.	   This	   tapping	   and	   re-­‐suspending	   step	   was	   repeated	   a	   further	   six	  
times	  to	  end	  up	  with	  a	  final	  cell	  suspension	  of	  50ml.	  	  
	  
The	  resulting	  cell	  suspension	  was	  pelleted	  by	  centrifugation	  at	  1500	  rpm	  for	  7	  minutes	  at	  4°C.	  
The	   supernatant	  was	  discarded	  and	   the	  pellet	  was	   resuspended	   in	   the	   residual	   volume	  by	  
vigorous	   tapping.	   Red	   blood	   cell	   (RBC)	   lysis	  was	   performed	   by	   adding	   1ml	   ice-­‐cold	   sterile	  
water	   (Sigma-­‐Aldrich)	   to	   the	   resuspended	   pellet	   for	   5	   seconds.	   The	   reaction	   was	   quickly	  
quenched	   by	   the	   addition	   of	   1ml	   2x	   (double-­‐strength)	   PBS	   supplemented	   with	   4%	   FBS	  
followed	   by	   20ml	   of	   supplemented	   HBSS-­‐solution.	   The	   sample	   was	   filtered	   before	  
centrifugation	  at	  2000	  rpm	  for	  5	  minutes	  at	  4°C.	  The	  resulting	  pellet	  was	  resuspended	  in	  1ml	  
of	  supplemented-­‐HBSS	  solution	  prior	  to	  antibody	  staining.	  	  
	   	  





	   2.1.2	  Antibody	  Staining	  of	  BM	  cells	  
Single-­‐cell	   suspensions	   of	   BM	   were	   labelled	   with	   conjugated	   antibodies	   to	   CD45	   (PE;	  
1µl/mouse),	   Ter-­‐119	   (PE;	   1µl/mouse),	   Sca-­‐1	   (FITC;	   1µl/mouse)	   and	   PDGFRα	   (APC;	  
2µl/mouse)	  for	  30	  minutes	  on	  ice.	  All	  antibodies	  were	  purchased	  from	  eBioscience	  (Hatfield,	  
UK).	   Relevant	   control	   tubes	   were	   prepared	   by	   adding	   1µl	   BM	   cell	   suspension	   to	   100µl	  
supplemented-­‐HBSS	   containing	   1µl	   each	   of	   PE-­‐CD45,	   FITC-­‐Sca-­‐1	   and	   APC-­‐PDGFRα	   and	  
incubated	  for	  30	  minutes	  on	  ice.	  	  
	  
After	   incubation,	   the	  main	   sample	   was	   washed	   in	   20ml	   of	   supplemented-­‐HBSS	   while	   the	  
control	  tubes	  were	  washed	  in	  1ml	  each	  of	  supplemented-­‐HBSS.	  Samples	  were	  spun	  at	  2000	  
rpm	   for	   5	  minutes	   at	   4˚C	  prior	   to	   re-­‐suspension	   in	   supplemented-­‐HBSS	   containing	  2µg/ml	  
propidium	   iodide	   (PI;	   Sigma-­‐Aldrich).	  All	   sample	   tubes	  were	   filtered	   through	  a	   sterile	   50µl	  
filter	  (Partec,	  Görlitz,	  DE)	  and	  stored	  on	  ice	  prior	  to	  cell	  sorting.	  	  
	  
	   2.1.3	  Purification	  of	  MSCs	  via	  Cell	  Sorting	  
Samples	  were	  sorted	  on	  a	  MoFlo	  XDP	  cell	  sorter	  (Beckman	  Coulter,	  CA,	  USA).	  Stream	  setup,	  
laser	  alignment	  and	  drop	  delay	  were	  calibrated	  before	  each	  sort.	  Single	  colour	  tubes	  were	  
run	   and	   appropriate	   compensation	   applied.	   Relevant	   gates	   were	   added	   to	   select	   the	   PI-­‐
negative	   live	  cell	  population,	  exclude	  PE-­‐CD45+/PE-­‐Ter119+	  haematopoietic	  cells	  and	  purify	  
APC-­‐PDGFRα+/FITC-­‐Sca-­‐1+	   cells	   of	   interest.	   Samples	   were	   run	   at	   approximately	   20,000	  
events	  per	  second	  for	  sorting.	  	   	  





2.2	  PαS	  Cell	  Culture	  
	   2.2.1	  Maintenance	  and	  Expansion	  
Sorted	   PαS	   cells	   were	   cultured	   in	   standard	   media	   (SM)	   consisting	   of	   αMEM	   (α-­‐modified	  
Minimum	  Essential	  Medium,	  Gibco)	  supplemented	  with	  10%	  FBS	  and	  1xPSG.	  Initial	  seeding	  
density	  was	   5000	   cells/cm2	   in	   6-­‐well	   plates.	   Cultures	  were	  maintained	   at	   37˚C,	   5%	  CO2	   in	  
humidified	   incubators.	   To	   test	   the	   effect	   of	   GF	   stimulation,	   SM	   was	   supplemented	   with	  
10ng/ml	   of	   murine	   PDGF-­‐BB	   (Peprotech,	   London,	   UK),	   FGF2	   (Peprotech)	   or	   TGF-­‐β1	   (New	  
England	  Biolabs,	  Hitchin,	  UK).	  	  
	  
	   2.2.2	  Passaging	  
PαS	  cultures	  were	  passaged	  when	  they	  reached	  90%	  confluency.	  Spent	  media	  was	  removed	  
and	   cultures	   were	   washed	   once	   in	   PBS.	   Pre-­‐warmed	   (37˚C)	   TrypLE	   Express	   (Gibco)	   was	  
added	  and	   incubated	  at	  37˚C	   for	  3	  minutes	  or	  until	   cells	  became	   fully	  detached.	  An	  equal	  
volume	  of	  SM	  was	  added	  to	  neutralise	  the	  TrypLE	  and	  cells	  were	  pelleted	  by	  centrifugation	  
at	  2000	  rpm	  for	  5	  minutes.	  Cultures	  were	  usually	  expanded	  at	  1:2	  or	  1:3	  ratios	   into	  bigger	  
culture	  dishes.	  	  
	   	  





2.3	  CFU-­‐F	  Assay	  
CFU-­‐F	  assay	  was	  performed	  on	  freshly	   isolated	  cells	  by	  seeding	  2000	  PαS	  MSCs	   in	  a	  10cm2	  
tissue	   culture	   petri	   dish.	   Cultures	  were	  maintained	   for	   14	   days	   before	   being	   fixed	   in	   10%	  
formal	  saline	  solution	  (Adams	  Healthcare,	  Northwich,	  UK)	  for	  5	  minutes.	  Fixed	  cultures	  were	  
washed	  once	  in	  PBS	  and	  then	  stained	  using	  0.5%	  crystal	  violet	  solution	  (Sigma-­‐Aldrich)	  for	  60	  
minutes	   at	   room	   temperature.	   Excess	   stain	  was	   removed	  with	   two	   further	  washes	   in	   tap	  
water	  and	  dishes	  were	  allowed	  to	  air	  dry	  before	  imaging.	  	  
	  
2.4	  Growth	  Curves	  
PαS	  MSCs	  were	  seeded	  at	  a	  density	  of	  4000	  cells	  per	  well	  of	  a	  48-­‐well	  plate	  in	  the	  presence	  
of	  SM	  or	  GF-­‐supplemented	  medium.	  Once	  confluent,	  cells	  were	  passaged	  into	  larger	  wells	  at	  
a	  1:2	  ratio.	  After	  50	  days	  an	  aliquot	  was	  taken	  to	  estimate	  final	  cell	  number	  and	  the	  samples	  
fixed	  for	  senescence	  staining.	  	  
	  
2.5	  Beta-­‐galactosidase	  staining	  	  
The	  expression	  of	  beta-­‐galactosidase	  (β-­‐gal)	  was	  used	  to	  estimate	  the	  level	  of	  senescence	  in	  
PαS	  MSC	  cultures.	  A	  senescence	  detection	  kit	  (Biovision,	  CA,	  USA)	  was	  used	  for	  this	  purpose	  
and	   the	   manufacturer’s	   instructions	   were	   followed.	   Briefly,	   this	   involved	   fixing	   PαS	   MSC	  
cultures	   and	   incubating	   them	   overnight	   in	   X-­‐Gal	   (a	   chromogenic	   substrate	   for	   β-­‐gal).	  
Senescent	  cells	  develop	  a	  blue-­‐green	  colour,	  which	  was	  then	  imaged	  and	  quantified	  from	  12	  
randomly	  selected	  fields	  of	  view	  per	  sample.	  	  	  





2.6	  Differentiation	  Cultures	  
To	   induce	   differentiation,	   SM	  was	   swapped	   over	   to	   commercially	   available	   differentiation	  
medium	  and	  GF	  treatment	  was	  stopped.	  Thus,	  the	  changes	  we	  saw	  in	  differentiation	  ability	  
were	  due	  to	  the	  ‘priming’	  effect	  of	  GFs	  used	  during	  the	  expansion	  stage	  only	  (Figure	  2.1).	  
	  
	  
Figure	  2.1	  |	  Effect	  of	  GF	  priming	  on	  PαS	  MSCs.	  GFs	  were	  added	  during	  the	  expansion	  stage	  of	  PαS	  MSC	  culture	  
only.	  Cells	  were	  washed	  thoroughly	  with	  PBS	  to	  remove	  GFs	  before	  conducting	  any	  experiments.	  	  
	  
	   2.6.1	  Osteogenic	  Differentiation	  &	  Alizarin	  Red	  Staining	  
To	   induce	  osteogenic	  differentiation,	  subconfluent	  MSCs	  were	  cultured	   in	  osteogenic	  basal	  
medium	  (Lonza,	  Cologne,	  DE)	   for	  16	  days,	  with	   the	  media	  swapped	  every	  4	  days.	  Cultures	  
were	  fixed	  in	  10%	  formal	  saline	  solution	  for	  15	  minutes	  and	  washed	  three	  times	  in	  distilled	  
water	   (dH20)	   prior	   to	   staining	   with	   an	   Osteogenesis	   Assay	   Kit	   (Millipore,	   Watford,	   UK)	  
according	   to	   manufacturer’s	   instructions.	   Briefly,	   this	   involved	   staining	   the	   fixed	   cultures	  
with	  alizarin	  red	  staining	  solution	  to	  mark	  any	  calcium	  deposits.	  Samples	  were	  imaged	  at	  this	  
point	  for	  visual	  analysis.	  	  





Quantitative	  analysis	  of	  alizarin	  red	  staining	  was	  performed	  by	  measuring	  the	  optical	  density	  
(OD)	  values	  of	  our	  samples	  compared	  to	  a	  set	  of	  known	  calcium	  standards.	  Alizarin	  red	  was	  
extracted	   from	   fixed	   cultures	   by	   incubating	   them	   in	   10%	   acetic	   acid	   for	   30	  minutes.	   The	  
supernatant	  was	  then	  transferred	  into	  a	  1.5ml	  eppendorf	  tube	  and	  vortexed	  vigorously	  for	  
30	  seconds	  before	  being	  heated	  to	  85˚C	  for	  10	  minutes.	  Samples	  were	  allowed	  to	  cool	  for	  5	  
minutes	   on	   ice	   and	   then	   centrifuged	   at	   20,000g	   for	   15	   minutes.	   The	   supernatant	   was	  
carefully	   transferred	   into	   a	   new	   eppendorf	   tube	   and	   neutralised	   with	   10%	   ammonium	  
hydroxide.	  150µl	  of	  samples	  and	  alizarin	  red	  standards	  were	  transferred	  into	  a	  flat-­‐bottomed	  
96	  well	  plate	  and	  OD405	  measured	  on	  a	  plate	  reader	  (Synergy	  HT,	  BioTek,	  Potton,	  UK).	  	  
	  
	   2.6.2	  Adipogenic	  Differentiation	  &	  Oil	  Red	  O	  Staining	  
To	   induce	   adipogenic	   differentiation,	   confluent	   PαS	  MSCs	   were	   cultured	   for	   four	   days	   in	  
adipogenic	   induction	   medium	   (Lonza),	   followed	   by	   four	   days	   in	   adipogenic	   maintenance	  
medium	   (Lonza).	   Differentiated	   cultures	   were	   fixed	   in	   10%	   formal	   saline	   solution	   for	   10	  
minutes	  before	  being	  incubated	  in	  60%	  isopropanol	  for	  5	  minutes.	  Oil	  Red	  O	  stock	  solution	  
was	  made	  by	  dissolving	  0.25g	  Oil	  Red	  O	  (Sigma-­‐Aldrich)	  in	  50ml	  100%	  isopropanol.	  This	  stock	  
was	  then	  diluted	  in	  water	  at	  a	  ratio	  1.5:1	  (Oil	  Red	  O:H2O).	  Freshly	  made	  Oil	  Red	  O	  working	  
solution	   was	   added	   to	   cultures	   and	   left	   for	   60	   minutes	   at	   room	   temperature.	   After	  
incubation,	   cultures	   were	   incubated	   in	   60%	   isopropanol	   for	   5	   minutes	   followed	   by	   two	  
washes	   in	   dH2O.	   Cultures	   were	   counterstained	   with	   Mayer’s	   haematoxylin	   for	   1	   minute	  
followed	  by	  two	  further	  washes	  in	  tap	  water	  before	  imaging.	  	  
	   	  





	   2.6.3	  Chondrogenic	  Differentiation	  &	  Toluidine	  Blue	  Staining	  
To	   induce	   chondrogenic	   differentiation,	   250,000	   PαS	   MSCs	   were	   re-­‐suspended	   in	  
chondrogenic	   differentiation	   medium	   (Lonza)	   supplemented	   with	   10ng/ml	   TGF-­‐β3	  
(Peprotech)	  in	  15ml	  polypropylene	  tubes.	  Samples	  were	  centrifuged	  at	  150g	  for	  5	  minutes	  to	  
pellet	  cells.	  The	  tube	  was	  transferred	  into	  a	  cell	  culture	   incubator	  and	  the	  cap	  loosened	  to	  
allow	  gas	  exchange.	  The	  pellets	  were	   left	  undisturbed	   for	  48	  hours	  before	  being	   flicked	  to	  
release	  them	  into	  suspension.	  Samples	  were	  incubated	  for	  21	  days	  with	  the	  media	  carefully	  
replaced	  every	  3	  days.	  	  
	  
After	   21	   days	   of	   differentiation,	   cartilage	   pellets	   were	   carefully	   aspirated	   onto	   a	   flat-­‐
bottomed	   foil	   boat	   and	   excess	   media	   was	   removed.	   Three	   drops	   of	   OCT	   embedding	  
compound	  (Sakura	  Tissue-­‐Tek,	  Thatcham,	  UK)	  was	  added	  to	  the	  foil	  boat	  and	  slowly	  frozen	  
in	   the	   vapour	   phase	  of	   liquid	   nitrogen	   to	   cryoembed	   the	   cartilage	  pellet.	   7µm	   sections	   of	  
cartilage	  pellets	  were	  cut	  on	  a	  cryostat	  and	  acetone-­‐fixed	  onto	  microscope	  slides	  (Superfrost	  
Plus,	  Thermo	  Scientific,	  MA,	  USA)	  and	  stored	  at	  -­‐20˚C	  until	  needed.	  	  
	  
Toluidine	  blue	  staining	  was	  used	  to	  visualise	  proteoglycan	  deposits	  in	  cartilage	  pellets.	  Slides	  
were	  allowed	  to	  defrost	  for	  10	  minutes	  and	  a	  wax	  ring	  was	  drawn	  around	  sections.	  200µl	  of	  
0.1%	  Toluidine	  blue	  (dissolved	  in	  a	  pH	  4.0	  acetic	  acid/sodium	  acetate	  buffer;	  Sigma-­‐Aldrich)	  
was	   added	   to	   each	   slide	   and	   incubated	  at	   room	   temperature	   for	  one	  minute.	   Slides	  were	  
then	   rinsed	   three	   times	   in	   tap	  water	   for	   2	  minutes	   each.	   Slides	  were	   then	  dehydrated	  by	  





passing	   through	   industrial	   methylated	   spirit	   (IMS;	   PFM	  Medical,	   Cheshire,	   UK)	   twice,	   and	  
Xylene	   solvent	   (PFM	   Medical)	   three	   times	   before	   mounting	   coverslips	   using	   DPX	   (Leica,	  
Wetzlar,	   DE).	   DPX	   was	   allowed	   to	   set	   overnight	   before	   imaging	   on	   a	   conventional	   light	  
microscope	  (Carl	  Zeiss	  AG,	  Oberkochen,	  DE).	  	  
	  
	   2.6.4	  Pathway	  Analysis	  of	  PαS	  MSC	  Differentiation	  
Preliminary	  studies	  on	  downstream	  signalling	  pathways	  were	  performed	  to	  identify	  how	  GFs	  
were	  exerting	  their	  effects	  on	  PαS	  cells.	  In	  a	  subset	  of	  experiments,	  PαS	  cell	  were	  cultured	  in	  
SM	  containing	  one	  of	  the	  following	  small-­‐molecule	  inhibitors:	  25nM	  dasatinib	  (gift	  from	  Prof.	  
Heath,	  University	  of	  Birmingham),	  20µM	  SU5402	  (Tocris,	  Abingdon,	  UK),	  and	  10ng/ml	  PDGF-­‐
AA	   (Peprotech).	   The	   growth	   curves	   and	   adipogenic	   differentiation	   of	   PαS	   cells	   were	   then	  
examined	  as	  described	  previously.	  	  
	  	  
	   	  





2.7	  Biochemical	  analysis	  of	  Chondrogenic	  Differentiation	  
Further	  quantitative	  analysis	  of	  chondrogenic	  differentiation	  was	  performed	  in	  collaboration	  
with	  Dr	  Shang	  Zhang	  and	  Prof.	  Anthony	  Hollander	  at	  Bristol	  University,	  Bristol,	  UK.	  	  
	  
	   2.7.1	  Micromass	  Pellet	  Cartilage	  Differentiation	  
5x105	   PαS	   MSCs	   were	   pelleted	   in	   15ml	   polypropylene	   tubes	   and	   resuspended	   in	  
chondrogenic	   differentiation	   media	   (Bristol	   formulation).	   Chondrogenic	   differentiation	  
media	  (Bristol	  formulation)	  consisted	  of	  DMEM	  (Gibco)	  supplemented	  with	  1x	  PSG	  (Gibco),	  
1mM	   sodium	   pyruvate	   (Sigma-­‐Aldrich),	   1x	   insulin-­‐transferrin-­‐selenium	   (Gibco),	   50	   µg/ml	  
ascorbic	   acid-­‐2-­‐phosphate	   (Sigma-­‐Aldrich),	   100nM	   dexamethasone	   (Sigma-­‐Aldrich)	   and	  
10ng/ml	   TGF-­‐β3	   (Peprotech).	   	   Fresh	  media	  was	   added	  every	   three	  days	   and	   an	   additional	  
50µg/ml	  insulin	  (Sigma-­‐Aldrich)	  was	  added	  at	  day	  seven	  to	  all	  cultures.	  Cartilage	  pellets	  were	  
harvested	  for	  biochemical	  analysis	  after	  21	  days	  culture.	  	  
	  
	   2.7.2	  Cartilage	  Tissue	  Engineering	  
Cartilage	   scaffolds	   were	   produced	   as	   described	   by	   Kafienah	   et	   al.	   (2007),	   with	   a	   few	  
modifications.	   Biofelt®	   polyglycolic	   acid	   (PGA)	   scaffolds	   (5mm	   diameter,	   2mm	   thickness;	  
Biomedical	  Structures,	  Warwick,	  UK)	  were	  sterilised	  in	  absolute	  ethanol	  (Sigma-­‐Aldrich)	  for	  5	  
minutes.	  Excess	  ethanol	  was	  removed	  and	  scaffolds	  were	  washed	  in	  PBS	  three	  times.	  Sterile	  
PGA	   scaffolds	   were	   coated	   in	   100µg/ml	   fibronectin	   (Sigma-­‐Aldrich)	   for	   30	   minutes	   and	  
allowed	  to	  air-­‐dry	  overnight.	  	  





A	  1%	  solution	  of	  agarose	  was	  used	  to	  coat	  empty	  wells	  of	  a	  24-­‐well	  plate	  and	  left	  to	  solidify.	  
One	   fibronectin-­‐coated	   PGA	   scaffold	  was	   added	   to	   each	   agarose-­‐coated	  well	   of	   a	   24-­‐well	  
plate.	   The	  agarose	   coating	  ensures	  PαS	   cells	   do	  not	   adhere	  onto	   the	   tissue-­‐culture	  plastic	  
after	  being	  seeded	  onto	  PGA	  scaffolds.	  PGA	  scaffolds	  were	  then	  rehydrated	  for	  30	  minutes	  
in	  SM.	  After	  incubation,	  SM	  is	  removed	  and	  the	  scaffolds	  were	  ready	  for	  seeding.	  	  
	  
PαS	  MSCs	  at	  P7	  were	  used	  for	  tissue	  engineering	  studies.	  6x105	  PαS	  MSCs	  were	  harvested	  as	  
described	  previously	  and	  placed	  in	  separate	  polypropylene	  tubes.	  Samples	  were	  centrifuged	  
at	  1500rpm	  for	  5	  minutes	  and	  resuspended	  in	  30µl	  of	  SM.	  This	  concentrated	  cell	  suspension	  
was	  slowly	  added	  to	  the	  PGA	  scaffolds	  and	  left	  to	  incubate	  overnight.	  Scaffolds	  were	  turned	  
over	   the	   next	   day	   to	   promote	   even	   seeding.	   1ml	   of	   chondrogenic	   differentiation	   media	  
(Bristol	  formulation)	  was	  then	  added	  to	  each	  well	  containing	  scaffolds	  and	  the	  plates	  were	  
placed	   on	   a	   rotating	   platform	   (50rpm)	   inside	   a	   37˚C,	   5%	   CO2	   humidified	   incubator.	   Fresh	  
differentiation	  media	  was	  then	  added	  every	  three	  days.	  Additional	  50µg/ml	  insulin	  was	  again	  
added	   to	   the	  differentiation	  media	   at	   day	   seven.	   Scaffolds	  were	  maintained	  on	   a	   rotating	  
platform	  for	  a	  total	  of	  35	  days	  before	  analysis.	  	  
	  
	   2.7.3	  Sample	  digestion	  and	  solubilisation	  
Micromass	  pellets	  or	  tissue-­‐engineered	  scaffolds	  were	  weighed	  after	  overnight	  freeze-­‐drying	  
in	   a	   Modulyo	   Freeze	   Drier	   (Thermo	   Scientific)	   prior	   to	   protease	   digestion.	   Samples	   were	  
digested	   in	   125µl	   digestion	   solution	   containing	   2mg/ml	   bovine	   pancreatic	   trypsin	  





supplemented	   with	   1mM	   iodoacetamide,	   1mM	   EDTA	   and	   10µg/ml	   pepstatin	   A	   (all	   from	  
Sigma-­‐Aldrich)	   for	   15	   hours	   at	   37˚C.	   Afterwards,	   a	   further	   125µl	   digestion	   solution	   was	  
added	   and	   samples	   heated	   to	   65˚C	   for	   2	   hours.	   Protease	   digestion	   was	   then	   stopped	   by	  
boiling	  samples	  for	  15	  minutes	  to	  inactivate	  trypsin.	  	  
	  
Digested	   samples	   were	   centrifuged	   at	   14,000rpm	   for	   5	   minutes	   and	   the	   solubilised	  
supernatant	   was	   collected	   and	   transferred	   into	   a	   new	   eppendorf	   tube.	   Any	   remaining	  
undigested	  sample	  was	  vortexed	  in	  500µl	  water	  and	  centrifuged	  at	  14,000rpm	  for	  5	  minutes.	  
The	   supernatant	   was	   discarded	   and	   the	   undigested	   material	   was	   again	   freeze-­‐dried	  
overnight	  and	  weighed.	  The	  weight	  of	  undigested	  sample	  was	  removed	  from	  the	  weight	  of	  
the	  freeze-­‐dried	  pellets/scaffolds	  taken	  at	  the	  start	  of	  this	  protocol	  to	  give	  the	  total	  weight	  
of	  the	  solubilised	  sample.	  	  
	  
	   2.7.4	  Quantification	  of	  Collagen	  Type	  I	  using	  Competition	  ELISA	  
The	  quantification	  of	  collagen	  type	  I	  (Col1)	  was	  performed	  using	  a	  competition	  ELISA	  assay	  
(Figure	  2.2)	  developed	  by	  the	  Hollander	  group	  using	  peptides	  and	  antibodies	  made	  in-­‐house	  
(Dickinson	  et	  al.,	  2005).	  Col1	  peptide	  (AH23;	  sequence:	  SFLPQPPQ)	  was	  dissolved	  in	  sodium	  
carbonate	  buffer	  (pH	  9.2)	  to	  give	  a	  final	  concentration	  of	  40µg/ml.	  50µl	  of	  this	  solution	  was	  
added	  to	  each	  well	  of	  a	  96	  well	  plate	  (Immulon-­‐2HB,	  Thermo	  Scientific)	  and	  left	  to	  incubate	  
at	  4˚C	  for	  three	  days.	  Coated	  plates	  were	  washed	  three	  times	  with	  PBS+0.05%	  (v/v)	  Tween-­‐
20	  (PBS-­‐T;	  Sigma-­‐Aldrich).	  Each	  well	  was	  then	  blocked	  with	  PBS+1%	  (v/v)	  BSA	  (Sigma-­‐Aldrich)	  
for	  30	  minutes	  at	  room	  temperature	  before	  being	  washed	  with	  PBS-­‐T	  and	  kept	  at	  4˚C.	  	   	  






Figure	  2.2	  |	  Principles	  of	  competition	  ELISA.	  The	  amount	  of	  antigen	  found	  in	  your	  samples	  directly	  competes	  
for	  the	  antibody	  with	  the	  antigen	  found	  in	  the	  pre-­‐coated	  wells,	  hence	  the	  name	  “Competition”	  ELISA.	  Note	  the	  
inverse	  relationship	  between	  the	  signal	  (colour	  change)	  and	  the	  amount	  of	  antigen	  found	  in	  the	  sample.	  	  
	  
AH23	  Col1	  peptide	  was	  used	  as	  the	  standards	  for	  this	  assay	  (sensitivity	  range	  4-­‐1000ng/ml).	  
Standards	  and	  solubilised	  samples	  were	  diluted	  in	  0.8%	  sodium	  dodecyl	  sulphate	  (SDS)-­‐Tris	  
solution.	   A	   proprietary	   rabbit	   anti-­‐AH23	   IgG	   antibody	   (diluted	   1:1000	   in	   Tris	   buffer+4%	  
Triton-­‐X100)	  was	  used	  to	  bind	  to	  the	  AH23	  peptide	  sequence	  on	  collagen	  1	  (Dickinson	  et	  al.,	  
2005).	   This	   mixture	   of	   antibody	   and	   samples	   (50µl	   samples/standards	   to	   50µl	   primary	  
antibody)	  were	  left	  to	  incubate	  overnight	  in	  uncoated	  96-­‐well	  plates	  at	  37˚C.	  
	  
Following	  overnight	   incubation,	   50µl	   of	   the	   antibody/sample	  mixture	  was	   transferred	   into	  
empty	  wells	  of	  the	  AH23-­‐coated	  96-­‐well	  plates	  prepared	  earlier.	  This	  was	  left	  to	  incubate	  for	  





30	   minutes	   at	   room	   temperature	   before	   being	   washed	   three	   times	   with	   PBS-­‐T.	   Alkaline	  
phosphatase	  (ALP)-­‐conjugated	  goat	  anti	  rabbit	  (Southern	  Biotech,	  Cambridge,	  UK)	  secondary	  
antibody	   was	   diluted	   1:1000	   in	   PBS-­‐T	   and	   added	   to	   each	   well	   of	   the	   AH23-­‐coated	   plate	  
containing	   samples.	   This	  was	   left	   to	   incubate	   for	   2	   hours	   at	   37˚C.	  After	   incubation,	   plates	  
were	  washed	  2x	   in	  PBS-­‐T	  and	  0.5mg/ml	  p-­‐nitrophenyl	  phosphate	  (substrate	  for	  AP;	  Sigma-­‐
Aldrich)	  was	  added	  to	  each	  well	  and	  left	  to	  incubate	  for	  20	  minutes	  for	  the	  colour	  to	  develop.	  
The	  absorbance	  was	  read	  at	  OD405	  on	  an	  Ascent	  plate	  reader	  (MTX	  Lab	  Systems,	  VA,	  USA).	  	  
	  
	   2.7.5	  Quantification	  of	  Collagen	  Type	  II	  using	  Competition	  ELISA	  
A	  similar	  competition	  ELISA-­‐based	  system	  was	  used	  for	  the	  measurement	  of	  type	  II	  collagen	  
(Col2;	  Dickinson	  et	  al.,	  2005).	  384-­‐well	  high-­‐binding	  ELISA	  plates	  (Corning)	  were	  coated	  with	  
40µg/ml	  bovine	  tracheal	  Col2	  (Sigma-­‐Aldrich)	  for	  3	  days	  at	  4˚C.	  Coated	  plates	  were	  washed	  
three	  times	  with	  PBS-­‐T	  and	  each	  well	  was	  then	  blocked	  with	  PBS+1%	  BSA	  for	  30	  minutes	  at	  
room	  temperature.	  Plates	  were	  then	  washed	  once	  with	  PBS-­‐T	  and	  kept	  at	  4˚C	  until	  needed.	  	  
	  
CB11B	  peptide	   (sequence:	  CGKVGPSGAP[OH]GEDGRP[OH]GPP[OH]GPQY)	  was	  used	  as	  Col2	  
standards	  in	  this	  assay	  (Hollander	  et	  al.,	  1994).	  The	  sensitivity	  range	  was	  between	  2-­‐10µg/ml.	  
A	  proprietary	  mouse	  IgG	  monoclonal	  antibody	  against	  Col2	  (diluted	  1:600	  in	  50mM	  Tris-­‐HCL,	  
pH	   7.6)	   was	   used	   as	   the	   primary	   antibody	   in	   this	   assay.	   An	   equal	  mixture	   of	   sample	   and	  
antibody	  (10µl	  samples	  to	  10µl	  diluted	  antibody)	  were	  incubated	  in	  triplicate	  in	  sealed	  384-­‐
well	  plates	  overnight	  at	  37˚C.	  	   	  





Following	  overnight	   incubation,	   10µl	   of	   the	   antibody/sample	  mixture	  was	   transferred	   into	  
empty	   wells	   of	   the	   bovine	   Col2-­‐coated	   384-­‐well	   plates	   prepared	   earlier.	   This	   was	   left	   to	  
incubate	  for	  30	  minutes	  at	  room	  temperature	  before	  being	  washed	  three	  times	  with	  PBS-­‐T.	  
AP-­‐conjugated	  goat	  anti	  mouse	  (Southern	  Biotech)	  secondary	  antibody	  was	  diluted	  1:1000	  in	  
PBS-­‐T	  and	  added	  to	  each	  well	  of	  the	  plate	  containing	  samples.	  This	  was	  left	  to	  incubate	  for	  2	  
hours	  at	  37˚C.	  After	  incubation,	  plates	  were	  washed	  2x	  in	  PBS-­‐T	  and	  0.5mg/ml	  p-­‐nitrophenyl	  
phosphate	  was	   added	   to	   each	  well	   and	   left	   to	   incubate	   for	   20	  minutes	   for	   the	   colour	   to	  
develop.	  The	  absorbance	  was	  then	  read	  at	  OD405	  on	  an	  Ascent	  plate	  reader.	  	  	  
	  
	   2.7.6	  Quantification	  of	  Glycosaminoglycans	  
The	  quantification	  of	  glycosaminoglycans	   (GAG)	  was	  done	  colourimetrically	  using	  a	   system	  
established	   by	   Handley	   and	   Buttle	   (1995).	   This	   assay	   is	   based	   around	   the	   ability	   of	   the	  
metachromatic	  dye	  dimethylmethylene	  blue	  (DMB)	  to	  form	  a	  complex	  with	  sulphated	  GAGs	  
under	   acidic	   pH	   conditions.	   Binding	   of	   DMB	   to	   GAGs	   causes	   a	   shift	   in	   their	   absorption	  
spectrum	   that	   can	  be	   read	  at	  OD525.	   This	   shift	   is	  proportional	   to	   the	  amount	  of	   sulphated	  
GAGs	   found	   in	   the	   sample	   and	   can	   be	   quantified	   via	   the	   use	   of	   known	   standards.	   Bovine	  
tracheal	   chondroitin	   sulphate	   (Sigma-­‐Aldrich)	   was	   used	   as	   standards	   (sensitivity	   range	   5-­‐
50µg/ml)	   in	   our	   experiments.	   250µl	   DMB	   solution	   (Sigma-­‐Aldrich)	   was	   added	   to	   20µl	  
samples	   in	  96-­‐well	   round-­‐bottomed	  plates.	   Samples	  were	  mixed	  and	   the	  absorbance	   read	  
immediately	  at	  525nm	  on	  an	  Ascent	  plate	  reader.	  	   	  





2.8	  In	  vitro	  Immunosuppression	  Assay	  
This	  purified	  assay	  used	  magnetic-­‐activated	  cell	  sorting	  (MACS)	  to	   isolate	  naive	  T	  cells	  that	  
were	  stimulated	  with	  anti-­‐CD3	  antibody	  and	  purified	  CD19	  B	  cells.	  Graded	  numbers	  of	  PαS	  
MSCs	   isolated	  from	  Balb/c	  mice	  were	  added	   in	  a	  subset	  of	  experiments	  and	  cultures	  were	  
maintained	  for	  3	  days	  before	  analysis.	  A	  pictorial	   representation	  of	  this	  experiment	  can	  be	  
found	   in	   Figure	   2.3.	   For	   immunosuppression	  using	  PαS	  MSCs	   isolated	   from	  C57BL/6	  mice,	  
see	  “Splenocyte	  reaction”	  (section	  2.9).	  	  	  
	  	  
	   2.8.1	  Preparation	  of	  Buffers	  and	  Culture	  Medium	  
P2	  wash	  buffer	  consisted	  of	  PBS	  supplemented	  with	  2%	  FBS.	  MACS	  buffer	  consisted	  of	  PBS	  +	  
0.5%	  FBS	  +	  2mM	  EDTA.	  C10	   culture	  medium	  consisted	  of	  Roswell	  Park	  Memorial	   Institute	  
(RPMI)	  basal	  media	  (Gibco)	  supplemented	  with	  10%	  FBS,	  50mM	  β-­‐mercaptoethanol	  (Sigma-­‐
Aldrich)	  and	  1x	  PSG.	  
	  	  
2.8.2	  Magnetic	  separation	  of	  CD19+	  B	  cells	  
8-­‐12	  week	  old	  Balb/c	  mice	  were	  sacrificed	  by	  cervical	  dislocation.	  The	  spleen	  was	  dissected	  
free	  and	  stored	  in	  cold	  P2	  buffer.	  A	  single	  cell	  suspension	  was	  made	  by	  gently	  pushing	  the	  
spleen	  through	  a	  70µm	  cell	  strainer	  (Corning)	  in	  RBC	  lysis	  buffer	  (Sigma-­‐Aldrich).	  Dissociated	  
tissue	  was	  pipetted	  up	  and	  down	  to	  ensure	  efficient	  RBC	  lysis	  for	  2	  minutes.	  Samples	  were	  
washed	   in	   excess	   P2	   buffer	   and	   centrifuged	   at	   1400rpm	   for	   7	  minutes	   at	   4°C.	   An	   aliquot	  
containing	   approximately	   40x106	   splenocytes	   was	   removed	   for	   the	   magnetic	   bead	  





purification	   stage.	  The	  cell	  pellet	  was	   resuspended	   in	  90µl	   cold	  MACS	  buffer	  per	  107	   cells.	  
CD19	   microbeads	   (Miltenyi	   Biotec,	   Cologne,	   DE)	   was	   added	   according	   to	   manufactures	  
instructions	   and	   left	   to	   incubate	   in	   the	   dark	   at	   4°C	   for	   15	  minutes.	   Following	   incubation,	  
samples	  were	  washed	  in	  excess	  P2	  buffer	  to	  remove	  unbound	  microbeads	  and	  centrifuged	  
at	  1400	  rpm	  for	  7	  minutes.	  The	  pellet	  was	  resuspended	  in	  500µl	  MACS	  buffer	  prior	  to	  MACS.	  	  
	  
MACS	   separators	   and	   LS	   columns	   (both	   Miltenyi	   Biotec)	   were	   set	   up	   according	   to	  
manufacturer’s	   instructions.	   Columns	   were	   prepared	   by	   running	   3ml	   warm	   MACS	   buffer	  
through	  it,	  followed	  by	  500µl	  of	  cell	  suspension	  and	  3x	  washes	  with	  3ml	  warm	  MACS	  buffer.	  
The	  flow	  through	  was	  discarded	  and	  the	  LS	  column	  removed	  from	  the	  MACS	  separator.	  4ml	  
of	   MACS	   buffer	   was	   flushed	   through	   the	   column	   using	   a	   plunger	   to	   ‘flush	   out’	   all	  
magnetically	  labelled	  CD19+	  cells	  from	  the	  LS	  column.	  Samples	  were	  spun	  again	  at	  1400rpm	  
for	  7	  minutes	  and	  resuspended	  in	  C10	  medium	  and	  stored	  on	  ice	  until	  needed.	  	  
	  
	   2.8.3	  Magnetic	  separation	  of	  CD4+CD25-­‐	  T	  cells	  
MACS	   was	   used	   to	   negatively	   isolate	   naive	   T	   cells	   using	   a	   CD4+CD25-­‐	   T	   cell	   isolation	   kit	  
(Miltenyi	  Biotec).	  8-­‐12	  week	  old	  Balb/c	  mice	  were	  sacrificed	  and	  their	  lymph	  nodes	  removed.	  
Lymph	  nodes	  were	  forced	  through	  a	  70µm	  cell	  strainer	  in	  1ml	  P2	  buffer	  to	  produce	  a	  single	  
cell	  suspension.	  Samples	  were	  washed	  in	  excess	  P2	  buffer	  and	  an	  aliquot	  taken	  for	  counting.	  
The	   cell	   pellet	   was	   resuspended	   in	   40µl	   MACS	   buffer	   and	   15µl	   of	   biotinylated	   antibody	  
cocktail	   (containing	   antibodies	   for	   CD8,	   CD11b,	   CD45,	   CD49	   and	   Ter-­‐119)	   per	   107	   cells.	  
Samples	  were	   left	   to	   incubate	   in	   the	  dark	  at	  4°C	   for	  15	  minutes.	  After	   incubation,	  30µl	  of	  





MACS	  buffer,	  20µl	  of	  anti-­‐Biotin	  microbeads	  and	  10µl	  of	  CD25-­‐PE	  antibody	  was	  added	  per	  
107	  cells	  and	  left	  to	  incubate	  for	  a	  further	  15	  minutes	  at	  4°C.	  Samples	  were	  then	  quenched	  in	  
excess	   MACS	   buffer	   to	   remove	   unbound	   antibodies	   and	   centrifuged	   at	   1400	   rpm	   for	   7	  
minutes.	  Cell	  pellets	  were	  resuspended	  in	  500µl	  MACS	  buffer	  prior	  to	  separation.	  	  
	  
MACS	  separators	  and	  LD	  columns	  (Miltenyi	  Biotec)	  were	  set	  up	  according	  to	  manufacturer’s	  
instructions.	   Columns	  were	  prepared	  by	   running	   2x	   1ml	  warm	  MACS	  buffer	   through,	  with	  
the	  flow-­‐through	  discarded.	  The	  cell	  suspension	  was	  then	  run	  followed	  by	  2x	  1ml	  washes	  in	  
warm	  MACS	  buffer	  to	  collect	  any	  remaining	  unlabelled	  cells.	  This	  flow-­‐through	  contains	  the	  
CD4+	   enriched	   population	   of	   cells.	   This	   population	   was	   washed	   in	   excess	   P2	   buffer	   and	  
pellets	  were	  resuspended	  in	  90µl	  MACS	  buffer	  and	  10µl	  anti-­‐PE	  microbeads	  per	  107	  cells	  and	  
incubated	  at	  4°C	  for	  15	  minutes.	  The	  samples	  were	  then	  washed	  in	  excess	  MACS	  buffer	  and	  
centrifuged	  at	  1400rpm	  for	  7	  minutes.	  Cell	  pellets	  were	  again	  resuspended	   in	  500µl	  MACS	  
buffer	  prior	  to	  the	  last	  round	  of	  magnetic	  separation.	  	  
	  
MACS	  separators	  and	  MS	  columns	  (Miltenyi	  Biotec)	  were	  set	  up	  according	  to	  manufacturer’s	  
instructions.	  The	  MS	  column	  was	  prepared	  by	   running	  a	  single	  wash	  of	  500µl	  warm	  MACS	  
buffer	  with	   the	   flow-­‐through	   discarded.	   The	   cell	   suspension	  was	   then	   run	   followed	   by	   3x	  
500µl	   washes	   in	   warm	  MACS	   buffer	   to	   collect	   any	   remaining	   unlabelled	   cells.	   This	   flow-­‐
through	   contains	   the	   CD4+CD25-­‐	   naive	   T	   cell	   population,	   which	   was	   resuspended	   in	   C10	  
medium	  and	  stored	  on	  ice	  until	  needed.	  	  
	  	   	  





	   2.8.4	  In	  vitro	  proliferation	  assay	  
Purified	  CD4+CD25-­‐	  naive	  T	  cells	  were	  cultured	  in	  C10	  media	  at	  a	  density	  of	  25,000	  cells	  per	  
well	   of	   a	   96-­‐well,	   round	  bottomed	  plate	   (Sarstedt,	  Nümbrecht,	  DE).	   Purified	  CD19+	  B	   cells	  
were	   added	   at	   a	   density	   of	   50,000	   cells	   per	  well	   (2:1	   ratio)	   to	   provide	   the	   co-­‐stimulatory	  
signal	  to	  T	  cells	  via	  CD28-­‐CD86	  interaction.	  The	  primary	  stimulus	  was	  provided	  by	  0.8µg/ml	  
anti-­‐mouse	   CD3e	   (BD	   Bioscience).	   A	   titrated	   dose	   of	   PαS	  MSCs	  was	   added	   in	   a	   subset	   of	  
experiments.	   Cultures	   were	   maintained	   for	   72	   hours	   at	   37°C,	   5%	   CO2	   in	   a	   humidified	  
incubator	  prior	  to	  flow	  cytometric	  analysis	  of	  T	  cell	  proliferation	  (Figure	  2.3).	  
	  
	  
Figure	   2.3	   |	  Overview	   of	   in	   vitro	   T	   cell	   proliferation	   assay.	   This	   diagram	   summaries	   the	   stages	   involved	   in	  
setting	  up	  this	  assay.	  See	  text	  for	  further	  details.	  	  
	   	  





2.8.5	  Flow	  Cytometric	  analysis	  of	  T	  cell	  proliferation	  	  	  	  	  	  	  	  	  	  	  	  
Cultures	  were	  pipetted	  up	  and	  down	   to	   remove	   the	  non-­‐adherent	   lymphocyte	  population	  
while	   leaving	  behind	   the	  adherent	  MSCs.	   Triplicate	   samples	  were	  merged	   together	   in	  one	  
FACS	   tube	   and	  washed	   in	   FACS	  buffer	   (PBS+2%	  FCS).	   Samples	  were	   resuspended	   in	   100µl	  
FACS	   buffer	   and	   conjugated	   antibodies	   to	   CD4	   (PerCP,	   1:100	   dilution;	   BD	   Bioscience)	   and	  
CD19	  (APC,	  1:100	  dilution;	  BD	  bioscience)	  were	  added	  and	  incubated	  at	  4°C	  for	  30	  minutes.	  
Unbound	  antibodies	  were	  removed	   in	  excess	  FACS	  buffer	  and	  the	  samples	  resuspended	   in	  
250µl	  FACS	  buffer	  prior	  to	  running	  on	  a	  Cyan	  ADP	  flow	  cytometer	  (Beckman	  Coulter).	  	  	  
	  
	   2.8.6	  Mechanistic	  studies	  on	  MSC-­‐mediated	  Immunosuppression	  
In	   a	   subset	   of	   experiments,	   small	   molecule	   inhibitors	   of	   previously	   reported	  mechanisms	  
were	  added	  to	   the	   in	  vitro	  T	  cell	   suppression	  assay.	  They	  were	  used	  at	   the	  concentrations	  
listed	  in	  Table	  2.1	  below.	  	  
	  
Table	  2.1	  |	  Details	  of	  inhibitors	  used	  to	  test	  mechanisms	  of	  immunosuppression.	  	  
Reagent	   Inhibits	   Solvent	   Final	  concentration	   Reference	  
Indomethacin	   PGE2	  release	   DMSO	   5µM	  
Nemeth	  et	  al.	  
(2009)	  
SB-­‐3CT	   MMP2/9	   DMSO	   6µM	  
Ding	  et	  al.	  
(2009)	  
1-­‐Methyltryptophan	   IDO	   Culture	  Media	   1MM	  
Meisel	  et	  al.	  
(2004)	  
L-­‐NMMA	   NO	  release	   dH2O	   1MM	  
Ren	  et	  al.	  
(2008)	  
	   	   	  





2.8.7	  Griess	  Assay	  of	  NO	  production	  
NO	  release	  from	  PαS	  MSCs	  was	  indirectly	  quantified	  using	  the	  Griess	  Assay	  kit	  (Promega,	  WI,	  
USA).	  This	  kit	  measures	  the	  total	  amount	  of	  nitrite	  (NO2-­‐)	  in	  cell	  culture	  supernatants,	  which	  
is	   a	   stable	   breakdown	   product	   of	   NO.	   PαS	  MSCs	   were	   cultured	   in	   96-­‐well	   plates	   (15,000	  
cells/well)	   in	   C10	   media	   supplemented	   with	   20ng/ml	   murine	   IFNγ	   and	   TNFα	   (both	   from	  
Peprotech)	   to	   recreate	   an	   inflammatory	   microenvironment	   in	   vitro.	   After	   overnight	  
incubation,	   supernatants	   were	   collected	   and	   processed	   according	   to	   manufacturer’s	  
instructions.	   The	   absorbance	   was	   read	   at	   520nm	   and	   nitrite	   values	   determined	   against	  
known	  standards	  that	  were	  run	  at	  the	  same	  time.	  	  
	   	  





2.9	  MSC-­‐mediated	  immunosuppression	  in	  the	  “Splenocyte	  reaction”	  
Strain-­‐specific	   differences	   in	   the	   immunosuppressive	   mechanism	   between	   Balb/c	   and	  
C57BL/6	  mice	   required	   the	   immunosuppression	   assay	   to	   be	  modified.	  When	   studying	   the	  
effects	  of	  PαS	  MSCs	   isolated	   from	  C57BL/6	  mice,	  un-­‐purified	   ‘bulk’	   splenocytes	  were	  used	  
that	  contained	  a	  mixture	  of	   lymphocytes,	  B	  cells,	  APCs	  and	  other	   immune	  and	  stromal	  cell	  
subsets.	  The	  lymphocytes	  were	  induced	  to	  proliferate	  using	  a	  variety	  of	  molecules	  including	  
plant	  lectins,	  CD3/CD28	  beads	  and	  T	  cell	  receptor	  (TCR)-­‐specific	  peptide	  sequences.	  	  
	  
	   2.9.1	  Isolation	  and	  staining	  of	  Splenocytes	  
8-­‐12	  week	  old	  C57BL/6	  or	  OT-­‐1	  mice	  (Jackson	  Laboratories)	  were	  sacrificed	  and	  their	  spleens	  
removed	   and	   stored	   in	   cold	   C10	   medium.	   A	   single	   cell	   suspension	   was	   made	   by	   gently	  
pushing	  the	  spleen	  through	  a	  70µm	  cell	  strainer	   in	  cold	  RBC	  lysis	  buffer.	  Dissociated	  tissue	  
was	   pipetted	   up	   and	   down	   to	   resuspended	   all	   cells	   and	   ensure	   efficient	   RBC	   lysis.	   This	  
reaction	  was	  stopped	  in	  excess	  C10	  media	  and	  samples	  were	  centrifuged	  at	  1400rpm	  for	  7	  
minutes	  at	  4˚C.	  An	  appropriate	  aliquot	  of	  cells	  was	  removed	  for	  staining	  with	  the	  remainder	  
kept	  for	  use	  later	  on	  as	  single-­‐colour	  controls.	  	  
	  
Splenocytes	  were	  stained	  using	  the	  membrane	  dye	  cell	  trace	  violet	  (CTV;	  Molecular	  Probes,	  
Paisley,	  UK)	   to	   track	   their	  proliferation	   in	   this	  assay.	  Pellets	  were	   resuspended	   in	  PBS	  at	  a	  
concentration	  of	  1x106	  cells/ml	  and	  5µM	  CTV	  was	  added	  to	  each	  sample	  and	   incubated	   in	  
the	  dark	  at	  37˚C	  in	  a	  shaking	  incubator	  (50rpm).	  Samples	  were	  then	  quenched	  by	  adding	  5x	  





the	   staining	   volume	   of	   C10	  media	   and	   incubating	   for	   a	   further	   5	  minutes	   at	   37˚C	   before	  
centrifugation	  at	  1400rpm	  for	  7	  minutes.	  Pellets	  were	  then	  resuspended	  in	  C10	  medium	  and	  
kept	  on	  ice	  until	  required.	  	  
	  
	   2.9.2	  Setting	  up	  the	  Splenocyte	  Reaction	  
CTV-­‐stained	  splenocytes	  were	  cultured	  in	  C10	  media	  supplemented	  with	  50U/ml	  murine	  IL-­‐2	  
(eBioscience)	  at	  a	  density	  of	  1x105	  splenocytes	  per	  well	  of	  a	  96-­‐well,	  round	  bottomed	  plate.	  
A	  variety	  of	  stimulatory	  signals	  were	  tested	  to	   induce	  T	  cell	  proliferation	   in	  the	  splenocyte	  
mixture	   (Table	  2.2).	  Cultures	  were	  then	   left	   to	   incubate	  overnight	  at	  37˚C,	  5%	  CO2.	  Graded	  
numbers	   of	   PαS	  MSCs	   from	   C57BL/6	  mice	   were	   then	   added	   the	   following	   day.	   The	   total	  
volume	   per	   well	   was	   made	   up	   to	   200µl	   with	   fresh	   C10	   media	   and	   cultures	   were	   left	   to	  
incubate	  for	  a	  further	  72	  hours	  before	  flow	  cytometric	  analysis	  of	  lymphocyte	  proliferation.	  	  
	  
Table	  2.2	  |	  Details	  of	  the	  molecules	  used	  to	  stimulate	  T	  cell	  proliferation.	  	  
Reagent	   Concentrations	  used	   Supplier	  
Concanavalin	  A	  	  
(ConA)	  
1µg/ml	  to	  100µg/ml	   Sigma-­‐Aldrich	  
CD3/CD28	  Dynabeads®	  
2000	  to	  500,000	  beads	  per	  
well	  
Gibco	  
OVA	  (257-­‐264)	  	  
[SIINFEKL]	  









	   2.9.3	  Intracellular	  staining	  and	  Flow	  Cytometric	  analysis	  
In	  a	  subset	  of	  experiments,	  final	  day	  (day	  4)	  samples	  were	  treated	  with	  1µg/ml	  brefeldin	  A	  
(BD	   Biosciences)	   to	   inhibit	   the	   extracellular	   secretion	   of	   cytokines.	   They	   were	   then	   re-­‐
stimulated	   with	   50ng/ml	   phorbol	   myristate	   acetate	   (PMA;	   Sigma-­‐Aldrich)	   and	   1µM	  
ionomycin	   (INO;	   Sigma-­‐Aldrich)	   for	   4	   hours	   to	   induce	   cytokine	   production.	   Samples	   were	  
then	  collected	  into	  FACS	  tubes	  by	  gentle	  pipetting	  to	  remove	  the	  non-­‐adherent	  immune	  cells	  
and	   leave	   behind	   PαS	   MSCs.	   Following	   one	   wash	   step	   in	   FACS	   buffer,	   all	   samples	   were	  
resuspended	   in	   PBS	   and	   stained	   using	   a	   Live/Dead	   marker	   (1µl/ml;	   eBioscience)	   for	   30	  
minutes	   at	   4˚C.	  Unbound	  dye	  was	  washed	   in	   an	   excess	   of	   FACS	   buffer	   and	   samples	  were	  
resuspended	  in	  100µl	  FACS	  buffer	  for	  surface	  staining.	  
	  
Surface	   staining	  was	   performed	   using	   a	   range	   of	   antibodies	   including	   CD3,	   CD4	   and	   CD8.	  
Details	  on	  the	  dilution	  factor,	  fluorophore	  and	  supplier	  information	  can	  be	  found	  in	  Table	  2.6.	  
Samples	  were	   incubated	   for	   30	  minutes	   at	   4˚C	   before	   being	  washed	  once	   in	   FACS	   buffer.	  
Samples	  were	  then	  permeabilised	  by	  incubating	  in	  Fix/Perm	  solution	  (BD	  Bioscience)	  for	  20	  
minutes	   at	  4˚C	   followed	  by	  one	  wash	   in	  Perm	  wash	  buffer	   (BD	  Bioscience).	   Samples	  were	  
then	  resuspended	  in	  50µl	  Perm	  wash	  buffer	  for	  intracellular	  staining.	  Samples	  were	  stained	  
for	   30	   minutes	   at	   4˚C	   followed	   by	   two	   washes	   in	   FACS	   buffer.	   All	   samples	   were	   filtered	  
through	  a	  50µm	  filter	  before	  analysis	  on	  a	  Cyan	  ADP	  flow	  cytometer.	  Compensation	  beads	  
(BD	  Bioscience)	  were	  used	  to	  minimize	  fluorescence	  spillover	  and	  data	  was	  analysed	  offline	  
using	  FlowJo	  v8.7	  software	  (TreeStar	  Inc,	  OR,	  USA).	  	  
	   	  





2.10	  RNA	  Isolation	  and	  Microarray	  Analysis	  
PαS	  MSCs	   from	  C57BL/6	  mice	  were	  cultured	   in	  SM±GFs	  as	  described	  previously.	  Confluent	  
cultures	   at	   P1	   were	   used	   for	   RNA	   isolation	   using	   an	   RNeasy	   mini	   kit	   (Qiagen,	   MD,	   USA)	  
according	  to	  manufacturer’s	  instructions.	  All	  samples	  underwent	  DNase	  I	  digestion	  (Qiagen)	  
to	   remove	   genomic	   DNA	   contamination.	   Good	   quality	   RNA	   isolates	   (OD260/280≈2.0	   and	  
OD260/230	  between	  2.0	  and	  2.2)	  from	  three	  independent	  PαS	  MSC	  isolations	  per	  condition	  
were	  used	  for	  downstream	  analysis.	  	  
	  
Samples	  were	  then	  hybridised	  onto	  individual	  whole-­‐genome	  GeneChip	  Mouse	  Exon	  1.0	  ST	  
Arrays	  (Affymetrix,	  High	  Wycombe,	  UK)	  for	  transcriptional	  profiling.	  Sample	  preparation	  and	  
hybridisation	  was	  performed	  by	  technical	  staff	  working	  for	  Affymetrix	  Microarray	  Service	  at	  
the	  University	  of	  Birmingham.	  Bioinformatics	  and	  heatmap	  generation	  was	  performed	  by	  Dr	  
Wenbin	  Wei,	  School	  of	  Cancer	  Sciences,	  University	  of	  Birmingham.	  	  
	   	  





2.11	  Karyotype	  Analysis	  
Chromosomes	  of	   C57BL/6	   PαS	  MSCs	   at	   P3	   and	  P5	  were	   analysed	   for	   the	  presence	  of	   any	  
culture-­‐induced	  abnormalities.	  The	  same	  culture	  was	  maintained	  between	  both	  time	  points,	  
allowing	  us	  to	  identify	  whether	  any	  clonal	  growth	  of	  abnormal	  cells	  took	  place	  (Figure	  2.4).	  
This	  work	  was	  done	   in	   collaboration	  with	  Ms	  Mary	  Strachan,	  Dr	   Sara	  Dyer	  and	  Prof.	  Mike	  
Griffiths	  at	  the	  West	  Midlands	  Regional	  Genetics	  Laboratory,	  Birmingham	  Women’s	  Hospital.	  
	  
	  
Figure	  2.4	  |	  Overview	  of	   PαS	  MSC	   karyotyping.	  PαS	  MSCs	  were	  grown	   in	  SM	  ±	  GFs.	  An	  aliquot	  of	   cells	  was	  
taken	   for	  G-­‐banding	  analysis	  at	  P3	  and	   the	   same	  culture	  was	  maintained	  until	  P5	  when	  another	  aliquot	  was	  
taken.	  This	  allows	  us	  to	  detect	  any	  clonal	  expansion	  that	  could	  have	  taken	  place.	  	  
	  
	   2.11.1	  PαS	  MSC	  Harvesting	  
PαS	  MSCs	  were	  expanded	  as	  described	  previously	   in	  SM±GFs.	  When	  cultures	  reached	  70%	  
confluency,	  a	  1:50	  dilution	  of	  B-­‐ONC	   (BRDU-­‐overnight	  colcemid)	  was	  added	  and	   incubated	  
overnight.	  Colcemid	  prevents	  spindle	  fibre	  formation	  and	  arrests	  dividing	  cells	  in	  metaphase.	  





Fresh	   colcemid	   was	   added	   the	   morning	   after	   to	   each	   flask	   and	   incubated	   for	   an	   hour.	  
Samples	  were	  washed	   in	  PBS	  and	  harvested	  using	  TrypLE	   to	  yield	  a	   single	  cell	   suspension.	  
Cell	  pellets	  were	  slowly	  resuspended	   in	  a	  hypotonic	  0.025M	  KCL	  solution	  and	   incubated	  at	  
37˚C	   for	   20	   minutes.	   This	   solution	   causes	   the	   cell	   nuclei	   to	   swell	   in	   size	   to	   prevent	   the	  
chromosomes	   from	   overlapping	   each	   other.	   After	   incubation,	   samples	   were	   spun	   at	  
1500rpm	  for	  5	  minutes	  and	  the	  supernatant	  discarded.	  The	  pellet	  was	   resuspended	   in	   the	  
residual	  volume	  that	  remained	  and	  flicked	  gently	  to	  ensure	  a	  single-­‐cell	  suspension.	  Samples	  
were	   then	   slowly	   fixed	   in	  Carnoy’s	   fixative	   (1	  part	  glacial	   acetic	  acid	   to	  3	  parts	  methanol).	  
Samples	  were	  then	  spun	  at	  1500rpm	  for	  5	  minutes	  and	  further	  fixative	  added	  in	  a	  drop-­‐by-­‐
drop	  basis.	  The	  supernatant	  was	  discarded	  after	  centrifugation	  and	  sample	  tubes	  stored	  at	  
4°C	  until	  slide	  making	  and	  Giemsa	  banding	  (G-­‐banding).	  	  
	  
	   2.11.2	  Chromosome	  Spreads	  
The	  fixed	  cell	  suspensions	  were	  used	  to	  make	  slides	  for	  cytogenetic	  examination.	  Fixed	  cell	  
samples	  were	  aspirated	  in	  a	  pipette	  and	  held	  over	  the	  middle	  of	  each	  slide	  from	  a	  height	  of	  
approximately	  50cm.	  One	  drop	  was	  allowed	  to	  fall	  and	  hit	  the	  slide,	  whereupon	  the	  nuclei	  
would	  burst	   and	   the	   chromosomes	  would	   spread	   across	   the	   slide.	   Slides	  were	   checked	   to	  
ensure	  minimal	  overlapping	  chromosomes	  and	  the	  cell	  density	  altered	  if	  necessary	  by	  adding	  
more	  fixative.	  Slides	  were	  then	  ‘aged’	  overnight	  at	  60°C	  prior	  to	  G-­‐banding.	  	  
	   	  





	   2.11.3	  Giemsa	  Banding,	  Imaging	  and	  Analysis	  
Leishman's	  stain	  (belonging	  to	  the	  same	  family	  of	  stains	  as	  Giemsa)	  was	  used	  in	  this	  study	  to	  
mark	  chromosomes	  for	  cytogenetic	  analysis.	  The	  banding	  pattern	  observed	  with	  Leishman’s	  
stain	   is	   virtually	   identical	   to	   Giemsa	   (Moore	   and	   Best,	   2001).	   As	   such,	   both	   stains	   can	   be	  
interchangeably	  used	  for	  analysis.	  	  
	  
‘Aged’	   slides	   were	   allowed	   to	   cool	   to	   room	   temperature	   and	   rinsed	   gently	   in	   tap	   water.	  
Slides	  were	  then	  incubated	  in	  0.25%	  trypsin	  for	  90	  seconds	  and	  then	  rinsed	  in	  saline	  solution.	  
Slides	  were	  incubated	  in	  Leishman’s	  stain	  for	  2	  minutes	  before	  being	  rinsed	  in	  excess	  saline.	  
Excess	   saline	  was	   removed	  using	  blotting	  paper	  and	   the	   slides	  were	   left	  on	  a	  hot	  plate	  at	  
60°C	  to	  air-­‐dry	  before	  coverslipping.	  	  
	  
Each	   slide	   was	   examined	   using	   a	   standard	   light	   microscope	   and	   images	   taken	   when	   a	  
metaphase	  spread	  contains	  all	  40	  non-­‐overlapping	  mouse	  chromosomes	  in	  the	  same	  optical	  
field	   was	   observed.	   Individual	   chromosomes	   were	   electronically	   cut	   and	   arranged	   to	  
produce	   a	   karyogram	   where	   sister	   chromatids	   are	   arranged	   in	   order.	   A	   total	   of	   60	  
metaphase	  spreads	  per	  culture	  condition	  at	  P3	  and	  P5	  were	  analysed	  by	  Ms	  Mary	  Strachan	  
for	  the	  presence	  of	  any	  karyotypic	  abnormalities.	  These	  findings	  were	  independently	  verified	  
by	  Dr	  Sara	  Dyer	  before	  the	  final	  karyotype	  was	  reported.	  	  	  	  	  
	   	  






2.12.1	  Formalin-­‐fixed	  Paraffin-­‐embedded	  (FFPE)	  Tissue	  
FFPE	   tissue	   blocks	   were	   cut	   at	   5µM	   thickness	   and	   fixed	   onto	   microscope	   slides	   (X-­‐tra	  
Adhesive,	   Leica).	   Slides	   were	   dewaxed	   and	   rehydrated	   by	   passing	   through	   xylene	   (3x	   2	  
minutes	  each),	  IMS	  (2x	  2	  minutes	  each)	  and	  water	  (1x	  2	  minute	  wash).	  Antigen	  retrieval	  was	  
performed	  using	  a	  high	  pH	  buffer	   (Vector	  Laboratories,	  Peterborough,	  UK).	  The	  buffer	  was	  
pre-­‐warmed	   in	  a	  microwave	  for	  5	  minutes	  at	  high	  power	  before	  slides	  were	  added.	   It	  was	  
then	  heated	  for	  a	  further	  15	  minutes	  before	  being	   left	  to	  stand	  for	  10	  minutes.	  The	  buffer	  
was	  cooled	  by	  the	  gentle	  addition	  of	  cold	  tap	  water	  until	  it	  reached	  room	  temperature.	  	  
	  
Slides	  were	  then	  dried	  and	  sections	  were	  encircled	  using	  a	  wax	  pen.	  Endogenous	  peroxidase	  
activity	   was	   blocked	   by	   incubating	   sections	   in	   a	   pre-­‐diluted	   peroxidase	   blocking	   solution	  
(Dako,	   Ely,	   UK)	   for	   40	   minutes.	   Slides	   were	   then	   washed	   in	   Tris-­‐buffered	   saline	   +	   0.1%	  
Tween20	  (TBS-­‐T;	  2x	  5	  minutes	  each)	  before	  blocking	  in	  1x	  casein	  buffer	  (Vector	  Laboratories)	  
for	  60	  minutes.	  Primary	  antibodies	  were	  diluted	   in	  TBS	  at	   the	  appropriate	  dilutions	   (Table	  
2.6)	  and	  added	  directly	  the	  after	  casein	  blocking	  stage.	  Slides	  were	  incubated	  with	  primary	  
antibody	  at	   room	  temperature	   for	  60	  minutes	  with	  gentle	   rocking.	  Unbound	  antibody	  was	  
removed	  by	  two	  further	  TBS-­‐T	  washes	  (5	  minutes	  each).	  Sections	  were	  then	  incubated	  with	  
pre-­‐diluted	   horseradish	   peroxidase	   (HRP)-­‐conjugated	   secondary	   antibody	   (Vector	  
Laboratories)	  for	  30	  minutes	  at	  room	  temperature	  with	  gentle	  rocking.	  Unbound	  secondary	  
antibody	   was	   removed	   in	   three	   TBS-­‐T	   washes	   (5	   minutes	   each)	   before	   chromogenic	  
visualisation.	  





3,3'-­‐Diaminobenzidine	   (DAB;	   AbD	   Serotec,	   Kidlington,	   UK)	   was	   prepared	   according	   to	  
manufacturer’s	   instructions	   and	   incubated	   with	   sections	   until	   brown	   staining	   was	   visible	  
(typically	  around	  30-­‐120	  seconds).	  Sections	  with	  an	   isotype-­‐matched	  control	  (IMC)	  primary	  
antibody	  were	  run	  at	  the	  same	  time	  to	  check	  for	  non-­‐specific	  binding.	  Excess	  substrate	  was	  
washed	  off	  in	  tap	  water	  for	  5	  minutes	  to	  stop	  the	  chromogenic	  reaction.	  Sections	  were	  then	  
counterstained	   in	  Mayer’s	   haematoxylin	   and	   “blued”	   for	   150	   seconds	   in	   tap	  water.	   Slides	  
were	   then	   dehydrated	   by	   passing	   through	   IMS	   twice	   and	   xylene	   three	   times	   before	  
mounting	   coverslips	   using	   DPX.	   DPX	   was	   allowed	   to	   set	   overnight	   before	   imaging	   on	   a	  
conventional	  light	  microscope	  (Carl	  Zeiss	  AG).	  	  	  
	  
	   2.12.2	  Snap-­‐Frozen	  Tissue	  
In	   some	  cases,	   tissue	  was	   snap-­‐frozen	   in	   liquid	  nitrogen	  and	  embedded	   in	  OCT	  compound	  
(Sakura	   Tissue-­‐Tek).	   7µm	   sections	  were	   cut,	  mounted	   on	   pre-­‐coated	   glass	   slides	   (Thermo	  
Scientific),	  and	  fixed	  in	  acetone	  for	  10	  minutes.	  Excess	  acetone	  was	  removed	  in	  two	  washes	  
of	  TBS-­‐T	  (5	  minutes	  each).	  Endogenous	  peroxidases	  were	  blocked	  by	  incubating	  slides	  for	  15	  
minutes	  in	  a	  pre-­‐diluted	  peroxidase	  blocking	  solution	  (Dako).	  Sections	  were	  then	  blocked	  in	  
1x	   casein	   buffer	   (Vector	   Laboratories)	   for	   30	  minutes	   before	   primary	   antibody	   (Table	   2.6)	  
was	  added.	  Sections	  were	  left	  to	  incubate	  at	  room	  temperature	  for	  60	  minutes	  with	  gentle	  
rocking.	  Unbound	  primary	  antibody	  was	  removed	  in	  two	  washes	  of	  TBS-­‐T	  (5	  minutes	  each)	  
and	  HRP-­‐conjugated	  secondary	  antibody	  (Vector	  Laboratories)	  was	  added	  for	  30	  minutes	  at	  
room	   temperature	   with	   gentle	   rocking.	   Sections	   were	   then	   washed,	   stained	   with	   DAB,	  
dehydrated	  and	  mounted	  in	  DPX	  as	  described	  above.	  	   	  





2.13	  OVA-­‐Bil	  model	  of	  Alloimmune	  Liver	  Injury	  
2.13.1	  Animal	  Husbandry	  
OT-­‐1	   and	  OT-­‐2	   T	   cell	   receptor	   transgenic	  mice	  were	   purchased	   from	   Jackson	   Laboratories	  
(Table	   2.5).	   OVA-­‐Bil	   mice	   were	   maintained	   as	   heterozygotes	   on	   a	   C57BL/6	   background	  
(Buxbaum	   et	   al.,	   2006).	   All	   animals	   were	   housed	   in	   accordance	   with	   established	   care	  
protocols	   at	   the	   University	   of	   Birmingham.	   All	   procedures	   using	   mice	   underwent	   ethical	  
review	  and	  were	  performed	   in	   accordance	  with	   the	  Animals	   (Scientific	   Procedures)	  Act	   of	  
1986	  under	  Home	  Office	  Project	  License	  70/7707.	  	  
	  
	   2.13.2	  Genotyping	  
Polymerase	   chain	   reaction	   (PCR)	  was	  used	   to	   confirm	   the	  genotype	  of	   transgenic	  animals.	  
Ear	  clippings	  were	  heated	  to	  95°C	  in	  50mM	  NaOH	  for	  20	  minutes	  to	  extract	  genomic	  DNA.	  
Samples	  were	   then	   cooled	  on	   ice	   for	   10	  minutes	   and	  neutralised	   in	   a	   1:10	  dilution	  of	   1M	  
Trizma	   base	   (Sigma-­‐Aldrich).	   PCR	   was	   performed	   using	   a	   Fast-­‐cycling	   PCR	   Kit	   (Qiagen)	  
containing	   a	   Hot-­‐start	   Taq	   DNA	   polymerase	   according	   to	   manufacturer’s	   instructions.	  
Samples	  were	  made	  up	  in	  a	  final	  volume	  of	  20µl	  containing	  2µl	  of	  genomic	  DNA	  and	  1µl	  of	  
each	  primer.	  Primer	  sequences	  and	  amplicon	  lengths	  can	  be	  seen	  in	  Table	  2.3.	  Samples	  were	  
then	  run	  on	  a	  G-­‐storm	  PCR	  thermal	  cycler	  (Somerton,	  UK)	  and	  the	  cycling	  conditions	  can	  be	  
found	  in	  Table	  2.4.	  PCR	  products	  were	  run	  in	  a	  2%	  agarose	  gel	  for	  60	  minutes	  at	  125mV	  prior	  
to	   imaging	   on	   a	   UV	   transilluminator.	   Band	   size	   was	   determined	   by	   comparison	   against	   a	  
100bp	  molecular	  weight	  ladder	  (Bioline,	  Hemel	  Hempstead,	  UK).	  	  	  	  	  





Table	  2.3	  |	  List	  of	  PCR	  primers	  used	  to	  genotype	  mice	  
Primer	   OVA-­‐Bil	  
Forward	   5’-­‐GGC	  GTG	  TTG	  AAA	  GTA	  AGC-­‐3’	  
Reverse	   5’-­‐CCA	  GAC	  AGA	  TTG	  GCT	  GAA	  GAG	  CTA-­‐3’	  
Amplicon	  length	   994bp	  
Primer	   OT-­‐1	  
Forward	   5’-­‐CAG	  CAG	  GTG	  AGA	  CAA	  AGT-­‐3’	  
Reverse	   5’-­‐GGC	  TTT	  ATA	  ATT	  AGC	  TTG	  GTC	  C-­‐3’	  
Amplicon	  length	   250bp	  
Primer	   iNOS-­‐/-­‐	  
Common	   5’-­‐ACA	  TGC	  AGA	  ATG	  AGT	  ACC	  GG-­‐3’	  
Wild-­‐type	   5’-­‐TCA	  ACA	  TCT	  CCT	  GGT	  GGA	  AC-­‐3’	  
Mutant	   5’-­‐AAT	  ATG	  CGA	  AGT	  GGA	  CCT	  CG-­‐3’	  
Amplicon	  length	   Mutant=275bp,	  Heterozygote=275bp	  and	  108bp,	  Wild-­‐type=108bp	  
	  
Table	  2.4	  |	  Thermal	  cycler	  settings	  for	  gene	  amplification	  
OVA-­‐Bil	  
Stage	   Temperature	  (°C)	   Duration	  (min)	   Cycles	  
Hot-­‐start	   95	   05:00	  
35	  Cycles	  
Denaturation	   96	   00:05	  
Annealing	   55	   00:05	  
Extension	   68	   00:30	  
Final	  Extension	   72	   01:00	  
OT-­‐1	  
Stage	   Temperature	  (°C)	   Duration	  (min)	   Cycles	  
Hot-­‐start	   95	   05:00	  
32	  Cycles	  
Denaturation	   96	   00:05	  
Annealing	   53	   00:05	  
Extension	   68	   00:30	  
Final	  Extension	   72	   01:00	  
iNOS-­‐/-­‐	  
Stage	   Temperature	  (°C)	   Duration	  (min)	   Cycles	  
Hot-­‐start	   95	   05:00	  
35	  cycles	  
Denaturation	   94	   00:15	  
Annealing	   59	   00:15	  
Extension	   72	   01:00	  
Final	  Extension	   72	   02:00	  





	   2.13.3	  Induction	  of	  Liver	  Inflammation	  
8-­‐12	  week	   old	  male	   OT-­‐1	   and	  OT-­‐2	  mice	  were	   sacrificed	   by	   cervical	   dislocation	   and	   their	  
spleens	  removed	  and	  stored	  in	  cold	  C10	  media.	  Single	  cell	  suspensions	  were	  made	  by	  gently	  
pushing	   the	   spleens	   through	   a	   70µm	   mesh	   in	   RBC	   lysis	   buffer.	   Dissociated	   tissue	   was	  
pipetted	  up	  and	  down	  to	  resuspended	  all	  cells	  and	  ensure	  efficient	  RBC	  lysis	  for	  2	  minutes.	  
Samples	  were	  washed	  in	  excess	  C10	  buffer	  and	  centrifuged	  at	  1400rpm	  for	  7	  minutes	  at	  4°C.	  
Cell	   pellets	   were	   resuspended	   in	   PBS	   and	   an	   aliquot	   of	   cells	   containing	   10x106	   OT-­‐1	  
splenocytes	   and	   4x106	   OT-­‐2	   splenocytes	   was	   removed	   and	   merged	   together.	   Cells	   were	  
made	   up	   in	   a	   final	   volume	   of	   200µl	   for	   infusion	   and	   adoptively	   transferred	   via	   a	   single	  
intraperitoneal	   (IP)	   infusion	   into	  male	  OVA-­‐Bil	  mice	  between	  8-­‐12	  weeks	  of	  age	   to	   initiate	  
inflammatory	  liver	   injury.	  Mice	  were	  sacrificed	  at	  different	  time	  points	  thereafter	  to	  assess	  
the	  degree	  of	  liver	  injury	  occurring.	  
	  
	   2.13.4	  Treatment	  of	  OVA-­‐Bil	  mice	  with	  PαS	  MSCs	  
PαS	  MSCs	  were	   cultured	   in	   SM±GFs	   as	   described	   previously.	  On	   the	   day	   of	   infusion,	   cells	  
were	   lifted	  off	  tissue	  culture	  plastic	  using	  TrypLE	  and	  resuspended	  in	  PBS.	  1x106	  PαS	  MSCs	  
were	  given	  at	  days	  3	  and	  7	  after	  the	  onset	  of	  injury	  via	  IP	  infusions	  (Figure	  2.5).	  	  
	   	  






Figure	  2.5	  |	  Overview	  of	  the	  OVA-­‐Bil	  model.	  Adoptive	  transfer	  of	  OVA-­‐specific	  CD4	  and	  CD8	  T	  cells	  into	  OVA-­‐
Bil	  mice	  results	  in	  their	  migration	  to	  the	  liver	  where	  they	  induce	  necro-­‐inflammatory	  damage.	  PαS	  MSCs	  were	  
infused	  after	  injury	  to	  see	  whether	  they	  could	  attenuate	  the	  immune	  response.	  	  	  
	  
2.13.5	  Blood	  and	  Tissue	  Collection	  
OVA-­‐Bil	  mice	  were	  anaesthetised	  in	  4%	  isoflurane	  in	  4	  litres/minute	  oxygen	  and	  blood	  was	  
collected	  via	  cardiac	  puncture	   through	  a	  25g	  needle.	   	  Approximately	  700µl	   to	  900µl	  blood	  
per	  mouse	  was	  aspirated	  before	  the	  mice	  were	  sacrificed	  via	  cervical	  dislocation.	  The	  livers	  
were	  then	  removed	  from	  each	  animal	  and	  placed	  inside	  a	  sterile	  petri	  dish.	  The	  largest	  liver	  
lobe	  was	  dissected	  out,	  weighed,	  and	  placed	  in	  C10	  media	  for	  cell	   isolation.	  The	  remaining	  
lobes	  were	   split	   evenly	  between	   formalin	  pots	   and	   snap-­‐freezing	   in	   liquid	  nitrogen.	   These	  
lobes	  were	   then	   processed	   accordingly	   and	   sections	   stained	   for	  markers	   of	   interest	   using	  
immunohistochemistry	  (IHC).	  	   	  





	   2.13.6	  Liver	  Function	  Tests	  
Whole	  blood	  was	  centrifuged	  at	  10,000	  rpm	  for	  5	  minutes	  to	  isolate	  serum.	  Approximately	  
100-­‐150µl	  serum	  was	  carefully	  removed	  and	  placed	  in	  13mm	  false-­‐bottomed	  sample	  tubes	  
(Sarstedt)	  and	  any	  remaining	  serum	  was	  stored	  at	  -­‐80˚C	  for	  future	  use.	  Serum	  was	  assayed	  
for	  alanine	  transaminase	  (ALT)	  and	  alkaline	  phosphatase	  (ALP)	  as	  markers	  of	  hepatocytic	  and	  
biliary	   damage	   respectively.	   Liver	   function	   tests	   (LFTs)	   were	   performed	   by	   the	   Clinical	  
Biochemistry	  team	  at	  Birmingham	  Women’s	  Hospital.	  	  
	  
	   2.13.7	  Isolation	  of	  Liver	  Lymphocytes	  
Liver	   lobes	  were	   placed	   in	   gentleMACS	   ‘C’	   Tubes	   (Miltenyi)	   with	   10ml	   of	   plain	   RPMI.	   The	  
tubes	  were	  then	  processed	  using	  the	  “Mouse	  spleen	  1.01”	  program	  to	  produce	  a	  single-­‐cell	  
suspension.	  Samples	  were	  then	  forced	  through	  a	  60µm	  mesh	  and	  washed	  with	  40ml	  RPMI.	  
Samples	  were	   then	   spun	   at	   50g	   for	   10	  minutes	   to	   remove	  hepatocytes	   from	  downstream	  
analysis.	   Supernatants	   were	   collected	   and	  washed	   three	   times	   in	   an	   excess	   of	   cold	   RPMI	  
until	   it	  appears	  clear	  and	   less	   fatty.	  At	  this	  stage,	  the	  cell	  pellets	  were	  resuspended	   in	  7ml	  
RPMI	  and	  passed	  through	  a	  50µm	  filter	  prior	  to	  density	  gradient	  separation.	  
	  
Lympholyte®-­‐Mouse	   cell	   separation	   media	   (Cedarlane,	   Burlington,	   CA)	   was	   used	   for	   the	  
isolation	   of	   viable	   lymphocytes	   from	   murine	   cell	   suspensions.	   7ml	   of	   room	   temperature	  
Lympholyte®	  was	   carefully	   added	   to	   a	   15ml	   polypropylene	   tube.	   An	   equal	   volume	   of	   cell	  
suspension	  was	  layered	  on	  top	  of	  the	  Lympholyte®	  with	  extra	  care	  taken	  to	  ensure	  a	  distinct	  





interphase	  is	  formed	  between	  solutions.	  	  Samples	  were	  then	  centrifuged	  at	  2000rpm	  for	  30	  
minutes	  with	   the	   brake	   set	   to	   zero.	   Successful	   separation	   results	   in	   a	   distinctive	   “cloudy”	  
layer	  of	  lymphocytes	  appearing	  at	  the	  interphase	  between	  the	  Lympholyte®	  and	  RPMI.	  This	  
was	  carefully	  aspirated	  with	  a	  Pasteur	  pipette	  and	  transferred	  into	  a	  new	  tube	  before	  being	  
washed	  twice	  in	  FACS	  buffer	  to	  remove	  residual	  Lympholyte®	  from	  the	  sample.	  	  
	  
Samples	   were	   then	   resuspended	   in	   PBS	   and	   stained	   using	   a	   Live/Dead	   dye	   as	   described	  
previously.	   Following	   one	  wash	   in	   FACS	   buffer,	   samples	  were	   resuspended	   in	   100µl	   FACS	  
buffer	  for	  staining	  with	  fluorescently	  conjugated	  antibodies	  (Table	  2.6)	  for	  60	  minutes	  at	  4˚C.	  
Samples	   were	   then	   washed	   once	   in	   an	   excess	   of	   FACS	   buffer	   to	   remove	   any	   unbound	  
antibodies.	  All	   samples	  were	   filtered	   through	  a	  50µm	   filter	  before	  analysis	  on	  a	  Cyan	  ADP	  
flow	   cytometer	   (FC).	   Compensation	   beads	   were	   used	   to	   minimize	   fluorescence	   spillover.	  
Results	   were	   then	   normalised	   back	   to	   the	   starting	   weight	   of	   each	   liver	   lobe	   to	   allow	  
comparison	  between	  mice.	  	  
	  
2.14	  Statistical	  Analysis	  
Statistical	  analysis	  was	  performed	  using	  Prism	  5.0	  (GraphPad	  Software,	  CA,	  USA).	  Normality	  
tests	   were	   performed	   before	   deciding	   which	   analysis	   to	   perform.	   Generally,	   values	   were	  
analysed	  using	  unpaired	  Student’s	  t-­‐test	  when	  comparing	  two	  groups,	  and	  one-­‐way	  ANOVA	  
with	   Bonferroni’s	   post-­‐hoc	   test	   when	   comparing	   three	   or	   more	   groups.	   Significance	   was	  
represented	  as:	  *≤0.05;	  **≤0.01;	  ***≤0.001.	  	   	  





2.15	  Supplier	  Information	  and	  Catalogue	  Numbers	  
	   2.15.1	  Details	  of	  Mice	  used	  in	  this	  Study	  
Table	  2.5	  |	  Details	  of	  mice	  used	  in	  this	  study.	  
Strain	   Background	   Supplier	   Catalogue	  Number	  
C57BL/6	   n/a	   Harlan	   057	  
Balb/c	   n/a	   Jackson	  Laboratory	   000651	  
OT-­‐1	   C57BL/6	   Jackson	  Laboratory	   003831	  
OT-­‐2	   C57BL/6	   Jackson	  Laboratory	   004194	  
OVA-­‐Bil	   C57BL/6	   Gift	  (Liver	  Laboratories)	   n/a	  
iNOS-­‐/-­‐	   C57BL/6	   Jackson	  Laboratory	   007072	  
	  
	   2.15.2	  Details	  of	  Antibodies	  used	  in	  this	  Study	  
Table	  2.6	  |	  List	  of	  primary	  and	  secondary	  antibodies	  used	  in	  this	  study.	  	  
Antibody	   Fluorophore	   Final	  Concentration	  
Intended	  
use	   Supplier	  
Catalogue	  
Number	  
CD3	   PE	   5µg/ml	   FC	   eBioscience	   12-­‐0031	  
CD3	   APC	   2.5µg/ml	   FC	   eBioscience	   17-­‐0031	  
CD3	   PE-­‐Cy7	   10µg/ml	   FC	   eBioscience	   25-­‐0031	  
CD3	   BV510	   5µl/test	   FC	   Biolegend	   100233	  
CD3e	   Purified	   0.8µg/ml	   Functional	   BD	  Bioscience	   553057	  
CD4	   BV421	   5µl/test	   FC	   Biolegend	   100544	  
CD4	   FITC	   2.5µg/ml	   FC	   eBioscience	   11-­‐0042	  
CD4	   PerCP	   1:100	   FC	   BD	  Bioscience	   561090	  
CD8	   PE-­‐Cy7	   5µg/ml	   FC	   eBioscience	   25-­‐0081	  
CD8	   APC	   1.25µg/ml	   FC	   eBioscience	   17-­‐0081	  
CD8	   APC-­‐Cy7	   1:100	   FC	   BD	  Bioscience	   561967	  
CD19	   APC	   1:100	   FC	   BD	  Bioscience	   561738	  
CD25	   PE	   1.25µg/ml	   FC	   eBioscience	   12-­‐0251	  
CD25	   APC	   1.25µg/ml	   FC	   eBioscience	   17-­‐0251	  
CD29	   PE	   10µg/ml	   FC	   eBioscience	   12-­‐0291	  
CD34	   FITC	   10µg/ml	   FC	   eBioscience	   11-­‐0341	  
CD44	   FITC	   5µg/ml	   FC	   eBioscience	   11-­‐0441	  
CD45	   PE	   1µl/mouse	   FACS	   eBioscience	   12-­‐0451	  
CD45	   Purified	   1:200	   IHC	   eBioscience	   14-­‐0451	  
	  





Antibody	   Fluorophore	   Final	  Concentration	  
Intended	  
use	   Supplier	  
Catalogue	  
Number	  
CD49e	   PE	   5µg/ml	   FC	   eBioscience	   12-­‐0493	  
CD62L	   APC	   0.6µg/ml	   FC	   eBioscience	   17-­‐0621	  
CD69	   FITC	   5µg/ml	   FC	   eBioscience	   11-­‐0691	  
CD69	   Pacific	  Blue	   2.5µg/ml	   FC	   Invitrogen	   HM4028	  
CD90	   PE	   0.3µg/ml	   FC	   eBioscience	   12-­‐0902	  
CD105	   FITC	   5µg/ml	   FC	   eBioscience	   12-­‐1051	  
F4/80	   FITC	   5µg/ml	   FC	   eBioscience	   11-­‐4801	  
F4/80	   Purified	   1:00	   IHC	   AbD	  Serotec	   MCA497R	  
Ter-­‐119	   PE	   1µl/mouse	   FACS	   eBioscience	   12-­‐5921	  
Sca-­‐1	   FITC	   1µl/mouse	   FACS	   eBioscience	   11-­‐5981	  
PDGFRα	   APC	   1µl/mouse	   FACS	   eBioscience	   17-­‐1401	  
FoxP3	   PE	   10µg/ml	   FC	   eBioscience	   12-­‐5773	  
Vα2	   PE	   5µg/ml	   FC	   eBioscience	   12-­‐5812	  
IFNγ	   FITC	   5µg/ml	   FC	   eBioscience	   11-­‐7311	  
TNFα	   PE	   2.5µg/ml	   FC	   eBioscience	   12-­‐7321	  
Live/Dead	  
Marker	   eFluor®780	   1µl/ml	   FC/FACS	   eBioscience	   65-­‐0865	  
HRP-­‐conjugated	  
anti	  rabbit	  Ig	   N/A	   Pre-­‐diluted	   IHC	  
Vector	  
Laboratories	   MP-­‐7401	  
HRP-­‐conjugated	  
anti	  rat	  Ig	   N/A	   Pre-­‐diluted	   IHC	  
Vector	  
Laboratories	   MP-­‐7444	  
AP-­‐conjugated	  
anti	  rabbit	  Ig	   N/A	   1:1000	   IHC	  
Southern	  
Biotech	   4010-­‐04	  
AP-­‐conjugated	  
anti	  mouse	  Ig	   N/A	   1:1000	   IHC	  
Southern	  
Biotech	   1030-­‐04	  
	  
2.15.3	  Details	  of	  General	  Reagents	  used	  in	  this	  Study	  
Table	  2.7	  |	  List	  of	  general	  laboratory	  reagents	  used	  in	  this	  study.	  
Item	   Supplier	   Catalogue	  Number	  
DAB	  substrate	   AbD	  Serotec	   BUF022	  
10%	  formal	  saline	  solution	   Adams	  Healthcare	   416479	  
OVA	  (257-­‐264)	  peptide	   AnaSpec	   60193-­‐5	  
Anti-­‐rat/hamster	  compensation	  beads	   BD	  Bioscience	   552845	  
Brefeldin	  A	   BD	  Bioscience	   555029	  
Fix/Perm	  Solution	   BD	  Bioscience	   554722	  
Perm	  wash	  buffer	   BD	  Bioscience	   554723	  
PCR	  Hyperladder	  100bp	   Bioline	   33029	  
	  





Item	   Supplier	   Catalogue	  Number	  
Senescence	  Detection	  Kit	   Biovision	   K320-­‐250	  
Lympholyte®-­‐Mouse	   Cedarlane	   CL5035	  
Peroxidase	  blocking	  solution	   Dako	   52023	  
IL-­‐2	   eBioscience	   16-­‐7022	  
CD3/CD28	  Dynabeads®	   Gibco	   11452	  
DMEM	   Gibco	   41965-­‐039	  
FBS	   Gibco	   10500	  
HBSS	   Gibco	   14170-­‐088	  
Insulin-­‐transferrin-­‐selenium	   Gibco	   41400-­‐045	  
Penicillin/Streptomycin/Glutamine	   Gibco	   10378-­‐016	  
RPMI	   Gibco	   31870-­‐025	  
TrypLE	  Express	   Gibco	   12605010	  
αMEM	   Gibco	   32561-­‐029	  
Dasatinib	   Gift	   N/A	  
DPX	  Mounting	  Medium	   Leica	   08600E	  
Adipogenic	  Differentiation	  Media	   Lonza	   PT-­‐3004	  
Chondrogenic	  Differentiation	  Media	   Lonza	   PT-­‐3003	  
Osteogenic	  Differentiation	  Media	   Lonza	   PT-­‐3002	  
Osteogenesis	  Assay	  Kit	   Millipore	   ECM815	  
CD19	  microbeads	   Miltenyi	  Biotec	   130-­‐052-­‐201	  
CD4+CD25-­‐	  T	  Cell	  Isolation	  Kit	   Miltenyi	  Biotec	   130-­‐091-­‐041	  
Cell	  Trace	  Violet	  Proliferation	  Kit	   Molecular	  Probes	   C34557	  
Murine	  recombinant	  TGF-­‐β1	   New	  England	  Biolabs	   5231LC	  
Human	  recombinant	  TGF-­‐β3	   Peprotech	   100-­‐36E	  
Murine	  recombinant	  FGF2	   Peprotech	   450-­‐33	  
Murine	  recombinant	  IFNγ	   Peprotech	   315-­‐05	  
Murine	  recombinant	  PDGF-­‐AA	   Peprotech	   315-­‐17	  
Murine	  recombinant	  PDGF-­‐BB	   Peprotech	   315-­‐18	  
Murine	  recombinant	  TNFα	   Peprotech	   315-­‐01	  
Industrial	  Methylated	  Spirit	   PFM	  Medical	   PRC/R/101	  
Xylene	   PFM	  Medical	   PRC/R/201	  
Griess	  Assay	  Kit	   Promega	   G2930	  
DNase	  I	   Qiagen	   79254	  
Fast-­‐cycling	  PCR	  Kit	   Qiagen	   203745	  
OCT	  Embedding	  Compound	   Sakura	  Tissue-­‐Tek	   4583	  
1-­‐methyl	  tryptophan	   Sigma-­‐Aldrich	   447439	  
Absolute	  ethanol	   Sigma-­‐Aldrich	   459844	  
Ascorbic	  acid-­‐2-­‐phosphate	   Sigma-­‐Aldrich	   A8960	  
Bovine	  pancreatic	  trypsin	   Sigma-­‐Aldrich	   T1426	  
Bovine	  tracheal	  chondroitin	  sulphate	   Sigma-­‐Aldrich	   C9819	  
Bovine	  tracheal	  type	  II	  collagen	   Sigma-­‐Aldrich	   C1188	  
Concanavalin	  A	   Sigma-­‐Aldrich	   C5275	  





Item	   Supplier	   Catalogue	  Number	  
Crystal	  Violet	   Sigma-­‐Aldrich	   C3886	  
Dexamethasone	   Sigma-­‐Aldrich	   D4902	  
Dimethylmethylene	  blue	  (DMB)	   Sigma-­‐Aldrich	   341088	  
EDTA	   Sigma-­‐Aldrich	   E6758	  
Fast	  Green	  Dye	   Sigma-­‐Aldrich	   F7252	  
Fibronectin	   Sigma-­‐Aldrich	   F0895	  
HEPES	   Sigma-­‐Aldrich	   H0887	  
Indomethacin	   Sigma-­‐Aldrich	   IL378	  
Insulin	   Sigma-­‐Aldrich	   I5500	  
Iodoacetamide	   Sigma-­‐Aldrich	   L1149	  
Ionomycin	   Sigma-­‐Aldrich	   I3909	  
L-­‐NMMA	   Sigma-­‐Aldrich	   M7033	  
Oil	  Red	  O	   Sigma-­‐Aldrich	   O0625	  
p-­‐nitrophenyl	  phosphate	   Sigma-­‐Aldrich	   71768	  
Pepstatin	  A	   Sigma-­‐Aldrich	   P5318	  
Phorbol	  myristate	  acetate	   Sigma-­‐Aldrich	   P8139	  
Propidium	  Iodide	   Sigma-­‐Aldrich	   P4170	  
RBC	  lysis	  buffer	   Sigma-­‐Aldrich	   R7757	  
Safranin	  O	  solution	   Sigma-­‐Aldrich	   S2255	  
SB-­‐3CT	   Sigma-­‐Aldrich	   S1326	  
SB431542	   Sigma-­‐Aldrich	   S4317	  
Sodium	  carbonate	  buffer	   Sigma-­‐Aldrich	   S7795	  
Sodium	  pyruvate	   Sigma-­‐Aldrich	   S8636	  
Toluidine	  blue	   Sigma-­‐Aldrich	   89640	  
Trizma	   Sigma-­‐Aldrich	   T1503	  
Tween-­‐20	   Sigma-­‐Aldrich	   P2287	  
Water	   Sigma-­‐Aldrich	   W3500	  
β-­‐mercaptoethanol	   Sigma-­‐Aldrich	   M6250	  
SU5402	   Tocris	   3300	  
Antigen	  retrieval	  high	  pH	  buffer	   Vector	  Laboratories	   H-­‐3301	  
Caesin	  buffer	   Vector	  Laboratories	   SP-­‐5020	  
Collagenase	   Wako	   034-­‐10533	  
	  
	   	  





	   2.15.4	  Details	  of	  Consumables	  used	  in	  this	  Study	  
Table	  2.8	  |	  List	  of	  general	  laboratory	  consumables	  used	  in	  this	  study.	  	  
Item	   Supplier	   Catalogue	  Number	  
70µm	  cell	  strainer	   Corning	   352350	  
50µm	  cell	  strainer	   Partec	   04-­‐004-­‐2327	  
X-­‐tra	  Adhesive	  Slides	   Leica	   38002032	  
Superfrost	  Slides	   Thermo	  Scientific	   4951PLUS4	  
Sterile	  FACS	  tubes	   BD	  Biosciences	   352063	  
FACS	  tubes	   BD	  Biosciences	   352002	  
Biofelt®	  PGA	  Scaffolds	   Biomedical	  Structures	   http://www.bmsri.com/biofelt/	  
Immulon-­‐2HB	  ELISA	  Plate	   Thermo	  Scientific	   10795026	  
384-­‐well	  HB	  ELISA	  Plate	   Corning	   3700	  
MACS	  Separators	   Miltenyi	  Biotec	   130-­‐042-­‐302	  
LS	  Columns	   Miltenyi	  Biotec	   130-­‐042-­‐401	  
LD	  Columns	   Miltenyi	  Biotec	   130-­‐042-­‐901	  
MS	  Columns	   Miltenyi	  Biotec	   130-­‐042-­‐201	  
gentleMACS	  ‘C’	  tubes	   Miltenyi	  Biotec	   130-­‐096-­‐334	  
RNeasy	  Mini	  Kit	   Qiagen	   74104	  
13mm	  false-­‐bottom	  tubes	   Sarstedt	   60.617.010	  
96-­‐well	  U-­‐bottom	  plate	   Sarstedt	   83.18357.500	  
96-­‐well	  flat-­‐bottom	  plate	   Corning	   353072	  
48-­‐well	  plate	   Corning	   3548	  
24-­‐well	  plate	   Corning	   3526	  
12-­‐well	  plate	   Corning	   3513	  
6-­‐well	  plate	   Corning	   3516	  
T25	  Culture	  flask	   Corning	   430639	  
T75	  Culture	  flask	   Corning	   430641	  
T150	  Culture	  flask	   Corning	   875823	  
T175	  Culture	  flask	   Corning	   353112	  
15ml	  polypropylene	  tubes	   Corning	   430791	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3.1	  Chapter	  Rationale	  and	  Aims	  
MSCs	   hold	   great	   promise	   for	   future	   use	   as	   a	   cellular	   therapy	   for	   regenerative	   or	  
immunosuppressive	   indications.	  However,	   the	  heterogeneous	  populations	  of	  MSCs	  used	   in	  
past	  studies	  have	  hampered	  efforts	  to	  reach	  agreement	  over	  potential	  mechanisms	  of	  action.	  	  
Difficulties	   in	   isolating	   a	   purified	   population	   of	  mouse	  MSCs	   has	   prevented	   the	   field	   from	  
studying	  the	  function	  of	  these	  cells	   in	  the	  absence	  of	  any	  contaminants	   (Anjos-­‐Afonso	  and	  
Bonnet,	  2011).	  This	  has	  also	  prevented	  us	  from	  studying	  the	  biology	  of	  these	  cells	  using	  the	  
large	   number	   of	   transgenic	   mouse	   models	   currently	   available.	   Thus,	   our	   current	  
understanding	   of	  MSC	  biology	   and	   function	   is	   inferred	   from	   the	   study	   of	   in	   vitro-­‐cultured	  
human	   MSCs	   as	   they	   can	   easily	   be	   isolated	   using	   plastic-­‐adherence.	   Despite	   the	   lack	   of	  
comprehensive	  murine	  data,	  MSCs	  have	  been	  used	  in	  small-­‐scale	  clinical	  trials	  in	  which	  many	  
report	   marginal	   clinical	   improvements	   after	   infusion.	   There	   is	   a	   pressing	   need	   to	   fully	  
understand	   the	   biology	   and	   function	   of	   these	   cells	   in	   the	  murine	   system	   to	   better	   design	  
culture	  conditions	  to	  optimise	  the	  therapeutic	  potential	  of	  MSCs.	  These	  findings	  can	  then	  be	  
translated	  towards	  the	  clinic	  to	  improve	  the	  efficacy	  of	  MSCs	  in	  patients.	  	  	  	  
	  
Mouse	   MSC	   isolation	   methods	   have	   traditionally	   been	   hampered	   by	   persistence	   of	  
contaminating	  cells	  (Phinney	  et	  al.,	  1999),	  slow-­‐growing	  cells	  (Baddoo	  et	  al.,	  2003)	  and	  the	  
lack	  of	  specific	  markers	  (Boxall	  and	  Jones,	  2012).	  The	  recent	  publication	  of	  three	  prospective	  
isolation	  methods	   (Pinho	   et	   al.,	   2013,	  Mendez-­‐Ferrer	   et	   al.,	   2010,	  Morikawa	   et	   al.,	   2009)	  
were	  the	  first	  to	  comprehensively	  describe	  markers	  of	  murine	  MSCs	  and	  test	  their	  function	  
in	   vivo	   using	   traditional	   assays	   of	   stem	   cell	   function.	   However,	   the	   uptake	   of	   these	   new	  





methods	  by	  the	  wider	  scientific	  community	  has	  been	  slow.	  Reasons	  for	  this	  could	  be	  due	  to	  
lack	  of	  access	  to	  a	  cell	  sorter	  and	  the	  more	  challenging	  nature	  of	  the	  protocols	  compared	  to	  
the	   plastic-­‐adherence	   approach.	   Importantly,	   the	   regenerative	   and	   immunomodulatory	  
potential	   of	   prospectively-­‐isolated	   mouse	   MSCs	   has	   not	   been	   studied	   previously,	   and	   it	  
remains	  to	  be	  seen	  whether	  purified	  MSCs	  are	  as	  effective	  as	  their	  non-­‐purified	  counterparts.	  	  
	  
To	  meet	  these	  needs,	   I	   set	  out	  to	  prospectively	   isolate	  PDGFRα+Sca-­‐1+	  (PαS)	  MSCs	  and	  use	  
these	  purified	  cells	  as	  a	  substrate	  for	  in	  vitro	  and	  in	  vivo	  studies	  on	  MSC	  biology	  in	  my	  thesis.	  
PαS	   MSCs	   were	   chosen	   over	   their	   Nestin+	   counterparts	   because	   their	   isolation	   does	   not	  
necessitate	   the	  use	  of	  a	  Nestin-­‐GFP	   transgenic	  mouse,	  allowing	   isolation	   from	  a	  variety	  of	  
mouse	   strains.	   This	   chapter	   focuses	  on	   the	   isolation,	   culture	  and	  phenotype	  of	  PαS	  MSCs.	  
The	  specific	  aims	  for	  this	  chapter	  were	  to:	  	  
	  
1. Reproducibly	  isolate	  PαS	  MSCs	  and	  successfully	  culture	  them	  in	  vitro	  
2. Characterise	  their	  grown,	  surface	  marker	  phenotype	  and	  tri-­‐lineage	  differentiation	  in	  
accordance	  with	  the	  ISCT	  criteria	  
3. Describe	   the	   immunosuppressive	  potential	  of	  PαS	  MSCs	  and	  depict	   the	  mechanism	  
behind	  this	  effect	  
4. Examine	  the	  immunosuppressive	  potential	  of	  PαS	  MSCs	  from	  different	  mouse	  strains	  
	   	  






3.2.1	  Isolation	  of	  PαS	  MSCs	  
Collagenase-­‐digested	  compact	  bone	  was	  processed	  and	  stained	  with	  conjugated	  antibodies	  
against	  CD45,	  Ter-­‐119,	  PDGFRα	  and	  Sca-­‐1	  (Houlihan	  et	  al.,	  2012,	  Morikawa	  et	  al.,	  2009).	  PI	  
was	  used	   to	  exclude	  non-­‐viable	  cells	   from	  downstream	  analysis	  and	   increase	   the	  purity	  of	  
our	  MSC	   cultures.	   PIlow	   cells	   typically	   represented	   80-­‐85%	   of	   the	   total	   population	   (Figure	  
3.1A).	   Next,	   the	   haematopoietic	   cells	   (CD45+Ter-­‐119+)	   were	   excluded	   by	   gating	   on	   PE-­‐
negative	  cells	  (<1%	  of	  viable	  cells;	  Figure	  3.1B).	  This	  PE-­‐negative	  fraction	  was	  then	  analysed	  
for	   PDGFRα	   and	   Sca-­‐1	   expression,	   and	   the	   double-­‐positive	   population	   was	   isolated	   using	  
FACS	  (Figure	  3.1C).	  PαS	  MSCs	  typically	  represented	  10-­‐15%	  of	  non-­‐haematopoietic	  cells,	  or	  
0.05%	  of	  all	  BM	  cells.	  The	  isolation	  was	  successful	  on	  all	  occasions	  and	  I	  routinely	  achieved	  a	  
purity	  of	  >95%	  and	  a	  yield	  approaching	  5,000-­‐8,000	  PαS	  MSCs/mouse.	  	  
	  
	  
Figure	  3.1	  |	  Representative	  FACS	  plots	  for	  PαS	  MSC	  isolation	  from	  C57BL/6	  mice.	  (A)	  A	  live	  cell	  gate	  is	  applied	  
around	  PIlow	  BM	  cells.	  (B)	  The	  non-­‐haematopoietic	  fraction	  is	  then	  selected	  and	  (C)	  analysed	  for	  PDGFRα/Sca-­‐1	  
expression.	  This	  double-­‐positive	  population	  is	  then	  collected	  in	  SM	  for	  in	  vitro	  culture.	  	  
	   	  





	   3.2.2	  Morphology	  and	  CFU-­‐F	  potential	  
Freshly	   isolated	  PαS	  MSCs	  were	  cultured	   in	  standard	  media	   (SM;	  α-­‐MEM+10%	  FBS)	  on	  un-­‐
coated	  tissue	  culture	  plastic.	  They	  were	  able	  to	  adhere	  within	  2	  hours	  and	  displayed	  spindle-­‐
shaped	  morphology	  characteristic	  of	  stromal	  cells	  (Figure	  3.2A).	  The	  media	  was	  replaced	  24	  
hours	   after	   plating	   to	   remove	   any	  dead	   cells	   (due	   to	   the	   cell	   sorting	   procedure)	   from	   the	  
culture.	  Thereafter,	  fresh	  media	  was	  added	  every	  3	  days	  to	  expand	  PαS	  MSCs.	  	  	  	  
	  
To	  examine	  CFU-­‐F	  potential,	  2000	  freshly	  isolated	  PαS	  MSCs	  were	  cultured	  in	  a	  10cm2	  petri	  
dish	  for	  14	  days.	  Samples	  were	  then	  fixed	  and	  stained	  with	  crystal	  violet	  to	  visualise	  separate	  
colonies	   (Figure	   3.2B).	   Colonies	   of	   MSCs	   with	   >50	   cells	   were	   counted	   as	   CFU-­‐Fs,	   which	  
revealed	  approximately	  30	  colonies	  per	  dish,	  a	  CFU-­‐F	  efficiency	  of	  1	   in	  every	  66	  PαS	  MSCs	  
(Figure	  3.2C).	  	  	  
	  
	  
Figure	  3.2	  |	  Morphology	  and	  CFU-­‐F	  of	  PαS	  MSCs.	  (A)	  PαS	  MSCs	  adopt	  a	  spindle-­‐shaped	  morphology	  on	  tissue-­‐
culture	  plastic.	  Image	  taken	  at	  100x	  magnification.	  Bar,	  25µm.	  (B)	  Representative	  image	  of	  CFU-­‐F	  potential	  of	  
PαS	   MSCs.	   10cm2	   petri	   dish	   stained	   with	   crystal	   violet	   showing	   colony	   formation.	   Image	   taken	   without	  
magnification.	   (C)	   Quantification	   of	   total	   colony	   number	   (clusters	   >50	   cells).	   Data	   shown	   as	   mean±SD,	   n=3	  
technical	  repeats.	   	  





	   3.2.3	  Growth	  of	  PαS	  MSCs	  in	  vitro	  
The	  ability	  of	  MSCs	  to	  undergo	  serial	  passaging	  in	  vitro	  under	  standard	  culture	  conditions	  is	  
one	   of	   the	   criteria	   used	   to	   define	  MSC	   populations	   (Dominici	   et	   al.,	   2006).	   4000	   freshly-­‐
isolated	  PαS	  MSCs	  were	  seeded	  in	  a	  96-­‐well	  plate	  and	  expanded	  at	  a	  1:2	  ratio	  over	  a	  50	  day	  
period.	  The	  number	  of	  population	  doublings	  (PD;	  Figure	  3.3A)	  and	  total	  cell	  number	  (Figure	  
3.3B)	  was	   recorded	   at	   different	   time	   points.	   A	   robust	   growth	   rate	  was	   observed,	  with	   an	  
initial	  doubling	  time	  of	  2-­‐3	  days.	  However,	  this	  increased	  to	  nearly	  12-­‐14	  days	  near	  the	  end	  
of	  the	  experiment	  as	  the	  growth	  rate	  of	  the	  cells	  slowed.	  Significant	  increases	  in	  cell	  number	  
were	  also	  observed	  at	  days	  30	  and	  50	  compared	  to	  baseline	  (Day	  0,	  p≤0.001).	  However,	  the	  
rate	  of	  increase	  did	  slow	  down,	  suggesting	  a	  drop	  in	  proliferative	  capacity	  of	  PαS	  MSCs	  after	  
extended	  in	  vitro	  culture.	  	  	  
	  
	  
Figure	   3.3	   |	  Growth	   of	   PαS	   MSCs	   over	   50	   days	   culture.	   (A)	   Population	   doublings	   over	   50	   days.	   Each	   line	  
represents	   an	   independent	   experiment	   on	   different	   cultures	   of	   PαS	   MSCs	   (n=3	   biological	   repeats).	   (B)	   Cell	  
counts	   at	   day	   30	   and	   50	   post	   seeding.	   Data	   shown	   as	   mean±SD,	   n=3	   biological	   repeats.	   Statistical	   analysis	  
performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Correction.	  	   	  





	   3.2.4	  Surface	  Marker	  Profile	  of	  PαS	  MSCs	  
The	   surface	   marker	   expression	   of	   P1	   PαS	   MSCs	   was	   examined	   using	   flow	   cytometry.	  
Propidium	  iodide	  was	  used	  to	  exclude	  dead	  cells	  were	  from	  analysis	  and	  the	  expression	  of	  
characteristic	  MSC	  markers	  were	  examined	  alongside	  IMCs	  and	  unstained	  cells	  as	  controls.	  
PαS	   MSCs	   were	   negative	   for	   haematopoietic	   and	   leukocytic	   markers	   CD45,	   Ter-­‐119	   and	  
CD34.	  High	  levels	  of	  expression	  (>85%	  positive)	  were	  seen	  for	  the	  ‘MSC	  markers’	  CD29,	  CD90,	  
CD49e,	  Sca-­‐1,	  CD44,	  CD105	  and	  CD140a	  (Figure	  3.4).	  	  
	  
	  
Figure	  3.4	  |	  Cell	  surface	  phenotype	  of	  PαS	  MSCs.	  Representative	  fluorescence	  histograms	  showing	  the	  surface	  
marker	  expression	  of	  P1	  PαS	  MSCs.	  PI	  was	  used	  to	  exclude	  dead	  cells	  from	  analysis.	  Unstained	  cells	  (grey	  bars)	  
and	  IMC	  controls	  (hatched	  lines)	  are	  included	  for	  comparison.	  	  	  
	   	  





	   3.2.5	  Tri-­‐lineage	  differentiation	  of	  PαS	  MSCs	  
Osteogenic	  differentiation	  samples	  were	  fixed	  and	  stained	  using	  Alizarin	  red,	  an	  organic	  dye	  
that	  stains	  calcium	  deposits.	  PαS	  MSCs	  readily	  underwent	  osteogenic	  differentiation	  (Figure	  
3.5A)	  and	  produced	  approximately	  600µM	  calcium	  (Figure	  3.5B).	  Adipogenic	  differentiation	  
was	  visualised	  with	  oil	  red	  O,	  which	  stains	  lipids	  in	  a	  red	  colour.	  Patches	  of	  oil	  red	  O-­‐positive	  
adipocytes	   could	   be	   found	   in	   samples	   after	   staining	   (Figure	   3.5C).	   Chondrogenic	  
differentiation	   was	   induced	   by	   micromass	   pellet	   culture	   in	   serum-­‐free	   differentiation	  
medium.	  Cartilage	  pellets	  were	  embedded,	  sectioned	  and	  stained	  with	  toluidine	  blue,	  which	  
stains	  proteoglycan	  deposits	  in	  a	  purple	  colour	  (Figure	  3.5D).	  	  
	  
Figure	  3.5	  |	  Tri-­‐lineage	   differentiation	   of	   PαS	  MSCs.	   (A)	  Osteogenic	  differentiation	  visualised	  by	  alizarin	   red	  
stain.	  (B)	  Quantification	  of	  calcium	  deposition.	  Data	  shown	  as	  mean±SD,	  n=6	  technical	  repeats.	  (C)	  Adipogenic	  
differentiation	   visualised	   by	   oil	   red	   O	   staining.	   Bar,	   25µm.	   (D)	   Chondrogenic	   differentiation	   visualised	   by	  
toluidine	  blue	  stain.	  Insert	  shows	  negative	  control.	   	  





	   3.2.6	  Modulation	  of	  T	  cell	  proliferation	  
The	   immunosuppressive	   phenotype	   of	   PαS	  MSCs	   has	   not	   been	   reported	   in	   literature.	   To	  
examine	  the	  effect	  of	  MSC	  co-­‐culture	  on	  T	  cell	  proliferation,	  graded	  numbers	  of	  P3	  PαS	  MSCs	  
were	   cultured	   alongside	   CD4+CD25-­‐	   naïve	   T	   lymphocytes	   that	   were	   stimulated	   with	   anti-­‐
CD3e	  antibody	  (binds	  to	  T	  cell	  receptor	  [TCR],	  provides	  primary	  signal)	  and	  CD19+	  B	  cells	  (co-­‐
stimulation	  via	  CD86-­‐CD28	  interaction).	  After	  72	  hours’	  co-­‐culture,	  the	  total	  number	  of	  CD4+	  
cells	   was	   quantified	   using	   flow	   cytometry	   (Figure	   3.6).	   The	   results	   are	   expressed	   as	   a	  
percentage±SD	   to	   the	   no-­‐MSC	   control,	   which	   have	   been	   normalised	   to	   100%.	   Significant	  
(p<0.001)	   reductions	   in	   T	   cell	   proliferation	   can	   be	   seen	   across	   all	   MSC	   ratio’s	   tested,	  
achieving	   80%	   suppression	   at	   the	   1:16	   ratio.	   The	   immunosuppressive	   effect	   plateaus	  
thereafter,	  with	  increasing	  numbers	  of	  MSCs	  producing	  smaller	  reductions	  in	  T	  cell	  numbers.	  	  
	  
Figure	  3.6	  |	  Immunosuppression	  by	  Balb/c	  PαS	  MSCs.	  PαS	  cells	  at	  P3	  (n=3	  biological	  repeats)	  were	  co-­‐cultured	  
with	  activated	  CD4	  T	  cells	  for	  72	  hours.	  Samples	  were	  then	  analysed	  by	  flow	  cytometry	  and	  total	  CD4	  numbers	  
counted	  and	  expressed	  as	   a	  percentage	   to	   the	  no-­‐MSC	   control.	  Data	   shown	  as	  mean±SD.	   Statistical	   analysis	  
performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Correction.	  P-­‐values	  calculated	  vs.	  no-­‐MSC	  controls.	  	  	  	  





	   3.2.7	  Mechanistic	  studies	  of	  Balb/c	  PαS	  MSC	  Immunosuppression	  
A	  variety	  of	  small	  molecule	  inhibitors	  of	  previously	  reported	  mechanisms	  were	  tested	  in	  the	  
T	   cell	   proliferation	   assay	   to	   determine	   how	   Balb/c	   PαS	   MSCs	   were	   exerting	   their	  
immunosuppressive	  effect.	  Cultures	  were	  maintained	  for	  72	  hours	  and	  analysed	  using	  flow	  
cytometry	   to	   see	   whether	   reversal	   of	   the	   suppressive	   phenotype	   could	   be	   observed	  
(summarised	  in	  Table	  3.1).	  	  
	  
Table	  3.1	  |	  Details	  of	  inhibitors	  used	  to	  study	  immunosuppressive	  mechanisms.	  	  
Mechanism	   Inhibitor/Method	   Reference	   Reversal	  of	  suppression	  seen?	  
Prostaglandin	  E2	   Indomethacin	   Nemeth	  et	  al.	  (2009)	   û	  
MMP2/MMP9	   SB-­‐3CT	   Ding	  et	  al.	  (2009)	   û	  
IDO	   1-­‐MT	   Ren	  et	  al.	  (2009)	   û	  
‘Indirect’	  effects	   Removal	  of	  B	  cells	   n/a	   û	  
Nitric	  Oxide	   L-­‐NMMA	   Ren	  et	  al.	  (2008)	   ü	  
	  
	  
Indomethacin	   is	   a	   non-­‐steroidal	   anti-­‐inflammatory	   that	   works	   by	   inhibiting	   the	  
cyclooxygenase	  enzymes	   responsible	   for	  prostaglandin	  E2	   synthesis	   (Mitchell	   et	   al.,	   1993).	  
Inhibition	   of	   PGE2	   release	   has	   been	   shown	   to	   reverse	   the	   suppressive	   phenotype	   of	  MSC	  
cultures	  (Nemeth	  et	  al.,	  2009,	  Spaggiari	  et	  al.,	  2008,	  Rasmusson	  et	  al.,	  2005).	  The	  addition	  of	  
indomethacin	   failed	   to	   prevent	   PαS	   MSC-­‐mediated	   immunosuppression	   (Figure	   3.7A).	  
Significant	   drops	   in	   T	   cell	   numbers	   were	   seen	   across	   all	   ratios	   tested,	   although	   some	  
variation	  was	   seen	   in	   the	   1:32	   and	   1:16	   samples.	   This	   suggests	   that	   PGE2	   secretion	   is	   not	  
responsible	  for	  the	  immunosuppressive	  effect	  seen	  in	  this	  assay.	  	  






Figure	   3.7	   |	  Mechanism	   behind	   Balb/c	   PαS	   MSC	   Immunosuppression.	   Graded	   numbers	   of	   P3	   PαS	   MSCs	  
isolated	  from	  Balb/c	  mice	  were	  co-­‐cultured	  with	  activated	  T	  cells	  in	  the	  presence	  of	  (A)	  Indomethacin	  (n=3),	  (B)	  
1-­‐MT	   (n=2),	   (C)	   SB-­‐3CT	   (n=2),	   (D)	   Dynabeads®	   (n=3)	   and	   (E)	   L-­‐NMMA	   (n=3).	   Total	   CD4	   T	   cell	   numbers	  were	  
quantified	  and	  expressed	  as	  a	  percentage	  to	  the	  no-­‐MSC	  control.	  Data	  shown	  as	  mean±SD.	  Statistical	  analysis	  
performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  P-­‐values	  calculated	  vs.	  no-­‐MSC	  
controls.	  In	  all	  experiments,	  n	  is	  indicative	  of	  biological	  repeats	  using	  different	  cultures	  of	  PαS	  MSCs.	  	  	  	  	  





IDO,	  the	  rate	  limiting	  enzyme	  responsible	  for	  tryptophan	  catabolism,	  has	  also	  been	  cited	  as	  a	  
potential	   mechanism	   of	   action	   (Meisel	   et	   al.,	   2004).	   1-­‐methyl	   tryptophan	   (1-­‐MT)	   is	   a	  
competitive	   inhibitor	   of	   IDO	   and	   prevents	   the	   breakdown	   of	   tryptophan	   from	   the	   local	  
microenvironment.	  Reversal	  of	  immunosuppression	  was	  not	  seen	  when	  1-­‐MT	  was	  added	  to	  
the	  T	  cell	  proliferation	  assay	  (Figure	  3.7B).	  This	  fits	  the	  current	  hypothesis	  that	  human	  MSCs,	  
not	  murine,	  primarily	  mediate	  immunosuppression	  via	  IDO	  secretion	  (Ren	  et	  al.,	  2009).	  	  
	  
SB-­‐3CT	   is	   a	   small	   molecule	   competitive	   inhibitor	   of	   metalloproteinases	   (MMP)	   2	   and	   9	  
(Kleifeld	  et	  al.,	  2001).	  MMP2/MMP9	  secretion	  by	  Balb/c	  MSCs	  has	  previously	  been	  shown	  to	  
prevent	  CD4	  T	  cell	  activation	  by	  cleavage	  of	  CD25	  from	  its	  surface	  (Ding	  et	  al.,	  2009).	  In	  our	  
hands,	  SB-­‐3CT	  had	  no	  effect,	  and	  PαS	  MSCs	  were	  still	  able	  to	  elicit	  significant	  reductions	  in	  T	  
cell	  number	  across	  all	  ratios	  tested	  (Figure	  3.7C).	  
	  
Removal	  of	  B	  cells	  from	  the	  proliferation	  assay	  was	  also	  examined	  to	  identify	  any	  potential	  
indirect	   effects	   of	   PαS	  MSCs	   on	   T	   cell	   proliferation.	   CD3/CD28	   Dynabeads®	   were	   used	   in	  
place	  of	  B	  cells	  to	  provide	  the	  signals	  necessary	  for	  T	  cell	  activation.	  Dynabeads®	  were	  added	  
at	   a	   1:1	   ratio	   to	   T	   cells	   and	   graded	   numbers	   of	   MSCs	   were	   added	   as	   before.	   A	   weaker	  
immunosuppressive	   response	  was	   seen	  with	   Dynabeads®	   stimulation,	   however	   PαS	  MSCs	  
were	   still	   able	   to	   cause	   significant	   reductions	   across	   all	   ratio’s	   tested	   (Figure	   3.7D).	   This	  
reduced	   response	  could	  be	  due	   to	   the	   ‘artificially-­‐enhanced’	  activating	  signals	  provided	  by	  
Dynabeads®	  over	  the	  more	  physiological	  signals	  produced	  by	  B	  cells.	  
	   	  





The	   final	  mechanism	   examined	  was	   the	   inhibition	   of	   NO	   release	   using	   NG-­‐Monomethyl-­‐L-­‐
arginine	  (L-­‐NMMA),	  a	  competitive	  inhibitor	  of	  the	  inducible	  NO	  synthase	  (iNOS)	  enzymes.	  A	  
profound	   reversal	   of	   suppression	   was	   seen	   when	   L-­‐NMMA	   was	   added	   to	   the	   co-­‐culture	  
(Figure	   3.7E).	   Lymphocyte	   proliferation	   returned	   to	   normal	   levels,	   and	   there	   was	   no	  
difference	   in	  T	  cell	  numbers	   in	  the	  MSC-­‐treated	  samples	  compared	  to	  the	  no-­‐MSC	  control.	  
This	  suggests	  that	  PαS	  MSCs	  primarily	  use	  NO	  release	  to	  prevent	  T	  cell	  suppression,	  backing	  
up	  previous	  findings	  by	  Ren	  et	  al.	  (2008)	  and	  Sato	  et	  al.	  (2007).	  	  
	  
	   3.2.8	  Effect	  of	  iNOS-­‐/-­‐	  PαS	  MSCs	  on	  T	  cell	  proliferation	  
To	  test	  the	  effect	  of	  NO	  release	  in	  greater	  detail,	  I	   isolated	  MSCs	  from	  iNOS	  knockout	  mice	  
that	  were	  bred	  on	  a	  Balb/c	  background.	  These	  mice	  have	  a	  targeted	  mutation	  on	  the	  Nos2	  
gene	  (iNOS)	  preventing	  them	  from	  synthesising	  NO	  in	  response	  to	  inflammatory	  stimuli.	  The	  
genotype	   of	   iNOS-­‐/-­‐	   mice	   was	   confirmed	   using	   conventional	   PCR,	   with	   homozygotes	  
producing	  a	  band	  approximately	  275bp	  in	  length	  (Figure	  3.8A).	  Overnight	  stimulation	  in	  IFNγ	  
and	   TNFα	  did	   not	   cause	   iNOS-­‐/-­‐	   PαS	  MSCs	   to	   secrete	   any	  NO,	   as	  measured	  by	   the	  Griess	  
Assay	  (0.2±0.09µM	  nitrite;	  Figure	  3.8B).	  By	  comparison,	  WT	  MSCs	  isolated	  from	  Balb/c	  mice	  
secreted	   71.2±3.8µM	   nitrite	   over	   the	   same	   time	   period.	   iNOS-­‐/-­‐	   PαS	  MSCs	   also	   failed	   to	  
prevent	  T	  cell	  proliferation	  in	  the	  in	  vitro	  suppression	  assay	  (Figure	  3.8C).	  Significantly	  higher	  
T	  cell	   counts	  were	   recorded	   in	   iNOS-­‐/-­‐	   samples	  compared	   to	  WT	  samples	  across	  all	   ratios.	  
These	  findings	  provide	  further	  evidence	  for	  NO	  secretion	  as	  the	  exclusive	  mechanism	  behind	  
the	  immunosuppressive	  phenotype	  of	  Balb/c-­‐derived	  PαS	  MSCs	  on	  CD4+	  T	  cell	  populations.	  	  
	  









Figure	   3.8	   |	   iNOS-­‐/-­‐	   PαS	  MSCs	   fail	   to	   suppress	   T	   cell	   proliferation.	   (A)	   The	   genotype	   of	   iNOS-­‐/-­‐	  mice	  was	  
confirmed	  using	  conventional	  PCR.	  Homozygotes	  produced	  a	  band	  275bp	   in	   length.	   (B)	  Total	   levels	  of	  Nitrite	  
was	  quantified	  using	   the	  Griess	  Assay.	   iNOS-­‐/-­‐	  PαS	  MSCs	   failed	   to	  produce	  NO	  after	  overnight	   stimulation	   in	  
TNFα	  &	  IFNγ	  (n=3	  per	  condition,	  p<0.001,	  Student’s	  T	  test).	  (C)	  Graded	  numbers	  of	  iNOS-­‐/-­‐	  PαS	  MSCs	  (n=3)	  or	  
Balb/c	  PαS	  MSCs	   (n=3)	  were	  co-­‐cultured	  with	  CD4	  T	  cells	   for	  72	  hours.	   iNOS-­‐/-­‐	  MSCs	   failed	   to	  prevent	  T	  cell	  
proliferation	  and	  significantly	  higher	  CD4	  T	  cell	  number	  was	  recorded	  across	  all	  ratios.	  Data	  shown	  as	  mean±SD.	  
Statistical	   analysis	   performed	   using	   One-­‐way	   ANOVA	   with	   Bonferroni’s	   Multiple	   Comparison	   Test.	   In	   all	  
experiments,	  n	  is	  indicative	  of	  technical	  repeats	  using	  the	  same	  culture	  of	  PαS	  MSCs.	  	  	  	  	  
	   	  





	   3.2.9	  C57BL/6-­‐derived	  PαS	  MSCs	  fail	  to	  suppress	  T	  cell	  proliferation	  
The	  work	  presented	  above	  used	  MSCs	  isolated	  from	  wild-­‐type	  Balb/c	  mice.	  To	  study	  possible	  
strain-­‐specific	   differences	   in	   immunosuppression,	   we	   then	   examined	   the	   potential	   of	   PαS	  
MSCs	  derived	   from	  C57BL/6	  mice,	   the	  most	  commonly	  used	  wild-­‐type	  strain	   in	  biomedical	  
research	   (Yoshiki	   and	  Moriwaki,	   2006).	   Graded	   numbers	   of	   PαS	  MSCs	   from	  C57BL/6	  mice	  
were	  added	  to	  the	  T	  cell	  proliferation	  assay	  and	  cultured	  as	  before	  for	  72	  hours.	  However,	  
C57BL/6-­‐derived	  MSCs	  failed	  to	  suppress	  T	  cell	  proliferation	  across	  all	   ratios	  tested	  (Figure	  
3.9).	  A	  pro-­‐proliferative	  effect	  was	  seen	  at	  higher	  MSC	  doses	  compared	  to	  no-­‐MSC	  controls	  
(118%±12%	  at	  1:4	  ratio).	  This	  experiment	  was	  repeated	  several	   times	   (n=6)	  with	  the	  same	  
result,	  suggesting	  that	  this	   ‘purified’	  assay	  of	  T	  cell	  proliferation	  was	  not	   ideal	  to	  study	  the	  
immunosuppressive	  phenotype	  of	  C57BL/6-­‐derived	  PαS	  MSCs.	  	  
	  
Figure	   3.9	   |	  C57BL/6-­‐derived	  MSCs	   fail	   to	   prevent	   T	   cell	   proliferation.	   Graded	   numbers	   of	   Balb/c	   (n=3)	   or	  
C57BL/6	   MSCs	   (n=3)	   were	   co-­‐cultured	   with	   activated	   T	   cells	   for	   72	   hours.	   Balb/c	   PαS	   MSCs	   were	   able	   to	  
suppress	   T	   cell	   proliferation,	   while	   C57BL/6	   MSCs	   failed	   in	   this	   assay.	   Data	   shown	   as	   mean±SD.	   Statistical	  
analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  In	  all	  experiments,	  n	  is	  
indicative	  of	  biological	  repeats	  using	  different	  cultures	  of	  PαS	  MSCs.	  	  	  	  	   	  





3.2.10	  Optimising	  the	  ‘Splenocyte	  reaction’	  
Previous	  mouse	   literature	   has	   identified	   differences	   in	   the	   biology	   of	  MSCs	   isolated	   from	  
different	   mouse	   strains,	   although	   their	   investigations	   were	   limited	   to	   the	   growth	   and	  
differentiation	  of	  these	  cells	   (Cunha	  et	  al.,	  2013,	  Peister	  et	  al.,	  2004,	  Phinney	  et	  al.,	  1999).	  
One	  study	  looked	  at	  the	  immunosuppressive	  properties	  of	  adipose-­‐derived	  MSC	  conditioned	  
media	   from	   C57BL/6	   and	   Balb/c	  mice	   and	   identified	   Balb/c	  mice	   to	   be	  more	   suppressive	  
(Hashemi	   et	   al.,	   2013).	   However,	   no	   study	   has	   performed	   a	   comparative	   analysis	   of	   the	  
immunosuppressive	  mechanism	  of	  Balb/c	  and	  C57BL/6	  strains	  using	  a	  purified	  population	  of	  
BM-­‐derived	  MSCs.	  	  
	  
We	   hypothesised	   that	   C57BL/6	  MSCs	  may	   indirectly	   suppress	   lymphocyte	   proliferation	   by	  
acting	  at	  the	  antigen	  presentation	  stage	  or	  on	  another	  cell	  (e.g.	  monocyte/macrophage).	  Our	  
current	   T	   cell	   proliferation	   assay	   bypassed	   the	   antigen	   presentation	   stage	   via	   the	   use	   of	  
antibodies	  or	  beads	  that	  bind	  directly	  to	  the	  TCR.	  Additionally,	  no	  supporting	  cells	  (except	  B	  
cells)	  were	  present	  in	  the	  mixture.	  To	  test	  this	  hypothesis,	  I	  developed	  a	  new	  assay	  that	  used	  
‘bulk’	  splenocytes	  instead	  of	  purified	  T	  and	  B	  cells	  (termed	  the	  ‘Splenocyte	  reaction’).	  Mouse	  
spleen	   contains	   a	   variety	   of	   cell	   types,	   including	   T	   cells,	   B	   cells,	   dendritic	   cells,	  
monocytes/macrophages	  and	  stromal	  cells	  (Hey	  and	  O'Neill,	  2012).	  I	  then	  tested	  the	  effect	  
of	   various	   stimulatory	   reagents	   in	   the	   splenocyte	   reaction	   to	   achieve	   a	   strong	   and	  
reproducible	  proliferative	  effect	  on	  the	  T	  cell	  population.	  	  
	   	  





	   	   3.2.10.1	  Concanavalin	  A	  Stimulation	  
The	   plant	   lectin	   Concanavalin	   A	   (ConA)	   is	   used	   to	   trigger	   T	   cell	   proliferation	   by	   binding	  
directly	   to	  the	  TCR	  (Palacios,	  1982).	  A	  range	  of	  ConA	  concentrations	   (1µg/ml	  to	  100µg/ml)	  
was	  used	  in	  splenocyte	  cultures	  and	  incubated	  for	  72	  hours.	  Cultures	  were	  stained	  with	  the	  
membrane	  dye	  cell	  trace	  violet	  (CTV)	  to	  assess	  proliferation	  and	  total	  numbers	  of	  CD4	  and	  
CD8	   T	   lymphocytes	   was	   then	   quantified	   using	   flow	   cytometry.	   Surprisingly,	   all	   ConA	  
concentrations	   tested	   failed	   to	   induce	  CD4	  T	   cell	   proliferation	   in	   this	   assay	   (Figure	  3.10A).	  
Some	  cell	  division	  was	  seen	  with	  5µg/ml	  ConA	  in	  the	  CD8	  T	  cell	  samples	  (Figure	  3.10B),	  but	  
the	  majority	   of	   cells	   remained	   undivided.	   Higher	   doses	   of	   ConA	   (>20µg/ml)	   could	   not	   be	  
tested	  on	  CD8	  T	  cell	  samples	  due	  to	  cell	  death	  at	  higher	  concentrations.	  	  
	  
	  
Figure	   3.10	   |	  Stimulation	   of	   splenocyte	   cultures	   with	   ConA.	   Proliferation	   of	   CD4	   (A)	   and	   CD8	   T	   cells	   (B)	   in	  
splenocyte	   cultures	   after	   incubation	   with	   different	   concentrations	   of	   ConA.	   Representative	   fluorescence	  
histograms	  of	  two	  independent	  repeats	  shown.	  	  	   	  





	   	   3.2.10.2	  CD3/CD28	  Dynabeads®	  Stimulation	  
CD3/CD28	  Dynabeads®	  bind	  directly	  to	  the	  TCR	  and	  CD28	  to	  provide	  both	  the	  primary	  and	  
secondary	   signals	   required	   for	  T	   cell	  proliferation.	   	  A	   range	  of	   concentrations	  was	  used	   to	  
induce	   proliferation	   in	   our	   splenocyte	   cultures	   (Table	   3.2).	   Low	   doses	   of	   Dynabeads®	  
(<15,000	  beads	  per	  well)	   failed	   to	   elicit	   a	   proliferative	   response	   in	   both	   the	  CD4	   and	  CD8	  
populations	  (Figure	  3.11A	  and	  B).	  Medium	  doses	  of	  Dynabeads®	  (100,000	  to	  300,000	  beads	  
per	  well)	  were	  able	  to	   induce	  a	  strong	  CD8	  response	  (≈80%	  proliferated)	  but	   less	  than	  half	  
the	   CD4	   population	   responded.	   High	   doses	   of	   beads	   (>400,000	   beads	   per	   well)	   were	  
required	  to	  generate	  a	  strong	  response	  in	  both	  lymphocyte	  populations	  (Figure	  3.11C	  and	  D).	  
As	  such,	  Dynabeads®	  stimulation	  was,	  in	  our	  hands,	  a	  cost-­‐ineffective	  method	  of	  inducing	  T	  
cell	   proliferation	   in	   the	   splenocyte	   reaction	   and	   alternative	   approaches	   involving	   TCR-­‐
specific	  peptide	  sequences	  were	  tested.	  	  
	  
Table	  3.2	  |	  Percentage	  of	  T	  cell	  proliferation	  after	  Dynabeads®	  stimulation.	  
Number	  of	  Beads/well	   Percentage	  of	  CD4
+	  T	  Cells	  that	  
proliferated	  (%	  )	  
Percentage	  of	  CD8+	  T	  Cells	  that	  
proliferated	  (%	  )	  
0	   0.18	   0.67	  
1875	   0.69	   1.00	  
3750	   0.67	   1.81	  
7500	   0.92	   1.79	  
15,000	   0.54	   1.83	  
30,000	   2.55	   35.4	  
60,000	   11.9	   77.5	  
100,000	   24.2	   51.5	  
200,000	   39.2	   73.2	  
300,000	   49.9	   81.1	  
400,000	   54.4	   85.1	  
500,000	   60.3	   89.5	  








Figure	  3.11	  |	  Stimulation	  of	  splenocyte	  cultures	  with	  Dynabeads®.	  Proliferation	  of	  CD4	  (A	  and	  C)	  and	  CD8	  (B	  
and	  D)	  T	  cell	  populations	  with	  low	  (upper	  row)	  and	  high	  (lower	  row)	  numbers	  of	  Dynabeads®	  per	  well.	  Cultures	  
were	  maintained	  for	  72	  hours	  before	  analysis.	  N=1	  biological	  repeat	  per	  condition.	  	  	  
	   	  





	   	   3.2.10.3	  Ovalbumin	  peptide	  stimulation	  
CD8	  T	  cells	   from	  OT-­‐1	  transgenic	  mice	  have	  a	  TCR	  that	   is	  specific	   for	   the	  ovalbumin	   (OVA)	  
peptide	   sequence	   SIINFEKL	  when	  presented	   in	   a	  MHC	   class	   I	   context	   (Wright	   et	   al.,	   2005,	  
Clarke	   et	   al.,	   2000).	   The	   addition	   of	   OVA	   peptide	   to	   OT-­‐1	   splenocyte	   cultures	   causes	  
expansion	   of	   antigen-­‐specific	   CD8	   T	   cells	   in	   a	   physiological	   manner.	   Unlike	   ConA	   and	  
CD3/CD28	  Dynabeads®,	  which	  can	  bind	  directly	  to	  T	  cells	   to	  cause	  activation,	  OVA	  peptide	  
needs	  to	  be	  processed	  and	  presented	  alongside	  a	  co-­‐stimulatory	  signal	   to	  cause	  activation	  
and	  proliferation	  of	  CD8	   lymphocytes.	  Additionally,	  stimulating	  OT-­‐1	  splenocytes	  with	  OVA	  
peptide	   is	   a	   good	   in	   vitro	   correlate	   of	   the	   OVA-­‐Bil	   mouse	   model	   (Chapter	   6)	   in	   which	  
adoptive	  transfer	  of	  OT-­‐1	  cells	  causes	  their	  migration	  to	  the	  liver	  (where	  OVA	  is	  expressed)	  
and	  induction	  of	  inflammatory	  liver	  injury	  (Buxbaum	  et	  al.,	  2006).	  	  
	  
The	  dose	  of	  OVA	  peptide	  was	  first	  optimised	  for	  this	  reaction.	  Past	   literature	  recommends	  
concentrations	  ranging	  from	  10µg/ml	  (Li	  et	  al.,	  2009,	  Rafiq	  et	  al.,	  2002)	  to	  50µg/ml	  (Huang	  et	  
al.,	   2010,	   Bedoret	   et	   al.,	   2009).	   Both	   doses	   of	   OVA	   peptide	   were	   incubated	   with	   OT-­‐1	  
splenocytes	  for	  72	  hours	  and	  the	  percentage	  of	  proliferated	  CD8	  T	  cells	  was	  quantified	  using	  
flow	  cytometry.	  Unstimulated	  cultures	  failed	  to	  proliferate	  (Figure	  3.12A),	  with	  0.32±0.1%	  of	  
CD8	   cells	   losing	   CTV	   fluorescence	   (Figure	   3.12D).	   Cultures	   stimulated	   with	   10µg/ml	   and	  
50µg/ml	  had	  significantly	  more	  CD8	  T	  cell	  proliferation	  compared	  to	  controls,	  but	  there	  was	  
no	   significant	   difference	   between	   the	   doses	   (32.3±2.1%	   vs.	   32.0±3%;	   Figure	   3.12B,	   C,	   D).	  
Therefore,	  10µg/ml	  OVA	  peptide	  dose	  was	  chosen	  for	  future	  experiments.	  	  






Figure	  3.12	  |	  Optimisation	  of	  OVA	  peptide	  dose	  with	  OT-­‐1	  splenocytes.	  CTV	  fluorescence	  histograms	  of	  CD8	  T	  
cells	  in	  OT-­‐1	  splenocyte	  cultures	  supplemented	  with	  (A)	  no	  OVA	  peptide	  (n=4),	  (B)	  10µg/ml	  OVA	  peptide	  (n=2),	  
and	   (C)	   50µg/ml	  OVA	  peptide	   (n=4).	   (D)	  Quantification	  of	   CD8	  T	   cell	   proliferation.	  Data	   shown	  as	  mean±SD.	  	  
Statistical	   analysis	   performed	   using	   One-­‐way	   ANOVA	   with	   Bonferroni’s	   Multiple	   Comparison	   Test.	   In	   all	  
experiments,	  n	  is	  indicative	  of	  technical	  repeats	  using	  the	  same	  culture	  of	  PαS	  MSCs.	  	  	  	  	  
	  
I	   then	  optimised	   the	  culture	   time	   to	  achieve	  maximal	  CD8	  T	  cell	  proliferation.	  As	   the	  OVA	  
peptide	   needs	   to	   be	   processed	   and	   presented,	   there	   will	   be	   a	   lag	   phase	   before	   T	   cell	  
proliferation.	  For	  example,	  co-­‐culture	  with	  Dynabeads®	   for	  72	  hours	  caused	  a	  proliferative	  
response	   in	  >90%	  of	  CD8	  T	  cells	   (Figure	  3.11D),	  while	  <35%	  divided	  when	  co-­‐cultured	  with	  
OVA	  peptide	   for	   the	   same	   time	  period	   (Figure	  3.12D).	  The	  effect	  of	  10µg/ml	  OVA	  peptide	  
stimulation	   for	   3,	   4	   and	   6	   days	   culture	   was	   examined.	   Significant	   increases	   in	   CD8	   T	   cell	  
proliferation	   were	   observed	   at	   days	   4	   and	   6	   compared	   to	   day	   3	   cultures	   (Figure	   3.13).	  





However,	   there	  was	  no	   significant	  difference	  between	   the	  CD8	  T	   cell	  proliferation	   seen	  at	  
day	  4	  (93.6±0.7%)	  compared	  to	  day	  6	  (94.4±1.1%).	  Flow	  cytometry	  histograms	  for	  all	  time-­‐
points	  alongside	  their	  matched	  controls	  are	  displayed	  in	  Figure	  3.14.	  As	  such,	  4-­‐day	  cultures	  
supplemented	   with	   10µg/ml	   OVA	   peptide	   was	   used	   to	   stimulate	   OT-­‐1	   CD8	   T	   cell	  
proliferation	  and	  to	  examine	  the	  effect	  of	  C57BL/6-­‐derived	  PαS	  MSC	  co-­‐culture.	  	  	  
	  
	  
Figure	   3.13	   |	   Optimisation	   of	   overall	   culture	   period	   with	   OT-­‐1	   splenocytes.	   OT-­‐1	   cells	   were	   cultured	  
unstimulated	   or	   stimulated	   with	   10µg/ml	   OVA	   peptide	   for	   three	   (n=5),	   four	   (n=5),	   or	   six	   (n=6)	   days.	   The	  
percentage	  of	  proliferated	  CD8	  T	  cells	  was	   then	  quantified	  using	   flow	  cytometry	  based	  on	  CTV	   fluorescence.	  
Data	   shown	   as	   mean±SD.	   	   Statistical	   analysis	   performed	   using	   One-­‐way	   ANOVA	   with	   Bonferroni’s	   Multiple	  
Comparison	  Test.	   In	  all	  experiments,	  n	   is	   indicative	  of	   technical	   repeats	  using	  the	  same	  culture	  of	  PαS	  MSCs.	  	  	  	  






Figure	  3.14	  |	  CTV	  fluorescence	  histograms	  of	  OT-­‐1	  CD8	  T	  cells	  cultured	  for	  different	  periods	  of	  time.	  No	  proliferation	  was	  observed	  in	  unstimulated	  control	  cultures	  
at	  days	  three	  (A;	  n=4),	  four	  (B;	  n=6),	  and	  six	  (C;	  n=3).	  Limited	  cell	  division	  was	  seen	  in	  stimulated	  cultures	  at	  day	  three	  (D;	  n=5),	  but	  over	  90%	  CD8	  T	  cell	  proliferation	  
was	  seen	  at	  day	  4	  (E;	  n=5)	  and	  6	  (F;	  n=6).	  In	  all	  experiments,	  n	  is	  indicative	  of	  technical	  repeats	  using	  the	  same	  culture	  of	  PαS	  MSCs.	  	  	  	  	  	  	  





3.2.11	  C57BL/6-­‐derived	  PαS	  MSCs	  in	  the	  ‘Splenocyte	  Reaction’	  
The	  immunosuppressive	  properties	  of	  C57BL/6-­‐derived	  PαS	  MSCs	  were	  tested	  in	  the	  newly	  
optimised	   splenocyte	   reaction.	   P4	   MSCs	   were	   added	   24	   hours	   after	   seeding	   OT-­‐1	  
splenocytes	  with	  OVA	  peptide	  to	  ensure	  an	  inflammatory	  microenvironment	  (Figure	  3.15A).	  
Graded	   numbers	   of	   MSCs	   were	   added	   and	   cultured	   for	   a	   further	   72	   hours	   before	  
quantification	   of	   total	   CD8	   T	   cell	   number	   by	   flow	   cytometry.	   Preliminary	   findings	   (n=1)	  
indicate	   that	   there	   was	   a	   dose-­‐dependent	   reduction	   in	   the	   total	   numbers	   of	   viable	   CD8	  
lymphocytes	   after	   MSC	   co-­‐culture	   (Figure	   3.15B).	   Intracellular	   straining	   also	   revealed	  
reductions	  in	  IFNγ	  production	  of	  CD8	  T	  cells	  after	  re-­‐stimulation	  with	  PMA	  and	  INO	  (Figure	  
3.15C).	  Although	  there	  was	  a	  reduction	  in	  total	  CD8	  T	  cell	  numbers	  after	  PαS	  MSC	  co-­‐culture,	  
the	   cells	   that	   remained	   alive	   were	   still	   proliferating	   (Figure	   3.15D).	   CTV	   fluorescence	  
histograms	   showing	   CD8	   T	   cell	   proliferation	   can	   be	   seen	   in	   Figure	   3.15E,	   F	   and	   G.	   These	  
results	  suggest	  that	  C57BL/6-­‐derived	  PαS	  MSCs	  can	  prevent	  T	  cell	  proliferation,	  but	  work	  via	  
a	  distinct	  mechanism	  to	  Balb/c-­‐derived	  MSCs.	  Future	  work	  should	  repeat	  this	  experiment	  to	  
ensure	  reproducibility	  and	  then	  attempt	  to	  elucidate	  the	  mechanism	  via	  the	  use	  of	  inhibitors.	  	  
	  
	  
Figure	   3.15	   (following	   page)	   |	   C57BL/6-­‐derived	   PαS	   MSCs	   in	   the	   splenocyte	   reaction.	   (A)	   Time	   course	   of	  
experiment.	  P4	  PαS	  MSCs	  were	  added	  24	  hours	  after	  OT-­‐1	  splenocytes	  and	  OVA	  peptide	  were	  seeded.	  Cultures	  
were	  maintained	  for	  an	  additional	  72	  hours	  before	  analysis.	  (B)	  Total	  viable	  CD8+	  T	  cell	  number	  was	  quantified	  
using	   flow	   cytometry.	   (C)	   Cultures	   were	   re-­‐stimulated	   with	   PMA	   and	   INO	   for	   4	   hours	   before	   intracellular	  
staining	   and	  quantification	  of	   total	   numbers	  of	   IFNγ+	  CD8	   cells	   using	   flow	   cytometry.	   (D)	   The	  percentage	  of	  
proliferated	   CD8	   T	   cells	  was	   quantified	   using	   flow	   cytometry	   based	   on	   CTV	   fluorescence.	   All	   data	   shown	   as	  
mean±SD.	  (E,F,G)	  CTV	  histograms	  of	  CD8	  T	  cells	  from	  unstimulated	  (E;	  n=3),	  10µg/ml	  OVA	  peptide	  stimulated	  
(F;	  n=3)	  and	  PαS	  MSC-­‐supplemented	  cultures	  (G;	  n=1	  per	  dose).	  	  












3.3.1	  Chapter	  Summary	  
PαS	   MSCs	   were	   successfully	   isolated	   and	   cultured	   according	   to	   previously	   published	  
protocols	  (Houlihan	  et	  al.,	  2012).	  These	  cells	  had	  characteristic	  spindle-­‐shaped	  morphology,	  
were	  able	  to	  form	  CFU-­‐F	  and	  undergo	  tri-­‐lineage	  differentiation	  into	  bone,	  fat	  and	  cartilage.	  
PαS	   MSCs	   were	   also	   able	   to	   be	   expanded	   in	   standard	   culture	   conditions	   and	   expressed	  
characteristic	   MSC	   markers,	   thereby	   meeting	   the	   ISCT	   criteria	   for	   MSCs	   (Dominici	   et	   al.,	  
2006).	   The	   immunosuppressive	   phenotype	   of	   PαS	  MSCs	   have	   also	   been	   described	   for	   the	  
first	  time,	  with	  different	  wild	  type	  mouse	  strains	  utilising	  distinct	  mechanisms	  to	  suppress	  T	  
cell	   proliferation.	   Balb/c-­‐derived	   PαS	   MSCs	   secreted	   NO	   to	   inhibit	   CD4	   lymphocytes	   that	  
were	  stimulated	  with	  anti-­‐CD3e	  antibody	  and	  CD19	  B	  cells.	  C57BL/6-­‐derived	  PαS	  MSCs	  failed	  
to	   suppress	   in	   the	   same	  assay,	   and	   required	   the	  development	  of	   a	  more	   complex	   in	   vitro	  
system	  involving	  the	  use	  of	  TCR	  transgenic	  OT-­‐1	  mice.	  Preliminary	  results	  show	  reduction	  in	  
CD8	   T	   cell	   numbers	   after	   co-­‐culture	   with	   C57BL/6-­‐PαS	   MSCs	   in	   the	   splenocyte	   reaction,	  
although	  more	  work	  is	  required	  to	  elucidate	  the	  mechanism	  behind	  this.	  
	  
	   3.3.2	  Phenotype	  of	  PαS	  MSCs	  
Protocols	   for	   the	   prospective	   isolation	   of	  murine	  MSCs	   represent	   a	  major	   advance	   in	   the	  
field.	  PαS	  MSC	  yields	  achieved	  from	  C57BL/6	  and	  Balb/c	  mice	  were	  similar	  in	  number	  to	  the	  
ones	   reported	   by	   Morikawa	   et	   al.	   (2009).	   Approximately	   5000	   to	   8000	   PαS	   MSCs	   were	  
isolated	   per	  mouse,	   and	   the	   flow	   cytometry	   plots	   looked	   similar	   to	   the	   original	   study.	   All	  





cells	  were	   fibroblastic	   in	  morphology,	   and	   cell	   surface	   staining	   revealed	   <1%	  positivity	   for	  
haematopoietic	   or	   leukocytic	   markers	   in	   PαS	   cultures	   after	   one	   passage.	   This	   compares	  
favourably	   with	   older	   protocols	   in	   which	   leukocytic	   cells	   persisted	   in	   culture	   for	   several	  
weeks,	   even	   after	   serial	   passaging	   (Meirelles	   Lda	   and	   Nardi,	   2003,	   Phinney	   et	   al.,	   1999).	  
Population	  doubling	  times	  for	  PαS	  cells	  at	  early	  passage	  was	  approximately	  55	  hours,	  which	  
is	   similar	   to	   the	   50.6	   hours	   reported	   by	  Morikawa	   and	   colleagues.	   Interestingly,	   we	   only	  
observed	  a	  CFU-­‐F	  forming	  efficiency	  of	  1	  in	  every	  66	  PαS	  MSCs,	  which	  is	  lower	  than	  the	  1	  in	  
50	  reported	  by	  Morikawa	  et	  al.	  (2009).	  As	  CFU-­‐F	  was	  performed	  on	  freshly-­‐sorted	  PαS	  MSCs,	  
cell	  death	  due	  to	  the	  sorting	  procedure	  may	  have	  negatively	  affected	  the	  CFU-­‐F	  efficiency.	  
Pinho	   et	   al.	   (2013)	   report	   similar	   CFU-­‐F	   forming	   efficiency	   in	   PDGFRα+CD51+	   MSCs,	   and	  
suggest	  that	  the	  “harsh”	  sorting	  procedure	  adversely	  affects	  their	  cell	  viability.	  I	  did	  observe	  
some	  dead,	  floating	  cells	  in	  PαS	  MSC	  cultures	  24	  hours	  after	  cell	  sorting,	  which	  gives	  further	  
evidence	   for	   this	   theory.	   As	   such,	   PDGFRα	   and	   Sca-­‐1	   enriches	   for	   cells	   with	   MSC-­‐like	  
phenotype	  from	  mouse	  BM,	  but	  not	  every	  PαS	  MSC	  can	  perform	  all	  the	  functions	  expected	  
of	   MSCs.	   However,	   the	   CFU-­‐F	   efficiency	   of	   PαS	   MSCs	   is	   significantly	   higher	   than	   those	  
reported	   in	  plastic-­‐adherent	  studies,	  which	  range	  from	  1	   in	  every	  9000	  BM	  cells	   (Meirelles	  
Lda	  and	  Nardi,	  2003)	  to	  1	  in	  3.3x106	  BM	  cells	  (Phinney	  et	  al.,	  1999).	  	  
	  
The	  tri-­‐lineage	  differentiation	  of	  PαS	  MSCs	  was	  demonstrated	  using	  well-­‐established	  in	  vitro	  
techniques.	   PαS	   MSCs	   readily	   underwent	   osteogenic	   and	   chondrogenic	   differentiation,	  
although	   adipogenic	   differentiation	   was	   less	   impressive.	   Clonal	   PαS	   MSC	   differentiation	  
studies	   by	  Morikawa	  et	   al.	   revealed	   all	   clones	   (6/6)	   could	   differentiate	   towards	   bone	   and	  





cartilage,	   but	   less	   than	   half	   (2/6)	   could	   differentiate	   towards	   fat	   (Morikawa	   et	   al.,	   2009).	  
Poor	  adipogenic	  differentiation	  (relative	  to	  osteogenic	  differentiation)	  was	  also	  observed	  in	  
previous	  studies	  of	  mouse	  (Cunha	  et	  al.,	  2013),	  sheep	  (Heidari	  et	  al.,	  2013),	  and	  rat	  (Peng	  et	  
al.,	  2008)	  MSC	  populations.	  	  The	  reasons	  behind	  this	  disparity	  are	  unclear	  and	  could	  be	  due	  
to	  heterogeneity	   in	   the	  PDGFRα+Sca-­‐1+	  population	  or	   the	   fact	   that	  BM	  MSCs	  are	  naturally	  
primed	  towards	  bone	  and	  cartilage	  (skeletal	  tissue)	  over	  fat	  (connective	  tissue).	  Additionally,	  
culture	  on	  a	  stiff	  surface	  has	  also	  been	  shown	  to	  enhance	  osteogenic	  differentiation	  in	  MSC	  
populations	  (Engler	  et	  al.,	  2006).	  	  
	  
	   3.2.3	  Immunosuppressive	  phenotype	  of	  PαS	  MSCs	  
In	   vitro	   T	   cell	   suppression	   assays	   demonstrated	   that	   Balb/c-­‐derived	   PαS	  MSCs	   suppressed	  
CD4	   T	   cell	   proliferation	   in	   a	   dose-­‐dependent	  manner.	   Blocking	   studies	   revealed	   that	   local	  
release	  of	  NO	  by	  PαS	  MSCs	  was	  responsible	  for	  immunosuppression.	  Additional	  experiments	  
using	  PαS	  MSCs	  isolated	  from	  transgenic	  iNOS-­‐/-­‐	  mice	  provided	  further	  proof	  for	  this	  finding.	  
A	   comparative	   study	   by	   Ren	   et	   al.	   (2009)	   identified	   that	  mouse	  MSCs	   exclusively	   use	   NO	  
secretion	   to	   immunosuppress	   while	   human	   MSCs	   secrete	   IDO.	   Our	   findings	   back	   up	   this	  
hypothesis,	  as	  we	  did	  not	  see	  any	  effect	  when	  using	  an	  IDO	  inhibitor.	  It	  is	  interesting	  to	  note	  
that	   inhibition	   of	   NO	   secretion	   caused	   a	   complete	   reversal	   in	   the	   immunosuppressive	  
phenotype	  of	  PαS	  MSCs.	  Past	  studies	  have	  noted	  that	  neutralisation	  of	  one	  factor	  secreted	  
by	  mouse	  or	  human	  MSCs	  does	  not	  result	  in	  a	  complete	  reversal	  of	  suppression,	  suggesting	  
that	  there	  are	  other	  factors	  in	  play	  (Ben-­‐Ami	  et	  al.,	  2011).	  This	  degree	  of	  redundancy	  could	  
be	  due	  to	  the	  heterogeneous	  stromal	  populations	  used	   in	  past	  studies,	  with	  each	  having	  a	  





different	  mechanism	  of	   immunosuppression.	  The	  purified	  population	  of	  PαS	  MSCs	  used	   in	  
this	  study	  displayed	  a	  ‘unified’	  response	  to	  the	  compounds	  tested	  and	  demonstrates	  nicely	  
how	  prospective	  isolation	  could	  help	  reduce	  diversity	  in	  the	  MSC	  field.	  	  
	  	  
NO	  is	  a	  potent	  signalling	  molecule	  with	  a	  short	  half-­‐life	  that	  is	  involved	  in	  many	  physiological	  
processes	   ranging	   from	  vasodilation	   to	   immune	   regulation	   (Bogdan,	  2001).	  NO	  production	  
by	  macrophages	  has	  been	  shown	  to	  suppress	  T	  cell	  proliferation	  via	  the	  inhibition	  of	  STAT5	  
phosphorylation,	   resulting	   in	   cell	   cycle	  arrest	   (Mazzoni	  et	   al.,	   2002,	  Bingisser	  et	   al.,	   1998).	  
Interestingly,	   Sato	  et	  al.	   (2007)	   identified	   the	   same	  mechanism	  at	  play	  with	  murine	  MSCs,	  
highlighting	   the	   importance	   of	   the	   NO-­‐STAT5	   axis.	   Future	   work	   could	   include	   western	  
blotting	   for	  phosphorylated	  STAT5	   in	  CD4	  T	  cells	   to	   identify	  whether	   the	  same	  mechanism	  
occurs	  with	  PαS	  MSC	  co-­‐culture.	  	  
	  
Recent	   studies	   have	   identified	   MSCs	   as	   key	   players	   in	   the	   HSC	   niche,	   as	   they	   are	   the	  
precursors	   of	  multiple	   niche	   components	   and	   can	   secrete	   factors	   that	   are	   crucial	   for	   HSC	  
maintenance	   (Frenette	   et	   al.,	   2013).	   However,	   the	   physiological	   role	   for	   MSC-­‐mediated	  
immunosuppression	   and	   NO	   release	   in	   the	   BM	   niche	   is	   unclear.	   Some	   authors	   have	  
suggested	   that	   MSCs	   may	   function	   to	   protect	   HSCs	   from	   immune	   mediated	   damage	   by	  
creating	  an	  ‘immunoprivileged	  zone’	  around	  these	  cells	  (Hsu	  and	  Fuchs,	  2012).	  However,	  an	  
elegant	  imaging	  study	  by	  Fujisaki	  et	  al.	  (2011)	  demonstrates	  that	  Tregs	  co-­‐localise	  with	  HSCs	  
in	  vivo	   to	  create	  an	   immunoprivileged	  site	   that	  enabled	  allogeneic-­‐HSCs	   to	  avoid	   rejection	  
for	  up	   to	  30	  days.	  A	   similar	   function	  has	  not	  been	  convincingly	  attributed	   to	  MSCs,	   and	   it	  





remains	  to	  be	  seen	  whether	  they	  do	  play	  an	  immunosuppressive	  role	  in	  the	  BM	  niche.	  Data	  
from	  the	  Matsuzaki	  group	  suggest	  that	  mismatched	  naïve	  PαS	  MSCs	  can	  trigger	  the	  onset	  of	  
GvHD	  in	  a	  mouse	  model	  of	  BM	  transplantation	  (Ogawa	  et	  al.,	  2012).	  The	  selective	  depletion	  
of	  PαS	  MSCs	  from	  BM	  grafts	  reduced	  fibrosis	  across	  all	  organs.	  From	  these	  findings,	  it	  can	  be	  
speculated	   that	  naïve	  PαS	  MSCs	  directly	   isolated	   from	  their	  niche	  are	  not	   suppressive	  and	  
that	   immunosuppression	   is	  a	  property	  acquired	   through	   in	  vitro	   culture.	  This	  hypothesis	   is	  
further	  backed	  up	  by	  the	  various	  human	  phase	  I/II	  trials	  using	   in	  vitro	  cultured	  MSCs	  in	  the	  
treatment	  of	  GvHD	  that	   report	   favourable	  outcomes	   (Le	  Blanc	  et	  al.,	  2008,	  Le	  Blanc	  et	  al.,	  
2004b).	  Future	  studies	  using	   freshly-­‐isolated	  PαS	  cells	   in	   immunosuppression	  assays	  would	  
be	  required	  to	  test	  this	  hypothesis.	  	  
	  
	   3.2.4	  Strain-­‐specific	  differences	  in	  Immunosuppression	  
PαS	  MSCs	  isolated	  from	  C57BL/6	  mice	  failed	  to	  suppress	  T	  cell	  proliferation	  in	  our	  standard	  
assay,	   leading	   us	   to	   hypothesise	   that	   there	   might	   be	   strain-­‐specific	   differences	   in	   the	  
immunosuppressive	  mechanism	  of	  MSCs	  isolated	  from	  Balb/c	  and	  C57BL/6	  mice.	  Hashemi	  et	  
al.	  (2013)	  compared	  the	  immunosuppressive	  properties	  of	  conditioned	  media	  (CM)	  isolated	  
from	  adipose-­‐derived	  MSCs	  of	  Balb/c	  and	  C57BL/6	  mice.	  They	  report	  that	  Balb/c	  MSC	  CM	  is	  
more	  suppressive	   than	  C57BL/6-­‐derived	  CM,	  partly	  due	   to	  higher	   levels	  of	   IDO,	  TGF-­‐β	  and	  
NO	  in	  Balb/C	  MSC	  supernatants.	  Although	  a	  comparative	  study	  of	  immunosuppression	  from	  
BM-­‐derived	   MSCs	   has	   not	   yet	   been	   performed,	   one	   can	   assume	   with	   the	   differences	  
observed	  in	  CFU-­‐F	  and	  differentiation	  from	  different	  mouse	  strains	  that	  immunosuppression	  
may	  vary	  as	  well.	  	  	  





We	  hypothesised	  that	  C57BL/6-­‐derived	  PαS	  MSCs	  were	  exerting	  an	  indirect	  effect	  on	  T	  cell	  
proliferation	   by	   inhibiting	   antigen	   presentation	   or	   polarising	   macrophages	   towards	   a	  
regulatory	   phenotype.	   To	   test	   this	   hypothesis,	   we	   moved	   away	   from	   a	   ‘purified’	   system	  
where	   no	   antigen	   presentation	   was	   required	   to	   a	   more	   complex	   splenocyte	   culture	  
containing	   several	  different	   immune	  cell	   subsets.	  After	  unsuccessful	   attempts	   to	   stimulate	  
splenocyte	  cultures	  with	  ConA	  or	  Dynabeads®,	  the	  OT-­‐1	  transgenic	  mouse	  was	  chosen	  as	  our	  
model	   system.	   CD8	   T	   cells	   from	  OT-­‐1	  mice	   have	   a	   TCR	   specific	   for	   the	   ovalbumin	   protein	  
(Wright	   et	   al.,	   2005).	   Exogenous	   addition	   of	   OVA	   peptide	   into	   OT-­‐1	   splenocyte	   cultures	  
causes	  antigen-­‐specific	  proliferation	  of	  CD8	   lymphocytes	   (Clarke	  et	  al.,	  2000).	  OVA	  peptide	  
needs	  to	  be	  processed	  and	  presented	  in	  a	  MHC	  class	  I	  context	  to	  CD8	  lymphocytes	  to	  cause	  
activation,	   thereby	  making	   this	   system	  more	  physiologically	   relevant	   than	   the	  use	  of	   TCR-­‐
binding	  antibodies	  or	  beads.	   It	   is	  also	  a	  good	   in	  vitro	   representation	  of	   the	  OVA-­‐Bil	  mouse	  
model,	  where	  ectopic	  expression	  of	  OVA	  on	  the	  biliary	  epithelium	  of	  the	   liver	  results	   in	  an	  
OT-­‐1	  mediated	  immune	  reaction	  and	  inflammation	  (Buxbaum	  et	  al.,	  2006).	  	  
	  
Our	  preliminary	  findings	  show	  that	  C57BL/6-­‐derived	  PαS	  MSCs	  can	  suppress	  CD8	  lymphocyte	  
proliferation	  in	  a	  dose-­‐dependent	  manner.	  We	  also	  saw	  reductions	  in	  the	  IFNγ	  production	  of	  
CD8	   cells	   after	  MSC	   co-­‐culture,	   a	   finding	   that	   has	   been	   shown	   before	   by	   Hof-­‐Nahor	   and	  
colleagues	  for	  human	  MSCs	  (Hof-­‐Nahor	  et	  al.,	  2012).	  Interestingly,	  although	  there	  were	  large	  
drops	   in	   total	   numbers	   of	   CD8	   T	   cells	   after	   PαS	  MSC	   co-­‐culture,	  we	   only	   observed	  minor	  
differences	   in	   the	  proliferation	  status	  of	  CD8	  cells	   that	   remained	  viable.	  This	   suggests	   that	  
MSCs	   could	   induce	   CD8	   lymphocyte	   apoptosis	   and	   that	   any	   lymphocytes	   which	   escaped	  





MSC-­‐mediated	  immunosuppression	  were	  still	  proliferating	  in	  response	  to	  OVA	  antigen.	  The	  
induction	  of	  CD8	  T	  cell	  apoptosis	  has	  been	  reported	  previously	  for	  human	  MSC	  populations	  
due	  to	   IDO-­‐mediated	  depletion	  of	  tryptophan	  from	  the	   local	  microenvironment	   (Plumas	  et	  
al.,	  2005).	  Further	  experiments	  are	  needed	  to	  see	  whether	  a	  similar	  mechanism	  is	  in	  play	  for	  
PαS	  MSCs.	  Further	  repeats	  are	  also	  needed	  to	   increase	  the	  sample	  size	  and	  to	  understand	  
the	   significance	   of	   these	   findings.	   Small	  molecule	   inhibitors	   of	   known	   immunosuppressive	  
pathways	  can	  be	  added	  to	  the	  splenocyte	  reaction	  to	  try	  and	  identify	  a	  mechanism	  of	  action.	  
Additionally,	  individual	  immune	  cell	  subsets	  (e.g.	  monocytes/macrophages,	  B	  cells,	  DCs)	  can	  
be	   selectively	   removed	   from	   the	   splenocyte	   mixture	   to	   study	   indirect	   effects	   on	   T	   cell	  


































4.1	  Chapter	  Rationale	  and	  Aims	  
PDGFRα+Sca-­‐1+	  marks	  cells	   in	  BM	  enriched	  for	  an	  MSC	  phenotype.	  However,	  the	  frequency	  
of	  these	  cells	  in	  BM	  is	  very	  rare,	  resulting	  in	  yields	  of	  approximately	  5000	  to	  8000	  PαS	  MSCs	  
per	  mouse.	  A	  degree	  of	  in	  vitro	  expansion	  is	  therefore	  required	  to	  reach	  the	  cell	  numbers	  we	  
need	  for	  experimentation	  or	  therapeutic	  infusions.	  Previous	  publications	  have	  injected	  single	  
doses	  of	  murine	  MSCs	  ranging	  from	  0.4x105	  (Ding	  et	  al.,	  2009)	  to	  1x106	  MSCs	  per	  mouse	  in	  
acute	  models	  of	   injury	  	  (Nemeth	  et	  al.,	  2009).	   	  More	  chronic	  models	  of	  graft	  rejection	  have	  
necessitated	  multiple	  infusions	  of	  1x106	  cells	  given	  before,	  during	  and	  after	  transplantation	  
(Casiraghi	  et	  al.,	  2008).	  Human	  clinical	  trials	  have	  used	  cell	  doses	  ranging	  from	  a	  single	  dose	  
of	  2x106	  MSCs/kg	  body	  weight	  (Le	  Blanc	  et	  al.,	  2004b)	  to	  multiple	  doses	  of	  2x106	  MSCs/kg	  
given	   twice	  weekly	   for	   one	  month	   (Kurtzberg	   et	   al.,	   2014).	   In	   all	   these	   cases,	  MSCs	  were	  
expanded	  in	  vitro	  before	  infusion.	  	  
	  
Although	   murine	   MSCs	   can	   be	   expanded	   in	   vitro,	   they	   are	   eventually	   susceptible	   to	  
replication-­‐induced	  senescence	  and	  loss	  of	  function	  (Coutu	  et	  al.,	  2011,	  Kretlow	  et	  al.,	  2008).	  
Senescence	  typically	  manifests	  as	  an	  increase	  in	  the	  expression	  of	  senescence-­‐associated	  β-­‐
galactosidase	   (SA-­‐β-­‐gal),	   an	   enzyme	   specifically	   expressed	   in	   senescent	   cells	   (Gary	   and	  
Kindell,	  2005).	   Senescent	  MSCs	   lose	   their	   spindle-­‐shaped	  morphology	  and	  display	  a	  wider,	  
more	  spread	  out	  morphology	  (Sethe	  et	  al.,	  2006).	  Their	  population	  doubling	  times	  increase	  
and	  their	  tri-­‐lineage	  differentiation	  ability	  is	  lost	  (Wagner	  et	  al.,	  2008).	  An	  impaired	  capacity	  
to	  migrate	  towards	  pro-­‐inflammatory	  signals	  has	  also	  been	  described	  for	  senescent	  human	  
MSCs,	  making	  them	  less	  effective	  in	  a	  mouse	  model	  of	  endotoxemia	  (Sepulveda	  et	  al.,	  2014).	  





A	   retrospective	   analysis	   of	   GvHD	   clinical	   trials	   has	   revealed	   that	   patients	   receiving	   older	  
MSCs	  (P3-­‐P4)	  had	  worse	  1-­‐year	  survival	  rates	  than	  patients	  receiving	  P1-­‐P2	  cells	  (von	  Bahr	  et	  
al.,	   2012).	   Passage	   five	   human	   MSCs	   were	   also	   shown	   to	   be	   cleared	   by	   the	   host	   much	  
quicker	  than	  younger	  cells	  (Moll	  et	  al.,	  2012).	  Finally,	  prolonged	   in	  vitro	  expansion	  can	  also	  
increase	  the	  risk	  of	  karyotypic	  abnormalities	  in	  murine	  MSCs,	  leading	  to	  transformation	  and	  
tumour	  formation	  (Tolar	  et	  al.,	  2007,	  Miura	  et	  al.,	  2006).	  	  
	  
The	  effect	  of	  prolonged	  in	  vitro	  expansion	  on	  PαS	  MSC	  function	  and	  immunosuppression	  has	  
not	  been	  described	  previously.	  This	  results	  chapter	  describes	  how	  PαS	  MSCs	  are	  vulnerable	  
to	  replication-­‐induced	  senescence	  and	  how	  this	  negatively	  impacts	  the	  functionality	  of	  these	  
cells.	  The	  specific	  aims	  for	  this	  chapter	  were	  to:	  
	  
1. Describe	  the	  effect	  of	  extended	  in	  vitro	  culture	  on	  PαS	  MSC	  senescence	  
2. Assess	  the	  ability	  of	  late-­‐passage	  PαS	  MSCs	  to	  undergo	  tri-­‐lineage	  differentiation	  
3. Examine	  the	  immunosuppressive	  potential	  of	  late-­‐passage	  PαS	  MSCs	  
	   	  






4.2.1	  PαS	  MSCs	  undergo	  Senescence	  
PαS	  MSC	  growth	  curves	  shown	  in	  the	  previous	  chapter	  demonstrated	   linear	  growth	  during	  
the	   first	   30	   days	   that	   ‘plateaued’	   thereafter	   (Figure	   3.3A).	   Concordant	   increases	   in	  
population	   doubling	   times	   were	   also	   observed	   with	   extended	   culture,	   rising	   from	  
approximately	  55	  hours	  between	  day	  0-­‐30	   to	  >10	  days	  by	  day	  50.	  These	  are	  characteristic	  
traits	   observed	   in	   cultures	   undergoing	   senescence	   (Wagner	   et	   al.,	   2008).	   To	   examine	  
whether	  PαS	  MSCs	  were	  becoming	  increasingly	  senescent,	  I	  first	  examined	  the	  morphology	  
of	   freshly	   isolated	  and	  culture-­‐expanded	  cells	   (Figure	  4.1).	  Older	  cells	  had	  an	  enlarged	  and	  
irregular	   morphology	   (Figure	   4.1B	   arrowheads)	   compared	   to	   freshly	   isolated	   PαS	   MSCs	  
(Figure	  4.1A).	  Older	  MSCs	  were	  also	  more	  ‘spread	  out’	  and	  flatter	  with	  decreased	  nuclear	  to	  
cytoplasm	  ratios,	  another	  trademark	  of	  more	  mature	  cells	  (Wlodkowic	  et	  al.,	  2011).	  	  	  	  	  	  
	  
	  
Figure	  4.1	  |	  Morphology	  of	   freshly	   isolated	  and	   culture-­‐expanded	  PαS	  MSCs.	   (A)	  Freshly	   isolated	  PαS	  MSCs	  
display	  a	  characteristic	  spindle-­‐shaped,	  fibroblastic	  morphology.	  All	  cells	  are	  roughly	  similar	  in	  size	  and	  shape.	  
(B)	  Culture-­‐expanded	  PαS	  MSCs	  are	  heterogeneous	   in	  size	  and	  shape,	  with	  some	  cells	  appearing	  much	  larger	  
than	  others	  (arrowheads).	  Images	  taken	  at	  100x	  magnification.	  Scale	  bar,	  25µm.	  





To	   examine	   this	   in	   greater	   detail,	   PαS	   MSCs	   at	   different	   passages	   were	   stained	   for	   the	  
expression	  of	  the	  senescence	  marker	  β-­‐gal.	  The	  chromogenic	  substrate	  X-­‐gal	  was	  added	  to	  
fixed	  cultures	  to	  visualise	  β-­‐gal+	  cells	  in	  a	  blue/green	  colour	  (Figure	  4.2A-­‐C).	  The	  percentage	  
of	   β-­‐gal+	  MSCs	   was	   then	   quantified	   (Figure	   4.2D).	   PαS	  MSCs	   at	   P3	   were	   2.3±0.9%	   β-­‐gal+,	  
while	  P5	  had	  a	  non-­‐significant	  increase	  to	  11.5±1.7%.	  Passage	  7	  MSCs	  had	  significantly	  more	  
β-­‐gal+	  cells	  than	  P3	  cultures	  samples	  (40.2±20.7%).	  These	  findings	  show	  that	  PαS	  MSCs	  are	  
susceptible	  to	  replicative	  senescence,	  which	  can	  limit	  the	  therapeutic	  potential	  of	  these	  cells.	  	  	  	  	  	  	  	  	  	  	  	  
	  	  
	  
Figure	  4.2	  |	  SA-­‐β-­‐gal	  expression	  in	  PαS	  MSCs.	  Representative	  images	  of	  SA-­‐β-­‐gal	  staining	  at	  (A)	  P3,	  (B)	  P5	  and	  
(C)	  P7.	  Images	  taken	  at	  100x	  magnification.	  Bar,	  25µm.	  (D)	  Quantification	  of	  SA-­‐β-­‐gal	  staining	  from	  12	  fields	  of	  
view	  per	  sample,	  3	  samples	  per	  condition.	  Data	  represented	  as	  mean±SD.	  Statistical	  analysis	  performed	  using	  
One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  	  	  





	   4.2.2	  Effect	  of	  Senescence	  on	  PαS	  MSC	  Tri-­‐lineage	  Differentiation	  
	   	   4.2.2.1	  Osteogenic	  Differentiation	  
The	  effect	  of	  extended	  culture	  on	  the	  tri-­‐lineage	  differentiation	  of	  PαS	  MSCs	  was	  examined.	  
Osteogenic	  differentiation	  was	   induced	  as	  before	   and	   cultures	   stained	  with	   alizarin	   red	   to	  
visualise	   calcium	   deposition	   (Figure	   4.3A).	   After	   imaging,	   the	   dye	  was	   extracted	   from	   the	  
stained	  monolayer	  and	  quantified	  against	  known	  calcium	  standards	  (Figure	  4.3B).	  PαS	  MSCs	  
exhibited	   robust	   osteogenic	   differentiation	   across	   all	   passages	   tested.	   Interestingly,	  
significant	   increases	   in	   calcium	  concentration	  were	  observed	  at	  P5	   compared	   to	  all	   earlier	  
passages.	   Similar	   findings	   have	   been	   reported	   previously	   (Wagner	   et	   al.,	   2008).	   It	   would	  
seem	  that	  tissue	  culture	  plastic	  is	  an	  independent	  promoter	  of	  osteogenic	  differentiation,	  as	  
the	  propensity	  for	  osteogenesis	   increased	  at	   later	  passages	   in	  growth	  factor-­‐supplemented	  
cultures	  as	  well	  (Chapter	  5).	  	  
	  
	   4.2.2.2	  Adipogenic	  Differentiation	  
Adipogenic	  differentiation	  was	  visualised	  using	  oil	  red	  O,	  which	  stains	  lipids	  in	  a	  red	  colour.	  
PαS	  MSCs	  underwent	  sporadic	  adipogenic	  differentiation	  at	  earlier	  passages,	  but	  this	  ability	  
was	   lost	   at	   P3	   onwards	   (Figure	   4.4).	   Loss	   of	   adipogenic	   potential	   is	   observed	   upon	  
senescence	  in	  mouse	  (Kretlow	  et	  al.,	  2008)	  and	  human	  MSCs	  (Welter	  et	  al.,	  2013),	  and	  the	  
authors	  of	   the	  original	  PαS	  MSC	   isolation	  paper	  also	  had	  difficulty	  pushing	   freshly-­‐isolated	  
PαS	   cells	   down	   the	   adipogenic	   lineage	   as	   well	   (Morikawa	   et	   al.,	   2009).	   In	   our	   hands,	  
adipogenesis	  was	  the	  first	  property	  to	  be	  lost	  as	  PαS	  MSCs	  became	  increasingly	  senescent.	  	  






Figure	  4.3	  |	  Effect	   of	   extended	   culture	   on	   PαS	  MSC	  osteogenesis.	   (A)	  Representative	   images	  of	  alizarin	   red	  
stained	   differentiation	   cultures	   at	   various	   passages.	   Images	   taken	   at	   100x	   magnification.	   Bar,	   25µm.	   (B)	  
Quantification	   of	   calcium	   concentration	   in	   differentiation	   samples	   (n≥5	   technical	   repeats	   per	   passage).	   Data	  




Figure	   4.4	   |	   Effect	   of	   extended	   culture	   on	   PαS	   MSC	   adipogenesis.	   Representative	   images	   of	   adipogenic	  
differentiation	   cultures	   stained	   with	   oil	   red	   O	   and	   counterstained	   with	   haematoxylin.	   Loss	   of	   adipogenic	  
potential	  can	  be	  seen	  from	  P3	  onwards.	  Images	  taken	  at	  100x	  magnification,	  n≥3	  per	  condition.	  Bar,	  25µm.	  	  





	   	   4.2.2.3	  Chondrogenic	  Differentiation	  
Chondrogenic	   differentiation	   of	   PαS	  MSCs	  was	   studied	   using	  micromass	   pellet	   cultures	   in	  
collaboration	   with	   Dr	   Zhang	   and	   Professor	   Hollander	   at	   Bristol	   University.	   Using	   their	  
proprietary	  methods,	  we	  were	  able	  to	  quantify	  the	  amount	  and	  quality	  of	  cartilage	  produced	  
in	  PαS	  MSC-­‐derived	  micromass	  pellets.	  Fixed	  numbers	  of	  PαS	  MSCs	  at	  P5	  and	  P9	  underwent	  
chondrogenic	  differentiation.	  Pellets	  were	  then	  freeze-­‐dried	  and	  weighed	  prior	  to	  enzymatic	  
digestion.	  Older	   P9	   PαS	  MSCs	   produced	   significantly	   smaller	   and	   lighter	   pellets	   than	   their	  
younger	  P5	  counterparts	  (p=0.0004;	  Figure	  4.5A).	  	  
	  
Cartilage	   pellets	   were	   then	   digested	   in	   trypsin	   to	   solubilise	   extracellular	   matrix	   (ECM)	  
components.	   The	  major	   ECM	   components	   of	   cartilage	   are	  water	   (65-­‐80%),	   collagen	   fibres	  
(10-­‐20%)	   and	   proteoglycans	   (5-­‐10%;	   Poole	   et	   al.,	   2001).	   Of	   the	   collagen	   fibres,	   type	   I	  
collagen	   (Col1)	   is	   synthesised	   by	   immature	   or	   de-­‐differentiated	   chondrocytes	   (Yang	   et	   al.,	  
2006).	   Col1	   is	   found	   in	   fibrocartilage,	   an	   inferior	   cartilage	   that	   is	   produced	   as	   a	   wound	  
healing	   response	   (Punwar	   and	   Khan,	   2011).	   Type	   II	   collagen	   is	   synthesised	   by	   fully	  
differentiated	   chondrocytes	   and	   predominates	   in	   hyaline	   cartilage.	   Col1	   and	   Col2	   were	  
detected,	  but	  there	  was	  no	  difference	  between	  groups	  (Figure	  4.5B-­‐C).	  The	  amount	  of	  Col2	  
produced	   was	   higher	   than	   Col1	   (approximately	   1.5µg	   Col2	   compared	   to	   <1ng	   Col1),	  
suggesting	   that	   PαS	   MSC-­‐derived	   chondrocytes	   are	   healthy	   and	   functional.	   The	   ratio	   of	  
Col2:Col1	   is	  also	  used	   to	  assess	   the	  quality	  of	  MSC-­‐generated	  cartilage,	  with	  higher	  values	  
representing	   better	   cartilage	   differentiation	   (Marlovits	   et	   al.,	   2004).	   No	   significant	  
differences	  were	  observed	  in	  the	  Col2:Col1	  ratio	  between	  P5	  and	  P9	  PαS	  MSCs	  (Figure	  4.5D).	  





Aside	  from	  collagen	  fibres,	  the	  other	  major	  ECM	  components	  of	  cartilage	  are	  proteoglycans.	  
Proteoglycans	  consist	  of	  a	  ‘core’	  protein	  onto	  which	  several	  glycosaminoglycan	  (GAG)	  chains	  
are	   covalently	   attached	   (Esko	   et	   al.,	   2009).	   Proteoglycans	   provide	   load	   bearing	   and	  
compression	   resistance	   properties	   to	   healthy	   cartilage	   and	   is	   an	   important	   marker	   of	  
chondrocyte	   function	   (Knudson	   and	   Knudson,	   2001).	   The	   total	   GAG	   content	   of	   PαS	  MSC-­‐
derived	  cartilage	  was	  quantified	  using	  a	  colourimetric	  assay.	  Passage	  5	  cells	  had	  significantly	  
more	  GAG	   compared	   to	   older,	   P9	   cells	   (2.3±1.2µg	   vs.	   0.8±0.04µg,	   p=0.049).	   These	   results	  
demonstrate	  that	  senescence	  has	  a	  negative	  effect	  on	  the	  size	  and	  GAG	  content	  of	  PαS	  MSC-­‐
derived	  cartilage,	  although	  their	  collagen	  content	  remained	  quite	  similar.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  
	  
	  
Figure	  4.5	  |	  Effect	  of	  extended	  culture	  on	  PαS	  MSC	  chondrogenesis.	  (A)	  Dry	  weight	  of	  MSC-­‐derived	  cartilage	  
after	   freeze	   drying.	   (B)	   Total	   amount	   of	   type	   I	   and	   (C)	   type	   II	   collagens	   in	   cartilage	   samples.	   (D)	   Ratio	   of	  
Col2:Col1	   as	   a	  marker	   of	   cartilage	  quality.	   (D)	   Total	   amount	  of	  GAGs	  present	   in	  MSC-­‐derived	   cartilage.	  Data	  
shown	  as	  mean±SD,	  n≥4	  biological	  repeats	  per	  passage.	  Statistical	  analysis	  performed	  using	  unpaired	  Student’s	  
T	  test.	  	   	  





	   4.2.3	  Effect	  of	  Senescence	  on	  PαS	  MSC	  Immunosuppression	  
The	  effect	  of	  extended	  culture	  on	  Balb/c-­‐derived	  PαS	  MSCs	  was	  examined	  using	  the	  ‘purified’	  
in	  vitro	  T	  cell	  proliferation	  assay.	  Early-­‐passage	  (P3)	  MSCs	  were	  able	  to	  suppress	   in	  a	  dose-­‐
dependent	   fashion	   as	   before,	   but	   P5	   MSCs	   fared	   slightly	   worse	   (Figure	   4.6A).	   Significant	  
increases	  in	  CD4	  T	  cell	  numbers	  (compared	  to	  P3)	  were	  seen	  at	  the	  1:32,	  1:16	  and	  1:8	  ratios,	  
with	  P5	  MSCs	  only	  being	  able	   to	  suppress	  equally	  well	  as	  P3	  cells	  at	   the	  highest	  1:4	  dose.	  
Late-­‐passage	   (P7)	   MSCs	   failed	   to	   suppress	   T	   cell	   proliferation	   across	   all	   ratios	   tested.	  
Significant	  increases	  in	  CD4	  T	  cell	  numbers	  (compared	  to	  P5)	  were	  seen	  at	  1:8	  and	  1:4	  ratios,	  
and	  across	  all	  ratios	  when	  compared	  to	  P3	  cells.	  Additionally,	  P7	  MSCs	  also	  failed	  to	  cause	  
significant	  drops	   in	  T	  cell	  number	  when	  compared	  to	   their	  no-­‐MSC	  control,	  demonstrating	  
that	  senescence	  completely	  eliminates	  the	  immunosuppressive	  phenotype	  of	  PαS	  MSCs.	  	  
	  
As	  NO	  secretion	  was	   the	  mechanism	  behind	  Balb/c-­‐derived	  PαS	  MSC	   immunosuppression,	  
we	   repeated	   the	   Griess	   assay	   using	   supernatants	   from	   late-­‐passage	   cells.	   A	   significant	  
decrease	   in	   the	   nitrite	   concentration	   of	   P7	   cells	   was	   observed	   after	   overnight	   incubation	  
with	  TNFα	  and	  IFNγ	  stimulation	  (71.1±2.5µM	  vs	  22.2±0.9µM	  nitrite,	  p<0.0001;	  Figure	  4.5B).	  
These	  findings	  demonstrate	  a	  profound	  reduction	  in	  the	  immunomodulatory	  function	  of	  PαS	  
MSCs	  after	  extended	  in	  vitro	  culture	  due	  to	  impaired	  production	  of	  NO	  in	  older	  cells.	  	  
	   	  






Figure	  4.6	  |	  Effect	   of	   extended	   culture	  on	  Balb/c-­‐derived	  PαS	  MSC	   immunosuppression.	   (A)	  Balb/c-­‐derived	  
PαS	  MSCs	  (n=3	  biological	  repeats	  for	  each	  passage)	  were	  co-­‐cultured	  for	  72	  hours	  with	  activated	  CD4+	  T	  cells.	  
Samples	  were	  then	  analysed	  by	  flow	  cytometry	  and	  total	  CD4	  numbers	  counted	  and	  expressed	  as	  a	  percentage	  
to	   the	   no-­‐MSC	   control.	   Data	   shown	   as	  mean±SD.	   Statistical	   analysis	   performed	   using	   Two-­‐way	  ANOVA	  with	  
Bonferroni’s	  Multiple	   Comparison	   Test.	   	   (B)	   Total	   levels	   of	   nitrite	   from	  P3	   and	   P7	   PαS	  MSCs	  was	   quantified	  
using	   the	  Griess	   assay	   (n=3	   technical	   repeats).	  Data	   shown	  as	  mean±SD.	   Statistical	   analysis	   performed	  using	  
unpaired	  Student’s	  T	  test.	  	  






4.3.1	  Chapter	  Summary	  
The	  rarity	  of	  PαS	  MSCs	  in	  BM	  mandates	  a	  period	  of	  in	  vitro	  expansion	  to	  reach	  cell	  numbers	  
required	   for	   experiments.	   The	   findings	   of	   this	   chapter	   demonstrate	   that	   PαS	   MSCs	   are	  
susceptible	  to	  replication-­‐induced	  senescence,	  characterised	  by	  a	  reduction	   in	  proliferative	  
capacity,	  an	  increase	  in	  cell	  size	  and	  increased	  expression	  of	  SA-­‐β-­‐gal.	  Increased	  senescence	  
has	   implications	   for	   the	   therapeutic	   application	   of	   PαS	   MSCs,	   as	   we	   saw	   reductions	   in	  
adipogenic	   and	   chondrogenic	   differentiation	   potential	   in	   aged	   cells.	   Interestingly,	   we	  
observed	   an	   increase	   in	   osteogenic	   differentiation	   at	   later	   passages,	   suggesting	   that	   aged	  
MSCs	   lose	   their	   multipotency	   and	   become	   lineage-­‐restricted	   towards	   bone.	   We	   also	  
observed	  a	  progressive	  loss	  of	  immunomodulatory	  function	  in	  P5	  and	  P7	  PαS	  MSCs,	  due	  to	  
decreased	  secretion	  of	  NO.	  	  
	  
	   4.3.2	  PαS	  MSCs	  undergo	  Senescence	  	  
Cellular	  senescence	  was	  first	  described	  by	  Leonard	  Hayflick	  in	  a	  seminal	  study	  that	  showed	  
human	  somatic	  cells	  have	  a	  limited	  capacity	  to	  divide	   in	  vitro,	  known	  as	  the	  “Hayflick	  limit”	  
(Hayflick,	  1965).	  Senescence	  is	  believed	  to	  be	  tumour-­‐suppressive	  mechanism	  as	  it	  prevents	  
mitotic	   cells	   from	   replicating	   indefinitely.	   Studies	   have	   shown	   that	   exposing	   a	   cell	   to	  
oncogenic	  or	  mitogenic	  stimuli	  can	   induce	  the	  onset	  of	  premature	  senescence	  as	  a	  way	  to	  
avoid	   transformation	   (Dimri,	   2005).	   The	   trademark	   characteristic	   of	   senescence	   is	   growth	  
arrest,	   but	   the	   senescent	   cells	   remain	   viable,	   metabolically	   active,	   and	   more	   resistant	   to	  





apoptosis	  (Hampel	  et	  al.,	  2004,	  Di	  Leonardo	  et	  al.,	  1994).	  Senescence	  also	  induces	  increased	  
expression	  of	  cell	  cycle	  inhibitors	  such	  as	  p21	  and	  p16	  in	  MSCs	  (Yu	  and	  Kang,	  2013,	  Campisi	  
and	  Fagagna,	  2007).	  Senescent	  human	  MSCs	  downregulate	  expression	  of	  genes	  involved	  in	  
mitosis	  and	  proliferation	  at	  later	  passages	  (Tsai	  et	  al.,	  2010,	  Schallmoser	  et	  al.,	  2010,	  Lee	  et	  
al.,	  2009a).	  Similar	  findings	  have	  also	  been	  reported	  for	  murine	  MSCs	  (Himeno	  et	  al.,	  2013).	  
Future	   work	   should	   examine	   the	   expression	   of	   senescence-­‐related	   genes	   in	   PαS	  MSCs	   to	  
confirm	  their	  senescent	  status	  after	  extended	  culture.	  
	  
The	  expression	  of	  senescence-­‐associated	  β-­‐galactosidase	  was	  used	  as	  a	  marker	  of	  senescent	  
cells	   in	  this	  study.	  SA-­‐β-­‐gal	   is	  defined	  as	  β-­‐gal	  activity	  detectable	  at	  pH	  6.0	  in	  cultured	  cells	  
that	   have	   undergone	   replicative	   senescence	   (Lee	   et	   al.,	   2006).	  We	   observed	   a	   significant	  
increase	  in	  SA-­‐β-­‐gal	  expression	  in	  PαS	  MSCs	  at	  P7,	  corresponding	  to	  approximately	  50	  days	  
culture.	   Senescent	   PαS	  MSCs	   appear	   larger,	   with	   a	   decreased	   nucleus	   to	   cytoplasm	   ratio	  
(“fried	   egg”	  morphology)	   that	   has	   been	  described	  before	   for	  MSCs	   and	  other	   stromal	   cell	  
populations	  (Wagner	  et	  al.,	  2010).	  Aside	  from	  the	  loss	  of	  function,	  the	  systemic	  infusion	  of	  
larger	  MSCs	  carries	  a	  risk	  of	  them	  being	  trapped	  in	  small	  capillaries	  in	  mouse	  models	  which	  
can	  lead	  to	  tissue	  ischemia	  and	  further	  injury	  (Furlani	  et	  al.,	  2009,	  Toma	  et	  al.,	  2009).	  	  
	  
In	  our	  studies,	  PαS	  MSCs	  cultured	  in	  SM	  displayed	  increased	  population	  doubling	  times	  after	  
50	  days	   in	   culture.	   This	  was	   a	   lot	   earlier	   than	   reported	  by	  Morikawa	  and	   colleagues,	  who	  
were	  able	  to	  expand	  PαS	  MSC	  for	  up	  to	  100	  days,	  yielding	  approximately	  107	  cells	  (Morikawa	  
et	  al.,	  2009).	  However,	  the	  number	  of	  population	  doublings	  was	  not	  reported	  in	  the	  original	  





paper,	  which	  makes	   it	   difficult	   to	   compare	   results.	   The	   reason	   behind	   this	   discrepancy	   in	  
proliferative	   capacity	   is	   unclear,	   and	   it	   remains	   to	   be	   seen	  whether	   PαS	  MSCs	   could	   have	  
been	  expanded	  past	  the	  50-­‐day	  limit	  used	  in	  this	  study.	  One	  potential	  reason	  could	  be	  that	  
our	   in	   vitro	   culture	   conditions	   are	   not	   optimised	   for	   PαS	   MSC	   expansion.	   Culture	   in	   3D,	  
under	   hypoxic	   conditions	   and	   supplemented	   with	   growth	   factors	   have	   been	   shown	   to	  
promote	   MSC	   growth	   and	   differentiation	   (Gharibi	   and	   Hughes,	   2012,	   Das	   et	   al.,	   2010).	  
Additionally,	   the	   prospectively-­‐isolated	   Nestin+	   and	   PDGFRα+CD51+	  murine	  MSCs	   required	  
3D	   culture	   as	   “mesenspheres”	   as	   they	   were	   not	   able	   to	   be	   expanded	   as	   2D	   monolayers	  
(Pinho	  et	  al.,	  2013,	  Mendez-­‐Ferrer	  et	  al.,	  2010).	  Identification	  of	  optimal	  culture	  conditions	  
for	  PαS	  MSCs	  should	  delay	  the	  onset	  of	  senescence	  and	  improve	  the	  therapeutic	  potential	  of	  
these	  cells.	  	  	  	  
	  
PαS	  MSCs	  also	  have	  a	  reduced	  proliferative	  capacity	  when	  compared	  to	  traditionally	  isolated,	  
plastic-­‐adherent	  murine	  MSCs	  that	  can	  be	  expanded	  to	  reach	  107	  cells	  within	  fourteen	  days	  
(Zhu	  et	  al.,	  2010).	  However,	  the	  contribution	  of	  contaminating	  and	  transformed	  cells	  in	  MSC	  
cultures	   could	   have	   had	   an	   impact	   in	   previous	   studies.	   Miura	   et	   al.	   (2006)	   showed	   that	  
mouse	  MSCs	  displayed	  signs	  of	  senescence	  at	  P5,	  but	  they	  overcame	  this	  “crisis	  phase”	  and	  
re-­‐acquired	   proliferative	   capacity	   through	   transformation.	   Transformed	   cells	   could	   be	  
expanded	  for	  >500	  PDs	  over	  a	  400	  day	  period	  and	  formed	  tumours	  after	  in	  vivo	  infusion.	  The	  
onset	   of	   senescence	   in	   PαS	   MSCs	   suggests	   that	   these	   cells	   are	   not	   prone	   to	   malignant	  
transformation,	  however	  future	  karyotypic	  studies	  must	  be	  performed	  to	  check	  the	  genetic	  
stability	  of	  these	  cells	  after	  extended	  culture.	  	   	  





4.3.3	  Effect	  of	  Senescence	  on	  PαS	  MSC	  Differentiation	  
The	  osteogenic	  differentiation	  potential	  of	  PαS	  MSCs	  increased	  at	  later	  passages,	  producing	  
significantly	   more	   calcium	   at	   P5.	   This	   finding	   goes	   against	   previous	   published	   literature,	  
which	   reports	   a	   loss	   in	   osteogenic	   potential	   with	   increasing	   passage	   number	   for	   murine	  
(Despars	  et	  al.,	  2013,	  Moerman	  et	  al.,	  2004)	  and	  human	  MSCs	  (Bajada	  et	  al.,	  2009,	  Sethe	  et	  
al.,	   2006).	   Only	   Wagner	   and	   colleagues	   report	   an	   increase	   in	   the	   amount	   of	   alizarin	   red	  
staining	  at	  later	  passages	  using	  human	  MSCs	  (Wagner	  et	  al.,	  2008).	  One	  possible	  reason	  for	  
this	  discrepancy	  could	  be	  due	  to	  prolonged	  culture	  on	  tissue	  culture	  plastic,	  a	  relatively	  ‘stiff’	  
culture	   matrix.	   The	   importance	   of	   matrix	   elasticity	   has	   been	   elegantly	   demonstrated	   by	  
Engler	  et	  al.	  (2006)	  and	  Oh	  et	  al.	  (2009),	  who	  were	  able	  to	  induce	  osteogenic	  differentiation	  
by	  culturing	  human	  MSCs	  on	   ‘stiff’	   culture	  matrices	  alone.	  To	   test	   this	   theory,	   it	  would	  be	  
interesting	   to	   see	   whether	   PαS	   MSCs	   cultured	   on	   softer	   hydrogels	   lose	   their	   osteogenic	  
potential	  and	  gain	  adipogenic	  potential	  at	  later	  passages.	  	  	  
	  
PαS	  MSCs	  lost	  their	  adipogenic	  and	  chondrogenic	  potential	  at	  later	  passages,	  suggesting	  that	  
senescent	  PαS	  cells	  become	  lineage-­‐restricted	  towards	  bone	  after	  in	  vitro	  expansion.	  Loss	  of	  
fat	  and	  cartilage	  differentiation	  has	  been	  described	  previously	  for	  aged	  MSCs	  (Sethe	  et	  al.,	  
2006).	   Loss	   of	   chondrogenesis	   has	   implications	   for	   future	   therapeutic	   uses.	   There	   is	  
increasing	   demand	   for	   alternative	   therapies	   for	   cartilage	   repair,	   and	   MSC-­‐derived	  
chondrocytes	  are	  one	  option	  currently	  being	  researched	  (Solchaga	  et	  al.,	  2011,	  Zhang	  et	  al.,	  
2009,	   Chen	   and	   Tuan,	   2008).	   Pre-­‐clinical	   studies	   have	   demonstrated	   the	   safety	   of	   MSC	  
infusion	  in	  patients	  with	  cartilage	  defects,	  but	  the	  degree	  of	  clinical	  benefit	  varied	  (Koga	  et	  





al.,	  2009).	  This	  reflects	  the	  relative	  technical	  complexity	  involved	  in	  differentiating	  MSCs	  into	  
chondrocytes	   compared	   to	   the	  other	  main	   lineages	   (Vinatier	  et	  al.,	  2009).	   In	   collaboration	  
with	  Bristol	  University,	  we	  were	  able	  to	  quantify	  collagen	  and	  proteoglycan	  deposits	  in	  PαS	  
MSC-­‐derived	  cartilage	  to	  fully	  assess	  the	  quality	  of	  cartilage	  produced.	  Passage	  5	  PαS	  MSCs	  
were	  able	  to	  produce	  large	  cartilage	  pellets	  rich	  in	  collagen	  type	  II	  and	  glycosaminoglycans.	  
Therefore,	   PαS	   MSCs	   can	   be	   used	   as	   a	   model	   system	   for	   future	   tissue	   engineering	  
approaches	  to	  make	  cartilage,	  with	  a	  view	  to	  translating	  any	  promising	  findings	  to	  the	  clinic.	  
Although	   the	   collagen	   content	   between	   P5	   and	   P9	   cells	   were	   similar,	   their	   size	   and	  
proteoglycan	   deposits	   were	   significantly	   different.	   Further	   work	   is	   necessary	   to	   identify	  
culture	  conditions	  that	  maintain	  the	  chondrogenic	  potential	  of	  PαS	  over	  extended	  culture.	  	  	  	  	  	  	  
	  
	   4.3.4	  Effect	  of	  Senescence	  on	  PαS	  MSC	  Immunosuppression	  
The	  effect	  of	  in	  vitro	  culture	  on	  MSC-­‐mediated	  immunosuppression	  has	  not	  been	  studied	  in	  
detail,	  and	  the	  limited	  literature	  on	  this	  topic	  describes	  the	  effect	  of	  senescence	  on	  human	  
MSC	  populations	  and	  not	  their	  murine	  equivalents	  (Asumda,	  2013).	  We	  have	  demonstrated	  
that	   PαS	   MSCs	   display	   a	   progressive	   loss	   of	   immunosuppressive	   function,	   with	   P7	   cells	  
having	   completely	   lost	   the	   ability	   to	   prevent	   CD4	   T	   cell	   proliferation	   due	   to	   an	   impaired	  
ability	  to	  secrete	  NO.	   In	  a	  similar	  study,	  Li	  and	  colleagues	  show	  that	  human	  MSCs	  cultured	  
for	  7	  passages	  in	  vitro	  lost	  their	  ability	  to	  suppress	  CD4	  T	  cell	  proliferation	  due	  to	  increased	  
senescence	   and	  downregulaton	  of	   IL-­‐10	   secretion	   (Li	   et	   al.,	   2012).	   Sepulveda	  et	   al.	   (2014)	  
also	  report	  loss	  of	  immunosuppression	  in	  senescent	  human	  MSCs	  after	   in	  vivo	   infusion	  in	  a	  
lethal	   endotoxaemia	   model.	   Interestingly,	   they	   did	   not	   see	   any	   difference	   in	   the	   in	   vitro	  





immunosuppressive	   capacity	   of	   senescent	  MSCs.	   Another	   interesting	   study	   demonstrated	  
that	   the	   onset	   of	   senescence	   in	   human	   fibroblasts	   triggered	   a	   complex	   ‘senescence-­‐
associated	  secretory	  phenotype’	  during	  which	  elevated	  levels	  of	  pro-­‐inflammatory	  cytokines	  
IL-­‐6	  and	  IL-­‐8	  were	  produced	  (Rodier	  et	  al.,	  2009,	  Fumagalli	  and	  Fagagna,	  2009).	  Although	  the	  
similarities	  observed	  between	  MSCs	  and	   fibroblasts	  make	   this	   an	   attractive	  mechanism	   to	  
explain	   loss	   in	   immunosuppression	   at	   later	   passages,	   a	   similar	   finding	   has	   not	   yet	   been	  
reported	  for	  purified	  MSC	  cultures.	  	  	  	  
	  
Finally,	   clinical	   evidence	   for	   a	   loss	   in	   immunosuppression	   is	   reported	  by	  Moll	   et	   al.	   (2014)	  
and	  von	  Bahr	  et	  al.	  (2012),	  who	  show	  that	  culture	  expanded	  MSCs	  perform	  worse	  in	  patients	  
with	  GvHD	  due	  to	  rapid	  clearance	  of	  infused	  cells	  from	  the	  host.	  The	  recent	  failed	  phase	  III	  
RCT	   (NCT00366145)	   investigating	   the	   potential	   of	   MSCs	   (PROCHYMAL®)	   in	   patients	   with	  
GvHD	  used	  MSCs	  that	  had	  been	  expanded	  using	  a	  proprietary	  method	  to	  yield	  10,000	  doses	  
(20x109	   cells)	   from	  a	   single	  BM	  donor	   (Galipeau,	   2013).	   PROCHYMAL®	  MSCs	  expressed	   all	  
markers	   defined	   by	   the	   ISCT	   criteria,	   but	   functional	   analysis	   of	   differentiation	   and	  
immunosuppression	  were	  not	  performed	  on	  the	  cells	   infused	  into	  patients.	  Given	  what	  we	  
now	  know	  about	  MSC	  senescence,	   it	   is	   likely	  that	  the	  majority	  of	   infused	  MSCs	  could	  have	  
undergone	   senescence	   that	  would	   explain	   the	   apparent	   lack	  of	   efficacy	   in	   patients.	   These	  


































5.1	  Chapter	  Rationale	  and	  Aims	  
Replicative	   senescence	   affects	   both	   human	   and	   mouse	   MSCs,	   leading	   to	   reductions	   in	  
growth	  and	  function	  (Sethe	  et	  al.,	  2006).	  Our	  data	  shows	  that	  PαS	  MSCs	  are	  also	  susceptible	  
to	  replication-­‐induced	  senescence,	  which	  limits	  their	  use	  as	  a	  pre-­‐clinical	  model	  population	  
of	  MSCs.	  To	  overcome	  these	  issues,	  several	  groups	  have	  examined	  the	  effect	  of	  hypoxia	  (Das	  
et	  al.,	  2010),	  3D	  culture	  (Pek	  et	  al.,	  2010b),	  matrix	  stiffness	  (Engler	  et	  al.,	  2006)	  and	  growth	  
factors	   (Rodrigues	   et	   al.,	   2010)	   as	   a	   way	   of	   improving	   MSC	   function.	   In	   this	   study,	   we	  
examined	   the	   effect	   of	   GF	   stimulation	   as	   a	   way	   of	   overcoming	   PαS	  MSC	   senescence	   and	  
augmenting	  their	  growth,	  differentiation	  and	  immunosuppressive	  characteristics.	  	  
	  
	   5.1.1	  Overcoming	  senescence	  using	  GFs	  
A	  wide	  variety	  of	  GFs	  have	  been	  studied	  previously	   to	  augment	  MSC	  growth	  and	   function	  
(reviewed	  in	  Introduction	  section	  1.7.2).	  Commonly	  used	  factors	  include	  FGF2,	  PDGF-­‐BB	  and	  
TGF-­‐β1	   (Jung	   et	   al.,	   2012,	   Coutu	   et	   al.,	   2011,	   Rodrigues	   et	   al.,	   2010).	   These	   three	   factors	  
have	   a	   potent	   mitogenic	   effect	   on	   MSCs,	   thereby	   reducing	   the	   in	   vitro	   expansion	   time	  
required	  to	  reach	  cell	  numbers	  for	  therapeutic	  infusions.	  They	  are	  also	  able	  to	  promote	  the	  
tri-­‐lineage	   differentiation	   of	   MSCs	   (Song	   et	   al.,	   2014,	   Ito	   et	   al.,	   2008,	   Jung	   et	   al.,	   2012).	  
Commercially	   available	  MSC	   culture	  media	   are	   frequently	   supplemented	  with	   undisclosed	  
“factors”	   that	  maintain	  MSC	   growth	   and	   tri-­‐lineage	   differentiation	   (Inamdar	   and	   Inamdar,	  
2013,	  Jung	  et	  al.,	  2012).	  These	  undisclosed	  “factors”	  are	  likely	  to	  be	  combinations	  of	  GFs	  that	  
have	  been	  described	  in	  previous	  literature.	  	  





However,	   there	   are	  many	   contradictory	   findings	   on	   the	   effects	   of	   GF-­‐supplementation	   on	  
MSC	  cultures.	  FGF2	  has	  been	  shown	  to	  inhibit	  the	  differentiation	  of	  mouse	  MSCs	  (Lai	  et	  al.,	  
2011,	  Osathanon	   et	   al.,	   2011,	   Baddoo	   et	   al.,	   2003)	  while	   other	   studies	   have	   described	   its	  
ability	   to	  enhance	  differentiation	   (Rodrigues	  et	  al.,	  2010).	  TGF-­‐β1	  has	  been	  reported	  to	  be	  
pro-­‐osteogenic	  in	  some	  studies	  (Roelen	  and	  Dijke,	  2003)	  and	  pro-­‐chondrogenic	  in	  others	  (Xu	  
et	  al.,	   2008).	   Similarly,	  PDGF-­‐BB	  can	  both	   inhibit	   (Gharibi	  and	  Hughes,	  2012)	  and	  promote	  
(Kratchmarova	   et	   al.,	   2005)	   adipogenic	   differentiation.	   The	   heterogeneous	   populations	   of	  
MSCs	  used	  in	  previous	  studies	  may	  be	  one	  reason	  for	  the	  contradictory	  findings;	  however,	  it	  
is	  also	   likely	   that	   the	  duration	  of	  GF-­‐exposure	  may	  also	  have	  an	  effect.	  Most	   studies	  have	  
examined	  the	  short-­‐term,	  transient	  effect	  of	  GF-­‐stimulation	  on	  MSC	  biology	  but	  the	  effect	  of	  
long-­‐term	   culture	   in	  GF-­‐supplemented	  medium	   is	   less	  well	   understood.	   It	   is	   likely	   that	  GF	  
supplementation	   can	   “prime”	   MSCs	   down	   specific	   lineages,	   which	   could	   have	   significant	  
implications	   for	   downstream	   therapeutic	   uses.	   Additionally,	   the	   effect	   of	   long-­‐term	   GF-­‐
supplementation	   on	   the	   immunosuppressive	   phenotype	   of	   MSCs	   has	   not	   been	   studied	  
previously	  and	  could	  be	  of	  major	  translational	  interest.	  	  
	  
	   5.1.2	  Lineage	  Priming	  of	  MSCs	  
Lineage	  priming	  can	  be	  defined	  as	  a	  model	  of	  stem	  cell	  differentiation	  in	  which	  a	  given	  stem	  
cell	   expresses	   a	   subset	   of	   genes	   related	   to	   the	   lineage	   they	   are	   already	   committed	   to	  
differentiate	   into.	   This	   model	   has	   been	   extensively	   studied	   and	   proven	   in	   the	   HSC	   field	  
(Månsson	  et	  al.,	  2007),	  but	   there	   is	  only	  one	  paper	   that	  has	  applied	   this	   concept	   to	  MSCs	  
(Delorme	  et	  al.,	  2009).	  In	  this	  study,	  Delorme	  and	  colleagues	  show	  that	  clonal	  populations	  of	  





undifferentiated	   human	   and	  mouse	  MSCs	   are	   primed	   towards	   the	   osteogenic,	   adipogenic	  
and	   chondrogenic	   lineages	   irrespective	   of	   any	   differentiation-­‐inducing	   stimuli.	   The	  
importance	   of	   this	   finding	   is	   that	   MSC	   differentiation	   into	   non-­‐primed	   lineages	   (e.g.	  
hepatocytes)	   would	   require	   extensive	   epigenetic	   reprogramming	   to	   turn	   off	   the	   “core	  
program”	  and	  switch	  on	  novel	  pathways	  (Delorme	  et	  al.,	  2009).	  
	  
The	   concept	  of	   lineage-­‐primed	  MSCs	   is	   also	   important	  when	   looking	  at	   future	   therapeutic	  
uses	   of	   these	   cells.	   For	   example,	   a	   surgeon	  would	   ideally	  want	  MSCs	   primed	   towards	   the	  
osteogenic	   lineage	   to	   treat	  patients	  with	   skeletal	  defects,	  while	  chondrocyte-­‐primed	  MSCs	  
would	  be	  ideal	  in	  patients	  with	  cartilage	  disorders.	  When	  transplanted,	  these	  lineage-­‐primed	  
MSCs	  would	  readily	  differentiate	  into	  bone	  and	  cartilage	  respectively,	  allowing	  us	  to	  infuse	  
lower	  numbers	  of	  MSCs	  to	  reach	  the	  same	  beneficial	  outcome.	  
	  
To	  this	  end,	  Ng	  et	  al.	  used	  a	  broad	  transcriptomics	  approach	  to	  identify	  PDGF,	  TGF-­‐β	  and	  FGF	  
as	  key	  signalling	  pathways	  regulating	  human	  MSC	  proliferation	  and	  differentiation	  (Ng	  et	  al.,	  
2008).	  PDGF	  signalling	  was	  active	  during	  adipogenesis	  and	  chondrogenesis;	  TGF-­‐β	  signalling	  
was	   active	   during	   chondrogenesis;	   and	   FGF	   signalling	   was	   active	   during	   osteogenesis,	  
adipogenesis	  and	  chondrogenesis	  (Figure	  5.1).	  Inhibition	  of	  any	  of	  these	  signalling	  pathways	  
resulted	  in	  an	  altered	  differentiation	  potential,	  cell	  death	  and	  increased	  population	  doubling	  
times.	   However,	   the	   exogenous	   addition	   of	   their	   respective	   ligands	   was	   sufficient	   to	  
maintain	  MSCs	  in	  serum-­‐free	  media	  (Ng	  et	  al.,	  2008).	  	  
	   	  






Figure	  5.1	  |	  Active	  signalling	  pathways	  during	  MSC	  differentiation.	  The	  findings	  of	  Ng	  et	  al.	  (2008)	  show	  that	  
the	  FGF	  pathway	  was	  active	  during	  osteogenic,	  adipogenic	  and	  chondrogenic	  differentiation	  of	  MSCs.	  The	  PDGF	  
signalling	  pathway	  was	  active	  during	  adipogenesis	  and	  chondrogenesis.	  The	  TGF-­‐β	  pathway	  was	  active	  during	  
chondrogenesis	  only.	  	  
	  
	   5.1.3	  Chapter	  Aims	  
GFs	   are	   commonly	   used	   to	   overcome	   senescence	   and	   augment	  MSC	   function	   in	   previous	  
literature.	   However,	   little	   is	   known	   about	   the	   effect	   of	   long-­‐term	  GF-­‐supplementation	   on	  
purified	  MSC	  cultures.	  Although	  GFs	  increase	  the	  proliferation	  and	  differentiation	  of	  MSCs	  in	  
the	  short	  term,	  they	  may	  also	  prime	  MSCs	  towards	  specific	  lineages	  after	  extended	  culture.	  
Defining	  culture	  conditions	  that	  prime	  MSCs	  towards	  pre-­‐determined	  fates	   is	  of	  significant	  
interest	  for	  future	  medical	  uses	  as	  it	  would	  allow	  culture	  conditions	  to	  be	  tailor-­‐made	  for	  the	  
clinical	  indication.	  Additionally,	  defining	  conditions	  that	  prolong	  the	  suppressive	  phenotype	  
of	  MSCs	  would	  also	  be	  beneficial	  for	  use	  in	  immune-­‐mediated	  disorders.	  
	  
The	   findings	   of	   Ng	   and	   colleagues	   have	   identified	   the	   FGF,	   PDGF	   and	   TGF-­‐β	   signalling	  
pathways	   to	   be	   active	   during	   MSC	   growth	   and	   differentiation	   down	   specific	   fates.	   We	  
hypothesised	   that	   the	   exogenous	   addition	   of	   their	   respective	   ligands	   (FGF2,	   PDGF-­‐BB	   and	  





TGF-­‐β1)	  may	  enhance	  MSC	  growth	  and	  prime	  MSCs	  down	  specific	  lineages.	  One	  key	  strength	  
of	   this	   study	   is	   that	  we	  were	  able	   to	  observe	   the	  effects	  of	   the	  aforementioned	  GFs	  on	  a	  
pure	  population	  of	  MSCs	  directly	  after	  isolation,	  thereby	  avoiding	  any	  bias	  associated	  with	  a	  
culture-­‐manipulated	  starting	  population.	  The	  specific	  aims	  of	  this	  chapter	  were	  to:	  
	  
1. Describe	   the	   effect	   of	   FGF2,	   PDGF-­‐BB	   and	   TGF-­‐β1	   on	   PαS	   MSC	   growth	   and	  
senescence.	  
2. Perform	   karyotype	   analysis	   on	   PαS	   MSCs	   to	   see	   whether	   GF-­‐treatment	   has	   a	  
detrimental	  effect	  on	  their	  genetic	  stability.	  
3. Examine	   whether	   GF-­‐treatment	   primes	   PαS	   MSCs	   down	   specific	   lineages	   at	   the	  
genetic	  and	  phenotypic	  level.	  
4. Examine	  the	  effect	  of	  GF-­‐treatment	  on	  PαS	  MSC	  immunosuppression.	  	  
	   	  






5.2.1	  Effect	  of	  PDGF-­‐BB,	  FGF2	  and	  TGF-­‐β1	  on	  PαS	  MSC	  Growth	  
To	   investigate	   the	  effects	  of	  GF-­‐supplementation	  on	  PαS	  MSCs,	   freshly	   isolated	   cells	  were	  
cultured	  in	  SM	  ±	  each	  individual	  GF	  at	  a	  concentration	  of	  10ng/ml.	  PαS	  MSCs	  cultured	  in	  SM	  
adopted	  a	  spindle-­‐shaped	  morphology	  as	  before	  (Figure	  5.2A),	  but	  the	  addition	  of	  PDGF	  or	  
FGF	   caused	   the	   cells	   to	   adopt	   a	   smaller,	   more	   ‘spindly’	   morphology	   (Figure	   5.2B,C).	   The	  
addition	   of	   TGF-­‐β	   caused	   PαS	  MSCs	   to	   grow	   in	   discrete	   colonies	   that	  were	   tightly	   packed	  
with	  cells,	  although	  the	  overall	  morphology	  was	  similar	  to	  the	  SM	  controls	  (Figure	  5.2D).	  No	  




Figure	   5.2	   |	  Morphologies	   of	   freshly	   isolated	   PαS	  MSCs	   with	   GFs.	   Representative	   images	   of	   P0	   PαS	  MSCs	  
cultured	  in	  (A)	  SM,	  (B)	  SM+10ng/ml	  PDGB-­‐BB,	  (C)	  SM+10ng/ml	  FGF2	  and	  (D)	  SM+10ng/ml	  TGF-­‐β1.	  All	   images	  
taken	  at	  100x	  magnification.	  Bar,	  25µm.	  	  





CFU-­‐F	  assays	  were	  performed	  to	  examine	  whether	  GF-­‐supplementation	  affected	  the	  colony	  
forming	  ability	  of	  PαS	  MSCs.	  Low	  numbers	  of	  PαS	  MSCs	  (2000	  per	  10cm2	  dish)	  were	  seeded	  
to	   ensure	   a	   clonal	   density	   and	   cultured	   for	   14	   days	   prior	   to	   staining	  with	   crystal	   violet	   to	  
visualise	  colony	  formation	  (Figure	  5.3).	  Addition	  of	  FGF	  or	  PDGF	  had	  the	  most	  pronounced	  
effect	  on	  CFU-­‐F	  ability,	  with	  increases	  in	  both	  the	  size	  and	  number	  of	  colonies	  formed.	  TGF-­‐β	  
supplementation	   had	   a	  more	  modest	   effect,	  with	   total	   colony	   number	   and	   size	   similar	   to	  
that	  of	  SM	  cultures.	  	  
	  
	  
Figure	   5.3	   |	   Effect	   of	   GF-­‐supplementation	   on	   CFU-­‐F.	  Whole-­‐dish	   image	   of	   10cm2	   petri	   dishes	   stained	  with	  
crystal	  violet	  to	  visualise	  colony	  formation.	  Representative	  images	  taken	  without	  magnification	  (n=2	  biological	  
repeats	  per	  condition).	  	  





A	  smaller	  cell	  size	  and	  improved	  CFU-­‐F	  efficiency	  are	  indicative	  of	  increased	  growth	  potential	  
in	  MSCs	  (Sethe	  et	  al.,	  2006).	  Growth	  curves	  over	  a	  50-­‐day	  period	  were	  performed	  to	  test	  the	  
effect	  of	  GF-­‐supplementation	  on	  PαS	  MSC	  proliferation.	  As	   expected,	  GF-­‐supplementation	  
had	  a	  mitogenic	  effect	  on	  PαS	  MSCs	  (Figure	  5.4A).	  MSCs	  grown	  in	  SM	  underwent	  7	  PDs	  over	  
a	  50-­‐day	  period	  compared	  to	  approximately	  10	  PDs	  in	  TGF-­‐β1	  supplemented	  media,	  11	  PDs	  
in	  PDGF-­‐BB	  supplemented	  media,	  and	  13	  PDs	  in	  the	  presence	  of	  FGF2.	  Growth	  curves	  for	  GF-­‐
supplemented	  MSCs	  were	  still	  in	  their	  lineage	  phase	  of	  growth	  at	  day	  50	  compared	  to	  cells	  in	  
SM	   that	   began	   to	   plateau	   after	   40	   days.	   This	   suggests	   that	  GF-­‐supplemented	  MSCs	   could	  
have	  been	  expanded	  further	  past	  the	  50	  days	  used	  in	  this	  study	  without	  slowing	  down	  and	  
undergoing	  senescence.	  	  
	  
Due	   to	   the	   differences	   in	   cell	   size	   and	   morphology	   seen	   with	   the	   addition	   of	   GFs	   (in	  
particular	   FGF2;	   Figure	  5.2),	   the	   total	   number	  of	  PDs	  does	  not	   fully	   portray	   the	  mitogenic	  
effect	  of	  these	  cytokines.	  To	  address	  this	  issue,	  cell	  counts	  were	  taken	  at	  day	  30	  to	  quantify	  
the	  total	  number	  of	  viable	  cells	  present	  (Figure	  5.4B).	  PαS	  MSCs	  in	  SM	  grew	  from	  4000	  cells	  
seeded	  at	  day	  0	  to	  reach	  205,000±53,000	  cells	  by	  day	  30.	  Increases	  in	  cell	  number	  were	  seen	  
following	   TGF-­‐β1	   (950,000±570,000	   cells)	   and	   PDGF-­‐BB	   (1.9x106±680,000	   cells)	  
supplementation,	   although	   this	   failed	   to	   reach	   statistical	   significance.	   By	   contrast,	   FGF2-­‐
supplemented	  PαS	  MSCs	  increased	  in	  number	  significantly	  over	  the	  30-­‐day	  period,	  yielding	  
cultures	  containing	  9.8x106±1.25x106	  viable	  MSCs.	  	  
	   	  






Figure	  5.4	  |	  Effect	  of	  GF-­‐supplementation	  on	  PαS	  MSC	  growth.	   (A)	  Population	  doublings	  over	  50	  days.	  Each	  
line	  represents	  an	   independent	  culture	  of	  cells,	  n=3	  biological	   repeats	  per	  condition.	   (B)	  Cell	  counts	   taken	  at	  
day	   30	   post	   seeding.	   Data	   shown	   as	   mean±SD,	   n=3	   biological	   repeats	   per	   condition.	   Statistical	   analysis	  
performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  	  
	  
	   5.2.2	  Effect	  of	  GF-­‐supplementation	  on	  PαS	  MSC	  Senescence	  	  
SA-­‐β-­‐gal	   staining	   was	   performed	   on	   days	   30	   and	   50	   to	   identify	   whether	   increased	  
proliferation	  was	  due	  to	  a	  reduction	  in	  senescence.	  Aged	  cells	   in	  SM,	  PDGF-­‐BB	  and	  TGF-­‐β1	  
groups	  displayed	  a	  shift	  in	  morphology	  towards	  larger,	  flatter	  cells	  (Figure	  5.5A	  arrowheads).	  
In	   contrast,	   FGF	   supplemented	   MSCs	   remained	   small	   and	   retained	   a	   spindle-­‐shaped	  
morphology.	   The	   percentage	   of	   SA-­‐β-­‐gal+	  MSCs	  were	   then	   quantified	   at	   both	   time	   points	  
(Figure	  5.5B).	  At	  day	  30,	  significant	  drops	  in	  the	  number	  of	  SA-­‐β-­‐gal+	  MSCs	  were	  observed	  in	  
FGF2	  and	  TGF-­‐β1	  supplemented	  cultures	  compared	  to	  SM,	  and	  a	  non-­‐significant	   reduction	  
was	  also	  seen	  in	  PDGF-­‐supplemented	  cells.	  An	  increase	  in	  the	  number	  of	  senescent	  cells	  was	  





seen	   across	   all	   groups	   at	   day	   50,	   but	   GF-­‐supplemented	   cultures	   had	   significantly	   lower	  
numbers	  of	  SA-­‐β-­‐gal+	  MSCs	  compared	  to	  SM	  alone.	  These	  findings	  show	  that	  GF-­‐treatment	  
can	  delay	  the	  onset	  of	  senescence	  in	  PαS	  MSCs	  during	   in	  vitro	  expansion	  and	  could	  explain	  




Figure	   5.5	   |	   Effect	   of	   GF-­‐supplementation	   on	   PαS	  MSC	   senescence.	   (A)	   Representative	   images	   of	   SA-­‐β-­‐gal	  
staining.	  Arrowheads	  pick	  out	  cells	  of	  interest/senescent	  cells.	  Images	  taken	  at	  100x	  magnification.	  Bar,	  20µm.	  
(B)	  Quantification	  of	  SA-­‐β-­‐gal	   staining	   from	  10	   fields	  of	   view	  per	   sample,	  3	   to	  6	   samples	  per	   condition.	  Data	  
represented	   as	   mean±SD.	   Statistical	   analysis	   performed	   using	   One-­‐way	   ANOVA	   with	   Bonferroni’s	   Multiple	  
Comparison	  Test.	  	   	  





	   5.2.3	  Karyotypic	  Stability	  of	  PαS	  MSCs	  
Prolonged	   in	   vitro	   expansion	   can	   predispose	   MSCs	   towards	   malignant	   transformation,	   a	  
phenomenon	   that	   preferentially	   affects	   murine	   cells	   (Rangarajan	   et	   al.,	   2004).	   The	  
karyotypic	  stability	  of	  PαS	  MSCs	  has	  not	  been	  reported	  previously.	  Our	  data	  demonstrates	  
that	  GF-­‐supplementation	  increases	  the	  proliferation	  (Figure	  5.4A)	  and	  lowers	  the	  senescence	  
(Figure	  5.5B)	  of	   PαS	  MSCs,	  which	   could	  be	  possible	   signs	  of	   immortalisation	   (Miura	   et	   al.,	  
2006).	   Chromosome	  analysis	  was	   therefore	  performed	  on	  P3	   and	  P5	  PαS	  MSC	   cultures	   to	  
observe	   whether	   GF-­‐treatment	   had	   a	   detrimental	   effect	   on	   the	   chromosomal	   stability	   of	  
these	  cells	  (Methods	  Figure	  2.4).	  	  
	  
Giemsa-­‐banding	  (G-­‐banding)	  chromosome	  analysis	  and	  chromosome	  breakage	  studies	  were	  
performed	  in	  collaboration	  with	  Mary	  Strachan,	  Dr	  Sara	  Dyer	  and	  Prof.	  Mike	  Griffiths	  at	  the	  
West	  Midlands	  Regional	  Genetics	  Laboratory,	  Birmingham.	  A	  total	  of	  60	  metaphase	  spreads	  
each	   of	   P3	   and	   P5	   MSCs	   cultured	   in	   SM±GFs	   were	   analysed.	   The	   number	   of	   gross	  
chromosomal	  abnormalities	  (changes	   in	  the	  total	  number	  of	  chromosomes)	  was	  quantified	  
(Figure	  5.6A).	  Representative	  examples	  of	  PαS	  MSC	  karyograms	  can	  be	   seen	   in	  Figure	  5.7.	  
93%	   (56/60	   metaphase	   spreads)	   of	   PαS	   MSCs	   grown	   in	   SM	   at	   P3	   had	   a	   normal	   mouse	  
karyotype	  of	  40,	  XY.	  Data	  for	  P5	  cells	  in	  SM	  are	  still	  under	  analysis.	  PDGF-­‐supplemented	  PαS	  
MSCs	  had	  slightly	  higher	  numbers	  of	  karyotypically	  normal	  metaphase	  spreads	  at	  P3	  (95%;	  
57/60)	  and	  P5	  (92%;	  55/60).	  FGF-­‐supplemented	  cultures	  were	  100%	  normal	  at	  both	  P3	  and	  
P5	  for	  all	  60	  metaphase	  spreads	  analysed.	  By	  comparison,	  TGF-­‐β1	  supplemented	  PαS	  MSCs	  
had	   a	   slightly	   reduced	   number	   of	   karyotypically	   normal	   metaphase	   spreads	   at	   P3	   (85%;	  





51/60)	  compared	  to	  all	  other	  culture	  conditions.	  By	  P5,	   this	  percentage	  had	  dropped	  even	  
lower	  to	  reach	  61%	  (37/60).	  Interestingly,	  all	  samples	  with	  abnormal	  chromosomal	  numbers	  
were	  cases	  of	  tetraploidy	  (80,	  XXYY;	  Figure	  5.7D).	  Tetraploidy	  is	  frequently	  observed	  in	  non-­‐
neoplastic	   tissues	   (e.g.	   heart	   and	   liver)	   as	   part	   of	   terminal	   differentiation	   and	   it	   has	   been	  
estimated	   that	   tetraploid	   cells	   can	   be	   found	   at	   a	   frequency	   between	   0.5-­‐20%	   in	   humans	  
(Storchova	   and	   Kuffer,	   2008).	   Conversely,	   tetraploidisation	   is	   also	   part	   of	   the	   neoplastic	  
process	  as	  changes	  in	  chromosome	  number	  are	  a	  hallmark	  of	  cancer	  (Albertson	  et	  al.,	  2003).	  
Surprisingly,	   Shoshani	   et	   al.	   (2012)	   report	   that	   tetraploidisation	   acts	   as	   a	   protective	  
mechanism	   against	   tumourigenesis	   in	   murine	   MSC	   cultures,	   but	   it	   remains	   to	   be	   seen	  
whether	   this	   applies	   to	   PαS	   MSCs,	   particularly	   TGF-­‐β1	   supplemented	   cells.	   Importantly,	  
there	  was	  no	  cytogenetic	  evidence	  of	  neoplastic	  transformation	  in	  SM	  or	  GF-­‐supplemented	  
cultures	  at	  P3	  and	  P5,	   suggesting	   that	   these	  cells	   are	  more	  genetically	   stable	   than	  plastic-­‐
adherent	  murine	  MSCs.	  	  	  	  	  	  	  	  	  
	  
Chromosome	   breakage	   analysis	  was	   also	   performed	   to	   examine	  DNA	   damage	   events	   that	  
manifest	  as	  chromosome	  gaps	  or	  breaks	   in	  PαS	  MSCs	  (Figure	  5.7E).	  P3	  PαS	  MSCs	  grown	  in	  
SM	  were	  77%	  (46/60	  metaphase	  spreads)	  normal	  (Figure	  5.6B).	  The	  frequency	  of	  damaged	  
cells	  was	  lower	  in	  all	  GF-­‐supplemented	  groups	  at	  P3	  and	  P5	  compared	  to	  SM.	  Interestingly,	  
damaged	   cells	   in	   PDGF-­‐supplemented	   cultures	   exhibited	   quadriradial	   (QR)	   chromosome	  
formation	   at	   P3	   and	   P5	   (Figure	   5.7F).	   As	   these	   involved	   homologous	   chromosomes,	   QR	  
chromosome	  formation	  may	  be	  indicative	  of	  an	  elevated	  level	  of	  sister	  chromatid	  exchanges.	  
QR	   chromosomes	   are	   formed	   when	   chromatid	   breaks	   in	   two	   separate	   chromosomes	   are	  





misrepaired	  and	  joined	  together	  (Joenje	  and	  Patel,	  2001).	  The	  presence	  of	  QR	  chromosomes	  
is	  elevated	  in	  genetic	  instability	  diseases	  such	  as	  Bloom’s	  syndrome	  (Singh	  et	  al.,	  2010)	  and	  
Fanconi’s	  anaemia	  (Joenje	  and	  Patel,	  2001).	  Further	  studies	  are	  required	  to	  fully	  understand	  
why	  the	  presence	  of	  QR	  chromosomes	  is	  found	  PDGF-­‐supplemented	  cultures	  only.	  	  
	  
	  
Figure	  5.6	  |	  Quantification	  of	  chromosomal	  abnormalities	  in	  PαS	  MSCs.	  60	  metaphase	  spreads	  were	  analysed	  
per	  culture	  conditions	  at	  each	  time	  point.	  (A)	  The	  number	  of	  metaphase	  spreads	  containing	  the	  normal	  mouse	  
male	  karyogram	  of	  40,	  XY	  was	  quantified	  and	  expressed	  as	  a	  percentage.	  (B)	  The	  number	  of	  metaphase	  spreads	  
displaying	  structural	  abnormalities	  was	  quantified	  and	  expressed	  as	  a	  percentage.	  TBC,	  to	  be	  confirmed.	  	  	  	  
	  
	   	  






Figure	   5.7	   |	  Representative	   images	   of	   PαS	  MSC	   karyotype	   analysis.	   (A)	   Giemsa	   stained	  metaphase	   spread	  
from	  P3	  PDGF	  supplemented	  PαS	  MSCs.	  (B)	  Ordering	  of	  homologous	  chromosomes	  from	  a	  P3	  PDGF	  culture	  to	  
form	  a	  karyogram	  with	  a	  normal	  karyotype	  of	  40,	  XY.	  (C)	  Representative	  karyogram	  from	  P5	  FGF-­‐supplemented	  
cells	  with	  a	  normal	  karyotype	  of	  40,	  XY.	  (D)	  Image	  showing	  a	  tetraploid	  (80,	  XXYY)	  metaphase	  spread	  form	  a	  P5	  
TGF-­‐b	  supplemented	  cell.	   (E)	   Image	  showing	   locations	  of	  chromosome	  breaks	  and	  gaps	   (arrowheads)	   in	  a	  P5	  
PDGF-­‐supplemented	  cell.	   (F)	   Image	  showing	  quadriradial	  chromosome	  formation	  (arrowheads)	   in	  a	  P5	  PDGF-­‐
supplemented	  cell.	  	  	  	   	  





	   5.2.4	  Genomic	  Analysis	  of	  ‘Lineage	  Priming’	  	  
	   	   5.2.4.1	  Summary	  of	  Differentially-­‐expressed	  Genes	  
Delorme	   and	   colleagues	   identified	   that	   MSCs	   express	   a	   subset	   of	   genes	   related	   to	   the	  
osteogenic,	   adipogenic	   and	   chondrogenic	   lineages	   irrespective	   of	   any	   differentiation-­‐
inducing	   stimuli,	   suggesting	   that	   MSCs	   are	   naturally	   ‘primed’	   towards	   these	   lineages	  
(Delorme	  et	  al.,	  2009).	  The	  findings	  of	  Ng	  et	  al.	  (2008)	  demonstrate	  that	  the	  FGF,	  PDGF	  and	  
TGF-­‐β	   signalling	   pathways	   are	   active	   during	   human	   MSC	   differentiation	   down	   certain	  
lineages	   (Figure	   5.1).	  We	   hypothesised	   that	   the	   addition	   of	   their	   respective	   ligands	   could	  
prime	   PαS	   MSCs	   down	   a	   specific	   lineage	   while	   maintaining	   them	   in	   a	   proliferative,	  
undifferentiated	   state.	   Thus,	   when	   any	   differentiation	   inducing	   stimuli	   is	   introduced,	   PαS	  
MSCs	  would	  readily	  differentiate	  towards	  the	  lineage	  they	  have	  been	  ‘primed’	  towards.	  	  
	  
Whole-­‐genome	  murine	  microarrays	   were	   performed	   to	   examine	   whether	   lineage	   priming	  
occurred	   in	   PαS	   MSCs	   following	   culture	   in	   GF-­‐supplemented	   medium	   compared	   to	   SM	  
controls.	   RNA	   was	   isolated	   from	   undifferentiated,	   P1	   cultures	   (Table	   5.1)	   and	   hybridised	  
onto	   Affymetrix	   mouse	   genome	   arrays	   containing	   a	   total	   of	   21,156	   genes.	   Twelve	  
independent	  PαS	  MSC	  cultures	  from	  C57BL/6	  mice	  were	  used	  to	  isolate	  RNA	  samples.	  They	  
were	  then	  hybridised	  onto	  separate	  microarrays	  for	  analysis.	  RNA	  workup	  and	  hybridisation	  
was	  performed	  by	  the	  Affymetrix	  Array	  Service	  at	  the	  University	  of	  Birmingham.	  	  
	   	  





Table	  5.1	  |	  Properties	  of	  RNA	  samples	  used	  for	  whole-­‐genome	  microarray	  analysis.	  	  
Culture	  Condition	   Sample	   Total	  RNA	  (µg)	   OD260/280	   OD260/230	  
SM	  
1	   3.88	   2.11	   2.01	  
2	   2.27	   2.15	   1.71	  
3	   1.87	   2.22	   1.80	  
+FGF2	  
1	   4.49	   2.13	   2.12	  
2	   5.94	   2.11	   2.17	  
3	   4.77	   2.11	   2.26	  
+PDGF-­‐BB	  
1	   2.73	   2.09	   1.84	  
2	   5.03	   2.07	   2.13	  
3	   5.21	   2.09	   2.09	  
+TGF-­‐β1	  
1	   3.70	   2.09	   1.86	  
2	   11.64	   2.03	   2.17	  
3	   5.94	   2.10	   2.14	  
	  
	  
Scanned	  images	  of	  microarrays	  were	  analysed	  using	  Affymetrix	  software.	  Genes	  with	  a	  fold	  
change	   >1.0	   and	   P<0.001	   were	   classed	   as	   ‘significantly	   differentially	   expressed’	   in	  
accordance	  with	  Smyth	  (2004).	  In	  FGF-­‐supplemented	  PαS	  MSCs,	  14.5%	  (3060/21,156)	  genes	  
were	  differentially	   expressed	   compared	   to	   SM	  controls,	  with	   1567	   genes	  upregulated	   and	  
1493	  genes	  downregulated	  (Figure	  5.8).	  PDGF-­‐supplemented	  PαS	  had	  differential	  expression	  
in	  8.1%	  (1707/21,156)	  genes	  compared	  to	  SM	  controls,	  with	  748	  genes	  upregulated	  and	  959	  
downregulated.	   TGF-­‐β-­‐supplemented	   PαS	   MSCs	   also	   had	   differential	   expression	   in	   8.1%	  
(1711/21,156)	  genes	  compared	  to	  SM	  controls,	  with	  597	  genes	  upregulated	  and	  1114	  genes	  
downregulated.	  	  
	  






Figure	  5.8	  |	  Summary	   of	   up-­‐	   and	   down-­‐regulated	   genes	   in	  GF-­‐supplemented	   PαS	  MSCs.	  Genes	  with	  a	   fold	  
change	  of	  >1.5	  and	  a	  p-­‐value	  <0.001	  compared	  to	  SM	  cultures	  were	  quantified	  and	  expressed	  as	  a	  percentage.	  
The	  total	  number	  of	  differentially	  regulated	  genes	  can	  be	  found	  below	  the	  pie	  chart.	  	  
	  
Gene	   ontology	   analysis	   was	   performed	   to	   gain	   a	   better	   understanding	   of	   the	   biological	  
relevance	   of	   differentially	   regulated	   genes	   in	   PαS	   MSC	   cultures.	   The	   Gene	   Ontology	  
Consortium	   database	   (www.geneontology.org)	   was	   queried	   using	   the	   “PANTHER”	  
classification	   system	   (www.pantherdb.org)	   to	   produce	   a	   list	   of	   annotated	   biological	  
processes	  (Mi	  et	  al.,	  2013).	  The	  top	  five	  up	  and	  down-­‐regulated	  biological	  processes	  for	  each	  
culture	   condition	   can	   be	   found	   in	   Table	   5.2.	   Interestingly,	   we	   observed	   similar	   biological	  
processes	  (e.g.	  signal	  transduction,	  cell	  adhesion,	  cell	  communication)	  being	  upregulated	  in	  
all	   GF-­‐supplemented	   cultures	   compared	   to	   SM.	   Similarly,	   genes	   related	   to	   DNA	   and	   RNA	  
processing	   were	   downregulated	   in	   all	   GF-­‐supplemented	   cultures	   compared	   to	   SM.	  	  





Table	  5.2	  |	  PANTHER	  Gene	  Ontology	  Analysis.	  Top	  5	  upregulated	  and	  downregulated	  biological	  processes	  shown.	  
Sample	   Biological	  Process	  	  (Upregulated)	  
Differentially	  




expressed	  genes	  	   P	  value	  
FGF2	  	  
vs.	  SM	  
Signal	  transduction	   916	   1.71e-­‐27	   Response	  to	  pheromone	   3	   1.19e-­‐11	  
Cell	  communication	   946	   1.25e-­‐26	   RNA	  metabolic	  process	   43	   1.10e-­‐08	  
Cell	  adhesion	   356	   2.44e-­‐25	   mRNA	  processing	   23	   1.61e-­‐08	  
Immune	  system	  process	   605	   1.82e-­‐23	   Nucleoside,	  nucleotide	  and	  nucleic	  acid	  metabolic	  process	   444	   5.68e
-­‐08	  




Signal	  transduction	   607	   3.64e-­‐39	   Nucleoside,	  nucleotide	  and	  nucleic	  acid	  metabolic	  process	   224	   3.96e
-­‐09	  
Cell	  communication	   623	   7.37e-­‐38	   Translation	   10	   3.14e-­‐07	  
Cellular	  process	   758	   9.29e-­‐30	   RNA	  metabolic	  process	   21	   1.03e-­‐06	  
Immune	  system	  process	   399	   8.95e-­‐29	   mRNA	  processing	   11	   2.60e-­‐06	  




Cell	  communication	   624	   1.35e-­‐36	   Nucleoside,	  nucleotide	  and	  nucleic	  acid	  metabolic	  process	   226	   2.87e
-­‐09	  
Signal	  transduction	   603	   1.97e-­‐36	   RNA	  metabolic	  process	   19	   1.05e-­‐07	  
Immune	  system	  process	   402	   1.05e-­‐28	   mRNA	  processing	   12	   6.19e-­‐06	  
Cell	  adhesion	   236	   1.00e-­‐25	   DNA	  metabolic	  process	   17	   2.71e-­‐05	  
Cellular	  process	   738	   2.21e-­‐23	   Response	  to	  pheromone	   4	   2.77e-­‐05	  





	   	   5.2.4.2	  Selection	  of	  lineage	  specific	  genes	  
To	  examine	  whether	   ‘lineage	  priming’	  of	  PαS	  MSCs	  occurred,	   the	  expression	  of	   key	  genes	  
related	   to	   osteogenic,	   adipogenic	   and	   chondrogenic	   lineages	   were	   examined	   in	   GF-­‐
supplemented	   PαS	  MSCs	   prior	   to	   the	   induction	   of	   differentiation.	   Candidate	   genes	   for	   all	  
three	  lineages	  were	  prospectively	  chosen	  from	  previous	  literature	  (Delorme	  et	  al.,	  2009,	  Ng	  
et	   al.,	   2008,	   Gesta	   et	   al.,	   2007,	   Engler	   et	   al.,	   2006,	   Goldring	   et	   al.,	   2006,	   Komori,	   2006a).	  
Selected	  genes	  were	  then	  split	  into	  two	  groups	  to	  identify	  the	  master	  regulators	  that	  have	  a	  
fundamental	   role	   in	   the	  differentiation	  process	  and	  downstream	  effectors	   that	  have	  a	   less	  
crucial	  role	  in	  the	  pathway	  (Table	  5.3).	  	  
	  









Alpl,	   Atf4,	   Bgn,	   Bmp4,	   Bmp6,	   Bmp6,	   Bmpr1a,	   Cbfb,	   Cebpb,	  
Col1a1,	  Col1a2,	  Comp,	  Csf1,	  Dcn,	  Dkk2,	  Dlx5,	  Dlx6,	  Egr2,	  Esr1,	  
Ets1,	   Gata1,	   Gata2,	   Gata3,	   Ibsp,	   Igf1,	   Il18,	   Jun,	   Kitl,	   Lifr,	  
Men1,	  Msx1,	  Msx2,	  Ogn,	  Opg,	  Opn,	  Pthr1,	  Smad1,	  SP3,	  Thy1,	  




Adfp,	   Adipoq,	   Angptl4,	   Aoc3,	   Apoe,	   Apol6,	   Aqp7,	   CD24,	  	  
Col6a2,	   Cspg4,	   Dlk1,	   Fabp4,	   Fgf1,	   Fgf10,	   Fgf16,	   Fgf19,	   Flrt3,	  
Gata3,	  Gli3,	   Gpc4,	  Gpd1,	  Hoxa10,	  Hoxa5,	   Hoxc8,	   Hoxc9,	   Lpl,	  





Agc1,	   Bmp2,	   Bmp4,	   CDRAP,	   Cebpb,	   Col10a1,	   Comp,	   Ctnnb1,	  
Fgf10,	   Fgfr3,	   Gli3,	   Hapln1,	   HoxA,	   HoxD,	   Hoxd11,	   Hoxd13,	  
Mapk1,	   Mapk14,	   Mapk3,	   Mef2c,	   Nkx3.2,	   Plzf,	   Ptch1,	   Pthr1,	  
Rankl,	   Runx3,	   Smad1,	   Smad5,	   Smad8,	   Smo,	   Sox6,	   Tfap2a,	  
Wnt2,	  Wnt2c.	  
	   	  





	   	   5.2.4.3	  Expression	  of	  Osteogenic	  Candidate	  Genes	  
Raw	  expression	  values	  for	  osteogenic	  lineage	  genes	  were	  converted	  into	  heatmaps	  for	  visual	  
analysis	   (Figure	  5.9).	  Heatmap	  generation	  was	  performed	  by	  Dr	  Wenbin	  Wei,	  University	  of	  
Birmingham.	  Microarray	  analysis	  revealed	  that	  major	  transcripts	  of	  the	  osteogenic	  program	  
were	  highly	  expressed	   in	  undifferentiated	  PαS	  MSCs	  cultured	   in	  SM	   in	   the	  absence	  of	  any	  
differentiation-­‐inducing	   stimuli	   (Figure	   5.9A).	   This	   included	   the	   master	   regulators	   of	  
osteogenesis,	  Runx2	   and	   Sp7	   (Osterix).	   FGF	   and	   PDGF-­‐supplemented	   PαS	  MSCs	   expressed	  
significantly	   less	  Runx2	   (FGF	   1.31	   fold	   decrease,	   PDGF	   1.30	   fold	   decrease,	   p<0.01)	   and	   all	  
three	  GFs	  expressed	   less	  Sp7	   (FGF	  1.7	   fold	  decrease,	  PDGF	  1.68	   fold	  decrease,	  TGF-­‐β	  2.25	  
fold	  decrease,	  p<0.01)	  compared	  to	  control	  SM	  cells.	  This	  suggests	  that	  culture	  in	  SM	  primes	  
MSCs	   down	   the	   osteogenic	   lineage,	   and	   could	   explain	   why	   we	   saw	   increased	   bone	  
differentiation	  of	  PαS	  MSCs	  at	  later	  passages	  (Chapter	  4,	  Figure	  4.3).	  	  
	  
Further	   proof	   of	   osteogenic	   priming	   in	   SM	   cultures	   can	   be	   observed	  when	   examining	   the	  
expression	   of	   downstream	   effector	   genes.	   A	   large	   group	   of	   genes	   including	  Alpl	   (alkaline	  
phosphatase),	  Ogn	   (osteoglycin),	   Comp	   (cartilage	   oligomeric	   matrix	   protein),	   Bmp4	   (bone	  
morphogenetic	  protein	  4)	  and	  Dlx5	   (distal-­‐less	  homeobox	  5)	  were	  significantly	  upregulated	  
in	  SM	  cultures	  compared	   to	  GF-­‐supplemented	  PαS	  cells.	  However,	  not	  all	   candidate	  genes	  
were	   highly	   expressed	   by	   SM	   cells,	   as	   some	   may	   require	   osteogenic	   induction	   prior	   to	  
expression.	  Furthermore,	  they	  may	  also	  have	  other	  roles	  in	  maintaining	  cellular	  homeostasis	  
in	  addition	  to	  their	  roles	  during	  bone	  formation	  and	  maturation.	  	  
	  








Figure	  5.9	  |	  Microarray	  heatmap	  of	  lineage	  priming	  in	  PαS	  MSCs.	  RNA	  isolated	  from	  undifferentiated,	  P1	  PαS	  
MSCs	   grown	   in	   SM±GFs	   were	   hybridised	   onto	   separate	   Affymetrix	   whole	   genome	   microarrays	   (n=3	   per	  
condition).	  The	  expression	  of	  key	  (A)	  osteogenic,	  (B)	  adipogenic,	  and	  (C)	  chondrogenic	  genes	  were	  examined.	  
The	  mean	  expression	  value	  for	  each	  gene	  across	  all	  samples	  was	  set	  as	  0	  (black	  box).	  A	  relative	  fold	  decrease	  in	  
gene	   expression	   (compared	   to	   the	  mean)	   is	   represented	   by	   a	   green	   square,	   and	   a	   relative	   fold	   increase	   is	  
represented	  by	  a	  red	  square.	  	  
	   	  





	   	   5.2.4.4	  Expression	  of	  Adipogenic	  Candidate	  Genes	  
Analysis	   of	   adipogenic	   lineage	   genes	   revealed	   that	   key	   transcripts	   of	   this	   pathway	   were	  
highly	  expressed	   in	  undifferentiated	  FGF	  and	  PDGF-­‐supplemented	  PαS	  MSCs	   (Figure	  5.9B).	  
These	   included	  master	   regulators	  Cebpa	   (FGF	   2.55	   fold	   increase,	   PDGF	   1.70	   fold	   increase,	  
p<0.01)	  and	  Pparg	  (FGF	  4.53	  fold	  increase,	  PDGF	  2.97	  fold	  increase,	  p<0.0001),	  which	  were	  
highly	  significantly	  upregulated	  compared	  to	  SM	  cultures.	   In	  contrast,	  TGF-­‐β	  supplemented	  
PαS	  MSCs	  expressed	  Cebpa	   (3.33	   fold	  decrease,	  p<0.0001)	  and	  Pparg	   (3.24	   fold	  decrease,	  
p<0.0001)	   at	   much	   lower	   levels	   than	   SM	   cultures,	   suggesting	   that	   culture	   in	   TGF-­‐β	   may	  
inhibit	  the	  adipogenic	  differentiation	  of	  MSCs.	  	  
	  
Analysis	  of	  downstream	  effector	  genes	  provides	  further	  proof	  of	  adipogenic	  priming	  in	  FGF	  
and	   PDGF-­‐supplemented	   PαS	   MSC	   cultures.	   These	   include	   the	   homeobox	   genes	   Hoxc8,	  
Hoxc9	  and	  Hoxa10,	  which	  are	  all	  involved	  in	  the	  development	  of	  adipose	  tissue	  (Cantile	  et	  al.,	  
2003).	   Interestingly,	   a	   subset	  of	  mature	  adipocyte	  genes	   such	  as	  Adipoq	   (adiponectin),	  Lpl	  
(lipoprotein	   lipase),	  Plin1	   (perilipin	   1)	   and	  Apoe	   (apolipoprotein	   E)	   are	   further	   enriched	   in	  
FGF-­‐supplemented	  samples	  compared	  to	  PDGF-­‐supplemented	  cultures.	  We	  did	  not	  observe	  
any	  spontaneous	  differentiation	  towards	  fat	  in	  FGF-­‐supplemented	  cultures,	  and	  further	  work	  
is	   required	   to	   understand	   the	   significance	   of	   mature	   adipocyte	   gene	   expression	   in	  
undifferentiated	  PαS	  MSCs	  in	  the	  presence	  of	  FGF.	  	  Taken	  together,	  this	  data	  suggests	  that	  
PαS	  MSCs	   expanded	   in	   FGF-­‐	   and,	   to	   a	   lesser	   extent,	   PDGF-­‐containing	  medium	  are	  primed	  
towards	  the	  adipogenic	  lineage.	  	  
	  





	   	   5.2.4.5	  Expression	  of	  Chondrogenic	  Candidate	  Genes	  
Analysis	  of	  chondrogenic	  lineage	  genes	  revealed	  higher	  expression	  of	  key	  transcripts	  in	  FGF	  
and	   PDGF-­‐supplemented	   PαS	   MSCs	   (Figure	   5.9C).	   Undifferentiated	   FGF	   and	   PDGF-­‐
supplemented	   cultures	  had	  higher	  expression	  of	   the	  master	   regulators	  of	   chondrogenesis,	  
Sox9	   (FGF	   1.42	   fold	   increase,	   PDGF	   1.38	   fold	   increase,	   p<0.05)	   and	   Sox5	   (FGF	   4.56	   fold	  
increase,	   PDGF	  3.28	   fold	   increase,	   p<0.0001),	   compared	   to	  un-­‐supplemented	   SM	  cultures.	  
They	   also	   had	   significantly	   upregulated	   expression	   of	   downstream	   effectors	   including	  
Hoxa11,	  Hoxa7,	  Bmp2	  and	  Hapln1	  (hyaluronan	  and	  proteoglycan	  link	  protein	  1)	  compared	  to	  
SM	  cultures,	  suggesting	  potential	  priming	  towards	  the	  chondrogenic	  lineage.	  	  	  
	  
Analysis	   of	   other	   downstream	   effector	   genes	   gave	   mixed	   results,	   with	   different	   culture	  
conditions	   highly	   expressing	   different	   clusters	   of	   chondrogenic	   genes.	   For	   example,	   PαS	  
MSCs	   cultured	   in	   SM	   expressed	   high	   levels	   of	  Hoxa13	   and	  Nkx3-­‐2	   compared	   to	   all	   other	  
samples,	  but	  had	  low	  expression	  of	  master	  regulators	  Sox9	  and	  Sox5.	  TGF-­‐β	  supplemented	  
cultures	  also	  expressed	  low	  levels	  of	  Sox9	  and	  Sox5,	  but	  had	  high	  expression	  of	  chondrocyte	  
maturation	  genes	  Hoxd11,	  Hoxd13	  and	  Runx3	  (Soung	  do	  et	  al.,	  2007).	  These	  mixed	  findings	  
suggest	  that	  it	  is	  relatively	  more	  difficult	  to	  prime	  MSCs	  down	  the	  chondrogenic	  lineage,	  and	  
this	   could	  be	  one	   reason	  behind	  why	  differentiating	  MSCs	  down	  the	  chondrogenic	   lineage	  
has	   always	   been	  more	   technically	   demanding	   than	   the	   osteogenic	   or	   adipogenic	   lineages	  
(Vinatier	  et	  al.,	  2009).	  	  
	   	  





	   5.2.5	  Phenotypic	  Analysis	  of	  ‘Lineage	  Priming’	  
	   	   5.2.5.1	  Effect	  of	  GFs	  on	  Osteogenic	  Differentiation	  
Genomic	   analysis	   of	   lineage-­‐specific	   genes	   revealed	   that	   culture	   conditions	   could	   have	   a	  
profound	  effect	  on	  MSC	  gene	  expression.	  PαS	  MSCs	  grown	   in	  SM	  highly	  expressed	  master	  
regulators	   of	   osteogenic	   differentiation	   compared	   to	  GF-­‐supplemented	   cells	   (Figure	   5.10).	  
FGF	  and	  PDGF-­‐supplemented	  PαS	  MSCs	  expressed	   significantly	  higher	   levels	  of	   adipogenic	  
and	   chondrogenic	   master	   regulators	   compared	   to	   SM	   and	   TGF-­‐β	   supplemented	   cultures.	  
Interestingly,	   TGF-­‐β	   supplemented	   PαS	  MSCs	   did	   not	   display	   evidence	   of	   priming	   towards	  
any	  lineage,	  suggesting	  that	  addition	  of	  TGF-­‐β	  may	  inhibit	  their	  differentiation.	  	  	  	  	  
	  
	  
Figure	  5.10	  |	  Summary	  of	  microarray	  analysis	  of	  lineage	  priming	  in	  PαS	  MSCs.	  Undifferentiated,	  P1	  PαS	  MSCs	  
expressed	   more	   osteogenic	   transcripts	   when	   grown	   in	   SM.	   FGF2	   and,	   to	   a	   lesser	   extent,	   PDGF-­‐BB	  
supplemented	   cells	   expressed	   more	   adipogenic	   genes.	   Master	   regulators	   of	   chondrogenesis	   were	   equally	  
upregulated	  in	  FGF2	  or	  PDGF-­‐BB	  supplemented	  cells.	  	  	  
	  
	  
	   	  





To	  test	  our	  hypothesis	  of	  lineage	  priming	  and	  to	  provide	  phenotypic	  evidence	  to	  back	  up	  our	  
microarray	  data,	  PαS	  MSCs	  were	  grown	  ±	  GFs	  and	  induced	  to	  differentiate	  towards	  bone,	  fat	  
and	   cartilage.	   GF	   treatment	   was	   stopped	   and	   cells	   were	   thoroughly	   washed	   before	  
differentiation	   to	  ensure	  any	   changes	  between	  groups	  were	  due	   to	   the	   ‘priming’	  effect	  of	  
GFs	  during	  the	  PαS	  MSC	  expansion	  stage	  only	  (Methods	  Figure	  2.1).	  	  
	  
Osteogenic	  differentiation	  was	   induced	  for	  16	  days	  before	  being	  stained	  using	  alizarin	  red.	  
Visual	  inspection	  showed	  reduced	  alizarin	  red	  staining	  in	  GF-­‐primed	  MSCs	  compared	  to	  SM	  
(Figure	   5.11).	   In	   particular,	   TGF-­‐β1	   primed	  MSCs	   had	   substantially	   less	   calcium	  deposition	  
compared	   to	   all	   other	   culture	   conditions.	   After	   imaging,	   the	   dye	   was	   extracted	   from	   the	  
stained	  monolayer	  and	  quantified	  against	  known	  calcium	  standards	  (Figure	  5.12).	  PαS	  MSCs	  
expanded	  in	  SM	  produced	  significantly	  more	  calcium	  than	  GF-­‐supplemented	  cultures	  at	  P0,	  
P1,	  P3,	  P4	  and	  P5,	  with	  the	  mean	  difference	  increasing	  at	  later	  passages.	  Interestingly,	  there	  
seems	  to	  be	  an	  overall	  trend	  for	  increased	  osteogenic	  differentiation	  at	  later	  passages	  across	  
all	   culture	   conditions,	   which	   suggests	   that	   extended	   culture	   on	   plastic	   is	   an	   independent	  
promoter	  of	  bone	  differentiation.	  	  
	  
These	  findings	  strongly	  support	  the	  concept	  of	  osteogenic	  lineage	  priming	  in	  PαS	  MSCs.	  Our	  
microarray	   data	   showed	   increased	   expression	   of	   key	   osteogenic	   transcripts	   in	  
undifferentiated	  MSCs	   grown	   in	   SM.	  When	   induced	   to	   undergo	   differentiation,	   PαS	  MSCs	  
expanded	   in	   SM	   readily	   underwent	   osteogenic	   differentiation	   and	   produced	   significantly	  
more	  calcium	  than	  their	  GF-­‐supplemented	  counterparts.	  	   	  








Figure	  5.11	  |	  Osteogenic	  priming	  of	  PαS	  MSCs	  expanded	  in	  SM.	  Representative	  images	  of	  alizarin	  red	  staining	  
of	   PαS	  MSCs	   grown	   in	   SM±GFs	   at	   different	   passage	   numbers	   (n≥4	   technical	   repeats	   per	   condition	   at	   each	  
passage).	  All	  images	  taken	  at	  100x	  magnification.	  Bar,	  25µm.	  	  
	  
	  




	   	  
	  
Figure	  5.12	  |	  Quantification	  of	  calcium	  in	  PαS	  MSC	  osteogenic	  differentiation	  cultures.	  Alizarin	  red	  dye	  was	  removed	  from	  all	  samples	  after	  imaging	  and	  quantified	  
against	  known	  calcium	  standards.	  Data	  shown	  as	  mean±SD,	  n≥4	  technical	  repeats	  per	  culture	  condition	  at	  each	  passage	  number.	  Statistical	  analysis	  performed	  using	  
Two-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  	  	  





	   	   5.2.5.2	  Effect	  of	  GFs	  on	  Adipogenic	  Differentiation	  
Microarray	   analysis	   revealed	   that	  undifferentiated	  PαS	  MSCs	  expanded	   in	   FGF-­‐2	   and,	   to	   a	  
lesser	  extent,	  PDGF-­‐BB	  supplemented	  medium	  had	  significantly	  higher	  expression	  of	  master	  
regulators	   and	   downstream	   effectors	   of	   adipogenesis.	   To	   test	   priming	   towards	   the	  
adipogenic	   lineage,	   fat	   differentiation	  was	   induced	   in	   one	   cycle	   of	   commercially	   available	  
‘induction’	   and	   ‘maintenance’	   differentiation	   medium.	   This	   was	   shorter	   than	   the	  
manufacturer’s	   recommendation	   of	   three	   cycles	   as	   the	   addition	   of	   GFs	   had	   a	   profound	  
impact	  on	  fat	  formation	  and	  cultures	  were	  undergoing	  necrosis	  due	  to	  excessive	  lipid	  droplet	  
formation.	  After	  differentiation,	  cultures	  were	  fixed	  and	  stained	  using	  oil	  red	  O.	  	  
	  
As	   was	   observed	   earlier,	   PαS	   MSCs	   expanded	   in	   SM	   underwent	   sporadic	   adipogenic	  
differentiation	  at	  earlier	  passages,	  but	   this	   ability	  was	   lost	   from	  P3	  onwards	   (Figure	  5.13).	  
However,	   the	   addition	   of	   FGF	   or	   PDGF	   profoundly	   increased	   the	   number	   of	   adipocytes	  
formed,	  and	  this	  ability	  was	  maintained	  until	  P5.	  FGF	  supplementation	  in	  particular	  caused	  
almost	   100%	   differentiation	   into	   adipocytes	   at	   earlier	   passages.	   By	   comparison,	   TGF-­‐β1	  
supplemented	  PαS	  MSCs	  again	  failed	  to	  undergo	  differentiation	  across	  all	  passages	  tested.	  	  
	  
These	   findings	   demonstrate	   that	   FGF	   and	   PDGF	   supplementation	   were	   able	   to	   strongly	  
induce	   and	   maintain	   adipogenic	   potential	   over	   several	   passages,	   even	   with	   a	   shortened	  
protocol.	   Taken	   together	   with	   the	   gene	   expression	   data	   from	   the	   microarray,	   this	  
differentiation	  data	  strongly	  supports	  the	  idea	  of	  adipogenic	  lineage	  priming	  in	  PαS	  MSCs.	  








Figure	   5.13	   |	   Adipogenic	   priming	   of	   PαS	   MSCs	   expanded	   in	   FGF	   or	   PDGF-­‐supplemented	   medium.	  
Representative	  images	  of	  oil	  red	  O	  stained	  cultures	  showing	  lipid	  droplet	  formation	  in	  MSC	  cultures	  at	  different	  
passage	   numbers	   (n≥3	   technical	   repeats	   per	   condition	   at	   each	   passage).	   Samples	  were	   counterstained	  with	  
haematoxylin	  to	  identify	  undifferentiated	  MSCs.	  Images	  taken	  at	  100x	  magnification.	  Bar,	  25µm.	  	  
	   	  





	   	   5.2.5.3	  Effect	  of	  GFs	  on	  Chondrogenic	  Differentiation	  
Genomic	  analysis	  of	  chondrogenic	  priming	  was	  less	  clear	  than	  the	  other	  two	  lineages,	  with	  
different	   culture	   conditions	   highly	   expressing	   different	   clusters	   of	   genes.	   However,	   the	  
master	  regulators	  Sox9	  and	  Sox5	  were	  significantly	  upregulated	  in	  undifferentiated	  FGF	  and	  
PDGF-­‐supplemented	  PαS	  MSCs.	  To	  examine	  the	  effect	  of	  GFs	  on	  chondrogenesis,	  micromass	  
pellet	  systems	  were	  used	  in	  collaboration	  with	  the	  Hollander	  group	  at	  Bristol	  University.	  	  
	  
Fixed	   numbers	   (5x105	   MSCs/pellet)	   of	   P5	   PαS	   MSCs	   expanded	   in	   SM±GFs	   underwent	  
differentiation	   to	   form	  cartilage-­‐like	  pellets.	   Significant	   increases	   in	  pellet	  weight	   could	  be	  
observed	  in	  MSCs	  expanded	  in	  FGF	  or	  PDGF-­‐containing	  medium	  compared	  to	  SM	  or	  TGF-­‐β	  
supplemented	  cells	   (Figure	  5.14A).	  TGF-­‐β	  primed	  MSCs	  made	  the	  smallest	  cartilage	  pellets	  
by	  weight.	   Examination	  of	   total	  Col1	   content,	   a	  marker	  of	   immature	   chondrocytes,	   in	  PαS	  
MSC-­‐derived	  cartilage	  pellets	   failed	  to	  show	  significant	  differences	  between	  groups	  (Figure	  
5.14B).	  Similarly,	  total	  levels	  of	  Col2,	  a	  marker	  of	  mature,	  healthy	  chondrocytes	  was	  similar	  
between	   SM,	   FGF,	   and	  PDGF-­‐supplemented	  MSCs	   (Figure	  5.14C).	   TGF-­‐β	  primed	  MSCs	  had	  
the	   lowest	  Col2	  content,	  but	  stopped	  short	  of	  reaching	  statistical	  significance.	  Examination	  
of	   Col2:Col1	   ratio,	   a	   marker	   of	   overall	   cartilage	   quality,	   showed	   similar	   readings	   in	   SM	  
cultures	   compared	   to	   FGF	   and	   PDGF	   primed	  MSCs,	   but	   reached	   significance	   compared	   to	  
TGF-­‐β1	  supplemented	  cells	  (Figure	  5.14D).	  Analysis	  of	  GAG	  content	  showed	  FGF-­‐primed	  cells	  
produced	  the	  largest	  proteoglycan	  deposits	  across	  all	  four	  culture	  conditions,	  although	  this	  
only	  reached	  statistical	  significance	  compared	  to	  TGF-­‐β	  primed	  cells	  (Figure	  5.14E).	  	  	  
	   	  






Figure	  5.14	  |	  Effect	  of	  GFs	  on	  chondrogenic	  differentiation	  of	  PαS	  MSCs.	  5x105	  PαS	  MSCs	  expanded	  in	  SM±GFs	  
at	   P5	  were	   induced	   to	  undergo	   chondrogenic	   differentiation	   in	  micromass	  pellet	   cultures.	   (A)	   The	  weight	  of	  
MSC-­‐derived	   cartilage	   pellets	   were	   recorded	   after	   freeze	   drying.	   (B)	   Total	   amount	   of	   type	   I	   and	   (C)	   type	   II	  
collagen	   in	   MSC-­‐derived	   cartilage	   pellets.	   (D)	   Ratio	   of	   Col2:Col1	   as	   a	   marker	   of	   cartilage	   quality.	   (E)	   Total	  
amount	  of	  GAGs	  present	  in	  MSC-­‐derived	  cartilage	  pellets.	  Data	  shown	  as	  mean±SD,	  n≥3	  independent	  samples	  
per	  culture	  condition.	  Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Correction.	  	  	  
	  
The	  lack	  of	  major	  differences	  between	  groups	  suggests	  that	  it	  is	  difficult	  to	  prime	  PαS	  MSCs	  
down	   the	   chondrogenic	   lineage.	   In	   summary,	   MSCs	   expanded	   in	   TGF-­‐β1	   supplemented	  
medium	   made	   the	   smallest	   pellets	   with	   a	   low	   Col2:Col1	   ratio	   and	   GAG	   content.	   SM-­‐
expanded	  cells	  made	  cartilage	  pellets	  of	  similar	  quality	  to	  FGF	  and	  PDGF-­‐supplemented	  cells,	  
but	  their	  cartilage	  pellets	  were	  significantly	  smaller	  in	  size.	  MSCs	  expanded	  in	  FGF	  or	  PDGF-­‐
supplemented	   medium	  made	   pellets	   of	   equal	   size	   and	   collagen	   content,	   but	   FGF-­‐primed	  
MSCs	  had	  a	  greater	  GAG	  content.	   	  





	   	   	   5.2.5.3.1	  Tissue	  Engineered	  Cartilage	  from	  PαS	  MSCs	  
Injection	  of	  MSC-­‐derived	   chondrocytes	   in	   suspension	   is	   feasible	   for	   the	   treatment	  of	   focal	  
lesions,	  however,	  the	  treatment	  of	   larger	   injuries	  would	  necessitate	  the	  use	  of	  scaffolds	  to	  
retain	  cells	  at	  the	  injury	  site	  for	  extended	  periods	  of	  time	  (Zhang	  et	  al.,	  2009).	  Immobilisation	  
of	  MSCs	  on	  biodegradable	   scaffolds	  would	  ensure	   that	   cells	   are	   retained	  by	   the	  host	   long	  
enough	  to	  produce	  enough	  ECM	  that	  bridges	  large,	  unconfined	  lesions.	  Additionally,	  the	  size	  
of	  MSC-­‐derived	   cartilage	   pellets	  made	   using	  micromass	   pellet	   cultures	   are	   suitable	   for	   in	  
vitro	   studies,	   but	   are	   too	   small	   to	   be	   of	   practical	   value	   in	   animal	  models.	   To	   address	   this	  
issue,	   cartilage	   tissue	   engineering	   experiments	   using	   PαS	   MSCs	   seeded	   onto	   fibronectin-­‐
coated	  biodegradable	  PGA	  scaffolds	  was	  performed	  as	  described	  by	  Kafienah	  et	  al.	   (2007).	  	  
FGF-­‐supplemented	   PαS	   MSCs	   were	   chosen	   for	   analysis	   as	   they	   had	   the	   greatest	   growth	  
potential	   (Figure	  5.4)	   and	  demonstrated	   robust	   chondrogenic	  differentiation	   in	  micromass	  
pellet	  cultures	  (Figure	  5.14).	  SM-­‐expanded	  cells	  were	  used	  as	  controls.	  	  
	  
Fixed	   numbers	   (6x105	   cells)	   of	   PαS	  MSCs	   at	   P7	   were	   used	   for	   tissue	   engineering	   studies.	  
Seeded	   scaffolds	   were	   incubated	   in	   chondrogenic	   differentiation	   media	   on	   a	   rotating	  
platform	  for	  35	  days	  during	  which	  the	  scaffold	  would	  dissolve,	   leaving	  behind	  MSC-­‐derived	  
ECM	  proteins.	  Macroscopic	  analysis	  after	  35	  days	  revealed	  the	  formation	  of	  shiny	  pink/white	  
tissue	  that	  resembled	  hyaline	  cartilage	  (Figure	  5.15A).	  Clear	  differences	  in	  size	  between	  SM-­‐
primed	   MSCs	   and	   FGF-­‐primed	   MSCs	   could	   be	   seen.	   Samples	   were	   then	   freeze-­‐dried,	  
weighed,	  and	  digested	  in	  trypsin	  to	  solubilise	  ECM	  proteins	  prior	  to	  analysis.	  As	  suggested	  by	  
its	  macroscopic	  appearance,	  significant	  increases	  in	  dry	  weight	  were	  observed	  between	  SM	  





and	   FGF-­‐primed	   MSC	   samples	   (0.2±0.1mg	   vs.	   1.0±0.4mg,	   p=0.002;	   Figure	   5.15B).	   No	  
significant	  differences	  were	  observed	  in	  the	  collagen	  content	  of	  tissue-­‐engineered	  cartilage,	  
although	   FGF-­‐primed	   cells	   had	  a	  higher	  Col2:Col1	   ratio	   than	   SM	  cells	   (0.8±0.3	   vs.	   5.4±7.0;	  
p=0.1;	  Figure	  5.15C-­‐E).	  Finally,	  the	  proteoglycan	  content	  of	  FGF-­‐primed	  cells	  was	  significantly	  
higher	  than	  SM	  cultures	  (1.1±1.1µg	  vs.	  9.3±2.7µg,	  p<0.0001;	  Figure	  5.15F).	  	  
	  
These	  studies	  demonstrate	  the	  value	  of	  PαS	  cells	  as	  a	  model	  MSC	  population	  for	  pre-­‐clinical	  
studies	  on	  cartilage	  repair.	  Compared	  to	  micromass	  pellet	  cultures	  (Figure	  5.14),	  FGF-­‐primed	  
MSC	  tissue	  engineered	  cartilage	  was	  up	  to	  4-­‐fold	  heavier	  in	  size	  and	  had	  a	  2-­‐fold	  increase	  in	  
collagen	   and	   proteoglycan	   content.	   These	   improvements	   were	   achieved	   with	   a	   small	  
increase	   in	  MSC	  number,	   from	  5x105	  cells	  per	  micromass	  pellet	  to	  6x105	  cells	  per	  scaffold.	  
Murine	   PαS	   MSC-­‐derived	   cartilage	   can	   be	   tested	   in	   transgenic	   mouse	   models	   to	   fully	  
understand	   and	   optimise	   conditions	   that	   promote	   optimal	   repair	   using	  MSCs	   (Chu	   et	   al.,	  
2010).	  These	  findings	  could	  then	  be	  translated	  to	  produce	  novel	  tissue	  engineered	  cartilage	  
therapies	  that	  improve	  on	  current	  methods	  used	  in	  human	  clinical	  trials	  (Delaere,	  2013).	  	  
	   	  






Figure	   5.15	   |	   Tissue	   engineered	   cartilage	   using	   PαS	  MSCs.	   Biodegradable	   PGA	   scaffolds	   were	   seeded	  with	  
6x105	   PαS	  MSCs	   expanded	   in	   SM±FGF2	   at	   P7.	   (A)	  Macroscopic	   analysis	   of	   tissue	   engineered	   scaffolds	   after	  
differentiation.	  Bar,	   1cm.	   (B)	   The	  weight	  of	   tissue	  engineered	   cartilage	  was	   recorded	  after	   freeze	  drying.	   (C)	  
Total	  amount	  of	  type	  I	  and	  (D)	  type	  II	  collagen	  in	  tissue	  engineered	  cartilage.	  (E)	  Ratio	  of	  Col2:Col1	  as	  a	  marker	  
of	  cartilage	  quality.	  (F)	  Total	  amount	  of	  GAGs	  present	  in	  tissue	  engineered	  cartilage.	  Data	  shown	  as	  mean±SD,	  
n=5	  for	  SM	  and	  n=8	  for	  FGF2	  samples.	  Statistical	  analysis	  performed	  using	  unpaired	  Student’s	  T	  test.	  	   	  





	   5.2.6	  Mechanism	  of	  GF	  Action	  
	   	   5.2.6.1	  Adipogenic	  priming	  by	  FGF2	  
Preliminary	  analysis	  of	  the	  signalling	  pathways	  involved	  in	  GF	  priming	  was	  performed	  using	  
small	  molecule	  inhibitors.	  The	  FGF	  family	  contains	  22	  different	  FGF	  ligands	  which	  bind	  to	  4	  
receptor	  tyrosine	  kinases	  (Ornitz	  and	  Itoh,	  2001).	  The	  downstream	  signalling	  pathway	  after	  
receptor	   dimerisation	   and	   activation	   are	   complex	   and	   involve	   recruitment	   of	   intracellular	  
signalling	  proteins	  to	  the	  activated	  receptor	  complex	  (summarised	  in	  Figure	  5.16).	  Activation	  
of	   the	   receptor	   can	   lead	   to	   the	   activation	   of	   Src	   family	   kinases	   and	   further	   downstream	  
signalling	   events	   (Cunningham	   et	   al.,	   2010).	   It	   can	   also	   lead	   to	   phosphorylation	   of	   the	  
receptor	   associated	   docking	   protein	   Frs2.	   Frs2	   can	   in	   turn	   recruit	   further	   downstream	  
effectors,	   the	   two	   most	   prominent	   being	   the	   recruitment	   of	   Gab1	   and	   activation	   of	   Akt	  
kinase,	  or	  the	  recruitment	  of	  Grb2	  and	  activation	  of	  Erk	  kinase	  (Eswarakumar	  et	  al.,	  2005).	  	  	  
	  
Figure	  5.16	   |	  FGF	   signalling	   pathway.	   Cartoon	   summarising	   the	   signalling	  pathways	  downstream	  of	   the	   FGF	  
receptor	  and	  the	  proteins	  inhibited	  by	  the	  small	  molecule	  compounds	  used	  in	  this	  study.	  	  	  





Previously	   reported	   small	   molecule	   inhibitors	   of	   FGF	   signalling	   proteins	   were	   used	   to	  
elucidate	  the	  downstream	  signalling	  pathways	  responsible	  for	  the	  adipogenic	  priming	  seen	  
with	   FGF	   supplementation.	   The	  Src-­‐family	   kinase	  pathway	  was	   inhibited	  using	  dasatinib,	   a	  
compound	   currently	   used	   as	   a	   treatment	   for	   chronic	   myeloid	   leukaemia	   and	   under	  
investigation	  for	  various	  other	  cancers	  (Montero	  et	  al.,	  2011,	  Buettner	  et	  al.,	  2008,	  Nam	  et	  
al.,	   2005).	   The	   Frs2-­‐dependent	   activation	   of	   Akt	   or	   Erk	   family	   kinases	  was	   inhibited	   using	  
SU5402,	   a	   FGF	   receptor	   tyrosine	   kinase	   blocker	   (Vallier	   et	   al.,	   2005,	   Gotoh	   et	   al.,	   2004,	  
Mohammadi	  et	  al.,	  1997).	  	  	  
	  
Freshly-­‐isolated	  PαS	  MSCs	  were	  expanded	  in	  FGF-­‐supplemented	  medium	  alongside	  dasatinib	  
or	  SU5402.	  MSC	  cultures	  were	  thoroughly	  washed	  and	  both	  FGF	  and	  inhibitor	  treatment	  was	  
stopped	  before	  adipogenic	  differentiation	  was	  induced.	  Visual	  inspection	  of	  oil	  red	  O	  stained	  
cultures	   revealed	   potent	   inhibition	   of	   fat	   differentiation	   in	   PαS	   MSCs	   that	   had	   been	  
expanded	  in	  FGF2+SU5402	  (Figure	  5.17A).	  Quantification	  of	  the	  total	  oil	  red	  O	  positive	  area	  
using	   Image	   J	   backed	   up	   this	   finding,	   with	   significant	   reductions	   in	   the	   SU5402	   samples	  
compared	  to	  all	  other	  groups	  at	  each	  passage	  tested	  (Figure	  5.17B).	  Significant	  drops	  were	  
also	  observed	  in	  fat	  differentiation	  following	  dasatinib	  treatment	  at	  P0	  and	  P2.	  These	  results	  
indicate	   that	   the	   adipogenic	   priming	   seen	   with	   FGF	   treatment	   is	   primarily	   mediated	  
downstream	  of	   the	   receptor	  docking	  protein	  Frs2	  and	  may	   involve	   the	  Akt	  or	  Erk	   kinases.	  
However,	   Src	   kinase	   could	   also	   have	   a	   minor	   role	   to	   play	   as	   we	   did	   see	   drops	   in	   fat	  
differentiation	  when	  cultures	  were	  expanded	  in	  medium	  containing	  dasatinib.	  	  	  	  	  
	   	  






Figure	  5.17	  |	  Signalling	  pathway	  behind	  FGF2-­‐mediated	  adipogenic	  priming.	  Freshly	  isolated	  PαS	  MSCs	  were	  
expanded	  in	  the	  presence	  of	  FGF2,	  FGF2+Dasatanib	  or	  FGF2+SU5402.	  Expanded	  cells	  were	  induced	  to	  undergo	  
adipogenic	  differentiation	  whereupon	  GF	  and	  inhibitor	  treatment	  was	  halted.	  (A)	  Representative	  images	  of	  oil	  
red	  O	  stained	  cultures.	  Images	  taken	  at	  100x	  magnification.	  Bar,	  20µm.	  (B)	  Quantification	  of	  total	  percentage	  
area	  oil	   red	  O	  positive	   using	   Image	   J.	  Data	   represented	   as	  mean±SD,	   n=3	   technical	   repeats	   per	   condition	   at	  
each	  passage.	  Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  	  





	   	   5.2.6.2	  Adipogenic	  priming	  by	  PDGF-­‐BB	  
The	   PDGF	   ligand	   family	   consists	   of	   four	   members	   that	   form	   homo-­‐	   or	   heterodimers	   to	  
become	  active	  (Betsholtz,	  2004).	  So	  far,	  five	  isoforms	  have	  been	  recorded:	  PDGF-­‐AA,	  PDGF-­‐
AB,	   PDGF-­‐BB,	   PDGF-­‐CC,	   and	   PDGF-­‐DD.	   Binding	   of	   these	   ligands	   to	   PDGF	   tyrosine	   kinase	  
receptors	  causes	  receptor	  dimerisation	  and	  activation	  of	  downstream	  pathways	  (Andrae	  et	  
al.,	   2008).	   PDGF-­‐BB	   (the	   ligand	   used	   in	   this	   study)	   binds	   to	   all	   receptor	   isoforms,	   and	   is	  
therefore	   used	   as	   a	   promiscuous	   activator	   of	   PDGF	   signalling	   (Figure	   5.18).	   PDGF-­‐AA	   is	  
selective	  for	  PDGFRα	  only	  (Fredriksson	  et	  al.,	  2004).	  	  
	  
	  
Figure	  5.18	  |	  PDGF	  receptor	  signalling.	  PDGF-­‐BB	  can	  signal	  through	  all	  three	  receptor	  combinations,	  making	  it	  
a	  promiscuous	  activator	  of	  the	  PDGF	  signalling	  pathway.	   In	  contrast,	  PDGF-­‐AA	  signals	  exclusively	  through	  the	  
PDGFRα	  homodimer.	  Figure	  modified	  from	  Fredriksson	  et	  al.	  (2004).	  	  
	   	  





The	   selectivity	   of	   PDGF	   ligands	   for	   specific	   receptor	   combinations	   has	   been	   exploited	   in	  
previous	   studies	   of	   PDGFR	   signalling	   (Ball	   et	   al.,	   2007,	   Cao	   et	   al.,	   2002,	   Lemström	   and	  
Koskinen,	   1997).	   We	   adopted	   the	   same	   procedure	   to	   identify	   which	   PDGF	   receptor	   was	  
responsible	   for	   priming	   PαS	  MSCs	   down	   the	   adipogenic	   lineage	   in	   the	   presence	   of	   PDGF.	  
Freshly-­‐isolated	   PαS	  MSCs	   were	   expanded	   in	   SM	   containing	   either	   PDGF-­‐BB	   or	   PDGF-­‐AA.	  
Adipogenic	   differentiation	   was	   then	   induced	   and	   GF	   treatment	   stopped.	   As	   shown	  
previously,	   PαS	   MSCs	   expanded	   in	   PDGF-­‐BB	   readily	   differentiated	   down	   the	   adipogenic	  
lineage	  across	  all	  passages	  tested	  (Figure	  5.19).	  However,	  PαS	  MSCs	  expanded	   in	  PDGF-­‐AA	  
underwent	  sporadic	  adipogenic	  differentiation	  that	  diminished	  by	  P3.	  This	   is	   similar	   to	   the	  
fat	  differentiation	   seen	  when	  PαS	  MSCs	  were	  expanded	   in	   SM	  alone	   (Figure	  5.13).	   	   These	  
results	   suggest	   that	   adipogenic	   priming	   seen	   using	   PDGF	   is	   not	   exclusively	   mediated	  
downstream	  of	  PDGFRα,	  as	  PDGF-­‐AA	  was	  not	  able	   to	   recreate	   the	  same	  effects	   that	  were	  















Figure	  5.19	  |	  Receptor	  complex	  behind	  PDGF-­‐mediated	  adipogenic	  priming.	  Representative	  images	  of	  oil	  red	  
O	  stained	  adipogenic	  differentiation	  of	  PαS	  MSCs	  expanded	  in	  SM	  containing	  PDGF-­‐AA	  (n=3)	  or	  PDGF-­‐BB	  (n=3).	  
Samples	  were	  counterstained	  with	  haematoxylin	  prior	  to	  imaging.	  All	  images	  were	  taken	  at	  100x	  magnification.	  
Bar,	  25µm.	  In	  all	  experiments,	  n	  is	  indicative	  of	  technical	  repeats	  using	  the	  same	  culture	  of	  PαS	  MSCs.	  	  	  	  	  	  	  	  	  	  	  





	   5.2.7	  Effect	  of	  GFs	  on	  Immunosuppression	  
There	   is	   currently	   very	   little	   literature	   on	   the	   effect	   of	   MSC	   culture	   conditions	   on	   their	  
immunosuppressive	   phenotype.	   We	   first	   examined	   the	   expression	   of	   previously	   reported	  
immunosuppressive	   genes	   from	   the	   microarray	   but	   failed	   to	   identify	   any	   clear	   patterns	  
between	   groups	   (Figure	   5.20).	   This	   was	   because	   PαS	   MSCs	   were	   not	   exposed	   to	  
inflammatory	   conditions	   prior	   to	   RNA	   isolation	   for	   the	   microarray,	   hence	   their	  
immunomodulatory	  functions	  were	  ‘switched	  off’	  (Ryan	  et	  al.,	  2007,	  Krampera	  et	  al.,	  2006).	  	  
	  
We	   then	  performed	  CD4+	  T	   cell	   suppression	  assays	   to	   identify	  whether	  GF-­‐treated	  Balb/c-­‐
derived	  PαS	  MSCs	  had	  varying	  capacities	  for	  immunomodulation.	  Passage	  3	  MSCs	  expanded	  
in	   SM±GFs	   were	   co-­‐cultured	   with	   CD4+CD25-­‐	   T	   cells	   that	   were	   activated	   with	   anti-­‐CD3e	  
antibody	  and	  CD19+	  B	  cells.	  Cultures	  were	  maintained	  for	  72	  hours	  and	  the	  total	  number	  of	  
CD4+	  cells	  quantified	  using	   flow	  cytometry.	  Our	  data	  shows	  profound	  differences	  between	  
the	   immunomodulatory	   capacities	   of	   PαS	   MSCs	   depending	   on	   their	   culture	   conditions	  
(Figure	   5.21).	   PαS	  MSCs	   expanded	   in	   SM	  were	   the	  most	   suppressive,	   achieving	   significant	  
drops	  in	  T	  cell	  proliferation	  across	  all	  ratio’s	  tested	  compared	  to	  the	  GF-­‐treated	  cells.	  TGF-­‐β1	  
primed	  MSCs	  achieved	  similar	  levels	  of	  suppression	  as	  SM	  MSCs	  at	  higher	  doses	  (1:8	  and	  1:4).	  
Significant	  decreases	  in	  T	  cell	  proliferation	  were	  also	  seen	  in	  TGF-­‐β	  primed	  cells	  compared	  to	  
FGF	  and	  PDGF-­‐primed	  MSCs	  at	  1:16,	  1:8	  and	  1:4	  doses.	  In	  contrast,	  MSCs	  expanded	  in	  FGF	  or	  
PDGF-­‐supplemented	   medium	   had	   an	   attenuated	   immunosuppressive	   phenotype.	   FGF-­‐
primed	  MSCs	  were	  able	  to	  reach	  50%	  suppression	  of	  SM	  cells	  at	  the	  highest	  dose,	  but	  PDGF-­‐
primed	  cells	  failed	  to	  pass	  the	  20%	  mark	  across	  all	  tested	  ratios.	  	  






Figure	   5.20	   |	  Effect	   of	   GF	   treatment	   on	   the	   expression	   of	   ‘immunosuppressive’	   genes.	   RNA	   isolated	   from	  
undifferentiated,	   P1	   PαS	  MSCs	   grown	   in	   SM±GFs	   were	   hybridised	   onto	   separate	   Affymetrix	   whole	   genome	  
microarrays	   (n=3	   per	   condition).	   The	   expression	   of	   previously	   reported	   ‘immunosuppressive	   genes’	   were	  
examined.	  The	  mean	  expression	  value	  for	  each	  gene	  across	  all	  samples	  was	  set	  as	  0	  (black	  box).	  A	  relative	  fold	  
decrease	   in	   gene	   expression	   (compared	   to	   the	  mean)	   is	   represented	   by	   a	   green	   square,	   and	   a	   relative	   fold	  
increase	  is	  represented	  by	  a	  red	  square.	  	  






Figure	  5.21	  |	  Effect	  of	  GFs	  on	  PαS	  MSC	  immunomodulation.	  P3	  PαS	  MSCs	  isolated	  from	  Balb/c	  mice	  were	  cultured	  and	  expanded	  in	  SM±GFs.	  MSCs	  were	  co-­‐cultured	  
with	  activated	  CD4+	  T	  cells	  for	  72	  hours.	  Samples	  were	  then	  analysed	  by	  flow	  cytometry	  and	  total	  CD4	  numbers	  counted	  and	  expressed	  as	  a	  percentage	  to	  the	  no-­‐
MSC	  control.	  Data	  shown	  as	  mean±SD,	  n≥3	  technical	  repeats	  per	  culture	  condition.	  Statistical	  analysis	  performed	  using	  Two-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  
Comparison	  Test.	  Black	  bars	  represent	  significance	  compared	  to	  SM	  MSCs,	  red	  bars	  to	  TGF-­‐β1	  primed	  cells	  and	  yellow	  bars	  to	  FGF2-­‐primed	  MSCs.	  	  





As	  NO	  secretion	  was	   the	  mechanism	  behind	  Balb/c-­‐derived	  PαS	  MSC	   immunosuppression,	  
we	  examined	  the	  effect	  of	  GF-­‐priming	  on	  NO	  production	  to	  explain	  whether	  differences	   in	  
immunomodulation	   were	   due	   to	   differential	   NO	   secretion.	   Our	   results	   validate	   this	  
hypothesis,	   as	   PαS	   MSCs	   expanded	   in	   SM	   produced	   significantly	   more	   nitrite	   than	   GF-­‐
supplemented	  cultures	  (Figure	  5.22).	  TGF-­‐β1	  primed	  cells,	  the	  next	  most	  suppressive	  group,	  
also	   produced	   significantly	   more	   nitrite	   than	   FGF	   or	   PDGF-­‐supplemented	   MSCs.	   FGF	   and	  
PDGF	   produced	   less	   than	   half	   the	   NO	   of	   the	   other	   groups,	   which	   explains	   their	   poor	  
immunomodulatory	  phenotype	  in	  CD4	  T	  cell	  suppression	  assays.	  Interestingly,	  no	  differences	  
in	   NO	   production	   were	   observed	   between	   FGF	   and	   PDGF-­‐primed	   cells	   even	   though	  
significant	  differences	  in	  CD4	  T	  cell	  number	  were	  observed	  in	  the	  suppression	  assay.	  	  
	  
Figure	  5.22	  |	  Effect	  of	  GF-­‐priming	  on	  NO	  secretion.	  PαS	  MSCs	  were	  expanded	  in	  SM±GFs	  until	  P3.	  Cells	  were	  
cultured	  overnight	  with	  20ng/ml	  IFNγ	  and	  TNFα	  and	  their	  supernatants	  examined	  for	  NO	  production	  using	  the	  
Griess	   Assay.	   Data	   shown	   as	   mean±SD,	   n=3	   technical	   repeats	   per	   condition.	   	   Statistical	   analysis	   performed	  
using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  	  





	   	   5.2.7.1	  TGF-­‐β1	  maintains	  Immunosuppressive	  Potential	  
The	   suppressive	  phenotype	  of	  PαS	  MSCs	   cultured	   in	   SM	  was	   lost	   at	   later	  passages	  due	   to	  
increases	   in	   the	   number	   of	   senescent	   cells	   and	   a	   reduction	   in	   NO	   secretion.	   Our	   data	  
demonstrates	   that	   TGF-­‐β1	   supplementation	   reduces	   the	   senescence	   of	  MSC	   cultures	   and	  
has	   a	   similar	   immunomodulatory	   profile	   to	   SM	   cells	   at	   P3.	  We	   hypothesised	   that	   TGF-­‐β1	  
treatment	   could	   maintain	   the	   immunosuppressive	   phenotype	   of	   MSCs	   after	   extended	  
culture,	   allowing	   us	   to	   expand	   PαS	   MSC	   populations	   to	   reach	   cell	   numbers	   required	   for	  
therapeutic	  infusions.	  	  
	  
Balb/c-­‐derived	   PαS	   MSCs	   were	   cultured	   in	   SM±TGF-­‐β1	   and	   expanded	   until	   P7.	   Graded	  
numbers	   of	   MSCs	   were	   co-­‐cultured	   with	   activated	   CD4+	   T	   cells	   as	   before,	   and	   the	   total	  
number	  of	  CD4+	  cells	  quantified	  using	  flow	  cytometry	  after	  72	  hours.	  As	  expected,	  P7	  MSCs	  
expanded	  in	  SM	  failed	  to	  suppress	  T	  cell	  proliferation	  across	  all	  ratios	  tested	  (Figure	  5.23A).	  
However,	   P7	   MSCs	   expanded	   in	   TGF-­‐β1	   supplemented	   medium	   retained	   their	  
immunosuppressive	   phenotype	   and	   were	   able	   to	   significantly	   reduce	   T	   cell	   proliferation.	  
Examination	  of	  NO	  production	  via	  the	  Griess	  Assay	  revealed	  that	  P7	  TGF-­‐β1	  MSCs	  produced	  
significantly	  more	  NO	   after	   overnight	   stimulation	  with	   IFNγ	   and	   TNFα	   (Figure	   5.23B).	   Our	  
findings	  clearly	  demonstrate	  that	  the	  suppressive	  potential	  of	  PαS	  MSCs	  changes	  over	  time	  
and	   is	   closely	   linked	   with	   NO	   production.	   TGF-­‐β1	   primed	   cells	   retain	   their	   suppressive	  
phenotype	  after	  extended	  due	  to	  enhanced	  NO	  secretion	  over	  SM	  cells.	  Thus,	  expansion	  of	  
MSCs	   in	   TGF-­‐β1	   containing	   medium	   may	   be	   beneficial	   for	   future	   uses	   of	   these	   cells	   in	  
autoimmune	  diseases.	  	  






Figure	  5.23	  |	  TGF-­‐β1	  maintains	  the	  immunosuppressive	  phenotype	  of	  PαS	  MSCs.	  (A)	  In	  vitro	  T	  cell	  suppression	  assay.	  Balb/c-­‐derived	  PαS	  MSCs	  were	  expanded	  in	  
SM±TGF-­‐β1	  until	  P7.	  Graded	  numbers	  of	  cells	  were	  co-­‐cultured	  with	  activated	  CD4	  T	  cells	  for	  72	  hours.	  Total	  CD4	  numbers	  are	  expressed	  as	  a	  percentage	  to	  the	  no-­‐
MSC	  control.	  Data	  shown	  as	  mean±SD,	  n=7	  technical	  repeats	  per	  condition.	  Statistical	  analysis	  represented	  by	  asterisks	  (*)	  performed	  using	  One-­‐way	  ANOVA	  with	  
Bonferroni’s	  Correction.	  Statistical	  analysis	  represented	  by	  diamonds	  (u)	  denote	  significant	  differences	  (P<0.01)	  performed	  using	  One-­‐sample	  T	  test	  compared	  to	  the	  
no-­‐MSC	  controls.	  (B)	  NO	  production	  as	  measured	  using	  the	  Griess	  Assay.	  Cells	  were	  cultured	  overnight	  with	  20ng/ml	  IFNγ	  and	  TNFα	  and	  their	  supernatants	  examined	  
for	  NO	  production.	  Data	  shown	  as	  mean±SD,	  n=3	  technical	  repeats	  per	  condition.	  Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Correction.	  	  	  







5.3.1	  Chapter	  Summary	  
The	   rarity	   of	   PαS	   MSCs	   and	   their	   susceptibility	   to	   undergo	   replicative	   senescence	   after	  
extended	  culture	  limits	  their	  use	  as	  a	  pre-­‐clinical	  population	  of	  purified	  MSCs.	  We	  have	  been	  
able	  to	  overcome	  senescence	  and	  increase	  the	  growth	  potential	  of	  PαS	  MSCs	  via	  the	  use	  of	  
FGF2,	   PDGF-­‐BB	   and	   TGF-­‐β1	   supplementation.	   These	   GFs	   were	   chosen	   as	   their	   respective	  
signalling	   pathways	   have	   been	   reported	   previously	   to	   control	   MSC	   proliferation	   and	  
differentiation	  down	  specific	  lineages	  (Ng	  et	  al.,	  2008).	  FGF2	  had	  the	  most	  potent	  effect	  on	  
PαS	  MSC	  proliferation,	  while	  PDGF-­‐BB	  and	  TGF-­‐β1	  had	  more	  modest	  mitogenic	  effects.	  	  	  
	  
We	   have	   also	   reported	   the	   karyotype	   of	   cultured	   PαS	   MSCs	   for	   the	   first	   time.	   Plastic-­‐
adherent	  murine	  MSCs	  are	  prone	   to	   culture-­‐induced	  karyotypic	  abnormalities	   that	   lead	   to	  
neoplastic	  transformation	  and	  tumour	  formation	  in	  vivo	  (Miura	  et	  al.,	  2006).	  No	  cytogenetic	  
evidence	  of	  neoplastic	  transformation	  could	  be	  observed	  in	  PαS	  MSCs	  cultured±GFs	  at	  P3	  or	  
P5,	   suggesting	   that	  prospectively-­‐isolated	  cells	   are	  more	   stable	   than	   their	  plastic-­‐adherent	  
counterparts.	  We	   did	   observe	   cases	   of	   polyploidy	   in	   TGF-­‐β1	   cultures	   and	   the	   presence	   of	  
quadriradial	   chromosomes	   in	   PDGF-­‐BB	   supplemented	   cells.	   More	   work	   is	   required	   to	  
elucidate	  the	  significance	  of	  this	  finding	  for	  PαS	  MSC	  cultures.	  	  	  
	  
The	   findings	   of	   Delorme	   et	   al.	   (2009)	   show	   that	   MSCs	   are	   ‘primed’	   at	   the	   genetic	   level	  
towards	   the	   lineages	   they	  can	  differentiate	   into.	  FGF,	  PDGF	  and	  TGF-­‐β	  signalling	  pathways	  






were	  the	  key	  regulators	  controlling	  MSC	  differentiation	  down	  these	  lineages	  (Ng	  et	  al.,	  2008).	  
We	  hypothesised	  that	  the	  addition	  of	  their	  respective	  ligands	  to	  MSC	  cultures	  could	  enhance	  
MSC	   differentiation	   down	   pre-­‐determined	   fates.	  Microarray	   analysis	   revealed	   evidence	   of	  
‘lineage	  priming’	   following	  GF	   supplementation	   in	  PαS	  MSCS.	  Culture	   in	   SM	  enhanced	   the	  
expression	  of	  osteogenic	  lineage	  genes	  in	  undifferentiated	  MSCs.	  When	  induced	  to	  undergo	  
differentiation,	   SM	   cultures	   readily	   went	   down	   the	   osteogenic	   lineage,	   producing	  
significantly	  more	  calcium	  than	  GF-­‐supplemented	  cells.	  FGF2	  and	  PDGF-­‐BB	  supplementation	  
upregulated	  key	  adipogenic	   lineage	  genes	   in	  undifferentiated	  MSCs,	  and	  we	  saw	  increased	  
lipid	  droplet	  formation	  in	  these	  cultures	  when	  induced	  to	  undergo	  differentiation.	  Evidence	  
for	  chondrogenic	  lineage	  priming	  was	  less	  clear,	  however	  our	  phenotypic	  data	  suggests	  that	  
culture	  in	  FGF2	  is	  beneficial	  for	  cartilage	  formation.	  In	  contrast,	  PαS	  MSCs	  expanded	  in	  TGF-­‐
β1	   supplemented	   medium	   had	   attenuated	   tri-­‐lineage	   differentiation	   but	   enhanced	  
immunosuppressive	  potential.	  This	  was	  due	  to	  a	  reduction	  in	  the	  number	  of	  senescent	  cells	  
and	  an	  increase	  in	  NO	  production	  in	  late-­‐passage	  TGF-­‐β1	  MSCs	  compared	  to	  SM	  MSCs.	  	  
	  
The	  findings	  of	  this	  chapter	  have	  significant	  implications	  for	  downstream	  therapeutic	  uses	  as	  
we	   reveal	   that	   culture	   conditions	   can	   functionally	   ‘prime’	   MSC	   fate	   (Figure	   5.24).	   The	  
maintenance	   of	   immunomodulatory	   capacity	   with	   TGF-­‐β1	   is	   useful	   for	   systemic	   immune	  
disorders	   where	   multiple	   doses	   of	   MSCs	   are	   required.	   Additionally,	   the	   use	   of	   a	   ‘lineage	  
primed’	  population	  in	  regenerative	  medicine	  would	  allow	  clinicians	  to	  infuse	  lower	  numbers	  
of	  MSCs	  to	  reach	  the	  same	  beneficial	  outcome	  in	  patients,	  thereby	  reducing	  the	  risk	  of	  any	  
adverse	  events	  occurring.	  	  







Figure	  5.24	  |	  Summary	  of	   lineage	  priming	  experiments.	  Expansion	  of	  PαS	  MSCs	   in	  SM	  promotes	  osteogenic	  
differentiation,	   while	   FGF2	   supplementation	   favours	   chondrogenesis	   and	   adipogenesis.	   TGF-­‐β1	   treatment	   is	  
able	  to	  maintain	  the	  immunosuppressive	  potential	  of	  PαS	  MSCs	  over	  extended	  passage.	  	  
	  
5.3.2	  Effect	  of	  GF	  supplementation	  on	  PαS	  MSC	  Growth	  	  
GF	  supplementation	  has	  been	  used	  by	  many	  groups	  to	  enhance	  the	  growth	  of	  human	  and	  
mouse	  MSC	  populations	   (Gharibi	  and	  Hughes,	  2012,	  Rodrigues	  et	  al.,	  2010).	   FGF2	  had	   the	  
most	  mitogenic	  effect	  on	  PαS	  MSCs,	   followed	  by	  PDGF-­‐BB	  and	  TGF-­‐β1.	   FGFs	  are	  historical	  
mitogens	  for	  stromal	  cell	  populations	  and	  are	  commonly	  added	  to	  MSC	  expansion	  medium	  
(Lai	  et	  al.,	  2011,	  Coutu	  et	  al.,	  2011,	   Jung	  et	  al.,	  2010,	   Ito	  et	  al.,	  2008).	  FGF2	  has	  also	  been	  
used	  to	  enhance	  proliferation	  and	  reduce	  the	  differentiation	  potential	  of	   immunodepleted	  
murine	  MSCs	   (Baddoo	   et	   al.,	   2003,	   Phinney	   et	   al.,	   1999).	   FGF	   primed	   cells	   also	   appeared	  
smaller	  and	  more	  slender	  than	  SM	  MSCs.	  The	  infusion	  of	  smaller	  cells	  can	  reduce	  the	  risk	  of	  
emboli	   formation	   and	   entrapment	   of	  MSCs	   in	   small	   capillaries	   in	   vivo,	   which	   can	   lead	   to	  
further	  ischaemic	  injury	  (Furlani	  et	  al.,	  2009).	  	   	  






The	   in	   vivo	   role	   for	   FGF2	   in	  maintaining	  BM	  MSC	  and	  HSC	  populations	  was	  described	   in	  a	  
recent	   publication	   by	   Itkin	   et	   al.	   (2012).	   Wild	   type	   mice	   treated	   with	   FGF2	   for	   seven	  
consecutive	   days	   displayed	   a	   2-­‐fold	   increase	   in	   the	   number	   of	   HSCs	   in	   BM.	   Concurrent	  
increases	   in	   the	   number	   of	   Nestin+	   MSCs	   was	   also	   observed	   after	   FGF2	   treatment.	   FGF-­‐
treated	   Nestin+	   MSCs	   had	   2-­‐fold	   increased	   CFU-­‐F	   and	   formed	   significantly	   more	  
‘mesenspheres’	  compared	  to	  control	  cells.	  FGF2	  treatment	  also	  reduced	  CXCL12	  production	  
and	   increased	   SCF	   secretion	   by	   Nestin+	  MSCs,	   thereby	   allowing	   HSCs	   to	   re-­‐enter	   the	   cell	  
cycle	   and	   increase	   in	   number.	   This	   study	   provides	   further	   proof	   of	   the	   close	   relationship	  
between	   MSCs	   and	   HSCs	   in	   the	   BM	   niche	   and	   demonstrates	   how	   an	   FGF2-­‐dependent	  
increase	  in	  MSC	  number	  can	  restore	  and	  expand	  the	  HSC	  pool	  during	  times	  of	  stress	  or	  injury.	  	  
	  
PDGF-­‐BB	   is	   another	   commonly	   added	   supplement	   to	   MSC	   expansion	   media	   (Jung	   et	   al.,	  
2010).	   Phinney	   et	   al.	   (1999)	   reported	   a	   2-­‐fold	   increase	   in	   plastic-­‐adherent	   murine	   MSC	  
number	  after	  expansion	   in	  PDGF-­‐BB	   for	  14	  days.	   Interestingly,	   they	  observed	  no	  effect	  on	  
MSC	   growth	   following	   culture	   in	   FGF2,	  which	   is	   contradictory	   to	   both	   our	   findings	   and	   to	  
other	   published	   papers.	   PDGF-­‐BB	   is	   crucial	   for	   the	   survival	   and	   proliferation	   of	   pericytes	  
during	  embryonic	  development	  (Lindahl	  et	  al.,	  1997).	  Therefore	  it	  is	  not	  surprising	  that	  MSCs,	  
who	  share	  many	  features	  with	  pericytes,	  respond	  to	  PDGF-­‐BB	  stimulation	  in	  the	  same	  way	  
(Meirelles	  et	  al.,	  2008).	  Further	  evidence	  comes	  from	  a	  study	  that	  showed	  MSCs	  cultured	  in	  
serum-­‐free	  media	  containing	  fresh	  frozen	  plasma	  (rich	  in	  PDGFs)	  exhibited	  enhanced	  growth	  
characteristics	  compared	  to	  FCS-­‐supplemented	  cells	  (Müller	  et	  al.,	  2006).	  	  
	   	  






TGF-­‐β1	  supplementation	   is	   less	  commonly	  used	   in	  MSC	  literature	  to	  enhance	  proliferation.	  
Jian	  et	  al.	  (2006)	  showed	  that	  TGF-­‐β1	  stimulated	  human	  MSC	  proliferation	  via	  cross-­‐talk	  with	  
the	  Wnt	  signalling	  pathway.	  Walenda	  and	  colleagues	  also	  reported	  pro-­‐proliferative	  effects	  
of	  TGF-­‐β1	  on	  human	  MSC	  populations	  (Walenda	  et	  al.,	  2013).	  Interestingly,	  the	  authors	  also	  
report	  that	  addition	  of	  TGF-­‐β1	  to	  human	  MSCs	  caused	  them	  to	  grow	  in	  clusters	  rather	  than	  
as	  a	  homogenous	  monolayer.	  We	  observed	   similar	  morphological	   changes	   in	  mouse	  MSCs	  
following	  TGF-­‐β1	  in	  this	  study,	  with	  PαS	  cells	  growing	  in	  discrete	  colonies	  containing	  tightly	  
packed	   cells.	   This	   could	   be	   due	   to	   an	   increase	   in	   actin	   expression	   in	   MSCs	   after	   TGF-­‐β1	  
treatment	   (Wang	  et	  al.,	  2004).	   In	   contrast,	  PDGF-­‐BB	   treatment	  has	  been	  shown	   to	   reduce	  
the	   expression	   of	   actin	   in	   human	  MSC	   cultures,	   which	   may	   explain	   the	   more	   elongated,	  
spindle-­‐shaped	  morphology	  of	  PDGF-­‐primed	  PαS	  MSCs	  (Kinner	  et	  al.,	  2002).	  	  
	  
5.3.3	  Effect	  of	  GF	  supplementation	  on	  PαS	  MSC	  Senescence	  
The	  accumulation	  of	  senescent	  cells	  limits	  the	  therapeutic	  applications	  of	  MSCs,	  especially	  in	  
cases	  where	   large	  numbers	  of	   cells	   are	   required	   to	   see	   a	   clinical	   benefit.	  We	  have	   shown	  
that	  PαS	  MSCs	  are	  susceptible	  to	  replicative	  senescence,	  resulting	  in	  reduced	  differentiation	  
and	  loss	  of	  immunomodulation.	  The	  effects	  of	  GF-­‐supplementation	  was	  tested	  in	  this	  study	  
as	  a	  way	  of	  overcoming	  senescence	  in	  PαS	  MSC	  cultures.	  Our	  results	  demonstrate	  significant	  
reductions	  in	  the	  number	  of	  senescent	  cells	  at	  days	  30	  and	  50	  in	  GF-­‐supplemented	  cultures	  
compared	  to	  SM.	  There	  is	  plenty	  of	  published	  evidence	  that	  highlights	  the	  importance	  of	  FGF	  
signalling	   in	   regulating	   senescence	   of	   stem	   cells	   (Coutu	   and	   Galipeau,	   2011).	   Ito	   and	  
colleagues	  report	  a	  reduction	  in	  senescence	  and	  restoration	  of	  proliferation	  in	  human	  MSC	  






cultures	   following	   FGF2	   treatment	  due	   to	  downregulation	  of	   cell	   cycle	   inhibitors	   p21,	   p16	  
and	  p53	  (Ito	  et	  al.,	  2007).	  Coutu	  et	  al.	  (2011)	  show	  that	  FGF2	  signalling	  is	  required	  to	  avoid	  
replicative	   senescence	  of	  mouse	  MSCs.	  A	   three-­‐fold	   increase	   in	   cell	  number	  was	  observed	  
after	   FGF2	   supplementation,	   however	   removal	   of	   the	   GF	   immediately	   induced	   cell	   cycle	  
arrest,	  which	  suggests	  that	  immortalisation	  had	  not	  taken	  place.	  Further	  mechanistic	  studies	  
revealed	  that	  FGF2	  treatment	  caused	  hyper-­‐phosphorylation	  and	  activation	  of	  MDM2,	  a	  key	  
regulator	  of	  senescence	  in	  mammalian	  cells	  (Coutu	  et	  al.,	  2011).	  	  
	  
Addition	  of	  PDGF-­‐BB	  or	  TGF-­‐β1	  in	  PαS	  MSC	  cultures	  also	  caused	  drops	  in	  the	  number	  of	  SA-­‐
β-­‐gal+	   cells	   at	   days	   30	   and	   50.	   The	   effect	   of	   TGF-­‐β1	   is	   interesting	   as	   it	   has	   been	   shown	  
previously	   to	   induce	   the	   onset	   of	   senescence	   in	   healthy,	   non-­‐transformed	   stromal	   cells	  
(Debacq-­‐Chainiaux	  et	  al.,	  2005).	  Murine	  C57BL/6	  MSCs	  also	  demonstrated	  a	  dose-­‐dependent	  
increase	  in	  the	  number	  of	  SA-­‐β-­‐gal+	  cells	  after	  24h	  exposure	  to	  TGF-­‐β1	  (Wu	  et	  al.,	  2014).	  Our	  
results	  contradict	  these	  findings,	  with	  TGF-­‐β1	  supplementation	  reducing	  the	  number	  of	  SA-­‐
β-­‐gal+	  PαS	  MSCs	  compared	  to	  SM	  controls.	  The	  reasons	  behind	  these	  contradictory	  findings	  
could	   be	   due	   to	   differences	   in	   the	   cell	   population	   used	   and	   the	   duration	   of	   TGF-­‐β1	  
stimulation	   between	   studies.	   Whereas	   Wu	   et	   al.	   (2014)	   exposed	   heterogeneous	   plastic-­‐
adherent	   MSCs	   to	   TGF-­‐β1	   for	   24	   hours,	   we	   studied	   the	   long-­‐term	   effects	   of	   TGF-­‐β	  
supplementation	  on	  a	  purified	  population	  of	  cells.	  Future	  work	  investigating	  the	  expression	  
of	   key	   senescence-­‐associated	   genes	   (p16,	   p21)	   in	   GF-­‐supplemented	   MSCs	   is	   required	   to	  
elucidate	  how	  GF	  treatment	  is	  reducing	  senescence	  in	  PαS	  MSC	  cultures.	  	  	  	   	  






5.3.4	  Karyotypic	  stability	  of	  PαS	  MSCs	  
Mouse	  MSCs	  are	   susceptible	   to	  karyotypic	  abnormalities	  after	   in	   vitro	   expansion.	  Previous	  
studies	  have	  shown	  that	  C57BL/6-­‐derived	  plastic-­‐adherent	  MSCs	  lost	  contact	  inhibition	  from	  
P3	  onwards	  and	  accumulated	  karyotypic	  errors	  with	  extended	  passage	   (Zhou	  et	  al.,	  2006).	  
Analysis	  of	  50	  metaphase	  spreads	  revealed	  aneuploidy	  in	  all	  50	  samples,	  with	  chromosome	  
numbers	  ranging	  between	  66	  and	  82	  per	  cell.	  Similar	  findings	  were	  reported	  by	  both	  Miura	  
et	   al.	   (2006)	   and	   Tolar	   et	   al.	   (2007),	   who	   identified	   that	   continuous	   passaging	   of	   murine	  
MSCs	   led	   to	   cytogenetic	   abnormalities	   and	   eventual	   malignant	   transformation.	   In	   vivo	  
infusion	  of	  transformed	  MSCs	  formed	  sarcomas	  in	  nude	  mice	  in	  both	  studies.	  	  
	  
In	   contrast,	   human	  MSCs	   demonstrate	   a	   good	   degree	   of	   genetic	   stability	   after	   extended	  
culture	  and	  no	  reports	  of	   tumour	   formation	  have	  been	  reported	   in	  clinical	   trials	   that	  have	  
used	   these	   cells	   (Lalu	   et	   al.,	   2012).	   There	   are	   some	   isolated	   reports	   of	   karyotypic	  
abnormalities	   involving	  human	  MSCs,	   although	   these	   changes	   in	   chromosome	  number	  did	  
not	  result	   in	  malignant	  transformation	  (Wang	  et	  al.,	  2013,	  Tarte	  et	  al.,	  2010).	  Nonetheless,	  
the	   use	   of	   minimally-­‐manipulated	   cells	   for	   therapy	   would	   be	   ideal	   to	   avoid	   any	   risk	   of	  
culture-­‐induced	  aberrations	  (Trounson	  et	  al.,	  2011).	  	  
	  
Pinpointing	  the	  reasons	  behind	  why	  murine	  MSCs	  are	  more	  prone	  to	  genetic	  instability	  than	  
their	   human	   counterparts	   is	   difficult	   but	   could	   be	   due	   to	   species	   differences.	   Human	  
fibroblasts	  have	  evolved	  to	  require	  alterations	  in	  six	  tumour	  suppressor	  signalling	  pathways	  






for	   oncogenic	   transformation,	   whereas	   murine	   fibroblasts	   need	   alterations	   in	   only	   two	  
(Rangarajan	   et	   al.,	   2004).	   Additionally,	   it	   also	   remains	   to	   be	   seen	   whether	   prospectively-­‐
isolated	  PαS	  MSCs	  are	  more	  karyotypically	   stable	   than	  plastic-­‐adherent	   cells,	   and	  whether	  
GF-­‐treatment	  has	  a	  detrimental	  effect	  on	  the	  stability	  of	  these	  cells.	  	  
	  
G-­‐banding	   analysis	   and	   chromosome	   breakage	   studies	   revealed	   that	   PαS	   MSCs	   were	  
genetically	  stable	  in	  vitro.	  There	  was	  no	  cytogenetic	  evidence	  of	  neoplastic	  transformation	  in	  
SM	  or	  GF-­‐supplemented	   cultures	   at	   P3	   or	   P5,	   suggesting	   that	   these	   cells	   are	  more	   stable	  
than	   plastic-­‐adherent	   murine	  MSCs.	   Compared	   to	   numerous	   previous	   studies	   that	   report	  
several	  abnormal	  chromosome	  numbers	  in	  early	  passage	  murine	  cells,	  we	  show	  that	  <10	  out	  
of	  60	  analysed	  metaphase	  spreads	  were	  abnormal.	  Interestingly,	  we	  observed	  an	  increase	  in	  
the	  number	  of	  tetraploid	  chromosomes	  (80,	  XXYY)	  in	  TGF-­‐β1	  supplemented	  PαS	  MSCs.	  Past	  
literature	   has	   reported	   polyploidisation	   to	   be	   a	   protective	   mechanism	   against	  
tumourigenesis	   in	  murine	  MSC	   cultures	   (Shoshani	   et	   al.,	   2012).	   In	   their	   study,	   injection	  of	  
tetraploid	  MSCs	  (4N)	  resulted	  in	  a	  13-­‐fold	  reduction	  of	  tumour	  formation	  in	  nude	  mice,	  while	  
the	   injection	   of	   over-­‐tetraploid	  MSCs	   (>4N)	   did	   not	   form	   any	   tumours	   at	   all.	  Mature	   cells	  
such	  as	  hepatocytes	  undergo	  dynamic	  changes	  in	  chromosome	  number	  as	  a	  mechanism	  to	  
adapt	   to	   the	   genotoxic	   stresses	   present	   in	   liver	   tissue	   (Duncan	   et	   al.,	   2010).	   However,	  
changes	  in	  chromosome	  number	  are	  also	  a	  hallmark	  of	  cancers	  (Davoli	  and	  de	  Lange,	  2011).	  
Further	   work	   is	   required	   to	   understand	   whether	   polyploidisation	   occurs	   as	   a	   ‘stress’	  
response	   in	   PαS	   MSC	   cultures	   following	   growth	   in	   TGF-­‐β1	   supplemented	   medium	   and	  
experiments	   involving	   injection	   into	   nude	   mice	   are	   required	   to	   find	   out	   whether	  
polyploidisation	  protects	  against	  transformation	  and	  malignancy	  in	  PαS	  cells.	  	   	  






Chromosome	   breakage	   studies	   were	   performed	   to	   identify	   DNA	   damage	   events	   that	  
manifests	  as	  gaps	  or	  breakages	  in	  chromosomes	  rather	  than	  changes	  in	  overall	  chromosome	  
number.	   Again,	   GF-­‐supplementation	   had	   a	   protective	   effect	   over	   SM	   cultures,	  with	   FGF2-­‐
treated	   cultures	   having	   the	   least	   number	   of	   errors.	   Interestingly,	   we	   did	   observe	   the	  
formation	   of	   quadriradial	   chromosomes	   exclusively	   in	   PDGF-­‐supplemented	   cultures.	   QR	  
chromosomes	   are	   formed	   when	   chromosome	   breaks	   in	   two	   homologous	   or	   non-­‐
homologous	  chromosomes	  are	  misrepaired	  and	  joined	  together	  (Joenje	  and	  Patel,	  2001).	  QR	  
chromosomes	   are	   defining	   characteristic	   of	   human	   genetic	   instability	   syndromes	   Bloom’s	  
disease	  and	  Fanconi’s	  anaemia	  (Singh	  et	  al.,	  2010,	  Joenje	  and	  Patel,	  2001).	  Patients	  suffering	  
from	  these	  rare	  conditions	  are	  much	  more	  likely	  to	  develop	  cancer	  at	  an	  early	  age.	  Patients	  
with	   Bloom	   syndrome	   display	   several	   incidences	   of	   chromosome	   breaks	   and	   QR	  
chromosome	   formation	   due	   to	   an	   inactivating	  mutation	   of	   the	   BLM	  DNA	  helicase	   protein	  
(Amor-­‐Guéret,	   2006).	   The	   significance	   of	   QR	   formation	   in	   PDGF-­‐supplemented	   cultures	   is	  
unclear.	  The	  fact	  that	  only	  ≈7/60	  PDGF-­‐supplemented	  metaphase	  spreads	  showed	  evidence	  
of	  QR	  chromosome	   formation,	  and	   the	   fact	   that	  we	  did	  not	   see	  an	   increased	   incidence	  of	  
chromosome	  gaps	  or	  breaks	  at	  a	  later	  passage	  would	  be	  argue	  against	  a	  ‘genetically	  unstable’	  
phenotype.	   Additionally,	   these	   DNA	   damage	   events	   did	   not	   cause	   changes	   in	   the	   gross	  
number	  of	  chromosomes	  in	  PDGF	  samples.	  Further	  studies	  analysing	  the	  karyotype	  of	  PDGF-­‐
supplemented	  at	  later	  passages	  are	  required	  to	  identify	  whether	  QR	  chromosome	  formation	  
preludes	  further	  karyotypic	  abnormalities	  in	  PDGF	  samples.	  	  
	   	  






5.3.5	  ‘Lineage	  Priming’	  using	  GFs	  
Human	  and	  murine	  MSCs	  are	  routinely	  cultured	  in	  medium	  containing	  GFs	  to	  enhance	  their	  
growth	   characteristics;	   however,	   the	   effect	   of	   extended	   culture	   in	   GF-­‐supplemented	  
medium	  on	   the	   tri-­‐lineage	  differentiation	   and	   immunosuppressive	   properties	   of	  MSCs	  has	  
not	   received	  much	   research	  attention.	   Expanding	  on	   the	   findings	  of	  Delorme	  et	   al.	   (2009)	  
and	  Ng	  et	  al.	  (2008),	  we	  hypothesised	  that	  GFs	  may	  ‘prime’	  MSCs	  down	  specific	  fates	  while	  
maintaining	  them	  in	  a	  proliferative,	  undifferentiated	  state.	  To	  prove	  that	  priming	  did	  occur	  
in	  PαS	  MSCs,	  we	  examined	  the	  expression	  of	  key	  osteogenic,	  adipogenic	  and	  chondrogenic	  
transcripts	   in	   undifferentiated	   cells.	   Our	   results	   demonstrate	   profound	   changes	   in	   gene	  
expression	   after	   expansion	   in	   GF-­‐supplemented	  media,	   resulting	   in	   altered	   differentiation	  
and	   immunosuppressive	   potential	   after	   expansion.	   Thus,	   the	   choice	   of	   GF	   used	   for	   MSC	  
expansion	  must	  be	  tailored	  to	  the	  clinical	  setting	  in	  order	  to	  maximise	  the	  efficacy	  of	  MSCs	  in	  
pre-­‐clinical	  models	  and	  in	  human	  clinical	  trials.	  	  	  	  
	  
	   	   5.3.5.1	  Osteogenic	  Lineage	  Priming	  
Microarray	   analysis	   revealed	   that	   key	   osteogenic	   lineage	   genes	   were	   significantly	  
upregulated	   in	   undifferentiated	   SM	   cultures	   compared	   to	   GF-­‐supplemented	   cells.	   These	  
included	   the	  master	   osteogenic	   regulators	  Runx2	   and	  Osterix.	   Runx2-­‐/-­‐	   and	  Osterix-­‐/-­‐	  mice	  
show	   a	   complete	   lack	   of	   mature	   osteoblasts,	   highlighting	   the	   importance	   of	   these	  
transcription	  factors	  in	  bone	  formation	  (Tu	  et	  al.,	  2008,	  Nakashima	  et	  al.,	  2002).	  Runx2	  also	  
inhibits	   the	  differentiation	  of	  mesenchymal	   cells	   into	  adipocytes	  or	   chondrocytes	   (Komori,	  
2006b),	   and	   it	   is	   interesting	   to	   note	   that	   FGF	   and	   PDGF-­‐primed	   cells	   (that	   readily	  
differentiated	  into	  fat	  and	  cartilage)	  expressed	  low	  levels	  of	  this	  transcription	  factor.	  	  	  






As	   suggested	   by	   the	   microarray,	   MSCs	   expanded	   in	   SM	   readily	   underwent	   osteogenic	  
differentiation	   and	  produced	   significantly	  more	   calcium	   than	  GF-­‐supplemented	   cells.	   FGF2	  
and	  PDGF-­‐BB	  primed	   cells	   produced	   similar	   levels	   of	   calcium,	  while	   TGF-­‐β1	   supplemented	  
MSCs	   lost	   the	   ability	   to	   differentiate	   towards	   bone	   at	   earlier	   passages.	   The	   decreased	  
osteogenic	   differentiation	   seen	   in	   FGF2-­‐primed	   PαS	   MSCs	   is	   surprising,	   as	   FGF	   has	   been	  
shown	  to	  support	  osteogenic	  differentiation	  in	  previous	  studies	   (Ng	  et	  al.,	  2008,	  Minamide	  
et	  al.,	  2007,	  Tsutsumi	  et	  al.,	  2001).	  However,	  there	  is	  some	  recent	  data	  that	  suggests	  FGF2	  
signalling	  might	   inhibit	  osteogenesis	   in	  MSC	  cultures	   (Gharibi	  and	  Hughes,	  2012,	   Lai	  et	  al.,	  
2011,	  Osathanon	  et	  al.,	  2011).	  Similarly,	  PDGF-­‐BB	  and	  TGF-­‐β1	  have	  also	  been	  shown	  to	  have	  
both	   pro-­‐	   and	   anti-­‐osteogenic	   effects	   on	  MSC	   differentiation	   in	   past	   studies	   (Zhen	   et	   al.,	  
2013,	  Zhao	  and	  Hantash,	  2011,	  Tokunaga	  et	  al.,	  2008,	  Ng	  et	  al.,	  2008).	  	  
	  
The	  contradictory	  findings	  in	  past	  literature	  could	  be	  due	  to	  species	  differences	  or	  due	  to	  the	  
heterogeneous	   populations	   of	   MSCs	   used	   in	   past	   studies.	   Additionally,	   the	   experimental	  
design	  used	  in	  this	  study	  and	  past	  literature	  is	  also	  subtly	  different.	  Here,	  GF	  treatment	  was	  
stopped	   prior	   to	   the	   induction	   of	   differentiation	   to	   ensure	   that	   any	   differences	   observed	  
between	   groups	   were	   due	   to	   differences	   in	   their	   expansion	   culture	   medium	   only.	   Past	  
studies	  were	  examining	  the	  contribution	  of	  certain	  signalling	  pathways	  to	  MSC	  growth	  and	  
differentiation	  by	  scrutinising	  the	  effect	  of	  GF-­‐supplementation	  for	  short	  periods	  of	  time	  (24-­‐
48	  hours;	  Wu	  et	  al.,	  2014)	  or	  during	  the	  differentiation	  process	  itself	  (Ng	  et	  al.,	  2008,	  Zhao	  
and	  Hantash,	  2011).	  As	  shown	  here,	   long-­‐term	  culture	   in	  GFs	   increases	  the	  proliferation	  of	  
PαS	  MSCs	  but	  skews	  their	  differentiation	  towards	  specific	  fates.	  	   	  






	   	   5.3.5.2	  Adipogenic	  Lineage	  Priming	  
Analysis	   of	   adipogenic	   lineage	   genes	   revealed	   that	   key	   transcripts	   of	   this	   pathway	   were	  
significantly	   upregulated	   in	   FGF	   and	   PDGF-­‐supplemented	   PαS	   MSCs	   compared	   to	   SM	  
controls.	   These	   included	   master	   regulators	   Cebpa	   and	   Pparg,	   which	   were	   expressed	  
approximately	  2-­‐fold	  and	  3-­‐fold	  higher	  than	  SM	  cells.	  In	  contrast,	  TGF-­‐β1	  supplemented	  cells	  
expressed	   these	  master	   regulators	   approximately	   3-­‐fold	   lower	   than	   SM	  cells,	   suggesting	   a	  
loss	   in	   fat	  differentiation	  potential.	  Cebpa-­‐/-­‐	  mice	   suffer	   from	  defects	   in	  glycogen	  and	   lipid	  
storage	  (Wang	  et	  al.,	  1995),	  and	  PPARγ-­‐GFP+	  adipocyte	  precursors	  were	  able	  to	  form	  ectopic	  
GFP+	  fat	  after	  in	  vivo	  infusion,	  demonstrating	  the	  importance	  of	  the	  Cebpa/Pparg	  axis	  in	  fat	  
development	  (Tontonoz	  and	  Spiegelman,	  2008).	  	  
	  
When	   induced	   to	   undergo	   differentiation,	   FGF	   or	   PDGF-­‐primed	   cells	   readily	   differentiated	  
towards	   fat	   as	   suggested	   by	   the	   microarray.	   The	   differentiation	   protocol	   had	   to	   be	  
shortened	  from	  24	  to	  8	  days	  to	  avoid	  cell	  death	  due	  to	  excessive	  lipid	  droplet	  formation	  in	  
these	   cultures.	   FGF	   and	   PDGF	   supplemented	   cells	   also	   maintained	   their	   adipogenic	  
differentiation	   potential	   until	   P5,	   while	   SM-­‐expanded	   cells	   lost	   this	   ability	   by	   P3.	   These	  
findings	  back	  up	  previous	  work	   in	  the	  MSC	  field	  that	  have	   identified	  FGF2	  and	  PDGF-­‐BB	  as	  
pro-­‐adipogenic	  factors	  (Ahn	  et	  al.,	  2009,	  Ng	  et	  al.,	  2008,	  Kratchmarova	  et	  al.,	  2005).	  TGF-­‐β1	  
primed	   MSCs	   failed	   to	   differentiate	   towards	   fat	   across	   all	   passages	   tested.	   TGF-­‐β	   has	  
historically	  been	  described	  as	  a	  potent	   inhibitor	  of	   adipogenic	  differentiation	   in	  MSCs	  and	  
other	  adipogenic	  precursors	   (Wang	  et	  al.,	  2012,	  Watabe	  and	  Miyazono,	  2009).	  Smad3/4,	  a	  
key	  intracellular	  signalling	  protein	  in	  the	  TGF-­‐β	  pathway,	  has	  been	  shown	  to	  directly	  interact	  






with	   the	  master	   adipogenic	   regulator	   Cebpa	   to	   inhibit	   its	   transcriptional	   activity	   in	  mouse	  
fibroblasts	  (Choy	  and	  Derynck,	  2003).	  It	  would	  be	  interesting	  to	  examine	  the	  kinetics	  behind	  
TGF-­‐β1	   mediated	   inhibition	   of	   adipogenesis	   to	   see	   whether	   GF-­‐removal	   restores	   the	  
adipogenic	  potential	  of	  TGF-­‐β1	  primed	  MSCs.	  	  
	  
	   	   5.3.5.3	  Chondrogenic	  Lineage	  Priming	  
Cartilage	   loss	   is	  a	  major	  cause	  of	  disability	   in	   the	  western	  world	   (Arden	  and	  Nevitt,	  2006).	  
Cartilage	  repair	  following	  injury	  is	  a	  slow	  and	  limited	  process	  due	  to	  the	  avascular	  and	  non-­‐
innervated	  nature	  of	  mature	  cartilage.	  MSCs	  are	  an	  ideal	  tool	  for	  cartilage	  repair	  due	  to	  their	  
ability	   to	   replace	   lost	   chondrocytes	   and	   their	   ability	   to	   prevent	   further	   immune-­‐mediated	  
damage	  from	  taking	  place	  (Boeuf	  and	  Richter,	  2010,	  Chen	  and	  Tuan,	  2008).	  	  	  
	  
Unlike	   the	   other	   two	   ‘main’	   lineages,	   chondrogenic	   differentiation	   of	   MSCs	   is	   technically	  
more	   challenging,	   requiring	   the	   use	   of	   3D	   culture	   and	   specialised	   differentiation	   media	  
(Gupta	  et	  al.,	  2012,	  Solchaga	  et	  al.,	  2011,	  Koga	  et	  al.,	  2009,	  Raghunath	  et	  al.,	  2007,	  Heng	  et	  
al.,	   2004).	  We	   examined	   the	   effect	   of	  GF-­‐priming	   on	   PαS	  MSCs	   in	   an	   attempt	   to	   improve	  
chondrogenic	   differentiation	   efficiencies	   and	  maximise	   the	   therapeutic	   potential	   of	   these	  
cells.	  Microarray	  analysis	  for	  chondrogenic	  lineage	  genes	  showed	  significant	  increases	  in	  the	  
expression	   of	   master	   regulators	   Sox9	   and	   Sox5	   in	   FGF	   and	   PDGF	   supplemented	   cells	  
compared	  to	  SM	  or	  TGF-­‐β1	  MSCs.	  Sox9	  and	  Sox5	  expression	  is	  essential	  for	  the	  formation	  of	  
cartilage	   and	   endochondral	   bone	   development	   (Akiyama,	   2008).	   Sox9-­‐/-­‐	   mouse	   embryos	  






display	  generalised	  chondrodysplasia	  due	  to	  mesenchymal	  progenitor	  cells	  being	  unable	  to	  
terminally	   differentiate	   into	   chondrocytes	   (Akiyama	   et	   al.,	   2003,	   Akiyama	   et	   al.,	   2002).	  
Analysis	   of	   downstream	  effector	   genes	   gave	  mixed	   results,	  which	   suggests	   that	   it	   is	  more	  
difficult	   to	  prime	  MSCs	  down	   the	   chondrogenic	   lineage	  using	  GFs	  alone	  and	   could	  explain	  
why	  complex	  3D	  culture	  systems	  are	  required	  for	  efficient	  chondrogenic	  differentiation.	  
	  
Micromass	   pellet	   cultures	  were	   used	   to	   induce	   chondrogenic	   differentiation	   of	  GF-­‐primed	  
PαS	  MSCs.	   As	   suggested	   by	   the	  microarray,	   FGF	   and	   PDGF-­‐primed	   cells	  made	   the	   largest	  
cartilage	  pellets	  that	  were	  rich	  in	  Col2	  and	  proteoglycans.	  PαS	  MSCs	  expanded	  in	  SM	  made	  
pellets	  that	  were	  of	  similar	  collagen	  and	  proteoglycan	  content	  to	  GF-­‐supplemented	  cells,	  but	  
their	   pellets	   were	   significantly	   smaller	   in	   size.	   TGF-­‐β1	   primed	   cells	   made	   the	   smallest	  
cartilage	   pellets	   that	   with	   the	   lowest	   Col2:Col1	   ratio,	   indicating	   the	   formation	   of	  
fibrocartilage,	  an	  inferior	  alternative	  to	  hyaline	  cartilage.	  	  
	  
The	   pro-­‐chondrogenic	   effects	   of	   FGF2	   and	   PDGF-­‐BB	   supplementation	   in	  MSC	   cultures	   has	  
been	  described	  previously,	  and	  our	   results	   further	  back	  up	   these	   findings	   (Handorf	  and	  Li,	  
2011,	   Ng	   et	   al.,	   2008,	   Ito	   et	   al.,	   2008).	   Interestingly,	   TGF-­‐β1	   treatment	   prevented	  
chondrogenic	   differentiation	   in	   PαS	  MSCs,	  which	   contradicts	   the	   findings	   of	   several	   other	  
groups	   (Mueller	   et	   al.,	   2010,	   Xu	  et	   al.,	   2008,	  Ng	  et	   al.,	   2008,	   Liu	   et	   al.,	   2007,	  Barry	   et	   al.,	  
2001).	  Again,	  species	  differences	  and	  variations	  in	  the	  timing	  and	  duration	  of	  GF	  treatment	  
may	  explain	  the	  differences	  observed	  between	  studies.	  	   	  






	   	   5.3.5.3.1	  Tissue	  Engineered	  Cartilage	  
MSC	  therapy	  for	  cartilage	  disorders	  faces	  many	  challenges,	  including	  the	  need	  for	  therapies	  
suitable	   for	   larger	   cartilage	   injuries.	  While	  micromass	   pellets	   are	   suitable	   for	   studying	   the	  
pathways	  controlling	  MSC	  differentiation,	  the	  amount	  of	  cartilage	  produced	  is	  too	  small	  to	  
be	   of	   practical	   value	   in	   animal	  models.	   To	   address	   this	   issue,	   cartilage	   tissue	   engineering	  
experiments	  using	  PGA	  scaffolds	  were	  performed	  to	  increase	  the	  amount	  of	  ECM	  produced	  
by	  PαS	  MSCs.	  PGA	  scaffolds	  undergo	  hydrolysis	  and	  degrade	  over	  time	  to	  leave	  behind	  MSC-­‐
derived	   ECM	   proteins.	   FGF-­‐primed	   cells	   were	   chosen	   for	   analysis	   due	   to	   their	   superior	  
growth	  and	  cartilage	  differentiation	  properties.	  SM-­‐expanded	  MSCs	  were	  used	  as	  controls.	  	  
	  
After	  35	  days	  differentiation,	  significant	  increases	  in	  weight	  and	  proteoglycan	  content	  were	  
observed	   in	   FGF-­‐primed	   samples	   compared	   to	   SM	   cells.	   FGF2-­‐primed	   cells	   also	   produced	  
more	   Col2	   and	   had	   a	   higher	   Col2:Col1	   ratio,	   but	   the	   increase	   was	   non-­‐significant.	   These	  
findings	  match	   the	   results	   obtained	   using	   the	  micromass	   pellet	   culture	   system.	   However,	  
there	  was	  a	  4-­‐fold	  increase	  in	  size	  and	  2-­‐fold	  increase	  in	  collagen	  and	  proteoglycan	  content	  
using	   PGA	   scaffolds	   compared	   to	   micromass	   pellets.	   These	   improvements	   were	   achieved	  
with	  a	  small	  increase	  in	  initial	  MSC	  seeding	  number	  (5x105	  per	  pellet	  compared	  to	  6x105	  per	  
PGA	   scaffold),	   demonstrating	   the	   power	   of	   scaffolds	   in	   improving	   chondrogenic	  
differentiation	  of	  MSCs.	  	  
	  






Testing	  cartilage	  repair	   in	  murine	  models	  and	  optimising	  strategies	   for	  MSC	  differentiation	  
would	  significantly	  reduce	  the	  cost	  and	  increase	  the	  clinical	  benefit	  seen	  in	  human	  patients	  
(Helminen	  et	  al.,	  2002).	  However,	  tissue	  engineering	  murine	  cartilage	  has	  been	  challenging	  
due	  to	  difficulties	  in	  isolating	  pure	  populations	  of	  mouse	  MSCs	  (Zhang,	  2014,	  Frenette	  et	  al.,	  
2013).	  Our	  results	  show	  that	  PαS	  MSCs	  can	  differentiate	   into	  good	  quality	  cartilage,	  which	  
can	  be	  further	  improved	  via	  the	  use	  of	  scaffolds.	  PαS	  cells	  can	  therefore	  be	  used	  as	  a	  model	  
pre-­‐clinical	  population	  of	  cells	  to	  design	  and	  optimise	  novel	  cartilage	  repair	  therapies.	  Future	  
studies	   can	   investigate	   the	  use	  of	  bioreactors	  or	   the	  effect	  of	  physical	   stimulation	   such	  as	  
shear	   stress	   and	   surface	   coatings	   on	   tissue-­‐engineered	   constructs	   as	   a	   way	   to	   improve	  
chondrogenic	  differentiation	  even	  further	  (Schulz	  and	  Bader,	  2007).	  	  
	   	  






5.3.6	  Maintenance	  of	  Immunosuppression	  using	  TGF-­‐β1	  
The	  immunosuppressive	  properties	  of	  MSCs	  make	  them	  an	  attractive	  cell	  source	  for	  future	  
stem	  cell	  therapies.	  We	  have	  shown	  that	  early-­‐passage	  (P3)	  PαS	  MSCs	  were	  able	  to	  strongly	  
suppress	  CD4+	  T	   cell	  proliferation	  via	   the	   secretion	  of	  NO.	  However,	  as	  PαS	  MSCs	  become	  
increasingly	  senescent,	  their	  ability	  to	  secrete	  NO	  is	  lost,	  resulting	  in	  a	  complete	  reversal	  of	  
their	   immunosuppressive	  phenotype.	  Due	  to	   the	  rarity	  of	  PαS	  MSCs	   in	  BM,	  a	  degree	  of	  ex	  
vivo	  expansion	  is	  required	  to	  reach	  cell	  doses	  needed	  for	  therapeutic	   infusions.	  To	  address	  
this	   issue,	   we	   examined	   the	   effect	   of	   GF-­‐supplementation	   on	   the	   immunomodulatory	  
functions	  of	  PαS	  MSCs	   to	   identify	   culture	   conditions	   that	   could	  enhance	  or	  maintain	   their	  
suppressive	  properties	  over	  extended	  in	  vitro	  culture.	  	  
	  
Our	   results	   demonstrated	   that	  MSCs	   expanded	   in	   SM	  were	   the	  most	   suppressive,	   closely	  
followed	   by	   TGF-­‐β1	   primed	   cells.	   FGF2	   and	   PDGF-­‐BB	   supplemented	   cultures	   fared	   much	  
worse	  and	  had	  significantly	  less	  suppressive	  capacity.	  Examination	  of	  NO	  secretion	  using	  the	  
Griess	  Assay	   followed	  the	  same	  trend,	  with	  SM	  cells	  producing	   the	  most	  NO	  and	  PDGF-­‐BB	  
primed	  MSCs	  producing	  the	  least.	  There	  is	  very	  little	  published	  literature	  that	  examines	  the	  
effect	   of	   senescence	   on	  murine	  MSC-­‐mediated	   immunosuppression.	   Li	   et	   al.	   (2012)	   show	  
that	  human	  MSCs	  at	  P7	  lost	  their	  ability	  to	  suppress	  T	  cell	  proliferation	  due	  to	  an	  increase	  in	  
the	   number	   of	   SA-­‐β-­‐gal+	   cells	   in	   culture.	   Sepulveda	   and	   colleagues	   report	   loss	   of	   in	   vivo	  
immunosuppression	  of	  aged	  human	  MSCs	  but	  demonstrate	  no	  differences	   in	   their	   in	   vitro	  
function	   (Sepulveda	   et	   al.,	   2014).	   Methods	   used	   to	   overcome	   senescence	   and	   boost	  
immunomodulatory	   functions	   include	  hypoxia	   (Roemeling-­‐Van	  Rhijn	  et	  al.,	  2013,	  Haque	  et	  






al.,	   2013)	   and	   the	   use	   of	   ‘MSC	   licensing’	   agents	   such	   as	   TNFα,	   IFNγ	   and	   TLR	   agonists	  
(Krampera,	  2011,	  DelaRosa	  and	  Lombardo,	  2010,	  Waterman	  et	  al.,	  2010).	  GF-­‐priming	  is	  one	  
avenue	   that	  has	  not	   received	  much	  attention.	  One	   study	  which	  examined	   this	  option	  was	  
performed	  by	  Auletta	  et	  al.	   (2011),	  who	  examined	  the	  effect	  of	   long-­‐term	  culture	   in	  FGF2-­‐
containing	   medium.	   Their	   findings	   contradict	   ours,	   as	   they	   report	   that	   FGF2	  
supplementation	   can	   expand	   human	   MSC	   numbers	   without	   diminishing	   their	  
immunosuppressive	  potential.	  However,	  preservation	  of	   immunomodulatory	   functions	  was	  
only	  observed	  in	  3/5	  BM	  donors,	  which	  suggests	  that	  the	  effect	  is	  not	  entirely	  reproducible.	  	  
	  
In	  our	  T	  cell	  suppression	  assay,	  P3	  TGF-­‐β1	  primed	  MSCs	  were	  equally	  as	  suppressive	  as	  SM	  
cells	  at	  the	  higher	  MSC	  doses.	  However,	  P7	  TGF-­‐β	  cells	  were	  significantly	  more	  suppressive	  
than	  SM	  cells	  across	  all	  ratios	  tested	  due	  to	  significant	  increases	  in	  NO	  secretion.	  Reductions	  
in	   SA-­‐β-­‐gal+	   MSCs	   following	   TGF-­‐β1	   supplementation	   could	   be	   one	   reason	   behind	   the	  
maintenance	   of	   immunosuppressive	   function;	   however,	   FGF	   and	   PDGF	   primed	   cells	   had	  
lower	   numbers	   of	   SA-­‐β-­‐gal+	   cells	   than	   TGF-­‐β	   samples	   but	   failed	   to	   perform	   in	   the	   T	   cell	  
suppression	  assay.	  FGF2	  has	  been	  shown	  to	  inhibit	  iNOS	  expression	  in	  human	  microglial	  cells	  
(Colasanti	  et	  al.,	  1995)	  and	  bovine	  epithelial	  cells	  (Goureau	  et	  al.,	  1995)	  after	  LPS	  and	  TNFα	  
stimulation.	  There	   is	  no	   literature	   that	  proves	  a	   causal	   link	  between	  TGF-­‐β1	  signalling	  and	  
increased	  NO	  production	  in	  mammalian	  cells.	  On	  the	  other	  hand,	  there	  is	  plenty	  of	  evidence	  
which	  proves	  NO	  can	  negatively	  regulate	  TGF-­‐β1	  signalling	  in	  models	  of	  organ	  injury	  (Saura	  
et	  al.,	  2005,	  Dreieicher	  et	  al.,	  2009).	  TGF-­‐β1	  is	  itself	  a	  potent	  immunosuppressive	  compound	  
which	  is	  secreted	  by	  MSCs	  and	  Tregs	  to	  downregulate	  the	  activity	  of	  immune	  cells	  (English	  et	  






al.,	   2009).	   Transfer	   of	   residual	   TGF-­‐β1	   on	   the	   surface	   of	  MSCs	   to	   the	   T	   cell	   co-­‐culture	   is	  
unlikely	  as	  MSCs	  were	  washed	  thoroughly	  before	  experimentation.	  	  	  
	  
Microarray	  analysis	  revealed	  that	  TGF-­‐β1	  primed	  cells	  expressed	  significantly	  higher	  levels	  of	  
Nos2	   (iNOS)	   compared	   to	   the	  other	   culture	  conditions,	  but	   the	   relevance	  of	   this	   finding	   is	  
debatable	   as	   the	   cells	   were	   not	   pre-­‐stimulated	   to	   ‘switch	   on’	   their	   immunosuppressive	  
properties	   (Krampera	  et	   al.,	   2013).	   It	   is	   interesting	   to	  note	   that	   TGF-­‐β1	  prevented	   the	   tri-­‐
lineage	   differentiation	   of	   MSCs	   but	   maintained	   their	   immunosuppressive	   phenotype.	  
Conversely,	   FGF	   and	   PDGF	   treatment	   enhanced	   tri-­‐lineage	   differentiation	   but	   failed	   to	  
maintain	   immunosuppression.	   Future	   work	   should	   try	   to	   identify	   how	   TGF-­‐β1	   treatment	  
maintains	  NO	  production	  in	  PαS	  MSCs.	  Further	  genetic	  and	  phenotypic	  analysis	  is	  required	  to	  
identify	   the	   lineage	   TGF-­‐β1	   is	   priming	   PαS	  MSCs	   towards.	   It	   would	   also	   be	   interesting	   to	  
examine	  whether	  C57BL/6-­‐derived	  MSCs,	  which	  suppress	  via	  a	  NO-­‐independent	  mechanism,	  
also	  maintain	  their	  immunosuppressive	  phenotype	  when	  expanded	  in	  TGF-­‐β1.	  
	  
In	   summary,	   these	   findings	  highlight	   the	  need	   to	   tailor	   culture	   conditions	   to	   the	   intended	  
future	  use	  of	  these	  cells	  and	  have	  significant	  implications	  for	  translational	  studies.	  Although	  
FGF2	   or	   PDGF-­‐BB	   treatment	   increases	   MSC	   yield	   in	   vitro,	   it	   may	   not	   be	   ideal	   for	   use	   in	  
patients	   with	   bone	   injuries	   or	   for	   immunosuppressive	   indications.	   Conversely,	   TGF-­‐β1	  





















IN	  VIVO	  EFFICACY	  IN	  A	  MOUSE	  MODEL	  OF	  















6.1	  Chapter	  Rationale	  and	  Aims	  
We	   have	   been	   able	   to	   overcome	   senescence	   in	   MSC	   cultures	   via	   the	   use	   of	   GFs,	   which	  
increase	   the	   proliferative	   capacity	   of	   PαS	   MSCs	   and	   also	   ‘primes’	   them	   down	   specific	  
lineages.	   In	   particular,	   TGF-­‐β1	   supplementation	   was	   able	   to	   maintain	   the	  
immunosuppressive	  phenotype	  of	  PαS	  MSCs	  over	  extended	  culture,	  which	  is	  of	  interest	  for	  
future	   uses	   in	   immune-­‐mediated	   disorders.	   In	   this	   chapter	   we	   tested	   the	   efficacy	   of	   PαS	  
MSCs	   in	   a	   transgenic	   mouse	   model	   of	   alloimmune	   liver	   injury	   to	   examine	   their	  
immunosuppressive	   phenotype	   in	   vivo	   and	   see	  whether	   late-­‐passage	   TGF-­‐β1	   primed	   cells	  
retained	  their	  immunomodulatory	  functions.	  	  
	  
	   6.1.1	  Autoimmune	  Liver	  Disease	  
The	   liver	   is	   the	   largest	  organ	   in	  the	  human	  body	  and	  has	  a	  number	  of	   important	  functions	  
including	  metabolism,	  detoxification	  and	  protein	  synthesis	  that	  are	  essential	  for	  survival.	  The	  
liver	   also	   plays	   an	   important	   role	   as	   a	   first-­‐line	   defence	   against	   foreign	   antigens	   entering	  
from	   the	   gut	   (Racanelli	   and	   Rehermann,	   2006).	   It	   must	   maintain	   a	   balance	   between	  
tolerance	   to	   dietary	   antigens	   and	   the	   need	   to	   generate	   an	   immune	   response	   against	  
pathogenic	  microorganisms.	  The	  coordinated	  action	  of	  Kupffer	  cells,	  dendritic	  cells,	  NKT	  cells	  
and	  others	  is	  required	  to	  maintain	  this	  balance,	  which,	  when	  disrupted,	  can	  trigger	  the	  onset	  
of	  autoimmune	  liver	  disease	  (Liaskou	  et	  al.,	  2012).	  
	   	  





Autoimmune	   hepatitis	   (AIH),	   primary	   biliary	   cirrhosis	   (PBC)	   and	   primary	   sclerosing	  
cholangitis	   (PSC)	  are	  all	  chronic,	   inflammatory	   liver	  diseases	  of	  unknown	  aetiology	  that	   fall	  
under	   the	  category	  of	  autoimmune	   liver	  diseases.	  These	  conditions	  make	  up	  an	  estimated	  
5%	  of	  all	   liver	  disease	   cases	   (Decock	  et	  al.,	   2009).	  Patients	  with	  AIH	   typically	  present	  with	  
altered	   serum	   biochemistry,	   showing	   elevated	   levels	   of	   alanine	   transaminase	   (ALT),	   a	  
biomarker	   of	   hepatocellular	   damage,	   but	   normal	   levels	   of	   alkaline	   phosphatase	   (ALP),	   a	  
marker	  of	  biliary	  injury	  (Manns	  et	  al.,	  2010).	  Examination	  of	  liver	  histology	  should	  reveal	  the	  
presence	  of	  interface	  hepatitis	  (disruption	  of	  the	  portal	  tract	  by	  a	  mononuclear	  cell	  infiltrate),	  
the	  defining	  hallmark	  of	  AIH	  (Czaja,	  2006).	  This	  infiltrate	  consists	  mainly	  of	  lymphocytes	  and	  
plasma	   cells.	  Unfortunately,	   treatment	   options	   for	   patients	  with	  AIH	   are	   limited.	   First-­‐line	  
therapy	  for	  patients	  with	  AIH	  are	  high-­‐dose	  corticosteroids	  (e.g.	  prednisone)	  to	  control	  the	  
inflammation	   (Manns	   et	   al.,	   2010).	   Those	   that	   fail	   to	   respond	   to	   steroids	   alone	   are	  
supplemented	  with	  an	  immunosuppressive	  agent	  such	  as	  azathioprine	  to	  further	  control	  the	  
injury.	  Common	  side-­‐effects	  with	   corticosteroids	  or	   azathioprine	   treatment	   include	  weight	  
gain,	   acne,	   osteopenia	   and	   cytopenia	   (Czaja,	   2008).	   Corticosteroid-­‐related	   side	   effects	   are	  
the	  most	  common	  causes	  for	  premature	  drug	  withdrawal	  in	  AIH,	  and	  there	  are	  subgroups	  of	  
patients	   (children,	   cirrhotics	   and	   pregnant	   women)	   for	   whom	   this	   therapy	   regimen	   is	  
unsuitable	  due	  to	  an	  increased	  risk	  of	  drug	  toxicity	  (Selvarajah	  et	  al.,	  2012,	  Levy,	  2012).	  	  
	  
Patients	   that	   do	   not	   respond	   to	   therapy	   (approximately	   10%),	   or	   were	   unsuitable	   for	  
corticosteroids	   or	   were	   simply	   left	   undiagnosed	   develop	   liver	   cirrhosis	   and	   require	   liver	  
transplantation	  (Manns	  et	  al.,	  2010).	  Transplantation	  carries	  a	  risk	  of	  further	  morbidity	  and	  





mortality	  and	  patients	  need	  to	  be	  placed	  on	  life-­‐long	  immunosuppression	  to	  avoid	  rejection	  
(Jain	   et	   al.,	   2000).	   However,	   advances	   in	   surgical	   techniques	   and	   management	   have	  
improved	  the	  5	  and	  10	  year	  survivals	  of	  patients	  with	  AIH	  that	  underwent	  transplantation	  to	  
approximately	   75%	   (NHS	   Blood	   and	   Transplant,	   2010,	   Vogel	   et	   al.,	   2004).	   The	   main	  
disadvantages	  of	  liver	  transplantation	  are	  the	  shortage	  of	  suitable	  donor	  organs,	  resulting	  in	  
an	  average	  waiting	  time	  of	  142	  days	  for	  adults	  and	  78	  days	  for	  children	  (NHS,	  2013).	  Up	  to	  
30%	   of	   AIH	   patients	   who	   received	   a	   transplant	   suffer	   from	   recurrent	   AIH	   in	   allografts,	  
resulting	  in	  the	  reintroduction	  of	  prednisone/azathioprine	  dual-­‐therapy	  and	  the	  side-­‐effects	  
that	  come	  with	  these	  medicines	  (Ratziu	  et	  al.,	  1999).	  Due	  to	  these	  issues,	  the	  search	  is	  on	  for	  
alternative	  therapies	  to	  combat	  autoimmune	  liver	  diseases.	  	  
	  
Due	   to	   their	   ability	   to	   module	   immune	   cell	   responses,	   MSC	   transplantation	   could	  
complement	  existing	  treatment	  regimens	  to	  dampen	  the	  proliferation	  of	  autoreactive	  T	  cells	  
and	   reduce	   liver	   injury	   (Czaja,	   2009).	   As	   mentioned	   in	   the	   Introduction	   (1.6.3	   –	   Clinical	  
evidence	   for	   Immunosuppression),	  MSCs	  have	  been	  used	  clinically	   in	  a	  variety	  of	   immune-­‐
mediated	   and	   autoimmune	   conditions	   including	   GvHD,	   SLE	   and	   Crohn’s	   Disease	   (Le	   Blanc	  
and	   Mougiakakos,	   2012).	   However,	   the	   evidence	   supporting	   MSC	   therapy	   in	   early-­‐to-­‐
medium	  stage	  AIH	  is	  limited	  to	  pre-­‐clinical	  animal	  models.	  Chen	  and	  colleagues	  demonstrate	  
that	   the	   systemic	   administration	   of	   murine	   MSCs	   ameliorated	   experimental	   AIH	   in	   mice	  
(Chen	  et	  al.,	  2014).	   Interestingly,	   they	  observed	  an	   improved	  response	  on	  serum	  ALT	  after	  
repeated	  dosing	  of	  MSCs.	  The	  majority	  of	  pre-­‐clinical	  and	  clinical	  studies	  have	  examined	  the	  
effect	  of	  MSC	  infusion	  in	  patients	  with	  late-­‐stage	  AIH,	  often	  those	  with	  decompensated	  liver	  





disease	   that	   require	   transplantation	   (Houlihan	   and	   Newsome,	   2008).	   As	   with	  most	   early-­‐
stage	  MSC	   trials,	   the	   results	   are	   varied	  with	   some	   studies	   showing	   clinical	   improvements	  
following	   infusion	   and	   others	   proving	   only	   the	   safety	   of	  MSC	   therapy	   (Meier	   et	   al.,	   2013,	  
Zhang	  and	  Wang,	  2013).	  Additionally,	  the	  majority	  of	  studies	  had	  poorly	  defined	  endpoints,	  
short-­‐term	   follow-­‐up	  or	   the	   lack	  of	   a	   comparator	   arm	  which	  makes	   it	   difficult	   to	  evaluate	  
therapeutic	  efficacy.	  Early	  work	  by	  Mohamadnejad	  et	  al.	  (2007)	  demonstrated	  MSC	  infusion	  
to	   be	   safe	   in	   a	   small-­‐scale	   trial	   involving	   four	   patients	   with	   decompensated	   cirrhosis.	  
Improvements	   in	   liver	   function	   were	   detected	   in	   2/4	   patients	   and	   improvements	   in	   QoL	  
questionnaire	  scores	  were	  seen	  in	  4/4	  patients	  after	  12	  months.	  A	  later	  study	  by	  the	  same	  
group	  recruited	  27	  patients	  with	  decompensated	  cirrhosis	  and	  randomised	  them	  to	  receive	  
either	  MSCs	  or	  placebo	  in	  a	  single-­‐blinded	  fashion	  (Mohamadnejad	  et	  al.,	  2013).	  Although	  no	  
adverse	   effects	   were	   seen	   after	   MSC	   infusion,	   no	   differences	   in	   liver	   function	   or	   liver	  
synthesis	  scores	  were	  observed	  between	  both	  arms	  of	  the	  study	  one	  year	  after	  treatment.	  
As	  such,	  the	  efficacy	  of	  MSC	  therapy	  in	  autoimmune	  liver	  disease	  still	  needs	  to	  be	  proven	  in	  
larger-­‐scale	   studies	   and	   questions	   still	   remain	   about	   the	  mechanism	  of	   action	   behind	   any	  
clinical	  improvements	  seen	  in	  patients	  after	  infusion.	  	  	  
	  
6.1.2	  Mouse	  model	  of	  Autoimmune	  Liver	  Injury	  (OVA-­‐Bil)	  
To	  test	  the	   in	  vivo	  efficacy	  of	  PαS	  MSCs,	  we	  utilised	  a	  transgenic	  mouse	  model	  of	  immune-­‐
mediated	  liver	  injury	  first	  described	  by	  Marion	  Peters’	  group	  in	  2006	  (Buxbaum	  et	  al.,	  2006).	  
OVA-­‐Bil	  mice	   express	  membrane	   bound	  ovalbumin	   (OVA)	   under	   the	   control	   of	   a	   bile	   acid	  
transporter	  promoter	  (ASBT	  –	  apical	  sodium-­‐dependent	  bile	  acid	  transporter).	  This	  limits	  the	  





expression	  of	  OVA	  to	  the	  biliary	  epithelium	  of	  their	  livers.	  OVA-­‐Bil	  mice	  are	  maintained	  on	  a	  
C57BL/6	   background	   and	   develop	   normally	   with	   no	   signs	   of	   liver	   inflammation	   when	  
assessed	  using	  histology	  (Figure	  6.1A),	  serum	  ALT	  or	  ALP.	  To	  induce	  immune-­‐mediated	  liver	  
injury,	   OVA-­‐specific	   CD8+	   T	   cells	   (isolated	   from	   OT-­‐1	   transgenic	   mice)	   and	   CD4+	   T	   cells	  
(isolated	   from	   OT-­‐2	   transgenic	   mice)	   are	   adoptively	   transferred	   into	   OVA-­‐Bil	   mice.	   These	  
OVA-­‐specific	   T	   cells	   migrate	   to	   the	   biliary	   tree	   where	   they	   proliferate	   and	   induce	   necro-­‐
inflammatory	   damage	   (Figure	   6.1A).	   Regions	   of	   interphase	   hepatitis,	   the	   characteristic	  
histological	  marker	  of	  AIH,	  could	  be	  seen	  around	  the	  portal	  triad	  in	  injured	  mice.	  The	  authors	  
identified	   through	   a	   series	   of	   dose-­‐titration	   experiments	   that	   co-­‐infusion	   of	   10x106	   OT1	  
splenocytes	  and	  4x106	  OT2	  splenocytes	  were	  optimal	  to	  cause	  peak	  liver	  injury.	  Interestingly,	  
infusion	   of	   up	   to	   10x106	  OT2	   splenocytes	   by	   itself	   does	   not	   result	   in	   any	   liver	   injury,	   and	  
infusion	   of	   OT1	   splenocytes	   alone	   only	   caused	   mild	   increases	   in	   liver	   transaminases,	  
suggesting	  that	  there	  is	  a	  synergistic	  partnership	  between	  OVA-­‐specific	  CD8	  and	  CD4	  T	  cells	  
in	  mediating	  liver	  injury	  in	  these	  animals.	  	  
	  
	  
Figure	  6.1	  |	   Induction	  of	   liver	   injury	   in	  OVA-­‐Bil	  mice.	   (A)	  H+E	  stained	  liver	  sections	  from	  normal	  and	  injured	  
OVA-­‐Bil	  mice.	   (B)	  Time	  course	  of	  serum	  ALT	  following	  adoptive	  transfer	  of	  OVA-­‐specific	  CD4	  and	  CD8	  T	  cells.	  
Figure	  modified	  from	  Buxbaum	  et	  al.	  (2006).	  	  





A	  time-­‐dependent	  30-­‐fold	  increase	  in	  serum	  ALT	  was	  observed	  following	  adoptive	  transfer	  of	  
OT1/OT2	  T	  cells	  (Figure	  6.1B).	  ALT	  readings	  peak	  at	  day	  10	  post	  adoptive	  transfer	  and	  drops	  
thereafter.	  The	  authors’	   report	   that	  histology	  and	  ALT	  readings	  return	  to	  baseline	  after	  28	  
days	  due	  to	  loss	  of	  adoptively	  transferred	  cells.	  Interestingly,	  only	  a	  two-­‐fold	  increase	  in	  ALP	  
was	   observed	   by	   Buxbaum	   and	   colleagues,	   demonstrating	   significant	   spillover	   of	   injury	  
towards	   hepatocytes	   from	   the	   OVA+	   biliary	   epithelium.	   In	   addition	   to	   changes	   in	   liver	  
transaminase	   enzymes,	   the	   authors	   also	   report	   a	   sharp	   increase	   in	   liver-­‐infiltrating	  
mononuclear	   cells,	  with	   the	  majority	   being	   Vα2+	   T	   cells,	   corresponding	   to	   the	   adoptively-­‐
transferred	  population.	   	  An	   increase	   in	   inflammatory	  cytokine	   (IFNγ	  and	  TNFα)	  production	  
was	  also	  observed	  during	  hepatobiliary	  inflammation.	  
	  
As	  such,	  OVA-­‐Bil	  mice	  are	  an	  antigen-­‐	  and	  organ-­‐specific	  model	  of	  immune-­‐mediated	  tissue	  
injury.	  Uninjured	  mice	  develop	  normally	  and	  show	  no	  signs	  of	  liver	  damage.	  Inflammation	  is	  
dependent	   on	   the	   adoptive	   transfer	   of	   OT1	   and	   OT2	   splenocytes,	   with	   OT1	   cells	   being	  
absolutely	  required	  and	  OT2	  cells	  augmenting	  the	  damage	  seen.	  Therefore,	  OVA-­‐Bil	  mice	  are	  
a	   model	   of	   alloimmune	   liver	   injury	   as	   host	   T	   cells	   are	   tolerant	   to	   the	   OVA	   antigen.	   The	  
symptoms	  displayed	  by	  injured	  mice	  closely	  resemble	  patients	  with	  AIH	  as	  we	  could	  observe	  
regions	  of	   interface	  hepatitis	   in	   injured	  animals.	  Additionally,	   significant	   increases	  ALT,	  but	  
not	  ALP	  give	  further	  evidence	  for	  their	  AIH	  phenotype.	  One	  key	  disadvantage	  of	  this	  model	  is	  
the	  transient	  nature	  of	  inflammation,	  which	  peaks	  at	  day	  10	  and	  falls	  thereafter	  due	  to	  the	  
loss	   of	   adoptively-­‐transferred	   cells.	   The	   natural	   resolution	   of	   injury	   in	  OVA-­‐Bil	  mice	  mean	  
that	   these	   animals	   do	   not	   develop	   liver	   cirrhosis	   or	   undergo	   liver	   failure,	   which	   are	  
frequently	  observed	  in	  patients	  with	  late-­‐stage	  AIH	  (Manns	  et	  al.,	  2010).	  	  





	   6.1.3	  Chapter	  Aims	  
Our	  previous	  findings	  show	  that	  PαS	  MSCs	  can	  suppress	  the	  proliferation	  of	  CD4	  and	  CD8	  T	  
cells	   in	   vitro,	   and	   that	   TGF-­‐β1	   supplementation	   can	   maintain	   the	   immunomodulatory	  
properties	   of	   these	   cells	   over	   extended	   in	   vitro	   culture.	   The	   aims	   of	   this	   chapter	  were	   to	  
characterise	   the	   immunosuppressive	   properties	   of	   PαS	   in	   vivo	   using	   the	  OVA-­‐Bil	  model	   of	  
hepatobiliary	  injury.	  The	  specific	  aims	  of	  this	  chapter	  were	  to:	  
	  
1. Establish	  the	  transgenic	  mouse	  colonies	  required	  to	  perform	  the	  OVA-­‐Bil	  model	  
2. Characterise	  the	  inflammatory	  damage	  seen	  in	  OVA-­‐Bil	  mice	  
3. Examine	   the	   effect	   of	   early-­‐passage	   PαS	  MSC	   infusion	   on	   overall	   liver	   damage,	  
infiltrating	  leukocyte	  numbers	  and	  their	  activation	  status	  
4. Examine	  the	  effect	  of	  late-­‐passage	  TGF-­‐β1	  primed	  PαS	  MSCs	  in	  vivo	  	  
	   	  






6.2.1	  Genotyping	  and	  Confirmation	  of	  OVA	  Expression	  
OVA-­‐Bil	  mice	  were	  maintained	  as	  heterozygotes	  on	  a	  C57BL/6	  background.	  Confirmation	  of	  
OVA	   expression	   was	   performed	   using	   conventional	   PCR	   as	   described	   by	   Buxbaum	   et	   al.	  
(2006).	  OVA+	  mice	  produce	  a	  band	  approximately	  990bp	  in	  size	  (Figure	  6.2A).	  OT-­‐1	  mice	  are	  
also	  maintained	  on	  a	  C57BL/6	  background	  and	  confirmation	  of	  OVA-­‐specific	  transgenic	  T	  cell	  
receptor	   expression	  was	   performed	  using	   PCR	   as	   described	  by	  Wright	   et	   al.	   (2005).	  OT-­‐1+	  
mice	  produce	  a	  band	  approximately	  250bp	  in	  size	  (Figure	  6.2B).	  OT-­‐2	  mice	  were	  maintained	  
as	  homozygotes	  and	  genotyping	  of	  breeders	  was	  outsourced	  to	  Transnetyx	  (Cordova,	  USA).	  	  
	  
Figure	  6.2	  |	  Genotyping	  OVA-­‐Bil	  and	  OT-­‐1	  mice.	  (A)	  OVA+	  mice	  produce	  a	  band	  990bp	  in	  size.	  Mice	  in	  lanes	  3-­‐8	  
were	  negative	  for	  the	  OVA	  transgene.	  (B)	  OT-­‐1+	  mice	  produce	  a	  band	  250bp	  in	  size.	  Mice	  in	  lanes	  1-­‐5	  and	  10	  
were	  negative	  for	  the	  OT-­‐1	  transgene.	  Control	  (Ctrl)	  lanes	  contained	  no	  DNA	  in	  PCR	  reaction.	  	  





Chromogenic	   immunohistochemistry	  (IHC)	  was	  used	  to	  confirm	  expression	  of	  ovalbumin	  at	  
the	  protein	   level.	   Liver	   sections	   from	  12-­‐week	  old	  OVA+	  OVA-­‐Bil	  mice	  were	  cut,	   incubated	  
with	  an	  anti-­‐ovalbumin	  antibody	  and	  counterstained	  using	  H&E.	  No	  positive	  staining	  could	  
be	  seen	  in	  the	  isotype-­‐matched	  controls	  (Figure	  6.3).	  Although	  the	  DAB	  stain	  was	  very	  faint,	  
expression	   of	   ovalbumin	   was	   confined	   to	   biliary	   epithelial	   cells	   of	   the	   liver	   (Figure	   6.3	  
arrowheads).	  No	  signs	  of	  liver	  damage	  or	  leukocytic	  infiltrate	  could	  be	  observed	  in	  the	  livers	  
of	  uninjured	  animals,	  confirming	  the	  previous	  findings	  of	  Buxbaum	  et	  al.	  (2006).	  
	  
	  
Figure	  6.3	  |	  Localisation	  of	  ovalbumin	  expression	  in	  OVA-­‐Bil	  mice.	  12-­‐week	  old	  male	  OVA-­‐Bil	  mice	  livers	  were	  
cut	  and	  incubated	  with	  an	  isotype	  matched	  control	  or	  ovalbumin	  antibody.	  Sections	  were	  counterstained	  using	  
H&E	  prior	  to	  imaging.	  Images	  taken	  at	  200x	  magnification.	  Scale	  bar,	  100µm.	  





	   6.2.2	  Time	  course	  of	  Liver	  Injury	  
Adoptive	  transfer	  of	  10x106	  OT-­‐1	  splenocytes	  and	  4x106	  OT-­‐2	  splenocytes	  via	  intraperitoneal	  
(IP)	   infusion	   into	  OVA-­‐Bil	  mice	  results	   in	  their	  migration	  to	  the	   liver	  where	  they	  proliferate	  
and	   cause	  damage.	   To	  assess	   the	   time	   course	  of	   liver	   injury,	   serum	  ALT	  and	  ALP	   readings	  
were	   taken	  at	  different	  periods	   after	   adoptive	   transfer.	   Significant	   increases	   in	   serum	  ALT	  
was	  observed	  between	  uninjured	  controls	  (22±8.5	  IU/L)	  and	  days	  eight	  (264±140	  IU/L),	  nine	  
(294±141	  IU/L)	  and	  ten	  (643±184	  IU/L)	  post-­‐adoptive	  transfer	  (Figure	  6.4A).	  As	  described	  by	  
Buxbaum	  et	  al.	  (2006),	  we	  too	  observed	  a	  peak	  in	  serum	  ALT	  at	  day	  10	  followed	  by	  a	  sharp	  
drop	  by	  day	  11	  (164±36	  IU/L)	  due	  to	  loss	  of	  adoptively	  transferred	  cells.	  Compared	  to	  ALT,	  
which	  rose	  approximately	  30-­‐fold	  compared	  to	  controls,	  serum	  ALP	  levels	  only	  rose	  2-­‐fold	  in	  
injured	  mine	  and	  remained	  elevated	  at	  day	  11	  (Figure	  6.4B).	  Due	  to	  its	  increased	  sensitivity,	  
serum	  ALT	  was	  chosen	  as	  a	  marker	  of	  overall	  liver	  injury	  for	  downstream	  experiments.	  	  
	  
Figure	  6.4	  |	  Time	   course	   of	   liver	   injury	   in	  OVA-­‐Bil	  mice.	  Mouse	  serum	  was	  analysed	   for	   the	  activity	  of	   liver	  
enzymes	  ALT	   (A)	  and	  ALP	   (B)	   following	  adoptive	   transfer	  of	  OT-­‐1	  and	  OT-­‐2	  splenocytes.	  Data	   represented	  as	  
mean±SD.	  Each	  data	  point	   represents	  one	  animal.	   Statistical	   analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  
Bonferroni’s	  Multiple	  Comparison	  Test.	  	  





	   6.2.3	  Liver	  Histology	  after	  Injury	  
Liver	   sections	   from	  uninjured	  and	  day	  10	   injured	  OVA-­‐Bil	  mice	  were	   fixed	   in	   formalin	   and	  
processed	  for	  IHC.	  H&E	  staining	  revealed	  normal	  liver	  architecture	  in	  uninjured	  animals	  with	  
no	  visible	  immune	  reaction	  against	  OVA+	  biliary	  cells	   in	  the	  portal	  areas	  of	  the	  liver	  (Figure	  
6.5A).	  Following	  injury,	  a	  widespread	  disruption	  of	  portal	  areas	  by	  infiltrating	  immune	  cells	  
could	  be	  seen	   (Figure	  6.5B).	  Regions	  of	   interphase	  hepatitis	  could	  be	  seen	  around	  the	  bile	  
ducts,	   and	   clusters	   of	   lymphocytes	   could	   also	   be	   observed	   in	   the	  wider	   liver	   parenchyma	  
(Figure	   6.5C).	   As	   ovalbumin	   is	   not	   expressed	   on	   hepatocytes,	   it	   was	   interesting	   to	   see	  
substantial	  spillover	  of	  lymphocytes	  into	  lobular	  regions.	  	  
	  
CD45	  was	  used	  to	  mark	  all	  leukocytes	  (Fedorcsák	  et	  al.,	  2007)	  and	  the	  F4/80	  antigen	  used	  to	  
mark	  murine	  macrophages	   in	   the	   livers	   of	   OVA-­‐Bil	  mice	   (Austyn	   and	   Gordon,	   1981).	   Low	  
numbers	   of	   CD45+	   leukocytes	   or	   F4/80+	   macrophages	   were	   detected	   in	   uninjured	   mice	  
(Figure	   6.5D,G).	   A	   sharp	   increase	   in	   the	   number	   of	   cells	   expressing	   either	   antigen	   was	  
observed	  in	  portal	  areas	  after	  injury.	  Matching	  the	  observations	  of	  the	  H&E	  stained	  sections,	  
spillover	  of	  CD45+	   cells	   into	   lobular	   regions	  was	  also	  observed,	  with	   clusters	  of	   leukocytes	  
present	   in	   parenchymal	   areas	   after	   injury	   (Figure	   6.5E,F).	   The	   numbers	   of	   F4/80+	   hepatic	  
macrophages	   in	  portal	  and	  lobular	  regions	  also	   increased	  after	   injury	  (Figure	  6.5H,I).	  These	  
findings	  suggest	  that	  although	  the	  damage	  is	  primarily	  targeted	  against	  biliary	  epithelium	  in	  
OVA-­‐Bil	  mice,	   there	   is	   considerable	   spillover	  of	  mononuclear	   infiltrate	   into	   lobular	   regions	  
resulting	  in	  moderate	  interphase	  hepatitis.	  This	  spillover	  of	  damage-­‐causing	  OT-­‐1	  and	  OT-­‐2	  
cells	  into	  lobular	  areas	  could	  account	  for	  the	  increase	  in	  serum	  ALT	  observed	  in	  this	  model.	  






Figure	  6.5	  |	  Liver	   Histology	   of	  OVA-­‐Bil	  mice	   after	   injury.	  Representative	   images	  of	  uninjured	  and	   injured	  mice	   (Day	  10)	   stained	  using	  H&E	   (A-­‐C)	  and	  antibodies	  
against	  CD45	  (D-­‐F)	  and	  F4/80	  (G-­‐I).	  Images	  A-­‐G	  were	  taken	  at	  200x	  magnification.	  	  Images	  H	  &	  I	  were	  taken	  at	  400x	  magnification.	  Scale	  bar,	  100µm.	  





	   6.2.4	  Effects	  of	  Early-­‐Passage	  PαS	  MSC	  infusion	  in	  the	  OVA-­‐Bil	  model	  
	   	   6.2.4.1	  Effect	  on	  Serum	  ALT	  
Our	   in	  vitro	  data	  shows	  that	  PαS	  MSCs	  cultured	   in	  SM	  were	   the	  most	  suppressive	  at	  early	  
passages	  (P3),	  but	  this	  ability	  was	  lost	  as	  cells	  became	  increasingly	  senescent.	  Cells	  expanded	  
in	  TGF-­‐β1	  medium	  were	  not	  as	  potent	  as	  SM	  cells	  early	  on,	  but	  TGF-­‐β1	  supplementation	  was	  
able	  to	  maintain	  the	  immunosuppressive	  potential	  over	  several	  passages.	  To	  back	  up	  these	  
in	  vitro	  findings,	  the	  OVA-­‐Bil	  model	  was	  used	  to	  test	  the	  in	  vivo	  immunosuppressive	  effects	  
of	  early-­‐passage	  PαS	  MSCs	  to	  see	  whether	  they	  could	  dampen	  liver	  injury	  in	  these	  animals.	  
	  
PαS	  MSCs	  expanded	  in	  SM±TGF-­‐β1	  were	  used	  at	  P4	  for	   in	  vivo	  studies.	  Two	  doses	  of	  1x106	  
MSCs	  were	  given	  via	  IP	  infusions	  after	  the	  induction	  of	  injury	  at	  days	  3	  and	  7.	  Animals	  were	  
then	   sacrificed	   at	   day	   10	   for	   analysis	   of	   liver	   inflammation	   (Figure	   6.6A).	   The	   timings	   and	  
dosage	  of	  MSCs	  were	  chosen	  after	  reviewing	  recent	   literature,	  which	  suggested	  that	  MSCs	  
were	  short-­‐lived	  and	  need	  to	  be	  in	  an	  inflammatory	  environment	  to	  be	  active	  (Krampera	  et	  
al.,	   2013).	   Day	   10	   was	   chosen	   as	   the	   end	   point	   from	   our	   earlier	   ALT	   time	   course	   data	  
showing	  peak	  damage	  at	  this	  time	  (Figure	  6.4A).	  	  
	  
Serum	   ALT	   levels	   were	   recorded	   in	   control	   and	   MSC-­‐treated	   animals	   to	   measure	   overall	  
hepatic	   damage	   (Figure	   6.6B).	   Significant	   reductions	   in	   ALT	   were	   observed	   in	   animals	  
receiving	   SM	  MSC	   treatment	   (339±220	   IU/L)	   compared	   to	   control	   animals	   (818±452	   IU/L,	  
p=0.005).	   TGF-­‐β1	   primed	   MSCs	   also	   caused	   a	   reduction	   in	   serum	   ALT	   (585±355	   IU/L)	  





compared	  to	  controls,	  but	  this	  difference	  did	  not	  reach	  statistical	  significance	  (p=0.2).	  These	  
findings	   back	   up	   our	   earlier	   in	   vitro	   data	   that	   showed	   early	   passage	   SM	   cells	   were	  more	  
suppressive	  than	  TGF-­‐β1	  primed	  cells.	  	  	  	  	  
	  
	  
Figure	   6.6	   |	  Effect	   of	   PαS	  MSC	   infusion	   on	   serum	   ALT	   readings	   from	   OVA-­‐Bil	   mice.	   (A)	   Experimental	   plan	  
outlining	  initiation	  of	  injury	  (Day	  0)	  followed	  by	  two	  MSC	  doses	  at	  days	  3	  and	  7	  and	  the	  end	  point	  at	  day	  10.	  (B)	  
Serum	   ALT	   from	   untreated	   control	   mice	   (n=13),	   P4	   SM-­‐primed	  MSC	   treated	   animals	   (n=11)	   and	   P4	   TGF-­‐β1	  
primed	  MSC	  treated	  animals	  (n=10).	  All	  mice	  were	  age	  and	  sex-­‐matched	  for	  each	  experiment.	  Data	  shown	  as	  
mean±SD.	  Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  
	   	  





	   	   6.2.4.2	  Characterisation	  of	  Liver	  Lymphocyte	  Populations	  
Flow	   cytometric	   analysis	   of	   liver-­‐infiltrating	   lymphocytes	  was	   performed	   to	   elucidate	   how	  
PαS	  MSCs	  were	  reducing	  serum	  ALT	  in	  injured	  animals.	  Liver	  lobes	  from	  day	  10	  animals	  were	  
weighed	   and	   processed	   to	   form	   a	   single	   cell	   suspension.	   Lymphocytes	  were	   then	   isolated	  
and	   stained	  with	   relevant	   antibodies.	   A	   live/dead	  marker	   was	   used	   to	   remove	   dead	   cells	  
from	   downstream	   analysis	   and	   absolute	   counts	   from	   the	   flow	   cytometer	   were	   then	  
normalised	  to	  the	  weights	  of	  the	  starting	  liver	  lobes	  to	  allow	  comparison	  between	  mice.	  	  	  
	  
One	   potential	  mechanism	   behind	   the	   beneficial	   effects	   seen	  with	  MSC	   infusion	   is	   via	   the	  
reduction	   of	   total	   leukocyte	   numbers	   in	   models	   of	   injury	   (Ma	   et	   al.,	   2014,	   Le	   Blanc	   and	  
Mougiakakos,	   2012,	   Uccelli	   et	   al.,	   2008).	   Analysis	   of	   viable	   CD3+	   lymphocytes	   revealed	   a	  
significant	  drop	   in	  the	  numbers	  of	  cells	   isolated	  from	  the	   livers	  of	  SM-­‐primed	  MSC-­‐treated	  
animals	   (225,119±150,669	   cells	   per	   gram	   of	   liver	   tissue)	   compared	   to	   control	   animals	  
(421,551±169,367	   cells	   /g	   liver,	   p=0.03,	   Figure	   6.7A).	   A	   non-­‐significant	   reduction	   was	  
observed	  in	  TGF-­‐β1	  primed	  MSC-­‐treated	  animals	  (305,848±173,589	  cells	  /g	  liver).	  Division	  of	  
CD3+	  T	  lymphocytes	  into	  CD3+CD4+	  T	  helper	  cells	  (Figure	  6.7B)	  and	  CD3+CD8+	  cytotoxic	  T	  cells	  
(Figure	  6.7C)	  revealed	  non-­‐significant	  reductions	  in	  MSC-­‐treated	  animals.	  Approximately	  2	  to	  
3-­‐fold	   higher	   numbers	   of	   CD8+	   T	   cells	   were	   isolated	   than	   their	   CD4+	   counterparts.	   These	  
findings	   suggest	   that	  MSC	   infusion	   produces	   improvements	   in	   serum	  ALT	   by	   reducing	   the	  
total	  numbers	  of	  damage-­‐causing	  lymphocytes	  in	  the	  livers	  of	  OVA-­‐Bil	  animals.	  
	   	  






Figure	  6.7	  |	  Quantification	   of	   liver	   lymphocyte	   populations	   from	  OVA-­‐Bil	  mice.	   Lymphocytes	  were	   isolated	  
using	  density	  gradient	  separation	  and	  absolute	  cell	  counts	  were	  normalised	  to	  the	  weights	  of	  the	  starting	  liver	  
lobe	  to	  allow	  comparison	  between	  animals.	  (A)	  Number	  of	  viable	  CD3+	  lymphocytes.	  (B)	  Number	  of	  viable	  CD4+	  
T	  helper	  cells.	  (C)	  Number	  of	  viable	  CD8+	  cytotoxic	  T	  cells.	  Data	  shown	  as	  mean±SD.	  Each	  data	  point	  represents	  
one	  animal.	  Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  
	  
In	   addition	   to	   their	   ability	   to	   decrease	   total	   lymphocyte	   numbers	   at	   sites	   of	   injury,	  MSCs	  
have	  also	  been	  reported	  to	  reduce	  the	  activation	  status	  of	  lymphocytes	  in	  vivo	  (Hof-­‐Nahor	  et	  
al.,	  2012,	  Park	  et	  al.,	  2011,	  Ding	  et	  al.,	  2009,	  Le	  Blanc	  et	  al.,	  2004a).	  To	  test	  this	  hypothesis,	  
we	  examined	  the	  expression	  of	  the	  early	  T	  cell	  activation	  marker	  CD69	  (Ziegler	  et	  al.,	  1994)	  
and	   the	   IL-­‐2	   receptor	  alpha	   chain	  CD25	   (Caruso	  et	  al.,	   1997)	  on	  CD4	  and	  CD8	  populations	  
isolated	  from	  OVA-­‐Bil	  mouse	  livers	  (Figure	  6.8).	  In	  general,	  there	  was	  considerable	  variation	  
in	  the	  activation	  status	  of	  lymphocytes	  isolated	  from	  control	  or	  MSC	  treated	  animals	  but	  the	  





mean	  values	  across	  all	  samples	  were	  broadly	  similar.	  CD25	  expression	  on	  CD8+	  T	  cells	  gave	  
mixed	  results,	  with	  one	  population	  of	  high	  expressers	  (5-­‐15%)	  and	  another	  population	  of	  low	  
expressers	  (<2%;	  Figure	  6.8D).	  	  More	  repeats	  are	  necessary	  to	  discern	  whether	  this	  was	  due	  
to	  operator	  error	  or	  whether	  this	  is	  a	  reproducible	  biological	  finding.	  In	  summary,	  the	  results	  
show	  that	  PαS	  MSC	   infusion	  significantly	   reduces	  total	  numbers	  of	   lymphocytes	   in	  OVA-­‐Bil	  
mice,	  but	  the	  activation	  status	  of	  the	  cells	  that	  remain	  seems	  unchanged.	  	  
	  
	  
Figure	  6.8	  |	  Activation	  marker	  expression	  of	   liver	   lymphocyte	  populations	  from	  OVA-­‐Bil	  mice.	  Lymphocytes	  
were	   isolated	   using	   density	   gradient	   separation	   from	   day	   10	   OVA-­‐Bil	   animals	   and	   analysed	   using	   flow	  
cytometry.	  The	  percentage	  of	  CD69	  and	  CD25	  positive	  T	  helper	  cells	  (A	  and	  B)	  and	  cytotoxic	  T	  cells	  (C	  and	  D)	  
were	  recorded.	  Data	  shown	  as	  mean±SD.	  Each	  data	  point	  represents	  one	  animal.	  





	   	   6.2.4.3	  Histological	  Analysis	  of	  MSC-­‐treated	  Animals	  
Liver	   sections	   from	   day	   10	   MSC-­‐treated	   OVA-­‐Bil	   animals	   were	   processed	   to	   examine	  
inflammation	   in	   more	   detail.	   H&E	   staining	   was	   performed	   to	   examine	   the	   numbers	   of	  
infiltrating	   immune	  cells	  and	  overall	   liver	  morphology.	  As	  suggested	  by	  the	  flow	  cytometry	  
data	  (Figure	  6.7),	  there	  appears	  to	  be	  a	  decrease	  in	  the	  number	  of	  infiltrating	  cells	  in	  MSC-­‐
treated	   animals	   compared	   to	   injured	   controls	   (Figure	   6.9).	   However,	   disruption	   of	   portal	  
areas	   by	   infiltrating	   immune	   cells	   could	   be	   seen	   in	   all	   groups,	   and	   there	  were	   clusters	   of	  
immune	  cells	  located	  in	  the	  wider	  liver	  parenchyma	  as	  well.	  	  
	  
	  
Figure	   6.9	   |	  H&E	   stained	   livers	   of	   MSC-­‐treated	   OVA-­‐Bil	   mice.	   Representative	   images	   of	   H&E	   stained	   liver	  
sections	  from	  injured	  and	  MSC-­‐treated	  animals.	  All	  images	  taken	  at	  100x	  magnification.	  Bar,	  100µm.	  	  
	  
Expression	   of	   the	   pan-­‐leukocyte	   marker	   CD45	   was	   used	   to	   quantify	   the	   differences	   in	  
immune	  cell	  number	  seen	  between	  groups.	  Multiple	   images	  of	  portal	  and	   lobular	  areas	  of	  
the	   liver	   were	   taken	   from	   each	   mouse	   under	   high	   magnification	   (Figure	   6.10A)	   and	   the	  
amount	  of	  staining	  quantified	  using	  Image	  J	  software	  (Figure	  6.10B).	  As	  expected,	  there	  was	  
a	   significant	   increase	   in	   CD45	   staining	   after	   injury	   in	   both	   portal	   and	   lobular	   regions	  
compared	  to	  uninjured	  controls.	  A	  significant	  reduction	  in	  CD45	  staining	  was	  seen	  in	  animals	  
receiving	   SM-­‐primed	  MSCs	   compared	   to	   injured	   controls	   in	   portal	   regions	   (20.5±9.1%	   vs.	  





9.0±5.1%	   CD45	   positive,	   p=0.02).	   Animals	   receiving	   TGF-­‐β1	   primed	   MSCs	   also	   displayed	  
significant	  reductions	  in	  CD45	  staining	  in	  portal	  regions	  compared	  to	  controls	  (20.5±9.1%	  vs.	  
9.7±2.8%	  CD45	  positive,	  p=0.03).	  Reductions	  in	  CD45	  staining	  were	  also	  observed	  in	  lobular	  
regions	  following	  MSC	  infusion,	  although	  these	  failed	  to	  reach	  statistical	  significance.	  	  	  
	  
Expression	   of	   F4/80	   antigen	   was	   then	   examined	   to	   quantify	   murine	   macrophages	   in	   the	  
livers	  of	  OVA-­‐Bil	   animals	   after	  MSC	   treatment.	  Multiple	   images	  were	   taken	  of	  both	  portal	  
and	   lobular	   regions	  of	   the	   liver	   (Figure	  6.11A)	  and	  the	  amount	  of	  staining	  quantified	  using	  
Image	   J	   software	   (Figure	   6.11B).	   As	   expected,	   significant	   increases	   in	   F4/80	   staining	   was	  
observed	  in	  injured	  animals	  compared	  to	  uninjured	  controls.	  Interestingly,	  SM-­‐primed	  MSC	  
treatment	  resulted	   in	  a	  small,	  non-­‐significant	  reduction	   in	  macrophage	  numbers	  compared	  
to	   injured	   controls	   in	   both	   portal	   (19.1±4.6%	   vs.	   15.9±3.7%	   F4/80	   positive,	   p=0.7)	   and	  
lobular	  regions	  (19.6±6.0%	  vs.	  16.2±3.2%	  positive,	  p=0.7).	  In	  contrast,	  animals	  receiving	  TGF-­‐
β1	   primed	   MSC	   treatment	   had	   significant	   reductions	   in	   F4/80	   staining	   in	   both	   portal	  
(19.1±4.6%	  vs.	  11.1±4.3%	  positive,	  p=0.006)	  and	  lobular	  (19.6±6.0%	  vs.	  12.3±2.9%	  positive,	  
p=0.02)	  regions	  compared	  to	  injured	  controls.	  The	  reason	  behind	  the	  selective	  retention	  of	  
macrophage	   numbers	   following	   SM-­‐primed,	   but	   not	   TGF-­‐β1	   primed	   MSC	   treatment	   is	  
currently	   unknown,	   and	   further	   work	   looking	   at	   macrophage	   polarisation	   is	   required	   to	  
elucidate	  the	  significance	  of	  this	  finding.	  	  
	   	  









Figure	  6.10	  |	  CD45	  expression	  in	  the	  livers	  of	  OVA-­‐Bil	  mice.	  (A)	  Representative	  images	  of	  CD45	  staining	  from	  
control	   and	   MSC-­‐treated	   OVA-­‐Bil	   mouse	   livers.	   All	   images	   taken	   at	   400x	   magnification.	   Bar,	   100µm.	   (B)	  
Quantification	   of	   CD45	   staining	   using	   Image	   J.	   Five	   images	   each	  were	   taken	   of	   portal	   and	   lobular	   areas	   for	  
quantification	  from	  uninjured	  controls	  (n=2),	  injured	  controls	  (n=7),	  SM-­‐primed	  MSCs	  (n=6)	  and	  TGF-­‐β	  primed	  
MSCs	  (n=6).	  Data	  shown	  as	  mean±SD.	  Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  
Multiple	  Comparison	  Test.	  	  
	  
	   	  










Figure	  6.11	  |	  F4/80	  expression	  in	  the	  livers	  of	  OVA-­‐Bil	  mice.	  (A)	  Representative	  images	  of	  F4/80	  staining	  from	  
control	   and	   MSC-­‐treated	   OVA-­‐Bil	   mouse	   livers.	   All	   images	   taken	   at	   400x	   magnification.	   Bar,	   100µm.	   (B)	  
Quantification	   of	   F4/80	   staining	   using	   Image	   J.	   Five	   images	   each	  were	   taken	   of	   portal	   and	   lobular	   areas	   for	  
quantification	  from	  uninjured	  controls	  (n=2),	  injured	  controls	  (n=8),	  SM-­‐primed	  MSCs	  (n=9)	  and	  TGF-­‐β	  primed	  
MSC	   animals	   (n=7).	   Data	   shown	   as	   mean±SD.	   Statistical	   analysis	   performed	   using	   One-­‐way	   ANOVA	   with	  
Bonferroni’s	  Correction.	  	  
	   	  





	   6.2.5	  Effects	  of	  Late-­‐Passage	  PαS	  MSC	  infusion	  in	  the	  OVA-­‐Bil	  model	  
	   	   6.2.5.1	  Effect	  on	  Serum	  ALT	  
Our	   in	   vitro	   and	   in	   vivo	   findings	   demonstrate	   that	   early-­‐passage	   (P4	   or	   lower)	   PαS	  MSCs	  
expanded	  in	  SM	  were	  more	  immunosuppressive	  than	  TGF-­‐β1	  supplemented	  cells.	  However,	  
SM-­‐primed	  MSCs	  lost	  their	  suppressive	  potential	  by	  P7	  due	  to	  the	  onset	  of	  senescence.	  TGF-­‐
β1	  supplementation	  was	  shown	  to	  maintain	  their	  immunomodulatory	  properties	   in	  vitro	  by	  
delaying	   the	  onset	  of	   senescence.	  Here,	  we	  again	  used	   the	  OVA-­‐Bil	  model	   to	  examine	   the	  
effect	  of	  late-­‐passage	  (P7)	  MSCs	  to	  see	  whether	  SM-­‐primed	  cells	  lost	  their	  ability	  to	  reduce	  
liver	   injury	  and	  observe	  whether	  TGF-­‐β1	  primed	  cells	  maintained	  their	   immunosuppressive	  
properties	  in	  vivo.	  	  
	  
Two	  doses	  of	   1x106	  MSCs	  were	   given	   via	   IP	   infusions	   after	   the	   induction	  of	   liver	   injury	   as	  
described	  before	  (Figure	  6.6A).	  Animals	  were	  sacrificed	  at	  day	  10	  and	  serum	  ALT	  levels	  were	  
recorded	  in	  controls	  and	  P7	  MSC-­‐treated	  animals	  to	  measure	  overall	  hepatic	  damage	  (Figure	  
6.12).	  No	  significant	  differences	  were	  observed	  between	  control	  animals	  (680±194	  IU/L)	  and	  
P7	   SM-­‐primed	  MSCs	   (580±77	   IU/L),	   validating	   our	   previous	   in	   vitro	   findings.	   Late-­‐passage	  
TGF-­‐β	  primed	  MSC	  infused	  caused	  the	  biggest	  mean	  reduction	  in	  serum	  ALT	  (410±300	  IU/L),	  
but	  the	  small	  sample	  size	  and	  variation	  observed	  between	  animals	  prevents	  this	  from	  being	  
statistically	  significant.	  Further	  repeats	  are	  required	  to	  increase	  our	  sample	  size	  to	  pick	  out	  
any	  potential	  significant	  differences	  between	  groups.	  	  
	   	  






Figure	   6.12	   |	   Effect	   of	   late-­‐passage	   PαS	   MSCs	   on	   serum	   ALT	   readings	   in	   OVA-­‐Bil	   mice.	   Serum	   ALT	   was	  
quantified	  from	  control	  animals	  (n=4),	  P7	  SM-­‐primed	  MSC-­‐treated	  animals	  (n=3)	  and	  P7	  TGF-­‐β1	  primed	  MSC-­‐
treated	   animals	   (n=4).	   All	   mice	   were	   age	   and	   sex-­‐matched	   for	   each	   experiment.	   Data	   shown	   as	   mean±SD.	  
Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	  	  
	  
	   	   6.2.5.2	  Characterisation	  of	  Liver	  Lymphocyte	  Populations	  
Flow	   cytometric	   analysis	   of	   liver-­‐infiltrating	   lymphocytes	   was	   performed	   to	   examine	   how	  
late-­‐passage	   PαS	   MSCs	   were	   working	   in	   this	   model.	   Total	   lymphocyte	   numbers	   were	  
quantified	   from	   all	   animals	   to	   examine	   whether	   late-­‐passage	   MSC	   treatment	   caused	   a	  
reduction	   in	   overall	   lymphocyte	   numbers	   in	   OVA-­‐Bil	   mice.	   Analysis	   of	   total	   viable	   CD3+	  
lymphocytes	   revealed	   a	   significant	   drop	   in	   animals	   receiving	   P7	   TGF-­‐β1	   primed	   MSCs	  
(90,220±30,000	   cells	   per	   gram	   of	   liver	   tissue)	   compared	   to	   injured	   control	   mice	  
(245,600±76,000	  cells	  /g	  liver,	  p=0.02,	  Figure	  6.13A).	  A	  mean	  reduction	  was	  also	  observed	  in	  





P7	  SM-­‐primed	  MSC-­‐treated	  animals	   (160,000±87,000	  cells	   /g	   liver)	  but	   this	   failed	   to	   reach	  
statistical	  significance.	  Sub-­‐division	  of	  CD3+	  T	   lymphocytes	  into	  CD4+	  T	  helper	  cells	  revealed	  
non-­‐significant	  reductions	  in	  MSC-­‐treated	  animals	  (Figure	  6.13B).	  However,	  quantification	  of	  
viable	  CD8+	  cytotoxic	  T	  cells	  revealed	  a	  significant	  reduction	  in	  the	  TGF-­‐β1	  group	  compared	  
to	  controls	  (71,100±18,000	  vs.	  31,400±14,000	  cells	  /g	  liver	  tissue,	  p=0.03,	  Figure	  6.13C).	  	  
	  
Figure	   6.13	   |	   Quantification	   of	   liver	   lymphocyte	   populations	   after	   late-­‐passage	   MSC	   treatment.	   Viable	  
lymphocytes	  were	  isolated	  using	  density	  gradient	  separation	  and	  absolute	  cell	  counts	  were	  normalised	  to	  the	  
weights	   of	   the	   starting	   liver	   lobe	   to	   allow	   comparison	   between	   animals.	   (A)	   Total	   number	   of	   viable	   CD3+	  
lymphocytes.	  (B)	  Number	  of	  viable	  CD4+	  T	  helper	  cells.	  (C)	  Number	  of	  viable	  CD8+	  cytotoxic	  T	  cells.	  Data	  shown	  
as	  mean±SD.	  Each	  data	  point	  represents	  one	  animal.	  Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  
Bonferroni’s	  Multiple	  Comparison	  Test.	  





The	  activation	  status	  of	  lymphocytes	  was	  examined	  by	  recording	  CD69	  and	  CD25	  expression.	  
In	  general,	   there	  was	  some	  variation	  but	   the	  mean	  values	  across	  all	   samples	  were	  broadly	  
similar.	   However,	   a	   significant	   reduction	   in	   CD69	   expression	   on	   CD4+	   T	   helper	   cells	   was	  
observed	  in	  animals	  receiving	  TGF-­‐β1	  primed	  MSC	  treatment	  compared	  to	  controls	  (29±3%	  
vs.	   21±1%	   CD69	   positive,	   p=0.01,	   Figure	   6.14A).	   Due	   to	   the	   low	   sample	   size,	   the	  
interpretation	   of	   these	   results	   is	   limited.	   Nevertheless,	   these	   findings	   suggest	   that	   late-­‐
passage	  MSCs	  work	  in	  a	  similar	  fashion	  to	  early-­‐passage	  cells	  by	  significantly	  reducing	  total	  
lymphocyte	  numbers	  but	  having	  a	  more	  modest	  effect	  on	  lymphocyte	  activation	  status.	  	  
	  
Figure	   6.14	   |	   Activation	   status	   of	   liver	   lymphocyte	   populations	   after	   late-­‐passage	   MSC	   treatment.	   The	  
percentage	  of	  CD69	  and	  CD25	  positive	  T	  helper	  cells	   (A	  and	  B)	  and	  cytotoxic	  T	  cells	   (C	  and	  D)	  was	  recorded.	  
Data	  shown	  as	  mean±SD.	  Each	  data	  point	  represents	  one	  animal.	  Statistical	  analysis	  performed	  using	  One-­‐way	  
ANOVA	  with	  Bonferroni’s	  Multiple	  Comparison	  Test.	   	  





	   	   	   6.2.5.2.1	  Analysis	  of	  Adoptively-­‐transferred	  Cells	  
The	  OVA-­‐Bil	  model	   is	  based	  on	  the	  adoptive	  transfer	  of	  damage-­‐causing	  OVA-­‐specific	  OT-­‐1	  
and	  OT-­‐2	  T	  cells	  into	  recipient	  OVA+	  mice.	  All	  OT-­‐1	  and	  OT-­‐2	  donor	  lymphocytes	  express	  Vα2	  
Vβ5	  chains	  on	  their	  T	  cell	   receptor	   (Gray	  et	  al.,	  2012,	  Lei	  et	  al.,	  2011,	  Gallegos	  and	  Bevan,	  
2004,	  Clarke	  et	  al.,	  2000)	  compared	  to	  <2%	  of	  host	  T	  cells	  (Buxbaum	  et	  al.,	  2006).	  Therefore,	  
a	   monoclonal	   antibody	   against	   Vα2	   was	   used	   to	   selectively	   isolate	   the	   damage-­‐causing,	  
adoptively	  transferred	  OVA-­‐specific	  T	  cell	  population	  from	  the	  livers	  of	  OVA-­‐Bil	  mice	  (Figure	  
6.15).	   Total	   numbers	   of	   Vα2+	   T	   cells	   were	   then	   quantified	   and	   their	   activation	   status	  
examined	  to	  elucidate	  the	  effect	  of	   late-­‐passage	  MSCs	  on	  these	  donor	  T	  cells	  compared	  to	  
the	  bulk	  lymphocyte	  population.	  
	  
	  
Figure	  6.15	  |	  Identification	  of	  adoptively	  transferred	  OT-­‐1	  and	  OT-­‐2	  T	  cells.	  Expression	  of	  the	  Vα2	  chain	  on	  T	  
cells	   isolated	   from	  OT-­‐1	  and	  OT-­‐2	  T	   cells	   allows	  us	   to	  mark	  damage-­‐causing	  adoptively-­‐transferred	  cells	   to	  a	  
reasonable	  degree	  of	  accuracy	  over	  the	  host’s	  own	  lymphocytes.	  	  
	   	  





Analysis	   of	   the	   total	   numbers	   of	   adoptively-­‐transferred	   CD4	   T	   cells	   revealed	   a	   significant	  
reduction	  in	  animals	  receiving	  TGF-­‐β1	  primed	  MSC	  treatment	  compared	  to	  injured	  controls	  
(3900±1100	  vs.	  1600±980	  cells	   /g	   liver	   tissue,	  p=0.03,	   Figure	  6.16A).	   Significant	   reductions	  
were	  also	  observed	  in	  the	  adoptively	  transferred	  CD8	  T	  cell	  population	  in	  the	  TGF-­‐β1	  group	  
(45,000±15,200	   vs.	   18,000±5900	   cells	   /g	   liver,	   p=0.03,	   Figure	   6.16B).	   Infusion	   of	   P7	   SM-­‐
primed	  PαS	  MSCs	  failed	  to	  elicit	  significant	  drops	  in	  either	  population,	  suggesting	  that	  these	  
cells	  have	  lost	  their	  in	  vivo	  immunosuppressive	  functionality	  at	  later	  passages.	  	  	  	  
	  
Examination	   of	   the	   activation	   marker	   status	   of	   adoptively-­‐transferred	   cells	   revealed	   that	  
expression	  of	   the	  early	  T	   cell	   activation	  marker	  CD69	  was	   significantly	   reduced	   in	   the	  CD4	  
and	   CD8	   population	   following	   TGF-­‐β1	   primed	  MSC	   infusion	   (Figure	   6.16C	   and	   E).	   In	   both	  
cases,	  a	  reduction	  was	  also	  observed	  in	  animals	  receiving	  SM-­‐primed	  MSCs,	  but	  this	  stopped	  
short	  of	  reaching	  statistical	  significance.	   In	  contrast,	  expression	  of	  the	   late-­‐stage	  activation	  
marker	   CD25	   was	   unchanged	   following	   MSC	   treatment	   on	   both	   CD4	   and	   CD8	   T	   cell	  
populations	  (Figure	  6.16D	  and	  F).	  	  
	  
These	   results	   show	   that	   P7	   TGF-­‐β1	   primed	   MSCs	   were	   able	   to	   reduce	   the	   number	   and	  
activation	  status	  of	  OT-­‐1	  and	  OT-­‐2	  cells	  in	  OVA-­‐Bil	  mice.	  By	  comparison,	  P7	  SM-­‐primed	  cells	  
failed	   to	   produce	   any	   clinical	   benefit.	   Further	   repeats	   are	   required	   to	   generate	   significant	  
reductions	   in	   serum	  ALT	   to	   further	   back	   up	   our	   hypothesis	   that	   culture	   and	   expansion	   in	  
TGF-­‐β1	  maintains	  the	  immunosuppressive	  potential	  of	  MSCs	  over	  extended	  culture.	  	  






Figure	  6.16	  |	  Effect	  of	  late-­‐passage	  PαS	  MSCs	  on	  adoptively	  transferred	  OT-­‐1	  and	  OT-­‐2	  T	  cells.	  Lymphocytes	  
were	   isolated	  from	  the	   livers	  of	  OVA-­‐Bil	  mice	  and	  analysed	  using	   flow	  cytometry.	  A	  monoclonal	  antibody	  for	  
Vα2	  was	  used	   to	  selectively	   identify	  adoptively	   transferred	  cells.	   (A)	  Total	  number	  of	  viable	  Vα2+	  CD4	  T	  cells	  
(from	  OT-­‐2	  mice)	  and	  (B)	  viable	  Vα2+	  CD8	  T	  cells	  (from	  OT-­‐1	  mice).	  The	  percentage	  of	  CD69	  and	  CD25	  positive	  
OT-­‐2	   (C	   and	   D)	   and	   OT-­‐1	   (E	   and	   F)	   T	   cells	   were	   also	   recorded.	   Data	   shown	   as	   mean±SD.	   Each	   data	   point	  
represents	  one	  animal.	  Statistical	  analysis	  performed	  using	  One-­‐way	  ANOVA	  with	  Bonferroni’s	  Correction.	  	  






	   6.3.1	  Chapter	  Summary	  
The	  findings	  of	  this	  chapter	  show	  that	  adoptive	  transfer	  of	  OVA-­‐specific	  CD4	  and	  CD8	  T	  cells	  
into	   recipient	   OVA-­‐Bil	   mice	   resulted	   in	   a	   sharp	   but	   transient	   immune-­‐mediated	   hepatic	  
injury.	   A	   30-­‐fold	   increase	   in	   serum	   ALT	   was	   observed	   in	   injured	   animals,	   alongside	   a	  
significant	   increase	   in	   the	   number	   of	   CD45+	   leukocytes	   and	   F4/80+	   macrophages.	   As	  
suggested	  by	  our	  in	  vitro	  data,	  mice	  treated	  with	  early-­‐passage	  P4	  SM-­‐primed	  MSCs,	  but	  not	  
TGF-­‐β1	  primed	  MSCs,	  displayed	  significantly	   reduced	  serum	  ALT	   readings.	  This	  was	  due	   to	  
drops	  in	  the	  total	  number	  of	  CD3	  T	  lymphocytes	  and	  CD45	  leukocytes	  in	  the	  livers	  of	  OVA-­‐Bil	  
animals.	   Interestingly,	   quantification	   of	   F4/80+	   macrophages	   revealed	   no	   differences	   in	  
animals	   receiving	  SM-­‐primed	  MSCs	  but	  a	   significant	   reduction	   in	  animals	   receiving	  TGF-­‐β1	  
primed	  cells.	  Further	  work	  is	  required	  to	  elucidate	  the	  significance	  of	  this	  finding.	  
	  
Infusion	  of	  late-­‐passage	  MSCs	  in	  the	  OVA-­‐Bil	  model	  backed	  up	  our	   in	  vitro	  findings	  with	  P7	  
TGF-­‐β1	   primed	   MSCs	   performing	   better	   than	   their	   SM-­‐primed	   counterparts.	   Although	  
significant	   reductions	   in	  serum	  ALT	  were	  not	  achieved,	  we	  did	  observe	  a	   reduction	   in	  CD3	  
lymphocyte	   number	   and	   CD69	   expression	   in	   animals	   receiving	   TGF-­‐β1	   primed	   cells.	  
Significant	   reductions	   in	   OT-­‐1	   and	   OT-­‐2	   T	   cell	   number	   and	   activation	   status	   were	   also	  
observed	   in	   the	  TGF-­‐β	  MSC	  group.	  Taken	   together,	   these	   findings	  clearly	  demonstrate	   the	  
importance	  of	  tailoring	  MSC	  culture	  and	  expansion	  conditions	  to	  the	  intended	  use	  of	  these	  
cells,	  and	  should	  be	  taken	  into	  account	  for	  future	  translational	  research	  using	  human	  cells.	  	   	  





	   6.3.2	  Characterisation	  of	  Liver	  Injury	  in	  OVA-­‐Bil	  Mice	  
OVA-­‐based	   models	   of	   injury	   have	   been	   used	   previously	   for	   various	   immune-­‐mediated	  
conditions	   including	   asthma	   (Zosky	   et	   al.,	   2008),	   type	   I	   diabetes	   (Van	   Belle	   et	   al.,	   2009),	  
dermatitis	  (Wang	  et	  al.,	  2007)	  and	  autoimmune	  hepatitis	  (Cebula	  et	  al.,	  2013).	  The	  OVA-­‐Bil	  
mice	  used	   in	  this	  study	  express	  OVA	  under	  the	  control	  of	  a	  bile	  acid	  transporter	  promoter	  
(ASBT),	  thereby	  limiting	  its	  expression	  to	  the	  biliary	  epithelium	  of	  the	  liver	  (Buxbaum	  et	  al.,	  
2006).	   IHC	   analysis	   of	  OVA	  expression	   revealed	  positive	   staining	   around	  biliary	   structures,	  
although	  the	  intensity	  was	  weak.	  This	  could	  be	  due	  to	  inefficient	  antigen	  retrieval	  or	  issues	  
with	   the	   monoclonal	   antibody	   used.	   However,	   no	   staining	   was	   observed	   on	   surrounding	  
hepatocytes	  which	  suggests	  that	  OVA	  expression	  is	  limited	  to	  biliary	  epithelium.	  Interestingly,	  
similar	   issues	  with	  OVA	  staining	  were	  also	  reported	  by	  Buxbaum	  et	  al.	   (2006),	  who	  used	  a	  
fluorescence-­‐based	  approach	  to	  identify	  (but	  not	  localise)	  OVA	  expression	  in	  the	  liver.	  
	  
We	  observed	  normal	  serum	  ALT,	  normal	  liver	  architecture	  and	  no	  signs	  of	  overt	  damage	  or	  
inflammation	   in	   OVA-­‐Bil	  mice	   prior	   to	   the	   infusion	   of	   OVA-­‐specific	   T	   cells,	   demonstrating	  
that	   these	   animals	  were	   tolerant	   to	   the	  OVA	   transgene.	  Adoptive	   transfer	  of	   10x106	  OT-­‐1	  
splenocytes	  and	  4x106	  OT-­‐2	  splenocytes	  resulted	  in	  a	  time-­‐dependent	  increase	  in	  serum	  ALT,	  
peaking	  10	  days	  after	  infusion.	  Our	  mean	  ALT	  reading	  (643±184	  IU/L)	  was	  slightly	  lower	  than	  
the	  one	   reported	  by	  Buxbaum	  and	   colleagues	   (846±415	   IU/L),	   but	   the	   spread	  of	  data	  was	  
more	  restricted	  in	  this	  study.	  There	  was	  a	  4-­‐fold	  reduction	  in	  serum	  ALT	  by	  day	  11	  in	  OVA-­‐Bil	  
mice,	  which	  could	  be	  due	  to	  loss	  of	  adoptively	  transferred	  cells	  or	  due	  to	  the	  host	  mounting	  
an	  active	  immune	  response	  against	  foreign	  cells.	  Similar	  transient	  injury	  profiles	  have	  been	  





reported	   in	   other	   OT-­‐1/OT-­‐2	   adoptive	   transfer	   studies	   (Derkow	   et	   al.,	   2007).	   Further	  
evidence	   for	   an	   active	   host	   immune	   response	   is	   provided	   by	   Buxbaum	   et	   al.	   (2006),	  who	  
reported	   that	   adoptive	   transfer	   of	   OVA-­‐specific	   T	   cells	   into	  OVA-­‐Bil	  mice	   bred	   on	   a	   Rag-­‐/-­‐	  
background	  produced	  an	  inflammatory	  reaction	  that	  remained	  constant	  over	  time.	  	  	  
	  
Interestingly,	   for	   a	   biliary-­‐specific	   damage	   model,	   we	   only	   observed	   a	   2-­‐fold	   increase	   in	  
serum	  ALP	  after	  injury.	  ALP	  is	  an	  enzyme	  found	  in	  the	  biliary	  cells	  of	  the	  liver,	  as	  well	  as	  bone,	  
kidney	  and	  placental	  tissue,	  with	  increases	  in	  serum	  ALP	  indicative	  of	  biliary	  damage	  or	  bone	  
diseases	   (Shipman	   et	   al.,	   2013).	   Therefore,	   as	   the	   antigen-­‐specific	   response	   seen	   in	   this	  
model	  is	  targeted	  against	  biliary	  epithelium,	  we	  should	  have	  seen	  elevated	  levels	  of	  ALP.	  We	  
did	  observe	  significant	   increases	   in	  the	  number	  of	   infiltrating	   lymphocytes,	  CD45+	  cells	  and	  
F4/80+	   macrophages	   in	   portal	   regions	   of	   the	   liver	   after	   adoptive	   transfer,	   but	   this	  
inflammatory	   response	  was	   insufficient	   to	   induce	   biliary	   cell	   death.	   The	   reasons	   behind	   a	  
poor	  ALP	  response	  in	  OVA-­‐Bil	  mice	  are	  currently	  unknown.	  One	  potential	  explanation	  could	  
be	  due	  to	  the	  transient	  nature	  of	  inflammation	  not	  lasting	  long	  enough	  to	  cause	  cholestasis,	  
which	   eventually	   results	   in	   biliary	   cell	   death	   and	   ALP	   release.	   It	   would	   be	   interesting	   to	  
measure	   other	   serum	   markers	   of	   biliary	   injury,	   such	   as	   gamma-­‐glutamyl	   transferase	   or	  
bilirubin	  in	  future	  studies	  to	  further	  characterise	  the	  biliary	  injury	  seen	  in	  OVA-­‐Bil	  animals.	  	  	  	  
	  
In	   contrast,	   a	   significant	   (30-­‐fold)	   increase	   in	   serum	  ALT	  was	   observed	   in	  OVA-­‐Bil	   animals	  
after	  adoptive	  transfer	  of	  OT-­‐1	  and	  OT-­‐2	  cells.	  ALT	  is	  an	  enzyme	  found	  in	  hepatocytes	  and	  an	  
increase	  in	  serum	  ALT	  is	  almost	  exclusively	  indicative	  of	  hepatocyte	  damage	  or	  death	  (Limdi	  





and	  Hyde,	  2003).	  There	  are	  several	  possible	  reasons	  for	  the	  hepatitis	  seen	  in	  OVA-­‐Bil	  mice.	  
Leakage	  of	  OVA	  expression	  from	  the	  biliary	  epithelium	  into	  neighbouring	  areas	  can	  result	  in	  
an	   immune	  reaction	  against	   these	  cells.	  Histologically,	  we	  did	  not	  observe	  OVA	  expression	  
on	   hepatocytes	   but	   we	   did	   observe	   widespread	   infiltration	   of	   hepatic	   architecture	   by	  
lymphocytic	  cells	  with	  regions	  of	  interphase	  hepatitis	  and	  clear	  ‘spreading’	  of	  immune	  cells	  
towards	  the	  wider	   liver	  parenchyma.	  Clusters	  of	  CD45+	  were	  found	   in	   lobular	  regions	  after	  
injury,	  which	  can	  induce	  hepatocyte	  injury	  and	  death.	  Future	  experiments	  using	  the	  TUNEL	  
assay	  and	  IHC	  for	  caspases	  3	  and	  7	  can	  be	  used	  to	  quantify	  hepatocyte	  death	  to	  back	  up	  this	  
hypothesis	   (Kyrylkova	   et	   al.,	   2012).	   Apoptotic	   hepatocytes	   can	   cause	   further	   injury	   via	   a	  
feed-­‐forward	  loop	  involving	  Kupffer	  cells	  (Malhi	  et	  al.,	  2010).	  Apoptotic	  bodies	  phagocytosed	  
by	   Kupffer	   cells	   results	   in	   the	   expression	   of	   death	   ligands	   on	   its	   surface,	   causing	   further	  
hepatocyte	   apoptosis	   by	   binding	   to	   their	   death	   receptors.	   Release	   of	   intracellular	  
components	  during	  necrosis	  can	  also	  illicit	  an	  immune	  response	  (Nanji	  and	  Hiller-­‐Sturmhofel,	  
1997).	   Intrahepatic	  accumulation	  of	  CD8+	  T	  cells	   in	  other	  antigen-­‐mediated	  models	  of	   liver	  
injury	  has	  been	  associated	  with	  hepatitis,	  whereby	  activated	  CD8+	  cells	   release	  TNF-­‐α	  and	  
IFN-­‐γ	   to	  mediate	   non-­‐specific	   hepatocyte	   damage	   (Bowen	   et	   al.,	   2002).	   Finally,	   bystander	  
activation	  of	  naïve	  host	  T	  cells	  could	  also	  contribute	  to	  hepatocyte	  injury	  (Boyman,	  2010).	  	  
	  
An	   independent	   study	   by	  Derkow	   et	   al.	   (2007)	   also	   generated	   transgenic	  mice	   expressing	  
OVA	   under	   the	   control	   of	   the	   ASBT	   promoter	   (ASBT-­‐OVA	   mice).	   Interestingly,	   they	   too	  
struggled	  to	  visualise	  OVA	  staining	  in	  small-­‐to-­‐medium	  size	  bile	  ducts,	  and	  only	  picked	  up	  a	  
positive	   signal	   in	   large	   ducts.	   Unlike	   our	   study,	   which	   adoptively	   transferred	   un-­‐purified	  
10x106	   OT-­‐1	   splenocytes	   and	   4x106	   OT-­‐2	   splenocytes	   into	   OVA-­‐Bil	   mice	   intraperitoneally,	  





Derkow	  and	  colleagues	  injected	  8x106	  purified	  OT-­‐1	  CD8+	  T	  cells	  systemically	  via	  the	  tail	  vein.	  
They	   report	   restricted	   localisation	   of	   injury	   to	   the	   portal/biliary	   areas	   of	   the	   liver	   after	  
adoptive	  transfer,	  with	  no	  signs	  of	  lobular	  inflammation	  or	  interphase	  hepatitis.	  Only	  a	  2-­‐fold	  
increase	  in	  ALT	  was	  observed	  in	  ASBT-­‐OVA	  mice,	  demonstrating	  the	  specificity	  of	  injury.	  This	  
increase	  in	  ALT	  was	  transient,	  peaking	  at	  day	  6	  and	  falling	  thereafter.	  However,	  the	  authors	  
failed	   to	  observe	  any	  differences	   in	  biliary	  damage	  markers.	  One	   reason	  behind	   the	  more	  
pronounced	  injury	  seen	  in	  OVA-­‐Bil	  compared	  to	  ASBT-­‐OVA	  mice	  might	  be	  due	  to	  the	  purity	  
of	   adoptively	   transferred	   cells.	   The	   heterogeneous	   population	   of	   splenocytes	   used	   in	   the	  
OVA-­‐Bil	  model	  contains	  a	  mixture	  of	  other	  immune	  cells	  alongside	  naive	  T	  lymphocytes	  that	  
may	   augment	   injury,	   including	   some	   activated	   T	   cells.	   Additionally,	   IP	   injection	   may	  
predispose	  homing	  of	  infused	  cells	  to	  the	  liver	  compared	  to	  systemic	  injection.	  	  	  
	  
In	  summary,	  while	  OVA-­‐Bil	  mice	  appear	  on	  paper	  to	  be	  a	  murine	  model	  of	  human	  PBC,	  our	  
results	   demonstrate	   that	   the	   injury	  more	   closely	   resembles	  AIH	  due	   to	   the	   lack	  of	   biliary-­‐
specific	   damage.	  More	   relevant	  mouse	  models	   of	   PBC	   include	  Mdr2-­‐/-­‐	  mice	   (Popov	   et	   al.,	  
2005),	  IL-­‐2Rα-­‐/-­‐	  mice	  (Wakabayashi	  et	  al.,	  2006)	  and	  NOD.c3c4	  mice	  (Irie	  et	  al.,	  2006)	  which	  
all	  share	  several	  symptoms	  seen	  in	  human	  patients	  that	  were	  not	  seen	  in	  OVA-­‐Bil	  mice	  (e.g.	  
biliary-­‐specific	   damage,	   cholestasis,	   increases	   in	   serum	   ALP,	   and	   periportal	   fibrosis).	  
However,	   these	  models	  develop	  symptoms	  over	  several	  weeks,	  which	  necessitate	  multiple	  
doses	  of	  MSCs	  to	  see	  a	  clinical	  benefit.	  By	  comparison,	  although	  the	  OVA-­‐Bil	  mice	  may	  not	  
recreate	  fully	  the	  pathology	  seen	  in	  patients	  with	  PBC,	  it	  is	  still	  a	  good	  model	  to	  study	  the	  in	  
vivo	   immunosuppressive	   effects	   of	   MSCs	   due	   to	   their	   reproducible	   injury	   profile	   and	  
comparatively	  short	  10-­‐day	  ‘incubation’	  times.	  	   	  





	   6.3.3	  Effect	  of	  Early-­‐Passage	  PαS	  MSC	  Infusion	  
Our	   in	   vitro	   data	   shows	   that	   early-­‐passage	   (P3)	   MSCs	   expanded	   in	   SM	   were	   the	   most	  
suppressive,	  but	  this	  ability	  was	  lost	  at	  P7	  due	  to	  the	  onset	  of	  senescence.	  Expansion	  in	  TGF-­‐
β1	  containing	  medium	  was	  able	  to	  maintain	  the	  suppressive	  phenotype	  of	  PαS	  MSCs	  until	  P7,	  
however	  their	  suppressive	  potency	  at	  P3	  was	  lower	  than	  that	  of	  SM	  cells.	  In	  vivo	  data	  using	  
the	  OVA-­‐Bil	  model	  fully	  backed	  up	  our	  in	  vitro	  findings,	  with	  animals	  receiving	  P3	  SM-­‐primed	  
MSCs	  displaying	  significantly	   reduced	  serum	  ALT	  readings	  compared	  to	   injured	  controls.	   In	  
contrast,	   animals	   receiving	   P3	   TGF-­‐β1	   primed	   MSCs	   displayed	   a	   smaller,	   non-­‐significant	  
reduction	   in	   ALT.	   Liver	   digest	   data	   showed	   that	   SM	   MSC	   treatment	   reduced	   the	   total	  
number	  of	  lymphocytes	  present	  in	  the	  liver	  after	  injury,	  however	  it	  does	  not	  appear	  to	  alter	  
their	   activation	   status.	   IHC	   analysis	   revealed	   that	  MSC-­‐treatment	   significantly	   reduced	   the	  
number	  of	  CD45+	  leukocytes	  in	  portal	  areas,	  and	  caused	  a	  smaller,	  non-­‐significant	  reduction	  
in	   lobular	   regions.	   Interestingly,	   the	   number	   of	   F4/80+	   macrophages	   was	   unchanged	  
following	   SM	   MSC	   treatment,	   and	   it	   remains	   to	   be	   seen	   whether	   skewed	   macrophage	  
polarisation	  is	  a	  potential	  mechanism	  behind	  the	  improvements	  seen	  in	  OVA-­‐Bil	  animals.	  	  
	  
	   	   6.3.3.1	  Timing	  of	  PαS	  MSC	  Infusion	  
The	   timing	  of	  MSC	   infusion	  has	  been	   reported	   to	  have	   a	  major	   impact	   on	   clinical	   efficacy	  
(Casiraghi	  et	  al.,	  2012,	  Casiraghi	  et	  al.,	  2008).	  We	  arbitrarily	  chose	  our	  infusion	  timings	  based	  
on	  previous	  literature	  which	  report	  that	  MSCs	  need	  to	  be	  in	  an	  inflammatory	  environment	  to	  
activate	   their	   immunosuppressive	   functions	   (Krampera,	   2011,	   Polchert	   et	   al.,	   2008,	  
Krampera	  et	  al.,	  2006).	  In	  a	  10-­‐day	  OVA-­‐Bil	  model,	  this	  left	  us	  a	  narrow	  therapeutic	  window	  





in	   which	  MSC	   infusion	   could	   have	   had	   an	   optimal	   effect.	   Casiraghi	   et	   al.	   show	   that	  MSC	  
infusion	   prior	   to	   transplantation	   had	   the	   best	   clinical	   outcome	   in	   their	  model	   of	   allograft	  
survival,	  while	  MSCs	  given	  at	  the	  time	  of	  transplant	  had	  no	  effect	  (Casiraghi	  et	  al.,	  2008).	  A	  
later	  study	  on	  kidney	  transplantation	  performed	  by	  the	  same	  group	  again	  demonstrated	  that	  
pre-­‐transplant	   infusion	   of	   MSCs	   caused	   a	   better	   outcome	   on	   graft	   function	   and	   survival	  
(Casiraghi	  et	  al.,	  2012).	  Animals	  receiving	  MSCs	  post-­‐transplant	  displayed	  signs	  of	  premature	  
graft	   dysfunction	   and	   rejection,	   with	   all	   mice	   rejecting	   the	   graft	   within	   20	   days.	   Animals	  
receiving	  a	  single	  or	  double	  dose	  of	  MSCs	  pre-­‐transplant	  displayed	  long-­‐term	  graft	  survival.	  
Interestingly,	   the	   double-­‐dose	   group	   displayed	   a	   trend	   towards	   better	   results.	   Other	   pre-­‐
clinical	   studies	   have	   also	   reported	   that	   multiple	   MSC	   doses	   tend	   towards	   better	   clinical	  
outcomes	   than	  a	  single	  dose	   (Hao	  et	  al.,	  2013,	  Si	  et	  al.,	  2012),	  and	  published	  clinical	   trials	  
using	  human	  MSCs	  have	  used	  multiple,	  large	  doses	  of	  MSCs	  in	  their	  studies	  (Lalu	  et	  al.,	  2012,	  
Le	  Blanc	  et	  al.,	  2008).	  One	  key	   rationale	   for	  multiple	  doses	   is	   the	   finding	   that	   systemically	  
administered	   MSCs	   are	   short	   lived	   and	   are	   rapidly	   cleared	   by	   the	   host	   after	   infusion	  
(Eggenhofer	  et	  al.,	  2012).	   It	   is	  possible	  that	  our	  dosing	  regimen	  of	  days	  3	  and	  7	  post	   injury	  
might	  miss	  the	  optimal	  therapeutic	  window	  for	  clinical	   improvements	   in	  OVA-­‐Bil	  mice,	  and	  
future	  work	  could	  focus	  on	  the	  effect	  of	  other	  infusion	  times	  to	  optimise	  efficacy.	  	  	  
	  
	   	   6.3.3.2	  Route	  of	  PαS	  MSC	  Infusion	  
One	   limitation	  of	  this	  study	   is	   the	   intraperitoneal	  route	  of	  administration	  used,	  which	   is	  of	  
limited	   translational	   feasibility	   in	   humans.	   IP	   injections	   are	   commonly	   used	   in	   veterinary	  
practice	  due	  to	  its	  ease	  of	  application,	  but	  are	  rarely	  used	  in	  humans	  (Chaudhary	  et	  al.,	  2010).	  





Early	  studies	  in	  our	  lab	  reported	  the	  formation	  of	  PαS	  MSC	  clumps	  when	  stored	  in	  PBS	  prior	  
to	   injection.	   Mechanical	   agitation	   of	   these	   clumps	   failed	   to	   disaggregate	   the	   cells,	   and	  
systemic	   administration	   of	   clumped	   MSCs	   formed	   harmful	   emboli	   in	   recipient	   animals.	  
Although	  MSCs	  remain	  viable	  for	  several	  hours	  when	  resuspended	  and	  stored	  in	  ice-­‐cold	  PBS	  
prior	  to	  infusion	  (Nikolaev	  et	  al.,	  2012,	  Pal	  et	  al.,	  2008),	  there	  is	  evidence	  for	  greater	  cellular	  
aggregation	  of	  MSCs	  in	  ice-­‐cold	  PBS	  compared	  to	  PBS	  at	  37°C	  (Heng	  et	  al.,	  2008).	  The	  use	  of	  
specialised	  media	   for	   resuspending	   and	   transporting	  MSCs	   prior	   to	   infusion	   is	   one	   option	  
available	  to	  limit	  cellular	  aggregation	  and	  maintain	  viability	  (Gálvez-­‐Martín	  et	  al.,	  2014).	  	  
	  
Another	   limitation	  of	  systemic	   infusion	   is	  risk	  of	   infused	  cells	  being	  trapped	  in	  the	   lungs	  of	  
recipient	   animals.	   Several	   studies	   using	   human	   and	  murine	  MSCs	   have	   reported	   that	   the	  
majority	   of	   systemically	   infused	  MSCs	   are	   trapped	   in	   the	   lung	   due	   to	   their	   large	   size	   and	  
expression	   of	   several	   adhesion	   proteins,	   preventing	   them	   from	   reaching	   the	   target	   organ	  
(Nystedt	   et	   al.,	   2013,	   Fischer	   et	   al.,	   2009,	   Schrepfer	   et	   al.,	   2007,	   Barbash	   et	   al.,	   2003).	  
Potential	  methods	   to	  bypass	   this	  pulmonary	   ‘first-­‐pass’	  effect	   include	   intraarterial	   infusion	  
(Mitkari	  et	  al.,	  2013)	  and	  direct	   infusion	   into	   injured	  organs	  (Kean	  et	  al.,	  2013,	  Chen	  et	  al.,	  
2004).	  Despite	   these	   limitations,	   it	   is	   important	   to	   note	   that	   several	   previous	   publications	  
have	   reported	   favourable	   outcomes	   after	   IV	   administration	   of	   MSCs	   in	   models	   of	   injury,	  
even	  in	  cases	  where	  MSC	  engraftment	  was	  not	  observed	  (Lee	  et	  al.,	  2009b).	  	  
	  
Due	  to	  the	  issues	  with	  cell	  clumping	  and	  the	  other	  limitations	  listed	  above,	  an	  IP	  approach	  
was	  used	  to	  deliver	  PαS	  MSCs	  to	  OVA-­‐Bil	  animals.	  No	  adverse	  events	  were	  observed	  in	  OVA-­‐





Bil	  mice	   after	  multiple	   IP	   injections	   and	   the	   reduction	   in	   injury	   seen	  demonstrate	   that	   IP-­‐
infused	  MSCs	  were	  functional.	  This	  finding	  raises	  some	  interesting	  questions	  regarding	  PαS	  
MSC	   homing	   from	   the	   peritoneum	   to	   the	   liver.	   The	   peritoneum	   can	   be	   viewed	   as	   a	   large	  
cavity	  with	  abundant	  vascularisation	  and	  lymphatic	  drainage	  systems	  (Parungo	  et	  al.,	  2007).	  
The	   substantial	   vascular	   surface	   area	   on	   offer	   facilitates	   the	   rapid	   uptake	   and	   systemic	  
delivery	  of	  injected	  drugs	  (Markman,	  2009).	  However,	  the	  uptake	  and	  systemic	  diffusion	  of	  
IP	   injected	  MSCs	   is	   less	  well	  understood.	  Castelo-­‐Branco	  et	  al.	   (2012)	  show	  that	   IP-­‐infused	  
MSCs	   specifically	   migrate	   towards	   inflamed	   bowel	   in	   a	   mouse	   model	   of	   colitis	   while	   IV-­‐
infused	  MSCs	  were	   found	   in	  other	  organs.	  Ghionzoli	   and	  colleagues	   report	   similar	   findings	  
following	  IP-­‐MSC	  infusion	  in	  healthy	  rats,	  with	  injected	  cells	  localised	  in	  the	  intestine	  (67%),	  
liver	   (25%),	   spleen	   (16%)	   and	   heart	   (15%;	   Ghionzoli	   et	   al.,	   2010).	   The	   reasons	   behind	  
preferential	  homing	   towards	   intra-­‐peritoneal	  organs	  over	  extra-­‐peritoneal	  organs	  could	  be	  
due	  to	  the	  proximity	  of	  intra-­‐peritoneal	  organs	  to	  the	  infusion	  site.	  	  	  	  
	  
Future	  work	  should	  study	  the	  migration	  of	  IP-­‐infused	  PαS	  MSCs	  to	  see	  whether	  they	  engraft	  
in	  the	  liver.	  Injection	  of	  quantum	  dot-­‐labelled	  MSCs	  would	  allow	  real-­‐time	  tracking	  using	  an	  
imaging	  system	  such	  as	  IVIS®	  or	  CryoViz®.	  Engrafted	  MSCs	  can	  also	  be	  identified	  using	  IHC	  on	  
serial	   sections	   of	   the	   liver.	   Furthermore,	   examination	   of	   draining	   lymph	   nodes	   of	   the	  
peritoneal	  cavity	  for	  the	  presence	  of	  PαS	  MSCs	  would	  also	  be	  interesting,	  as	  this	  is	  one	  area	  
where	  MSCs	  can	  directly	  interact	  with	  APCs	  and	  other	  immune	  cells	  to	  reduce	  the	  activation	  
of	  OT-­‐1	  and	  OT-­‐2	  T	  cells,	  thereby	  preventing	  further	  hepatic	  injury.	  	   	  





	   	   6.3.3.3	  Liver	  Lymphocyte	  and	  Macrophage	  Populations	  
Flow	  cytometric	  analysis	  of	  liver-­‐resident	  lymphocyte	  populations	  was	  performed	  to	  identify	  
potential	  mechanisms	   of	   action.	  Quantification	   of	   total	   lymphocyte	   number	   revealed	   that	  
SM-­‐primed	   MSC	   treatment	   caused	   a	   significant	   reduction	   in	   the	   total	   numbers	   of	   CD3+	  
lymphocytes	  in	  OVA-­‐Bil	  mice	  after	  injury.	  A	  reduction	  was	  also	  seen	  following	  TGF-­‐β1	  primed	  
MSC	  infusion,	  but	  this	  failed	  to	  reach	  significance.	  This	  finding	  fits	  our	   in	  vitro	  data	  and	  the	  
anti-­‐proliferative	  effect	  of	  MSCs	  on	  lymphocytes	  has	  also	  been	  described	  in	  detail	  elsewhere	  
(Ma	  et	  al.,	  2014,	  Uccelli	  et	  al.,	  2008).	  	  
	  
Interestingly,	   we	   did	   not	   observe	   any	   difference	   in	   the	   activation	   status	   of	   lymphocytes	  
between	  injured	  and	  MSC-­‐treated	  mice.	  This	  was	  surprising	  as	  there	  are	  several	  past	  reports	  
describing	   the	   inhibition	   of	   lymphocyte	   activation	   after	  MSC	   co-­‐culture	   (Park	   et	   al.,	   2011,	  
Ding	  et	  al.,	  2009,	  Le	  Blanc	  et	  al.,	  2004a).	  However,	  analysis	  of	  ‘bulk’	  lymphocyte	  populations	  
(as	  done	  here)	  over	  adoptively	   transferred	  OT-­‐1	  and	  OT-­‐2	  populations	   could	  have	  masked	  
any	  subtle	  effects	  MSCs	  were	  having	  on	  these	  damage-­‐causing	  cells.	  As	  the	  OVA-­‐Bil	  model	  
does	  not	  have	  a	  significant	  autoimmune	  component,	  it	  is	  important	  to	  separate	  OVA-­‐specific	  
T	   cells	   from	   the	   total	   lymphocyte	   population	   when	   performing	   future	   experiments.	  
Additionally,	  examination	  of	   the	  cytokine	  production	  of	  adoptively	   transferred	  cells	   should	  
also	  be	  examined,	  as	  MSCs	  have	  previously	  been	  shown	  to	  skew	  the	  cytokine	  secretion	  of	  
CD4+	  cells	  towards	  an	  anti-­‐inflammatory	  TH2	  state	  (Aggarwal	  and	  Pittenger,	  2005).	  	  
	   	  





Analysis	   of	   liver	   macrophage	   populations	   using	   F4/80	   expression	   revealed	   some	   very	  
interesting	   findings	   following	   MSC	   infusion	   in	   OVA-­‐Bil	   mice.	   Animals	   that	   received	   SM-­‐
primed	  MSCs	  (which	  displayed	  significant	  reductions	  in	  serum	  ALT	  and	  lymphocyte	  numbers)	  
had	  similar	  numbers	  of	   liver-­‐resident	  macrophages	  as	   injured	  control	  animals.	  By	  contrast,	  
animals	  receiving	  TGF-­‐β1	  primed	  MSCs	  (which	  failed	  to	  show	  significant	  reductions	  in	  ALT	  or	  
lymphocyte	  counts)	  had	  significantly	  less	  F4/80+	  compared	  to	  controls.	  	  
	  
Our	   working	   hypothesis	   to	   explain	   this	   finding	   is	   that	   control	   mice	   may	   harbour	   a	  
predominantly	  pro-­‐inflammatory	  M1	  macrophage	  population,	  but	  SM-­‐primed	  MSC	  treated	  
animals	   may	   have	   higher	   numbers	   of	   M2	   macrophages.	   These	   anti-­‐inflammatory	   M2	  
macrophages	  work	  synergistically	  with	  PαS	  MSCs	  to	  dampen	  the	  proliferation	  and	  activation	  
of	  OVA-­‐specific	   T	   cells	   and	   reduce	   overall	   liver	   injury.	   The	   effect	   of	  MSCs	   on	  macrophage	  
polarisation	  towards	  M1	  or	  M2	  phenotypes	  is	  well	  understood,	  and	  there	  is	  a	  lot	  of	  evidence	  
that	   demonstrates	   MSCs	   can	   skew	   macrophage	   polarisation	   towards	   a	   M2	   phenotype	   in	  
vitro	   and	   in	   vivo	   (Cho	   et	   al.,	   2014,	   Le	   Blanc	   and	   Mougiakakos,	   2012,	   Choi	   et	   al.,	   2011,	  
Nemeth	   et	   al.,	   2009).	   To	   address	   this	   hypothesis,	   future	   work	   should	   concentrate	   on	  
identifying	   macrophage	   subsets	   in	   OVA-­‐Bil	   mice	   after	   MSC	   treatment.	   Expression	   of	  
characteristic	  markers	  of	  M1	  (iNOS,	  MHC	  class	  II	  and	  CD86)	  and	  M2	  macrophages	  (Arginase-­‐
1,	  CD206,	  CD163	  and	  IL-­‐10)	  macrophages	  can	  be	  examined	  using	  a	  combination	  of	  RT-­‐PCR,	  
IHC	  and	  functional	  assays	  (Barros	  et	  al.,	  2013).	  Additionally,	  the	  cytokine	  profile	  of	   isolated	  
macrophages	   can	   also	   be	   used	   to	   identify	   their	   polarisation	   status	   (Martinez	   and	  Gordon,	  
2014,	  Martinez	  et	  al.,	  2006).	  	   	  





	   6.3.4	  Effect	  of	  Late-­‐Passage	  PαS	  MSC	  Infusion	  
Due	  to	  the	  rarity	  of	  PαS	  MSCs	  in	  BM,	  a	  degree	  of	  in	  vitro	  expansion	  is	  required	  to	  reach	  the	  
cell	  numbers	  needed	  for	  therapeutic	  infusions.	  We	  were	  able	  to	  overcome	  senescence	  and	  
maintain	  immunosuppression	  in	  MSC	  cultures	  via	  the	  use	  of	  TGF-­‐β1	  supplementation,	  which	  
is	   of	   interest	   for	   future	   translational	   work	   in	   immune-­‐mediated	   disorders.	   Here,	   we	  
examined	  the	  effect	  of	  P7	  PαS	  MSCs	  expanded	  in	  SM±TGF-­‐β1	  in	  the	  OVA-­‐Bil	  model	  to	  back	  
up	  our	  in	  vitro	  findings	  in	  a	  mouse	  model	  of	  injury.	  
	  
Examination	  of	   serum	  ALT	   in	  day	  10	  OVA-­‐Bil	  mice	   revealed	  no	  difference	  between	   injured	  
controls	   and	   SM-­‐MSC	   treated	   animals,	   which	   fits	   in	   nicely	   with	   our	   in	   vitro	   findings.	  
Promisingly,	   animals	   receiving	   TGF-­‐β1	   primed	   MSCs	   tended	   to	   have	   much	   lower	   ALT	  
readings,	  but	  the	  variation	  between	  animals	  prevented	  the	  data	  from	  reaching	  significance.	  
This	  experiment	  is	  currently	  being	  repeated	  in	  our	  lab	  to	  increase	  the	  sample	  size	  to	  pick	  out	  
any	  significant	  differences	  between	  groups.	  	  
	  
	   	   6.3.4.1	  Liver	  Lymphocyte	  Populations	  after	  P7	  PαS	  MSC	  treatment	  
Flow	  cytometric	  analysis	  of	  bulk	   lymphocyte	  populations	  provided	  further	  evidence	  for	  the	  
maintenance	   of	   immunosuppressive	   phenotype	   in	   late-­‐passage	   TGF-­‐β1	   primed	   PαS	  MSCs.	  
Significant	  reductions	  in	  total	  CD3+	  lymphocytes,	  particularly	  CD3+CD8+	  T	  cells	  were	  observed	  
in	  animals	  receiving	  TGF-­‐β	  primed	  MSCs.	  Animals	  receiving	  SM-­‐primed	  MSCs	  failed	  to	  show	  
significant	  reductions	  in	  lymphocyte	  numbers	  compared	  to	  control	  mice.	  These	  findings	  are	  





a	  reversal	  of	  the	  results	  obtained	  with	  early-­‐passage	  cells,	  where	  SM-­‐primed	  MSCs,	  but	  not	  
TGF-­‐β1	  primed	  cells,	  caused	  significant	  reductions	  in	  lymphocyte	  number.	  	  
	  
We	  were	  also	  able	  to	  specifically	  analyse	  the	  effect	  of	   late-­‐passage	  MSC	  infusion	  on	  donor	  
OT-­‐1	   and	   OT-­‐2	   lymphocyte	   populations	   using	   Vα2	   expression.	   Unlike	   host	   OVA-­‐Bil	  
lymphocytes,	   donor	   lymphocytes	   express	   Vα2	   Vβ5	   chains	   on	   their	   transgenic	   TCR	   which	  
allows	   us	   to	   separate	   the	   two	   populations	   (Buxbaum	   et	   al.,	   2006,	   Clarke	   et	   al.,	   2000).	  
Significant	   reductions	   in	   the	   total	   number	  of	   adoptively	   transferred	  CD4+	   (OT-­‐2)	   and	  CD8+	  
(OT-­‐1)	   lymphocytes	   were	   observed	   in	   animals	   receiving	   TGF-­‐β1	   primed	   MSC	   treatment	  
compared	  to	  injured	  controls.	  We	  also	  observed	  a	  significant	  reduction	  in	  the	  expression	  of	  
the	   early	   activation	  marker	   CD69	   on	   CD4+	   and	   CD8+	   lymphocytes	   in	   the	   TGF-­‐β	   group.	   No	  
significant	  differences	  in	  lymphocyte	  number	  or	  activation	  status	  were	  observed	  in	  the	  SM-­‐
primed	   MSC	   group,	   providing	   further	   evidence	   for	   their	   loss	   of	   function.	   These	   findings	  
demonstrate	  that	  late-­‐passage	  TGF-­‐β1	  primed	  MSCs,	  but	  not	  SM-­‐primed	  cells,	  can	  inhibit	  the	  
proliferation	   and	   activation	   of	   damage-­‐causing	   donor	   OT-­‐1	   &	   OT-­‐2	   cells,	   and	   could	   be	   a	  
potential	   mechanism	   behind	   the	   improvements	   in	   serum	   ALT	   observed	   in	   TGF-­‐β	   MSC-­‐



































7.1	  Summary	  of	  Principle	  Findings	  
MSCs	  are	  an	  attractive	  source	  of	  cells	   for	   future	   therapies	  due	  to	   their	  potent	   trophic	  and	  
immunomodulatory	  characteristics,	  enabling	  their	  use	  in	  a	  wide	  variety	  of	  clinical	  indications	  
(Ma	   et	   al.,	   2014,	   Mendicino	   et	   al.,	   2014,	   Ranganath	   et	   al.,	   2012).	   Promising	   pre-­‐clinical	  
studies	   in	   animal	   models	   have	   been	   quickly	   translated	   into	   small-­‐scale	   human	   trials	  
examining	   the	   efficacy	   of	   MSC	   infusion	   in	   GvHD,	   cardiovascular	   disease,	   liver	   failure	   and	  
others.	   Although	   a	   recent	   meta-­‐analysis	   of	   MSC	   trials	   has	   reported	   favourable	   safety	  
outcomes,	   the	   degree	   of	   clinical	   benefit	   varied	   (Lalu	   et	   al.,	   2012).	   One	   possible	   reason	  
behind	   the	   lack	   of	   efficacy	   could	   be	   due	   to	   the	   heterogeneous	   populations	   of	   plastic-­‐
adherent	  cells	  used	   in	  past	  studies,	   in	  which	  only	  a	  small	  percentage	  of	  cells	  were	  actually	  
MSCs	  (Bianco	  et	  al.,	  2013,	  Bianco	  et	  al.,	  2008).	  Additionally,	  difficulties	  in	  isolating	  a	  purified	  
population	  of	  murine	  MSCs	  has	  prevented	  the	  field	  from	  studying	  the	  biology	  and	  functions	  
of	  these	  cells	  using	  the	  large	  number	  of	  transgenic	  mouse	  models	  currently	  available	  (Anjos-­‐
Afonso	  and	  Bonnet,	  2011).	  Our	  current	  understanding	  of	  MSC	  biology	   is	  therefore	   inferred	  
from	   the	   study	   of	   in	   vitro	   cultured	   human	   cells	   due	   to	   their	   ease	   of	   isolation.	   There	   is	   a	  
pressing	  need	  to	  understand	  the	  biology	  of	  these	  cells	  in	  the	  murine	  system	  to	  better	  design	  
culture	   conditions	   that	   optimise	   their	   therapeutic	   potential.	   These	   findings	   can	   then	   be	  
translated	  into	  human	  trials	  to	  improve	  the	  efficacy	  of	  MSCs	  in	  patients.	  	  
	  
Mouse	  MSC	   isolation	  has	   traditionally	  been	  hampered	  by	   the	   lack	  of	   specific	  markers	   and	  
the	   persistence	   of	   contaminating	   cells	   in	   culture	   (Boxall	   and	   Jones,	   2012).	   Three	   recent	  
publications	   have	   comprehensively	   described	   markers	   and	   methods	   to	   isolate	   purified	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murine	  MSCs	  and	  tested	  their	  function	   in	  vivo	  using	  traditional	  assays	  of	  stem	  cell	  function	  
(Pinho	   et	   al.,	   2013,	   Mendez-­‐Ferrer	   et	   al.,	   2010,	   Morikawa	   et	   al.,	   2009).	   However,	   the	  
therapeutic	  or	  immunosuppressive	  properties	  of	  these	  prospectively	  isolated	  MSCs	  were	  not	  
studied,	  and	  it	  remains	  to	  be	  seen	  whether	  purified	  cells	  function	  as	  effectively	  as	  their	  non-­‐
purified	  counterparts.	  To	  meet	  these	  needs,	  this	  thesis	  focused	  on	  the	  PαS	  (PDGFRα+Sca-­‐1+)	  
population	   of	   murine	   MSCs	   and	   investigated	   their	   regenerative	   and	   immunosuppressive	  
phenotype	  in	  vitro	  and	  in	  vivo.	  	  
	  
	   7.1.1	  Phenotype	  and	  Loss	  of	  Function	  of	  PαS	  MSCs	  
Although	   the	   original	   paper	   describing	   the	   identification	   and	   isolation	   of	   PαS	   MSCs	   was	  
published	   over	   three	   years	   ago,	   there	   are	   no	   primary	   research	   articles	   published	   to	   date	  
which	   have	   used	   this	   this	   population	   of	   cells	   in	   their	   studies.	   Reasons	   behind	   this	   are	  
unknown,	  but	  could	  be	  due	  to	  difficulties	   in	  replicating	  the	   isolation	  procedure	  because	  of	  
the	   subtle	   complexities	   involved	   in	   BM	   sample	   preparation	   and	   sorting.	   As	   described	   in	  
Chapter	  3,	  we	  have	  been	  able	  to	  successfully	  isolate	  PαS	  MSCs	  from	  multiple	  wild-­‐type	  and	  
transgenic	  mouse	   strains	   and	   test	   their	   functions	   in	   vitro.	   Early-­‐passage	  PαS	   cells	   perform	  
many	   of	   the	   functions	   expected	   of	   MSCs,	   including	   in	   vitro	   proliferation,	   tri-­‐lineage	  
differentiation	  and	  CFU-­‐F	   formation.	  This	  study	  also	  describes	   for	   the	   first	   time	  the	  potent	  
immunosuppressive	  phenotype	  of	  Balb/c-­‐derived	  PαS	  MSCs,	  which	  was	  exclusively	  mediated	  
via	   the	   release	   of	   NO.	   Preliminary	   analysis	   also	   revealed	   strain-­‐specific	   differences	   in	  
immunosuppressive	  mechanism,	  with	  MSCs	  isolated	  from	  C57BL/6	  mice	  failing	  to	  suppress	  T	  
cell	  proliferation	   in	  our	  standard	  assay.	   Immunosuppression	  was	  restored	  when	  we	  moved	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away	  from	  a	  ‘purified’	  system	  where	  no	  antigen	  presentation	  was	  required	  towards	  a	  more	  
complex	   ‘splenocyte	   reaction’	   containing	   several	   different	   immune	   cell	   subsets.	   Further	  
work	   is	   ongoing	   to	   elucidate	   the	   mechanism	   behind	   C57BL/6-­‐derived	   PαS	   MSC	  
immunosuppression	  and	  the	  effects	  of	  GF-­‐supplementation	  on	  this	  feature.	  	  
	  
Due	   to	   the	   rarity	  of	  PαS	  MSCs	   in	  BM	   (approximately	  5000-­‐8000	  cells	  per	  mouse),	   and	   the	  
high	  numbers	  of	  MSCs	  required	  to	  see	  a	  clinical	  benefit	  in	  previous	  mouse	  models	  of	  injury	  
(up	  to	  1	  million	  cells	  per	  animal;	  Nemeth	  et	  al.,	  2009,	  Casiraghi	  et	  al.,	  2008),	  a	  degree	  of	   in	  
vitro	  expansion	  is	  therefore	  required	  to	  reach	  cell	  numbers	  needed	  for	  experimentation.	  The	  
findings	  of	  Chapter	  4	  demonstrate	  that	  PαS	  MSCs	  are	  susceptible	  to	  senescence,	  resulting	  in	  
reduced	   proliferative	   capacity	   and	   upregulation	   of	   SA-­‐β-­‐gal	   expression.	   Increased	  
senescence	  has	  implications	  for	  future	  therapeutic	  uses	  of	  these	  cells,	  as	  PαS	  MSCs	  become	  
increasingly	   lineage-­‐restricted	   towards	   bone	   and	   lose	   their	   chondrogenic	   and	   adipogenic	  
differentiation	  ability	  at	   later	  passages.	  Importantly,	  PαS	  MSCs	  also	  displayed	  a	  progressive	  
loss	  of	  immunomodulatory	  functions	  at	  later	  passages	  due	  to	  decreased	  NO	  production.	  	  	  	  	  
	  
	   7.1.2	  Overcoming	  Senescence	  using	  GF-­‐priming	  
Growth	   factors	   are	   frequently	   added	   to	  MSC	   growth	  media	   to	   increase	  MSC	   growth	   and	  
function	   (Inamdar	   and	   Inamdar,	   2013,	   Rodrigues	   et	   al.,	   2010).	   However,	   there	   are	   many	  
contradictory	   findings	  on	   the	  effects	  of	  GF-­‐supplementation	  on	  MSC	  cultures,	  which	  could	  
again	  be	  due	  to	  the	  heterogeneous	  populations	  of	  plastic-­‐adherent	  cells	  used	  in	  past	  studies.	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Previous	  studies	  have	  also	  not	  addressed	  the	  effect	  of	  long-­‐term	  exposure	  to	  GFs	  on	  the	  tri-­‐
lineage	  and	  immunosuppressive	  phenotype	  of	  MSCs.	  Although	  GFs	  increase	  the	  proliferation	  
and	  differentiation	  of	  MSCs	  during	  the	  short	  term,	  they	  may	  also	  prime	  MSCs	  down	  specific	  
lineages	  after	  extended	  culture.	  Defining	  culture	  conditions	   that	  prime	  MSCs	   towards	  pre-­‐
determined	  fates	   is	  of	  significant	   interest	   for	   future	  medical	  uses	  as	   it	  would	  allow	  culture	  
conditions	  to	  be	  tailor-­‐made	  for	  the	  clinical	  indication.	  	  
	  
Chapter	   5	   describes	   the	   effect	   of	   FGF2,	   PDGF-­‐BB	   and	   TGF-­‐β1	   supplementation	   on	   MSC	  
growth	  and	   function.	   These	  GFs	  were	   chosen	  as	   their	   respective	   signalling	  pathways	  were	  
reported	  to	  control	  MSC	  proliferation	  and	  differentiation	  down	  specific	   lineages	   (Ng	  et	  al.,	  
2008).	  Our	  findings	  demonstrate	  enhanced	  growth	  and	  reduced	  senescence	  in	  the	  presence	  
of	  GFs,	  with	  FGF2	  having	  the	  most	  potent	  effect.	  We	  also	  report	  novel	  data	  on	  the	  karyotype	  
of	  PαS	  MSCs,	  and	  observed	  no	  cytogenetic	  evidence	  of	  neoplastic	  transformation	   in	  SM	  or	  
GF-­‐supplemented	   cultures	   at	   P3	   and	   P5,	   suggesting	   that	   prospectively-­‐isolated	   cells	   are	  
more	  stable	  than	  their	  plastic-­‐adherent	  counterparts	  (Tolar	  et	  al.,	  2007,	  Miura	  et	  al.,	  2006).	  
	  
The	   findings	  of	   Chapter	   5	   also	  provides	   evidence	  of	   ‘lineage	  priming’	   in	   PαS	  MSC	   cultures	  
after	   expansion	   in	   GF-­‐supplemented	   media	   (Delorme	   et	   al.,	   2009).	   Microarray	   analysis	  
revealed	   significant	   upregulation	   of	   osteogenic	   lineage	   genes	   in	   undifferentiated	   MSCs	  
expanded	  in	  SM	  media.	  When	  induced	  to	  undergo	  differentiation,	  SM	  cultures	  readily	  went	  
down	   the	  osteogenic	   lineage,	   producing	   significantly	  more	   calcium	   than	  GF-­‐supplemented	  
cells.	   FGF2	   and	   PDGF-­‐BB	   supplementation	   upregulated	   key	   adipogenic	   lineage	   genes	   in	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undifferentiated	  MSCs,	  and	  we	  saw	  increased	  lipid	  droplet	  formation	  in	  these	  cultures	  when	  
induced	  to	  undergo	  differentiation.	  Evidence	  for	  chondrogenic	  lineage	  priming	  was	  less	  clear	  
than	  the	  other	  two	  lineages,	  however	  our	  phenotypic	  data	  suggests	  that	  culture	   in	  FGF2	  is	  
beneficial	  for	  cartilage	  formation.	  Interestingly,	  late-­‐passage	  PαS	  MSCs	  expanded	  in	  TGF-­‐β1	  
supplemented	   medium	   had	   attenuated	   tri-­‐lineage	   differentiation	   but	   enhanced	  
immunosuppressive	  potential.	  This	  was	  due	  to	  a	  reduction	  in	  the	  number	  of	  senescent	  cells	  
and	  an	  increase	  in	  NO	  production	  in	  TGF-­‐β1	  MSCs	  compared	  to	  SM	  MSCs.	  
	  
	   7.1.3	  In	  vivo	  Immunosuppression	  in	  the	  OVA-­‐Bil	  Model	  
The	   OVA-­‐Bil	   model	   of	   alloimmune	   liver	   injury	   was	   used	   to	   demonstrate	   in	   vivo	  
immunosuppressive	   functions	  of	  PαS	  MSCs	  and	  examine	  whether	  TGF-­‐β1	  supplementation	  
could	  maintain	  the	  suppressive	  potential	  of	   late-­‐passage	  cells.	  Characterisation	  of	   the	   liver	  
injury	  observed	  in	  OVA-­‐Bil	  mice	  following	  adoptive	  transfer	  of	  OT-­‐1	  and	  OT-­‐2	  cells	  revealed	  a	  
sharp	  but	   transient	   immune-­‐mediated	  hepatic	   injury.	  A	  30-­‐fold	   increase	   in	   serum	  ALT	  was	  
observed	   in	   injured	  animals,	  alongside	  significant	   increases	   in	   the	  number	  of	   liver-­‐resident	  
CD45+	  leukocytes	  and	  F4/80+	  macrophages.	  As	  suggested	  by	  our	   in	  vitro	  data,	  mice	  treated	  
with	  early-­‐passage	  P4	  SM-­‐primed	  MSCs,	  but	  not	  TGF-­‐β1	  primed	  MSCs,	  displayed	  significantly	  
reduced	  serum	  ALT	  readings	  compared	  to	  control	  animals.	  This	  was	  due	  to	  drops	  in	  the	  total	  
number	  of	  CD3+	  T	   lymphocytes	  and	  CD45+	   leukocytes	   in	  the	   livers	  of	  OVA-­‐Bil	  animals	  after	  
MSC	   treatment.	   We	   also	   observed	   selective	   retention	   of	   F4/80+	   macrophages	   in	   animals	  
receiving	  SM-­‐primed	  MSC	  treatment,	  and	  further	  work	  studying	  macrophage	  polarisation	  is	  
currently	  underway	  to	  examine	  the	  significance	  of	  this	  finding.	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Infusion	   of	   late-­‐passage	   PαS	  MSCs	   again	   backed	   up	   our	   in	   vitro	   findings,	   with	   P7	   TGF-­‐β1	  
primed	  MSCs	  performing	  substantially	  better	  than	  P7	  SM-­‐primed	  cells.	  Although	  significant	  
reductions	   in	   serum	  ALT	  were	  not	   reached,	  we	  did	  observe	   significant	   reductions	   in	   ‘bulk’	  
lymphocyte	  number	  and	  activation	  status	  following	  TGF-­‐β1	  primed	  MSC	  infusion.	  Analysis	  of	  
the	   adoptively	   transferred	   population	   revealed	   significant	   reductions	   in	   the	   total	   number	  
and	  activation	  status	  of	  OT-­‐1	  and	  OT-­‐2	  cells	  in	  the	  TGF-­‐β	  group	  but	  not	  the	  SM	  group.	  	  	  	  
	  
These	   results	   have	   significant	   implications	   for	   downstream	   therapeutic	   uses	   as	   we	   reveal	  
that	  culture	  conditions	  can	  functionally	  ‘prime’	  MSCs	  down	  specific	  fates.	  For	  example,	  MSCs	  
expanded	   in	   SM	  media	   are	   best	   suited	   for	   bone	   repair,	  while	   FGF-­‐supplemented	   cells	   are	  
best	   suited	   for	   cartilage	   regeneration.	   Conversely,	   TGF-­‐β1	   primed	   MSCs	   do	   not	   appear	  
suitable	   for	   regenerative	  medicine	  purposes	  but	  are	   ideal	   for	   immune-­‐mediated	  disorders.	  
The	  use	  of	  a	  lineage-­‐primed	  population	  would	  allow	  us	  to	  infuse	  lower	  numbers	  of	  MSCs	  to	  














7.2	  Implications	  for	  Future	  Translational	  Work	  
Our	  findings	  have	  significant	  implications	  for	  downstream	  therapeutic	  uses	  as	  we	  reveal	  that	  
culture	   conditions	   can	   functionally	   ‘prime’	   MSCs	   down	   specific	   fates.	   For	   example,	   MSCs	  
expanded	   in	   SM	  media	   are	   best	   suited	   for	   bone	   repair,	  while	   FGF-­‐supplemented	   cells	   are	  
best	   suited	   for	   cartilage	   regeneration.	   Conversely,	   TGF-­‐β1	   primed	   MSCs	   do	   not	   appear	  
suitable	   for	   regenerative	  medicine	  purposes	  but	  are	   ideal	   for	   immune-­‐mediated	  disorders.	  
The	  use	  of	  a	  lineage-­‐primed	  population	  in	  future	  clinical	  trials	  would	  allow	  us	  to	  infuse	  lower	  
numbers	  of	  MSCs	   to	   reach	   the	   same	  beneficial	  outcome,	   thereby	   reducing	   the	   risk	  of	   any	  
adverse	  events	  occurring.	  
	  
Difficulties	  in	  isolating	  a	  purified	  population	  of	  murine	  MSCs	  has	  drawn	  criticism	  from	  certain	  
groups	   and	   hampered	   attempts	   to	   reach	   agreement	   on	   potential	   mechanisms	   of	   action	  
(Bianco	   et	   al.,	   2013,	   Haniffa	   et	   al.,	   2009).	   The	   recent	   publication	   of	   three	   murine	   MSC	  
isolation	  methods	  have	  the	  potential	  to	  transform	  the	  field,	  but	  the	  uptake	  of	  these	  methods	  
by	  the	  wider	  scientific	  community	  has	  been	  slow.	  No	  primary	  research	  article	  has	  used	  the	  
PαS	  MSC	  population	   in	   their	  publication	  to	  date,	  and	  there	  has	  only	  been	  a	  handful	  which	  
have	  used	  the	  Nestin+	  MSCs	  in	  their	  work	  (Ding	  et	  al.,	  2012,	  Itkin	  et	  al.,	  2012).	  The	  reasons	  
behind	  the	  lack	  of	  uptake	  of	  PαS	  MSCs	  are	  unknown,	  but	  could	  be	  due	  to	  subtle	  intricacies	  
involved	   in	   BM	   sample	   preparation	   prior	   to	   sorting.	   We	   have	   been	   able	   to	   successfully	  
isolate	  and	  culture	  PαS	  MSCs	  from	  multiple	  mouse	  strains	  and	  the	  methods	  section	  of	  this	  
thesis	  describes	  these	  steps	   in	  detail	   to	  allow	  replication	   from	  other	  groups.	  We	  have	  also	  
been	   able	   to	   describe	   their	   regenerative	   and	   immunosuppressive	   potential	   and	   identified	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culture	  conditions	  that	  enhance	  these	  properties.	  These	   findings	  can	  be	  directly	   translated	  
to	   the	   human	   MSC	   field,	   and	   it	   would	   be	   very	   interesting	   to	   observe	   whether	   lineage	  
specification	  with	  FGF,	  PDGF	  or	  TGF-­‐β	  occurs	  in	  a	  purified	  population	  of	  human	  MSCs	  as	  well.	  	  
	  
This	   thesis	   also	   evaluated	  PαS	  MSCs	   in	   clinically-­‐relevant	  models	   of	   cartilage	   regeneration	  
and	   immune-­‐mediated	   liver	   injury.	  Cartilage	   injures	  are	  a	  major	  cause	  of	  disabilities	   in	   the	  
western	  world,	  and	  repair	  following	  injury	  is	  a	  slow	  and	  limited	  process	  due	  to	  the	  avascular	  
nature	  of	  mature	  cartilage	  (Arden	  and	  Nevitt,	  2006).	  Individual	  case	  studies	  and	  small-­‐scale	  
trials	   have	   described	  MSC	   infusion	   to	   be	   as	   effective	   as	   ACI	   in	   repairing	   cartilage	   defects,	  
however,	   there	   are	   other	   studies	  which	   describe	   a	  more	  modest	   benefit	   of	  MSC	   therapy,	  
suggesting	   that	   there	   is	   still	   scope	   for	  optimisation	   (Nejadnik	  et	   al.,	   2010,	  Chen	  and	  Tuan,	  
2008).	   Testing	   cartilage	   repair	   in	   mouse	   models	   of	   injury	   and	   optimising	   protocols	   for	  
chondrocyte	   differentiation	   in	   vitro	   would	   significantly	   reduce	   the	   cost	   and	   improve	   the	  
efficacy	  of	  future	  clinical	  studies	  (Helminen	  et	  al.,	  2002).	  However,	  tissue	  engineering	  murine	  
cartilage	   has	   been	   challenging	   due	   to	   difficulties	   in	   isolating	   a	   pure	   population	   of	  mouse	  
MSCs	   (Zhang,	   2014,	   Frenette	   et	   al.,	   2013),	   and	   the	   requirement	   for	   3D	   culture	   and	  
specialised	  differentiation	  media	  (Gupta	  et	  al.,	  2012,	  Solchaga	  et	  al.,	  2011,	  Koga	  et	  al.,	  2009).	  
We	  have	  shown	  for	  the	  first	  time	  that	  PαS	  MSCs	  can	  differentiate	  into	  good	  quality	  cartilage	  
in	   both	  micromass	   pellet	   cultures	   and	   biodegradable	   PGA	   scaffolds,	  making	   them	   a	   good	  
pre-­‐clinical	  model	  population	  of	  cells	  to	  design	  and	  optimise	  novel	  cartilage	  repair	  therapies.	  
Notably,	   we	   were	   able	   to	   demonstrate	   the	   power	   of	   tissue	   engineering	   approaches	   by	  
showing	  a	  4-­‐fold	  increase	  in	  size	  and	  a	  2-­‐fold	  increase	  in	  collagen	  and	  proteoglycan	  content	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in	   tissue-­‐engineered	   cartilage	   compared	   to	  micromass	  pellets	  when	   starting	  with	  a	   similar	  
number	  of	  MSCs	  in	  both	  experiments	  (5x105	  MSCs	  per	  micromass	  pellet	  compared	  to	  6x105	  
MSCs	  per	  PGA	  scaffold).	  These	  in	  vitro	  findings	  lay	  the	  groundwork	  for	  future	  in	  vivo	  studies	  
in	  mouse	  models	  of	   cartilage	   repair	   to	   further	  optimise	  our	  differentiation	   strategies	  even	  
further	  (Chu	  et	  al.,	  2010).	  	  	  	  
	  
This	  thesis	  also	  demonstrates	  for	  the	  first	  time	  the	  potent	  immunosuppressive	  properties	  of	  
PαS	  MSCs	  and	  the	  effect	  of	  TGF-­‐β1	  in	  maintaining	  the	  suppressive	  potential	  over	  extended	  in	  
vitro	   culture.	   Nitric	   oxide	   was	   identified	   as	   the	   key	   molecule	   responsible	   for	   PαS	   MSC-­‐
mediated	  immunosuppression,	  with	  fits	   in	  nicely	  with	  previous	  murine	  MSC	  literature	  (Ren	  
et	   al.,	   2009,	   Ren	   et	   al.,	   2008).	   The	   most	   promising	   clinical	   examples	   of	   MSC	   therapy	   for	  
immune-­‐mediated	  disorders	  occur	   in	  patients	  with	  GvHD,	   in	  whom	  MSC	  therapy	  has	  been	  
shown	  to	  be	  safe	  and	  efficacious	  in	  phase	  I	  and	  II	  trials	  (Le	  Blanc	  et	  al.,	  2008,	  Le	  Blanc	  and	  
Ringden,	   2007,	   Ringdén	   et	   al.,	   2006).	   However,	   a	   larger-­‐scale,	   phase	   III	   randomised	   trial	  
involving	  244	  GvHD	  patients	  showed	  no	  difference	  in	  the	  complete	  response	  rate	  in	  patients	  
receiving	  MSCs	  or	  placebo	  (Martin	  et	  al.,	  2010).	  One	  reason	  for	  this	  failure	  is	  that	  the	  infused	  
MSCs	  were	  culture-­‐expanded	  using	  a	  “proprietary”	  method	  to	  yield	  almost	  20x109	  cells	  from	  
a	  single	  donor	  (Galipeau,	  2013).	  The	  importance	  of	  passage	  number	  was	  also	  made	  clear	  by	  
von	   Bahr	   et	   al.	   (2012),	   who	   described	   a	   significant	   reduction	   in	   1-­‐year	   survival	   of	   GvHD	  
patients	   receiving	   P3-­‐4	   MSCs	   compared	   to	   those	   that	   received	   P1-­‐2	   cells	   (21%	   vs	   75%	  
respectively).	  Furthermore,	  Moll	  and	  colleagues	  demonstrated	  that	  older	  MSCs	   (>P5)	  were	  
cleared	  by	  the	  host	  quicker	  than	  younger	  cells,	  resulting	  in	  diminished	   in	  vivo	  efficacy	  (Moll	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et	   al.,	   2014,	  Moll	   et	   al.,	   2012).	   In	   this	   context,	   our	   finding	   that	   TGF-­‐β1	   can	  maintain	   the	  
immunosuppressive	  potential	  of	  PαS	  MSCs	  over	  extended	  passage	   is	  of	   significant	   interest	  
for	   translational	   work.	   Future	   studies	   on	   purified	   populations	   of	   human	   MSCs	   should	  
examine	   whether	   TGF-­‐β1	   can	   maintain	   the	   suppressive	   phenotype	   of	   human	   MSCs	   in	   a	  
similar	   fashion	   to	   their	  murine	   counterparts.	   If	   the	   effects	   are	   transferrable,	   then	   clinical-­‐
grade	  MSCs	  should	  be	  expanded	  in	  TGF-­‐β1	  as	  a	  method	  to	  bypass	  the	  long	  standing	  hurdle	  
of	  diminished	  efficacy	  after	  culture	  expansion.	  	  
	  
7.3	  Limitations	  of	  this	  Study	  
The	  identification,	  isolation	  and	  characterisation	  of	  PαS	  MSCs	  represent	  a	  major	  advance	  for	  
the	  murine	  MSC	   field,	   however	   this	   technique	   does	   have	   some	   limitations	  which	   limit	   its	  
translational	   feasibility.	   Firstly,	   the	   isolation	  method	   places	   a	   high	   tally	   on	   the	   number	   of	  
animals	  required	  to	   isolate	  MSCs	  over	  the	  course	  of	  this	  PhD,	  which	  both	  incurs	  high	  costs	  
for	  mice	   and	   goes	   against	   the	   guidance	   of	   the	   NC3Rs	   committee	   (Festing	   and	  Wilkinson,	  
2007).	  The	  delicate	  isolation	  method	  and	  requirement	  to	  use	  a	  cell	  sorter	  for	  several	  hours	  
also	  adds	  to	  the	  costs	  involved	  and	  can	  limit	  access	  to	  some	  research	  groups	  wanting	  to	  use	  
PαS	  MSCs	  in	  their	  studies.	  	  
	  
Secondly,	  it	  is	  currently	  unknown	  whether	  PαS	  MSCs	  exist	  in	  human	  BM.	  A	  negative	  finding	  
will	  severely	  limit	  the	  relevance	  of	  PαS	  MSCs	  as	  a	  model	  pre-­‐clinical	  population	  of	  MSCs,	  and	  
future	  work	  should	  try	  and	   identify	  whether	  the	  same	  marker	  combination	  pulls	  out	  MSCs	  
from	  humans.	  However,	  the	  lineage	  priming	  aspects	  of	  this	  study	  may	  still	  be	  transferrable	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across	   species.	   Another	   factor	   limiting	   the	   translational	   feasibility	   of	   PαS	   MSCs	   is	   the	  
requirement	  for	  BM	  isolation.	  Although	  BM	  aspiration	  is	  a	  relatively	  routine	  and	  safe	  process,	  
the	  procedure	   itself	   is	  a	  painful	  and	  costly	  process	  and	  carries	  with	   it	   certain	   risks	   such	  as	  
infection	   and	   bleeding	   (Bain,	   2005).	   This	   limits	   the	   number	   of	   cells	   which	   could	   be	  
successfully	   isolated	   from	   BM	   aspirates	   (Mosna	   et	   al.,	   2010).	   By	   comparison,	   adipose-­‐
derived	  MSCs	   share	  many	   of	   the	   functionalities	   of	   BM-­‐derived	  MSCs,	   but	   have	   some	   key	  
advantages	   including	   ‘ease-­‐of-­‐harvesting’	   through	   a	   less	   invasive	   liposuction	   procedure	  
(Locke	   et	   al.,	   2011,	   Yarak	   and	   Okamoto,	   2010).	   Adipose	   tissue	   is	   also	   abundant	   and	  
accessible	  due	  to	  it	  being	  classified	  as	  a	  “waste	  product”	  of	  many	  routine	  cosmetic	  surgeries,	  
allowing	  a	  larger	  yield	  of	  cells	  to	  be	  isolated	  (Gupta	  et	  al.,	  2013).	  Isolation	  of	  PαS	  MSCs	  from	  
other	   sources	   in	  mice	  was	   outside	   the	   scope	   of	   this	   study,	   but	   it	   has	   been	   performed	   by	  
other	  groups	  (Sara	  Rankin,	  personal	  communication).	  Further	  work	  is	  necessary	  to	  perform	  a	  
comparative	   analysis	   of	   PαS	   MSCs	   from	   BM	   and	   adipose	   tissue,	   as	   there	   are	   reports	   of	  
differences	   in	   the	  molecular	   phenotype,	   differentiation	   potential	   and	   immunosuppressive	  
capacity	   of	  MSCs	   isolated	   from	   different	   sources	   (Al-­‐Nbaheen	   et	   al.,	   2013,	   Ribeiro	   et	   al.,	  
2013,	  Pendleton	  et	  al.,	  2013,	  Wagner	  et	  al.,	  2005).	  If	  both	  populations	  behave	  similarly,	  then	  
adipose-­‐derived	  PαS	  MSCs	  may	  be	  more	  suitable	  for	  clinical	  translation.	  	  
	  
Another	   technical	   limitation	   of	   this	   work	   was	   due	   to	   the	   use	   of	   FBS	   in	   PαS	  MSC	   culture	  
medium	  in	  experiments	  involving	  GF-­‐priming.	  Although	  batch-­‐to-­‐batch	  variation	  in	  FBS	  was	  
minimised	   by	   bulk	   purchasing,	   FBS	   is	   by	   nature	   an	   undefined	   product	   with	   varying	  
concentrations	  of	   cytokines	   and	  growth	   factors	   (Zheng	  et	   al.,	   2006,	   Jochems	  et	   al.,	   2002).	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Strictly	  speaking,	  the	  GF-­‐priming	  experiments	  should	  be	  repeated	  in	  serum-­‐free,	  chemically-­‐
defined	  medium	   to	   bypass	   any	   potential	   confounding	   effects	   of	   FBS	   (van	   der	   Valk	   et	   al.,	  
2010).	  However,	  it	  is	  important	  to	  note	  that	  the	  effects	  of	  GFs	  were	  clear	  and	  reproducible	  
over	   numerous	   experiments	   spanning	   several	   years	   with	   different	   batches	   of	   FBS,	   which	  
argues	  against	  a	  confounding	  role	  for	  this	  undefined	  substrate	  in	  our	  experiments.	  
	  
Finally,	  the	  use	  of	  FBS	  is	  again	  a	  limitation	  as	  it	  carries	  a	  risk	  of	  xenoantigen	  incorporation	  in	  
MSC	  cultures	  and	  goes	  against	  Good	  Manufacturing	  Practice	  (GMP)	  guidelines	  (Copland	  and	  
Galipeau,	   2011,	   Sensebe	   et	   al.,	   2011).	   An	   interesting	   study	  by	   Spees	   et	   al.	   (2004)	   showed	  
that	   a	   standard	   preparation	   of	   10x107	   human	  MSCs	   (a	   dose	   equivalent	   to	   those	   used	   in	  
human	   trials)	   internalised	   between	   7	   to	   30mg	   of	   xeno-­‐proteins	   which	   could	   make	   them	  
immunogenic	   in	   vivo.	  A	   similar	  effect	  has	  been	  described	   for	  human	  embryonic	   stem	  cells	  
(Martin	  et	  al.,	  2005)	  and	  adipose-­‐derived	  MSCs	  (Komoda	  et	  al.,	  2009),	  which	  internalised	  and	  
expressed	   the	   nonhuman	   sialic	   acid	   (N-­‐glycolylneuraminic	   acid)	   after	   culture	   in	   animal	  
serum-­‐containing	  media.	  Although	  the	  stem	  cell	  therapy	  field	  as	  a	  whole	  is	  gradually	  moving	  
towards	  xeno-­‐free,	  GMP-­‐compliant	  culture	  platforms	  (Tannenbaum	  et	  al.,	  2012),	   it	   is	  again	  
important	   to	   note	   that	   a	   meta-­‐analysis	   of	   safety	   in	   MSC	   clinical	   trials	   revealed	   no	  
relationships	  between	  MSC	  infusion	  and	  “acute	  infusional	  toxicity”	  (Lalu	  et	  al.,	  2012).	  Out	  of	  
the	  36	  trials	  examined,	  27	  used	  MSCs	  cultured	  in	  FBS,	  five	  used	  human	  serum	  and	  four	  used	  
serum	   from	   an	   unknown	   source.	   Therefore,	   there	   is	   currently	   no	   evidence	   for	   increased	  
toxicity	  or	  immunogenicity	  in	  MSCs	  cultured	  in	  FBS,	  although	  it	  would	  be	  wise	  to	  avoid	  xeno-­‐
products	  wherever	  possible	  in	  future	  studies.	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7.4	  Future	  Work	  
The	  findings	  of	  this	  study	  raise	  several	  interesting	  questions,	  particularly	  regarding	  potential	  
mechanisms	  of	  action	  in	  the	  OVA-­‐Bil	  model.	  These	  are	  summarised	  briefly	  below:	  
	  
7.4.1	  Mechanism	  of	  C57BL/6-­‐derived	  PαS	  MSC	  Immunosuppression	  
One	  of	   the	  most	   interesting	   findings	  of	   this	   study	   is	   the	  observation	   that	  C57BL/6-­‐derived	  
PαS	   MSCs	   suppress	   via	   a	   different	   mechanism	   to	   Balb/c-­‐derived	   MSCs.	   Strain-­‐specific	  
differences	   in	   immunosuppression	   have	   not	   received	   much	   research	   attention	   in	   MSC	  
literature,	  but	  the	  implications	  of	  this	  finding	  could	  have	  an	  impact	  on	  the	  choice	  of	  mouse	  
strain	  used	  in	  future	   in	  vivo	  experiments.	  Further	  studies	  using	  small	  molecule	  inhibitors	  of	  
known	   immunosuppressive	   pathways	   (e.g	   IDO,	   L-­‐NMMA,	   1-­‐MT	  or	   SB-­‐3CT)	   can	   be	   used	   to	  
identify	   a	   potential	   mechanism	   of	   action.	   Additionally,	   selective	   removal	   of	   immune	   cell	  
subsets	   (e.g.	   monocytes/macrophages,	   B	   cells,	   DCs)	   can	   also	   be	   used	   to	   study	   possible	  
indirect	  effects	  of	  PαS	  MSCs	  on	  T	  cell	  proliferation.	  Finally,	   it	   is	  also	  necessary	   to	  examine	  
whether	   TGF-­‐β1	   can	   maintain	   the	   suppressive	   phenotype	   of	   C57BL/6	   MSCs	   in	   a	   similar	  
fashion	  to	  Balb/c-­‐derived	  cells.	  Our	  in	  vivo	  findings	  in	  the	  OVA-­‐Bil	  model	  suggest	  this	  may	  be	  
the	  case,	  although	  further	  in	  vitro	  proof	  is	  required	  to	  substantiate	  this	  hypothesis.	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   7.4.2	  Characterisation	  of	  PαS	  MSC	  Senescence	  	  
Senescence	   was	   defined	   as	   the	   appearance	   of	   β-­‐gal+	   cells	   in	   this	   study.	   To	   further	  
understand	  the	  kinetics	  of	  senescence	  in	  PαS	  MSCs,	  it	  is	  necessary	  to	  study	  the	  expression	  of	  
senescence-­‐associated	   genes	   and	   cell-­‐cycle	   inhibitors	   p21,	   p16,	   p19	   and	   p53	   using	   a	  
combination	   of	   RT-­‐PCR	   and	   western	   blotting	   (Koch	   et	   al.,	   2012,	   Schallmoser	   et	   al.,	   2010,	  
Wagner	  et	  al.,	  2010).	  It	  would	  also	  be	  interesting	  to	  observe	  whether	  late-­‐passage	  PαS	  MSCs	  
acquire	   a	   pro-­‐inflammatory	   “senescence-­‐associated	   secretory	   phenotype”	  which	   has	   been	  
reported	   for	  other	   stromal	   cell	   subsets	   (Coppe	  et	  al.,	  2010,	  Fumagalli	   and	  Fagagna,	  2009).	  
Finally,	   to	   prove	   that	   immortalisation	  or	   transformation	  did	   not	   occur	   in	   PαS	  MSCs	   in	   the	  
presence	  of	  GFs,	   it	   is	  necessary	  to	  demonstrate	  re-­‐acquisition	  of	  senescence	  upon	  removal	  
of	  GF-­‐supplementation,	  as	  has	  been	  described	  previously	  by	  Coutu	  et	  al.	  (2011).	  	  
	  
7.4.3	  Karyotypic	  analysis	  of	  PαS	  MSCs	  
Metaphase	  karyotype	  analysis	   revealed	  no	  cytogenetic	  evidence	  of	   clonal	   abnormalities	   in	  
PαS	  MSC	  cultures.	  However,	  we	  did	  observe	  increased	  tetraploidy	  in	  TGF-­‐β1	  supplemented	  
cells	  compared	  to	  other	  culture	  conditions.	  Although	  tetraploidisation	  of	  murine	  MSCs	  has	  
been	   reported	   to	   be	   a	   protective	  mechanism	   against	  malignancy	   in	   vivo	   (Shoshani	   et	   al.,	  
2012),	  changes	  in	  chromosome	  number	  are	  also	  a	  hallmark	  of	  cancer	  (Albertson	  et	  al.,	  2003).	  
Therefore,	  it	  is	  necessary	  to	  perform	  in	  vivo	  transplantation	  experiments	  in	  NOD/SCID	  mice	  
to	  examine	  whether	  PαS	  MSCs	  also	  use	  tetraploidisation	  as	  a	  protective	  mechanism	  against	  
malignancy	  (Hatakeyama	  et	  al.,	  2010).	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Another	  interesting	  finding	  from	  our	  karyotype	  analysis	  was	  the	  occurrence	  of	  quadriradial	  
chromosomes	  in	  PDGF-­‐supplemented	  cells.	  QR	  chromosomes	  are	  indicative	  of	  an	  increased	  
rate	   of	   sister	   chromatid	   exchange	   (SCE)	   in	   genetic	   instability	   disorders	   such	   as	   Bloom’s	  
Disease	   (Singh	   et	   al.,	   2010).	   The	   rate	   of	   SCE	   can	   be	  monitored	   by	   culturing	   cells	   in	   BrdU-­‐
containing	  medium	  to	  differentially	  stain	  sister	  chromatids.	  Metaphase	  spreads	  are	  prepared	  
as	   before	   and	   analysed	   for	   regions	   of	   discontinuous	   staining	   that	   occur	   after	   reciprocal	  
exchanges	  of	  genetic	  material	   (Moore	  and	  Best,	  2001).	  This	  analysis	  would	  reveal	  whether	  
PDGF-­‐supplementation	  predisposes	  PαS	  MSCs	  towards	  genetic	  instability,	  and	  further	  work	  
examining	   the	   karyotype	   of	   cells	   at	   later	   passages	   (P7	   onwards)	   would	   reveal	   the	  
downstream	  significance	  of	  elevated	  SCE	  and	  QR	  chromosome	  formation	  in	  PDGF	  cultures.	  	  	  	  	  
	  
7.4.4	  Kinetics	  of	  Growth	  Factor	  Action	  &	  Combination	  Studies	  
Growth	   factors	   were	   added	   to	   freshly	   isolated	   MSCs	   and	   maintained	   throughout	   their	  
expansion	  period	  in	  this	  study.	  It	  would	  be	  interesting	  to	  examine	  whether	  short-­‐term	  (24-­‐
48h)	  stimulation	  with	  GFs	  produces	  the	  same	  genotypic	  and	  phenotypic	  differences	   in	  PαS	  
MSC	   differentiation	   and	   immunosuppression	   seen	   with	   long-­‐term	   culture.	   Additionally,	   it	  
would	   also	   be	   interesting	   to	   study	   whether	   removal	   of	   GFs	   results	   in	   a	   loss	   of	   priming	  
‘memory’	   and	   observe	   the	   kinetics	   behind	   the	   possible	   loss	   in	   lineage-­‐specific	   gene	  
expression.	   Studies	   using	   combinations	   of	   GFs	   (e.g.	   FGF2	   for	   growth	   and	   TGF-­‐β1	   for	  
immunosuppression)	   can	   also	   be	   performed	   to	   overcome	   the	   limitations	   of	   each	  GF	   used	  
individually.	  	  	  
	   	  
Chapter  7  






7.4.5	  Mechanism	  of	  Growth	  Factor	  Action	  
Addition	   of	   GFs	   caused	   profound	   genotypic	   and	   phenotypic	   changes	   in	   PαS	   MSCs,	  
particularly	   in	  FGF2	  and	  TGF-­‐β1	  supplemented	  cultures.	  Our	  preliminary	  analysis	   identified	  
potential	  pathways	  regulating	  adipogenic	  priming	  in	  FGF2	  and	  PDGF-­‐BB	  supplemented	  cells.	  
Future	   work	   should	   concentrate	   on	   how	   FGF2	   enhances	   the	   growth	   and	   chondrogenic	  
differentiation	  of	  PαS	  MSCs	  and	  how	  TGF-­‐β1	  maintains	  their	  immunosuppressive	  potential.	  
The	   FGF	   pathway	   can	   be	   studied	   using	   dasatanib	   and	   SU5402	   as	   before,	   and	   the	   TGF-­‐β1	  
pathway	   examined	   using	   SB431542,	   a	   selective	   inhibitor	   of	   the	   type	   I	   TGF-­‐β	   receptor	  
(Stewart	  et	  al.,	  2010,	  Inman	  et	  al.,	  2002).	  Further	  analysis	  of	  PDGF-­‐BB	  signalling	  can	  also	  be	  
performed	  at	  the	  receptor	  level	  and	  on	  downstream	  signalling	  proteins	  using	  small-­‐molecule	  
inhibitors	  (CP-­‐673,451;	  Roberts	  et	  al.,	  2005)	  or	  antibodies	  (Heldin,	  2013).	  
	  
7.4.6	  Toll-­‐like	  Receptor	  Priming	  
An	  emerging	  field	  in	  MSC	  biology	  involves	  the	  study	  of	  TLR	  stimulation	  and	  its	  effect	  on	  the	  
immunosuppressive	  capacity	  of	  MSCs	  (Keating,	  2012).	  Murine	  MSCs	  express	  TLRs	  1-­‐6,	  with	  
TLR3	  and	  TLR4	  being	  key	  receptors	  controlling	  the	  switch	  between	  a	  pro-­‐inflammatory	  and	  
an	   anti-­‐inflammatory	   phenotype	   (DelaRosa	   and	   Lombardo,	   2010,	   Waterman	   et	   al.,	   2010,	  
Tomchuck	  et	  al.,	  2008).	  It	  would	  be	  interesting	  to	  study	  the	  feasibility	  of	  TLR3	  priming	  (using	  
double	  stranded	  RNA)	  and	  TLR4	  priming	  (using	  LPS)	  as	  a	  method	  to	  enhance	  the	  migratory	  
and	   suppressive	   phenotype	   of	   PαS	   MSCs	   even	   further.	   Additionally,	   it	   would	   also	   be	  
interesting	  to	  examine	  whether	  TGF-­‐β1	  treatment	  alters	  the	  expression	  of	  TLRs	  on	  PαS	  MSCs.	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7.4.7	  OVA-­‐Bil	  model	  of	  Alloimmune	  Liver	  Injury	  
PαS	  MSCs	  were	  able	   to	   significantly	   reduce	   inflammatory	   liver	  damage	   in	  OVA-­‐Bil	  mice	  by	  
lowering	  the	  total	  numbers	  of	  damage-­‐causing	  lymphocytes	  in	  their	  livers	  after	  infusion.	  The	  
key	  unanswered	  questions	  in	  this	  model	  concern	  the	  localisation	  and	  mechanism	  of	  action	  of	  
infused	   MSCs.	   The	   topic	   of	   MSC	   migration	   has	   always	   been	   a	   contentious	   issue	   in	   MSC	  
literature,	  with	  some	  studies	  demonstrating	  efficient	  migration	  to	  areas	  of	  injury	  and	  others	  
demonstrating	   a	   more	   systemic	   effect	   (Choi	   et	   al.,	   2011,	   Karp	   and	   Teol,	   2009).	   Homing	  
studies	   using	   labelled	   PαS	   MSCs	   could	   be	   performed	   to	   observe	   whether	   they	   migrate	  
towards	  and	  engraft	  in	  the	  liver	  or	  work	  systemically	  from	  the	  peritoneal	  cavity.	  Examination	  
of	   the	   draining	   lymph	   nodes	   of	   the	   peritoneum	  would	   also	   reveal	  whether	  MSCs	   directly	  
affect	  lymphocyte	  activation	  at	  these	  sites.	  	  Alternatively,	  dual-­‐colour	  labelling	  of	  adoptively	  
transferred	   OT-­‐1	   and	   OT-­‐2	   cells	   and	   PαS	   MSCs	   would	   also	   allow	   us	   to	   study	   any	   direct	  
interactions	  between	  these	  cells.	  	  
	  
We	   observed	   a	   selective	   retention	   of	  macrophages	   in	   animals	   receiving	   early-­‐passage	   SM	  
MSC	  treatment,	  which	  could	  be	  a	  potential	  mechanism	  of	  action.	  Liver	  sections	  need	  to	  be	  
stained	  for	  markers	  of	  M1	  and	  M2	  macrophages	  to	  study	  whether	  PαS	  MSC	  infusion	  skews	  
macrophage	   polarisation	   towards	   an	   anti-­‐inflammatory	   M2	   phenotype.	   Alternatively,	  
animals	   can	   be	   treated	   with	   clodronate	   to	   deplete	   macrophages	   to	   see	   whether	   the	  
beneficial	   effect	   of	   PαS	   MSC	   infusion	   is	   lost	   (Weisser	   et	   al.,	   2012,	   Nemeth	   et	   al.,	   2009).	  
Finally,	   further	   analyses	   using	   the	   TUNEL	   assay	   and	   IHC	   for	   caspases	   3	   and	   7	   would	   also	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